<SEC-DOCUMENT>0001104659-21-138092.txt : 20211112
<SEC-HEADER>0001104659-21-138092.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112161755
ACCESSION NUMBER:		0001104659-21-138092
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		211403777

	BUSINESS ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		295 MADISON AVENUE,
		STREET 2:		SUITE 2400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>eyen-20210930x10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/12/2021 11:05:52 AM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: ae7a6989-5512-4b3c-87b7-4a2207ab286e -->

  <html xmlns:eyen="http://www.eyenoviabio.com/20210930" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" xs:nil="true" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_1RgLe8I-bkex9JfHegYumg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" xs:nil="true" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_JskXH9EJUUeZv0DhFI7gJQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Zpy7aVwBy0-Lv8WhOHXNTA">0.21</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" sign="-" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_cbG6_6ZmOk-FkJmzEa1rHw">0.23</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_pjIxGAhFRkavWEUwCGLB3Q">0.61</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" sign="-" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden__pXBRFNzo02E8aJpBpfeaw">0.79</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_tkGiDTxPi0K_pGbG6MFwQw">26052483</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_IXhkrl1xBU6hnHIlgILgfg">22206195</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_TdF7yINdLEuyx2Jf6GYcGQ">25773098</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_9cP8NU4rWUqcVr6GzJ5YpQ">19802999</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_QKy5Dk4L5U21ypNDqI_eFg" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Hidden_0pjWYEGDNkentV_xYyZQGA">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_XtjRsqCqhUWe6dM1LlWLYQ" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Hidden_0rah1dwiwUKGvejQzLqdgw">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityIncorporationStateCountryCode" id="Hidden_NP4wZA_uF06ifKNMb15MNA">DE</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityCentralIndexKey" id="Tc_8mD3YO7KBEW8Loi88kQcsA_2_1">0001682639</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:CurrentFiscalYearEndDate" id="Tc_mH3nc5s9JUOFMwo5Hd2P0A_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentFiscalYearFocus" id="Tc_rCJsXRhcNU-rnriUGGK4HA_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentFiscalPeriodFocus" id="Tc_ZPV7oV9piEyoeiamnz_SCA_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:AmendmentFlag" id="Tc_AV-vx2tnL0W6x7AMNYAxxA_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_3Zy0UOScXEaWdhOuseYwgQ" decimals="0" name="eyen:LeaseMonthlyBaseRent" id="Hidden_D_hRu6Vn6kiVuoZDbI2E-w">5404</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_N9ZooPSTykGh4q7NxSG9rA" decimals="0" name="eyen:LeaseMonthlyBaseRent" id="Hidden_nuJjRqoS1k-5yZXc6XLgrw">4012</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" sign="-" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Hidden_eoq4WkYJv0u9e_1CVVO3Uw">93202584</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" name="us-gaap:NetIncomeLoss" id="Hidden_wncAopnaD0uKiQynCGwpOA">15761665</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" sign="-" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" name="us-gaap:NetIncomeLoss" id="Hidden_p4gZozmYS0S7balkCzNXaw">15563005</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Hidden_ux28YaoNUkm5oVQ06xjkHA">14997807</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" sign="-" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Hidden_XUae-FPTXkaSLR7npSF_nw">11853369</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_3MWSsXXWsESbShjb4H9pdQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_oERaqE77QE2N-3RROB8Lyw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_3Hdz33n-GkW0wPKEq9SnqA">25963185</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_d9weVYGAekqwmy1K-j8EiQ">24978585</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" name="us-gaap:ProceedsFromWarrantExercises" id="Hidden_MimNBTPoWU-6QCm4o9Gk6Q">2646091</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_6_2020_To_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_qW8ClKspyUqkLxfdKlUpyA" decimals="0" name="eyen:LeaseMonthlyBaseRent" id="Hidden_ZGcx3U_Ha0Oyk6Kg7P3ESg">5247</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eyen-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_VN0zw8sCNECXKkjFp3cH-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_hm_lAyvBM0qOeJoA1nk2ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2020_To_3_24_2020_bTfSRHfxlkeROm6p3tdnwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_166ZAmZBBki2ZJaq_2i7OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_egysx-a5s0CwPDQUHEvdqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yoZZp1S-YkSK0slqbGBuYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UIjArcXu4kWTOOHrTlosoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_2iIqhP5zKUSGnKrT3fT8EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_xmAWV6mUSKUNDQxJrP0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mQSiaUfq50W0yaz5UztvLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_1iHEOc5UZ0iZyDD69rBDVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j4B1KYQ0MEWecgQLPbVQNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kth875WnPUKg3agMaWI0Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZLzQ6a3ZdkCqP8h95qZo5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_11APGkRcvEiinWn5XMPudQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8jVnW9XRk-de3gCif1Ngg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aERtWPLXHE-NyWVDKwVKKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_uk3nxzgTF02apB9F1dX2kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8iU0YDKFkWOzxWgCoFXPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QsJXwwdhUU-D4UcQ-cvUsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_vwX5UftH6k2nB0oxeBOzmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L_q-9Sd8ckKHkP5XYRlMzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HJTe8zro2Uuqwss6XoUeeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_lMHKpMczF0i8b2pWYttO7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_txshmOfMEEmvxCweLiMsTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_Am_mT9HJA0SSfr6CiMZH_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_aOl2qdArnUe539L8lxXVIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_UpMsAYqFqU6-i1LSMPeaFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_FM7GpRWW9Euozoy65TKphg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_7ngFNRaQXEyNp3ttRONFSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_c-dzlES2H06x3UbgBeoj7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_80d3KmGzV0ebsJXfreNHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_BHSo-xH0_02gL68u6nLG7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_Mhliuin-iE-lwHos4zJZUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_QKy5Dk4L5U21ypNDqI_eFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_bogZl4gZq0O_dB0iHUQz0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_Cignz6GZIEqawyto9jO6zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_LJewsOeuEk6TAXKmOshhVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_t3aQtXqbMUqyY_l_s90kFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSeventeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_fMRMT8Kzq0GnRyxYiQBXKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_pdxT137AQUSnpOvc-s2HeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_2pIbQgQQM021F_Zqq-Clqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_smJVukydaEOrt-QPyWs5Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_T5bwOHqjaUKS0LJJ4b5ozA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_XtjRsqCqhUWe6dM1LlWLYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_DIdgnF05VESFzCtSdTkV_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSeventeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_JRmA5vMSfky7e2TsSVzjhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_OZ8nqWdLB0CI7i4-5Qnk5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember__XCTy9gD4EmCBR0M73gnyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_7pE77VrTWUCPTGSIttM0Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_w1sjpiHNKkuLE2e28hGLqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9phIPy7ZLESGi02EKB1vbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-27</xbrli:startDate><xbrli:endDate>2021-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tUqOu0dbMESf7ibzQiMF9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-27</xbrli:startDate><xbrli:endDate>2021-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-27</xbrli:startDate><xbrli:endDate>2021-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_4f7WqPnHVkCgD1MTwLBKxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_yWodK4nHxUqdTmAUJR3I_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_0KZL2TVKrUmrWMPejjnE0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_29_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_L9bBY0VpvUGL4oYGXOsvdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DebtMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IQWi_hUUskCPeb77ph-Kwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M_Xp5Nb4D0mDo0QoESXKLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nzq8FK4mAkKZ5R2RZ9KIUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember_dyafUeHTdE6cz1HM3PEKSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">eyen:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_QoZ2KGe6NUGCeXRNsv3DqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:BankDirectCapitalFinanceLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:BankDirectCapitalFinanceLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember__7M2VxLcG0C8xOn47atQ4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pj3iXu39uEaE-ra1uxJM1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pOlvfs6TQUyzUKtXgpDcEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_KnS0U6aBO0mO5JTiaLy6jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_JuJfIkOVj0CQftJ-_I1QGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_fv_THQb6o0GG_A4a0SrB1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_72LTFu3OPkuIXbgOUgsnxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_c2IjVI1hiUyhj_jiFRUrvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VL8MKBI58UiYMm_viCZP0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_8dZNtKxwmkiqkPx6oMKrZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_whpYAzEDtkOSZXmSQSWepw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_os_kMS_z0EKpasXd_445Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_4_qEKYrc8Euhf2_8V5qnGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_7Pfs622rJ02-2GjGaBo6sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_XlWzbj9LNU6tzxL4LlSTxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_A7hLgIFxxUKBiuI527JBGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Jy8VhLNmEkGHN5MuNuthNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ntknW_Gv5UC-DQSr8ZSQOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qNX7m30BZEuTbysvLOcMQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rbh1OVNxSEyBxxZbh4fjoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_x35crJWltUqP-Ltc2GMthw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CJ4gskFkJUSoYcy73Hqa0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_w6HGMgcXbEmE_fB8OrHwwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_bcWFEL6RI0aDOWIz9I9cow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_40ylzH8p4E6F0T980U5jPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_dm3PbdzDGkKl6-8dwnZVtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IKbBe5b9Dk2-O_EZG5UCIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_ag4DlDgBVE2npGpPYLG-BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_ThirdAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_36SWG7orek6gpITdi6VlKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:ThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_SecondAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_Xo9_8_071Euty-FIgDxP6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:SecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_FirstAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_nLEH9d3WgkSONkevFlrepw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:FirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-07</xbrli:startDate><xbrli:endDate>2021-05-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-24</xbrli:startDate><xbrli:endDate>2021-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-11</xbrli:startDate><xbrli:endDate>2020-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-14</xbrli:startDate><xbrli:endDate>2021-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-14</xbrli:startDate><xbrli:endDate>2021-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_C3bKFFHaP0eGVFPtm44auA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:SenjuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_DQU3YqFEXEeMyoIAZgkB6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-09</xbrli:startDate><xbrli:endDate>2020-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-10</xbrli:startDate><xbrli:endDate>2020-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_7NBatIvU1UScUlDnCWwfjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_3Zy0UOScXEaWdhOuseYwgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-15</xbrli:startDate><xbrli:endDate>2020-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_6_2020_To_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_qW8ClKspyUqkLxfdKlUpyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_15_2018_To_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_N9ZooPSTykGh4q7NxSG9rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-15</xbrli:startDate><xbrli:endDate>2018-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_9IMRqv6brkyXUIlqI0AdYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_14_2021_To_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_N1KXYZq5fUuqk4TSeXUFnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-14</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_i3TWieKEpEOqRjVjfBglLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:SenjuLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_x2ajygQN6EKb6JGnk3ADLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9AtIdFEIokuL0HQ8uzCAsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-24</xbrli:startDate><xbrli:endDate>2020-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_s7sYagQq6kerzRAgAyzWvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_kdodtnQEgkKApSH7Ar3_7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Im1QKFMiwEyIc4Nt8pdKyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_10_2021__RwvPqpFAUaT2tpu7xbEIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_g_mpTWDoikWYZzf7J4YxvQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2" toRefs="_d37eaf7b_983e_4a30_a376_18834d02315c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_eC2iacNYQUmPuhllN3b-WA_23_14" toRefs="_d37eaf7b_983e_4a30_a376_18834d02315c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8" toRefs="_d37eaf7b_983e_4a30_a376_18834d02315c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_aHrCmOBr3UW1GniaD9mjIg_23_5" toRefs="_d37eaf7b_983e_4a30_a376_18834d02315c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_O5vsiEfkEkOvZyoF8tznfg_23_11" toRefs="_d37eaf7b_983e_4a30_a376_18834d02315c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_D0YzUAQVWE62L_TShdiWZg_7_2" toRefs="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_qOmJQXwe3keWplvbtt2sSQ_7_14" toRefs="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8" toRefs="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_IitobebuVk-v9Zwz1GQADw_7_5" toRefs="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_KIDooAWzYk6H1VhhxJeQug_7_11" toRefs="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14" toRefs="_fd9dc05a_1c6c_48bf_a594_db51ef746b77" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kzbIalpKPk-fHEULMdpRUg_19_8" toRefs="_fd9dc05a_1c6c_48bf_a594_db51ef746b77" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9MTARuC3fUqgCgb-kF9CBw_30_6" toRefs="_979b107d_26ff_4430_be91_8b7b2590c736" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_788d13db_b9d4_4d0b_b03c_e000c5278cf3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, DC 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentType" id="Narr_9HiG0WNkEEKP9vYi-MHiDA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentQuarterlyReport" id="Narr_sFhhA4oLjkyvRiJz0pVSQg"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9746;</b></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><b style="font-size:8pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 22pt;"><b style="font-size:8pt;font-weight:bold;">For the quarterly period ended: </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentPeriodEndDate" id="Narr_qChFxaQSwkmdinBEV_GnLA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">September 30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 22pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:DocumentTransitionReport" id="Narr_ojEVj5YGZ0SP5HYmtxwffQ"><b style="font-family:'Segoe UI Symbol';font-size:8pt;font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;</span><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 22pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">to </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">COMMISSION FILE NUMBER: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityFileNumber" id="Narr_rs1O-wbxp0e29Fv_CP-LDA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">001-38365</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityRegistrantName" id="Narr_EFZR0frdJ0iGNZ4K7AmEfA"><b style="font-weight:bold;">EYENOVIA,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_5d365e3c_c417_4f74_9ae3_d9cd7cf433ac"></a><a id="Tc_sxlddIJ2hE-DvH8rPXkzxA_1_0"></a><a id="Tc_G-yBcv47tEqMSm7x2sViLw_1_2"></a><a id="Tc_Jixzby7gV0KJjGrY_tbQ4w_3_0"></a><a id="Tc_qj7uEPoBIkeZvvFnWc6Faw_4_0"></a><a id="Tc_QWqnIVnQr0mgO0bKdxzJjg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NP4wZA_uF06ifKNMb15MNA;"><b style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:bold;text-align:center;">DELAWARE</b></span></p></td><td style="vertical-align:bottom;width:20%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityTaxIdentificationNumber" id="Tc_a-PyXfXiekiqOrydMknXMg_0_2"><b style="font-size:8pt;font-weight:bold;">47-1178401</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of<br />Incorporation or Organization)</p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(I.R.S. Employer<br />Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityAddressAddressLine1" id="Narr_aY4QRe_o5E-t8MenffLhjA"><b style="font-size:8pt;font-weight:bold;">295 Madison Avenue, Suite&#160;2400</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityAddressCityOrTown" id="Narr_RuYuLC_CV02-BUtqvyG8pw"><b style="font-size:8pt;font-weight:bold;">NEW YORK</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityAddressStateOrProvince" id="Narr_o8pJp_qzyEOggZQBR22ocg"><b style="font-size:8pt;font-weight:bold;">NY</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:20%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityAddressPostalZipCode" id="Tc_BV9yMQU5ykC9wKb25gWUHw_3_2"><b style="font-size:8pt;font-weight:bold;">10017</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: </b><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:CityAreaCode" id="Narr_hZikFdA650eUo_VJrVnQDQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">917</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:LocalPhoneNumber" id="Narr_BwnTNgkSsEuqUFAiFSTKjQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">289-1117</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_35dc5539_ddd3_41f4_8301_4b24cf4144e1"></a><a id="Tc_iqGISmXD-0OaiELDIoU5-Q_1_0"></a><a id="Tc_Y4DrRwhKo0u0nkSEHEhI4Q_1_2"></a><a id="Tc_WCybchkbMUOobk4E7-ebHA_1_4"></a><a id="Tc_CSIvC_PtpEWe4BxTduuD7A_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:Security12bTitle" id="Tc_kxgHbwXnwUqUZkOzfs9GlA_2_0"><span style="font-size:8pt;">Common Stock, $0.0001 Par Value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:TradingSymbol" id="Tc__Ln1PB8QdUWbnbiw4Vp3Zw_2_2"><span style="font-size:8pt;">EYEN</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:SecurityExchangeName" id="Narr_eUxj0ngPG0a2XAlne4fGBw"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Capital Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityCurrentReportingStatus" id="Narr_tkJb9IL1Zkeb-8dHdqTe_Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:6pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityInteractiveDataCurrent" id="Narr_CLGejyNCcECKUQnIqD0c7w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_9dc29323_e367_4b82_b1a0_5d02cf7cef02"></a><a id="Tc_LP038yPzTkuYlM2vR4zcZw_0_0"></a><a id="Tc_3lbGW5s2MkyBm-C6m5bk2A_0_1"></a><a id="Tc_axHVYOT4pkiOHXoSmH9GFQ_0_2"></a><a id="Tc_iWXVAsruR0iDCWGJAUPqrA_0_3"></a><a id="Tc_mjyeGzB6GkykqHMYOXtMjQ_2_1"></a><a id="Tc_3W2vCo5bWUCDf1KnLJP35Q_2_2"></a><a id="Tc_2CVUZ9eJpUyG8JMyzcLsQg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityFilerCategory" id="Tc_IePL-r4XzEyi9ziPKhd11Q_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntitySmallBusiness" id="Tc_Bc0vMxul002xAD_hRZn19Q_2_3"><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityEmergingGrowthCompany" id="Tc_qI2YJ9AtsEORMOj8GCJkZw_4_3"><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;"> </span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any news or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityExTransitionPeriod" id="Narr_HmLyXqL4s06h8fzTaSQ1gg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;">&#160;No&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="dei:EntityShellCompany" id="Narr_967PW8RHUUSyiYf73xJyiw"><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">The number of outstanding shares of the registrant&#8217;s common stock was<span style="font-size:10pt;"> </span><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_10_2021__RwvPqpFAUaT2tpu7xbEIQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_cXWa1SIG4U276C9IqpGmWg">28,398,789</ix:nonFraction> as of November 10, 2021<span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fe732026_fb68_4f06_b67d_47616bb35ce0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FORM&#160;10-Q</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_797329"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;I - FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item1FinancialStatements_797935"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a> <a href="#Item1FinancialStatements_797935"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><a href="#CondensedBalanceSheets_20940"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Balance Sheets as of September 30, 2021 (Unaudited) and December&#160;31, 2020</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><a href="#StatementsofOperations_269542"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unaudited Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><a href="#ChangesinStockholdersEquity_934028"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unaudited Condensed Statements of Changes in Stockholders&#8217; Equity for the Three&#160;and Nine Months Ended September 30, 2021 and 2020</span></a>&#160;</p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><a href="#StatementsofCashFlows_626714"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unaudited Condensed Statements of Cash Flows for the Nine&#160;Months Ended September 30, 2021 and 2020</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><a href="#Note1BusinessOrganization_738474"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Unaudited Condensed Financial Statements</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item2ManagementsDiscussionandAnalysis_62"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a> <a href="#Item2ManagementsDiscussionandAnalysis_62"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a> <a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item4ControlsandProcedures_795021"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a> <a href="#Item4ControlsandProcedures_795021"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_210178"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">PART&#160;II - OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item1LegalProceedings_458954"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a> <a href="#Item1LegalProceedings_458954"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item1ARiskFactors_613824"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a> <a href="#Item1ARiskFactors_613824"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors.</span></a></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a> <a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds.</span></a></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item3DefaultsuponSeniorSecurities_662766"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a> <a href="#Item3DefaultsuponSeniorSecurities_662766"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item4MineSafetyDisclosures_19173"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a> <a href="#Item4MineSafetyDisclosures_19173"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item5OtherInformation_587983"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a> <a href="#Item5OtherInformation_587983"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><a href="#Item6Exhibits_406166"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a> <a href="#Item6Exhibits_406166"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits.</span></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:93.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_5708"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">SIGNATURES</b></a></p></td><td style="vertical-align:middle;width:6.34%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_74974c7e_9c57_45e0_9a54_ac13c87f1edc"></a><a id="PARTIFINANCIALINFORMATION_797329"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_797935"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 3pt 0pt;">Item&#160;1. Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 3pt 0pt;">EYENOVIA,&#160;INC.</p><a id="CondensedBalanceSheets_20940"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_bdb3db61_5754_4494_9c92_8c515598b29a"></a><a id="Tc_AP7q66-8OEmefBh8QIu2Vg_1_2"></a><a id="Tc_FgqPxn_5SkG7UuKumRAz7A_1_5"></a><a id="Tc_Ex9Y-g_uPUSw5nTv5wfGbQ_2_2"></a><a id="Tc_JfxoMudBl0GUdh4S3i1ckg_2_5"></a><a id="Tc_zz40JW87UkabCkok8T3IjA_3_2"></a><a id="Tc_uESD0gjd2kWSMg6Go7bLuA_4_0"></a><a id="Tc_cCx6H4HuOkyneJbQfKmnSg_6_0"></a><a id="Tc_AXb5UZVHpECB1U2VLw1zgw_7_0"></a><a id="Tc_VaibUHJ-IkaCkVp1WZfIdg_7_2"></a><a id="Tc_tNLkt60ZP0ucbOiIpzNvjw_7_5"></a><a id="Tc_sA8vaV6vhUCnSmno46R6WQ_8_0"></a><a id="Tc_LF3eV2YCM02OgzSp9r68Xw_8_6"></a><a id="Tc_KF8V8e-a202VGnShfvCPpw_9_0"></a><a id="Tc_Q7ZyaOUVnE2OIJVBBQ_lAw_9_3"></a><a id="Tc_q9KCw7mGIUGFidaqWfYmsw_10_0"></a><a id="Tc_k4dIb8Tj7U-btdOkmt4OFA_11_0"></a><a id="Tc_6WEmifkqBUahbo_l4puCDw_13_0"></a><a id="Tc_lgpG2jL4Y0aIKpI6ipkoEA_15_0"></a><a id="Tc_pWmzdPkbHUScgLxJ2YhQ8A_16_0"></a><a id="Tc_zBrLEvj1k0K36g8RDVU2Jw_18_0"></a><a id="Tc_6m1inMoHPEKmUSQsI1PMMA_18_2"></a><a id="Tc_PdjJKhEIT0KyoZaLCQrctA_18_5"></a><a id="Tc_ntBhUjd5t0-P2e7UEFiNLg_20_0"></a><a id="Tc_q7dzex6u00WTcjvh3ayPkQ_22_0"></a><a id="Tc_przAD2WiGUWq5uo7YP7JNg_23_0"></a><a id="Tc_hnzuCGxNr02R9d_YULppWw_23_2"></a><a id="Tc_Rif1bxgpvkeaGeahIHXOGQ_23_5"></a><a id="Tc_x_HEEbZ5f0Sc4PT6ERqhug_24_0"></a><a id="Tc_2UzbGo9PakmSojGejNgL4w_25_0"></a><a id="Tc_JUPBfGB2R0KfWVndQo7YFw_26_0"></a><a id="Tc_uSXdw7976UC67f-tV2Iuqg_27_0"></a><a id="Tc_WZciwmMIHEOFPllpGnaz_w_28_0"></a><a id="Tc_ap9jWc0HD0qh0SFS2PLSCg_30_0"></a><a id="Tc_pFA8seh4M0eLWl1BK2fkHA_32_0"></a><a id="Tc_RT0KSwgGpkGYzGkxcpyu4w_33_0"></a><a id="Tc_5-u_stK4dECO6OmpY2lRog_33_3"></a><a id="Tc_0LlwoPfoPUuLDJuT7WpCGw_35_0"></a><a id="Tc_pEOzo-4_DUWQr-u1HLEgDA_37_0"></a><a id="Tc_yPXWSC4mj0m_03RI9bfzXw_39_0"></a><a id="Tc_EohHE3vMLUelubeMDmY1Wg_40_0"></a><a id="_038586ab_4e0b_4763_9a55_e93b246090a3"></a><a id="_038586ab_4e0b_4763_9a55_e93b246090a3_2"></a><a id="_038586ab_4e0b_4763_9a55_e93b246090a3_3"></a><a id="Tc_YRV3tKr80kWtP92yK2TJGw_41_0"></a><a id="Tc_oTJjT437M0eeWZdCPR4GRA_42_0"></a><a id="Tc_b8rlkQJ8O0O10fIRp9tJtQ_43_0"></a><a id="Tc_L5D38mx65EWpBtMduKbWyw_45_0"></a><a id="Tc_1I3uHGg4ZUORh3tbJtYP4Q_47_0"></a><a id="Tc_ZbhUI2HbG06DdXnmoZ0VrA_47_2"></a><a id="Tc_qx77B8WVAki_VRN8ASvxEQ_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_3-XjeG44bECB1u2eSjVOmQ_7_3">13,500,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_cT-nNZ74jE28tvs7UFhcKQ_7_6">28,371,828</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_kUZHmBCEREqNZ2JTjClR7g_8_3">7,875,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred license costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredCostsCurrent" scale="0" id="Tc_K91UeZGtGkGheGea0eYwfA_9_6">1,600,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">License fee and expense reimbursements receivables</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:LicenseFeeAndExpenseReimbursementsReceivables" scale="0" id="Tc_YklHRmxhF0WD29k7JaDynw_10_3">960,180</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:LicenseFeeAndExpenseReimbursementsReceivables" scale="0" id="Tc_jxw8pwHTlki0hJnVFcrWfg_10_6">2,966,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_1uZF7tjOC0etGEAPPiz6Zg_11_3">1,123,289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_SYPZxRvm80a10RETKvEmWA_11_6">453,478</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_Izt1rAMoIkWirQelJEMUhw_13_3">23,459,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_U3KtfYQ4nUOCGpnmAAWRKg_13_6">33,391,345</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_x5OfE-YNzkaMbhlqdIcOWg_15_3">1,413,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_adwOYQZEfEun_3t-vo1V1Q_15_6">396,380</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_AyzLhxZK6EivkGb0dvhD7A_16_3">119,035</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_zhnqdb2ZKUKmHlnEbKsKpw_16_6">119,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_EzClQXZaNkOdRXl0NU-EVg_18_3">24,991,576</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_pCA2uTEK6UmcGzAG7e2zrw_18_6">33,906,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_8-LVUzus70GeC-1os49LHg_23_3">1,684,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_evw476ZBeUWLqWSS9eaWeA_23_6">1,461,665</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" id="Tc_fZsXhTOyTkSSLP98K1omZw_24_3">1,184,236</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="0" id="Tc_f9Cn-QLa60i2eqhGB0wB5Q_24_6">1,150,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedExpensesAndOtherLiabilitiesCurrent" scale="0" id="Tc_Qny33pAHyEmFC2S8p6c8RQ_25_3">552,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedExpensesAndOtherLiabilitiesCurrent" scale="0" id="Tc_hfn-xCnKRkeQ2A4gdEeRJQ_25_6">1,480,692</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred rent - current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="0" id="Tc_qWW2AaF1502O0N2dWQyivg_26_3">16,037</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditCurrent" scale="0" id="Tc_rM_1mWqfzUC7awf5voqkog_26_6">7,809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred license fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_HFR-z447fEq2bz7EiT8ZoA_27_3">10,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_ql-C_mzsW0uA96wbksnvwA_27_6">14,000,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Notes payable - current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_muUvt3dQHUqS0p0XcGUyxA_28_3">7,282,037</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_yF9n__jtjkKvvljv30MFjg_28_6">97,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Current Liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_R8lU7_dXzUCQ4UMbCo1ZZA_30_3">20,719,379</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_LooyRWh8f0ev3Wrn2st8zw_30_6">18,198,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred rent - non-current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="0" id="Tc_3Xd22g3B1kWaZ4_hMXCOzQ_32_3">26,059</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="0" id="Tc_oeSqz8kCw0iXJlQC5aQYqA_32_6">38,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notes payable - non-current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_bI71TxB0vUid-JwofD7wjw_33_6">365,814</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_jvxFrugoIUqGz2OmTSFalg_35_3">20,745,438</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_udIi5jwV40-Eypbvd90DJQ_35_6">18,602,875</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note&#160;7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; Equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_qiYh8uv0r0i29yFsRyo3LA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_LCukT05TUUWyvfdxFdPR7w">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_RR1I5ompQUmaT-ogSQUZ3g"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_ZXDCww9jU0yR8THuHLI9TQ">6,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_m-LKO2gqz0abvL1Fj_0gjA"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_TNJkaMheikmRpQxrLfyL1A">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2021 and December&#160;31, 2020, respectively</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="Tc_vQN8KEUaZUuM5UU9rH_otw_40_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="0" id="Tc_9xzexkj6cESnm4cvjVIDiA_40_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_M1Zr43Jl5USoweuDQOxIcA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_v8gKGkI4o0eHVLf6H9yQEQ">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_daTa2QGTjEWyC0FkS1_vTA"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_D2fBQMaYh0a_ORi6_eTsRQ">90,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_3suNuEXbx0mMAO_ZCpTc0Q">25,963,185</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_7R6E0m60pEyyfcedNeLEEw">24,978,585</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_3Hdz33n-GkW0wPKEq9SnqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_d9weVYGAekqwmy1K-j8EiQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span> as of September 30, 2021 and December&#160;31, 2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_zVI8P9d9HEyx5IkksVOhbA_41_3">2,597</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_pAAZPID3EEqpdHty8f0tbQ_41_6">2,498</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_3OqeTv9u6EqJ4anXtTSCXQ_42_3">97,446,125</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_EMVDYjR7bU6SSfmU4LBTvw_42_6">92,742,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_0yRthFfhoEGtYo5CAf_P-Q_43_3">93,202,584</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_lC1psxqnEUSCECg6hZQDxg_43_6">77,440,919</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_zdIFNPEUhUiq28gIX_u2Tg_45_3">4,246,138</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wIdu8vuzCESkDs322D5HLA_45_6">15,303,885</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Liabilities and Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_2CW9u7KOfEaIW6HExM5fNA_47_3">24,991,576</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_b1A6v7mODk2hTyZoCDcD4w_47_6">33,906,760</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5e13d45c_561e_48a7_9c5e_8500419d04e4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">EYENOVIA,&#160;INC.</p><a id="StatementsofOperations_269542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bef895b5_55e1_4758_b377_6e1ce91abe47"></a><a id="Tc_M0iGsF6Oe0-VP6k3WcAJBw_1_2"></a><a id="Tc_m8CLy11EPkCPACAPpwsW2g_1_8"></a><a id="Tc_P8t7Wv5wKEiv4rrVM-rmwQ_2_2"></a><a id="Tc_JRhPUTNdVUeTVCzkSuUvMQ_2_8"></a><a id="Tc_KBCRhD78o0-mZmQL2emi6A_3_2"></a><a id="Tc_N7MXlEuGwEu8bDl1XCLg-w_3_5"></a><a id="Tc_MSKITu2usk2doExY7zlmcw_3_8"></a><a id="Tc_x_r-sf9880Wupn39VWofNw_3_11"></a><a id="Tc_FxYrn-T61kq9iRV3kNbShQ_4_0"></a><a id="Tc_ojfw0fwdGkquKbvs4fXFcQ_5_0"></a><a id="Tc__JZe0pS40ki9bvTNFk9FmA_5_2"></a><a id="Tc_FAyVzqE6r0uoYvxZHkMNag_5_3"></a><a id="Tc_FBmED0Dj5k2zCvpvwjwDSA_5_5"></a><a id="Tc_YB0NCVUJFEKjSaECA4odqg_5_6"></a><a id="Tc_j7-5cjsWoESJxVewVp-Qew_5_8"></a><a id="Tc_5wjDhe4re06OjVvLdnkKhQ_5_11"></a><a id="Tc_uauVMI54DkWDb_9ftwocTg_5_12"></a><a id="Tc_EjprXbtNUUiI0rsyF7Bd2Q_6_0"></a><a id="Tc_nGeXXvuxwk-vrVtyXUoeoQ_6_3"></a><a id="Tc_T_Ok2XDKkUK76vFxLDDbCw_6_6"></a><a id="Tc_6xvpSCO17EK0gvHL_NxdIg_6_12"></a><a id="Tc_gExasJtDsEyTgFhoIxEFnA_7_0"></a><a id="Tc_Zv33Sr7vqUedE7-5srRL6Q_7_3"></a><a id="Tc_5O1PV7a8LEaNKlkxf4hBTQ_7_6"></a><a id="Tc_tG-9nXx-FEqOef9EeY5wKg_7_12"></a><a id="Tc_Yw1gTnWs9k2SeeRBYWIElg_9_0"></a><a id="Tc_1FPlY8GgNkG8I--_7hu13Q_10_0"></a><a id="Tc_IzXgugZfiE6qfyXO_zYx6A_11_0"></a><a id="Tc_6v20J0igCECBCfzZiJVgmQ_12_0"></a><a id="Tc_wKH8h_EDNki4ISeU6GdxyA_14_0"></a><a id="Tc_FmgrcivhpE2PaMUImKlUcA_16_0"></a><a id="Tc_pMdBNzIG4kCrLNNgNumffw_17_0"></a><a id="Tc_YWg7jeFfTUaurMYsfeNB_A_17_3"></a><a id="Tc_ol45UQ5KIUaQQgYs_o6gdA_17_6"></a><a id="Tc_jfgRylOzJ0uUkleqlyuFBg_17_9"></a><a id="Tc_VsYNRuECJkCoii8U-HnjwA_18_0"></a><a id="Tc_crRz87HNdEapfvHPAgfHxw_18_6"></a><a id="Tc_vi5vQkObGEKBroWU8G9dmA_18_12"></a><a id="Tc_dH3pbSCORUi3VPd5BZID-g_19_0"></a><a id="Tc_7f5bJO8C2UqapxaekmTqUg_19_6"></a><a id="Tc_S5kmP9smlEmWBISk8P47-Q_19_12"></a><a id="Tc_NUnLf65X40S6pJgDJA_ScQ_20_0"></a><a id="Tc_urvxQPR7oEuY8LdhGdPWBQ_21_0"></a><a id="Tc_wgvM3pDiukGB8N0751SYbQ_23_0"></a><a id="Tc_G06SUZtBckC_BYAKis9l0w_23_2"></a><a id="Tc_de6mI02xsU6JfzR6NWXXGQ_23_5"></a><a id="Tc_hLyQtNiI4UC-q_OvJpJ0wQ_23_8"></a><a id="Tc_vTRixB3b0Eaps2WeHiEG4w_23_11"></a><a id="Tc_zWmfodw1nEyianekeSr2ig_25_0"></a><a id="Tc_hRxIYgbwZ0qp-mOWYzDpPA_26_0"></a><a id="Tc_8fB2F89LyESlzQ7ZaWaPuQ_28_0"></a><a id="Tc_4U_-c2g6nkmZyHob823o7Q_29_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Income</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_o-DyEGwq5kSYNvHxk4hs4w_5_9">4,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="0" id="Tc_0V9NQ43RMUS0-m5cfwmS-A_6_9">1,600,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross Profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_6ApBe-2BzEuL4_kSeqH4Aw_7_9">2,400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_mRmih1t3FES0HAN1WkdBBg_10_3">3,470,188</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_bmp1oCMOWECmw1cnvvc9pg_10_6">3,363,759</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Q6A0vPRKVkWEvw1pvDIhjA_10_9">11,334,296</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_pZDMmGnb1UG7AKDE8BigPA_10_12">9,913,296</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_nQCPq1jOMUqSt4JQC643Mg_11_3">2,435,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_3NhHtfzaVUqAxvyIEMOyXg_11_6">1,728,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_BkzJ32F9OECn0FqcdGvFRQ_11_9">7,082,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_fJ1gtn_gC0e1PZ9M1DpJPA_11_12">5,669,311</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total Operating Expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_NbdNSURPYEmyN-1CADGvuA_12_3">5,905,329</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_cpMRaDkiAk66EBHycAHB1w_12_6">5,092,125</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_1Uc37T82e06Cyu8OWhhFzA_12_9">18,416,955</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_3EzixadLQUGlIrY9YxZMbw_12_12">15,582,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss From Operations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_nAL-80rpkUWSxWuoR8S2XA_14_3">5,905,329</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_pZUVOB4cckuPR_TLIzGHaQ_14_6">5,092,125</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_V0ZpiJa6YkWMvQnloANS9Q_14_9">16,016,955</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_rkwNUQr4BUegXKSo6u04Kg_14_12">15,582,607</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Income (Expense):</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Small Business Administration Economic Injury Disaster Grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:SmallBusinessAdministrationEconomicInjuryDisasterGrant" scale="0" id="Tc_Z88jJy-5j0u3NEocP2442Q_17_12">10,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Extinguishment of PPP 7(a) loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Tc_0yIW0LvkHE29CmrMyfZRFA_18_3">463,353</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Tc_O5exew2jrk-0kipSxJfb3Q_18_9">463,353</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_NAlYBinpcUSOO9OLXu8WKA_19_3">8,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="0" id="Tc_VkPauxrXU0C79nQS4UwF3A_19_9">8,010</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_hMbcq1aHmkaRsmav4SVeHw_20_3">119,212</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_Aql3yePTNE6VCUSLRvBJUg_20_6">4,945</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_xtYB19cskEK9JVPJjUtcHA_20_9">202,407</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_gTc5T6D9aUCcEwEwUb3Dkw_20_12">14,977</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_y87_9cNvjEKhGBPWoRsvBw_21_3">600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_58QBlQMT30y5qL0ehUfTYg_21_6">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_R9ciFWu7NEqtMFUOUXoM6A_21_9">2,354</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_dL67z9uzM0-RvbRXSXM3Mg_21_12">24,579</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_9nD-LWhTo0-nDN_iz1AJSQ_23_3">5,568,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VtmAsU87CUiWJRsy1tR4NQ_23_6">5,096,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_PveSerKpWEGiNbLEA5978w_23_9">15,761,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_TutV0VZ9XECQOuxsJF4CmA_23_12">15,563,005</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net Loss Per Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">- Basic and Diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Zpy7aVwBy0-Lv8WhOHXNTA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_I5Tax7rDdU22rL0PwRebKQ_26_3">0.21</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_cbG6_6ZmOk-FkJmzEa1rHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_SManfofD80un1wSN1LsNlw_26_6">0.23</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_pjIxGAhFRkavWEUwCGLB3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_lPEb8vlqkES-LB8Q0foM2g_26_9">0.61</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden__pXBRFNzo02E8aJpBpfeaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_N_7g5mbomUejqA0OsmqPrQ_26_12">0.79</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted Average Number of Common Shares Outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">- Basic and Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_RLPQlewIj0imHN5XGiSXbQ_29_3">26,053,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_K_HBzFS0bUmL2nJAIL6bCA_29_6">22,206,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_h8mJaP5eN0yxu74QWfjaQA_29_9">25,773,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_B9ZE5myytkW7rO-AEQ6hQg_29_12">19,802,999</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:8.05pt;"><a id="_5993fe26_edc3_46ae_a96a_43c66debf252"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">EYENOVIA,&#160;INC.</p><a id="ChangesinStockholdersEquity_934028"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Statements of Changes in Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><a id="_0b63339c_38aa_4633_9799_857bc262154f"></a><a id="Tc_XD7gTBWf6E-F9xxZiYPLSQ_1_2"></a><a id="Tc_qBt-67rUu0SdRDFvfBhtQg_2_7"></a><a id="Tc_oyDnyg4u20mh_ZCFM5BvOA_2_13"></a><a id="Tc_rMdUAUOk6keKQgrl-KAUpg_3_2"></a><a id="Tc_l6AosfQQqUO7K12X0gM5wQ_3_7"></a><a id="Tc__XhUzepoWUiBm1r8CmYn0w_3_10"></a><a id="Tc_8VTqQD_6mkiaoxMEAqokHg_3_13"></a><a id="Tc_LrTS0GPQmUGDvADkGBBrGA_4_2"></a><a id="Tc_hDPvBeaf0US3-fBrHz67fg_4_4"></a><a id="Tc_MRvDWe8imEufIOUvnwFBwg_4_7"></a><a id="Tc_QDKqP2M5s0-OvEO2sRIFHQ_4_10"></a><a id="Tc_IONGEgdjQEilqdD0utb_VA_4_13"></a><a id="Tc_yPCohSgcpUGiUJezeuHcvQ_5_0"></a><a id="Tc_AeoGN3z_akSCUbf7xLl81Q_5_4"></a><a id="Tc_ZXKLvRQjJk-sTDNWsjmmTA_5_7"></a><a id="Tc_TnANZUr0pE-mK8-ehROmfg_5_10"></a><a id="Tc_xalGj8EiC0GyGQvHWKPVaA_5_13"></a><a id="Tc_r4pexSLBqE6LL-elo1-3Eg_7_0"></a><a id="Tc_sXBD-Oln5kideb-kYNZ1iA_7_11"></a><a id="Tc_K14cSNEphEqq6dv1lKfkHA_9_0"></a><a id="Tc_YLfazMwVFEmWIib0z-rWpg_11_0"></a><a id="Tc_UEwB0zEFW06hMsZaNFuhHw_13_0"></a><a id="Tc_GwoZJimYzEqasjhj6LJ1PA_15_0"></a><a id="Tc_BqPfXK_9g0uL3ytsyKCtDQ_15_11"></a><a id="Tc_vtFUPYDN_ki7btk_9b0V9g_17_0"></a><a id="Tc_aiHkwXbYg0mB3SqMwJcu-w_17_11"></a><a id="Tc_yEBr-xIlV0iHZBqVRrFFuA_19_0"></a><a id="Tc_xsv5qDLEOEiIr7r-l2RJ1g_19_2"></a><a id="Tc_b9PjIsGpJ0ax6qdOPCxn2A_19_5"></a><a id="Tc_Zl4ThJFz3EWeY0DX47xRXw_19_11"></a><a id="Tc_660-ZtZwOUa0IeGg45Mexg_21_0"></a><a id="Tc_KSdhOQlgsUuxeY8G_-memA_21_2"></a><a id="Tc_DXCCUVvUd0KURTdLKzVDOw_21_5"></a><a id="Tc_ivnRk3-0fEiTMVRAbNQJwg_21_11"></a><a id="Tc_0Ub45mLYp0eLZFE2XoLR5A_23_0"></a><a id="Tc_F1gJ_LrP3Ua_67wId6n7Dw_23_2"></a><a id="Tc_QQ9WjgihmUCmuEpwAEPAgw_23_5"></a><a id="Tc_EDuqPGrnNEK6vGLqc9iV3A_23_8"></a><a id="Tc_38YgLbL8d0yLda6EbyLgpA_25_0"></a><a id="Tc_O3SO3zuEIEa3eH8bJ-oIRg_27_0"></a><a id="Tc_nVo2QoKZREq5I-7zBAHQxA_27_11"></a><a id="Tc_GPiawWSStU-2qf0HhnEavw_29_0"></a><a id="Tc_rvZ1qE_vXUmChOVZBuqUTA_29_2"></a><a id="Tc_ZZLRNCG6pU-4ZM2-PL9YJQ_29_5"></a><a id="Tc_n-krRDTF8UqZf20xvQqhvg_29_11"></a><a id="Tc_HPLN43DavUCxG56PcfTfOQ_31_0"></a><a id="Tc_2qq2bmCcpkqdezNQ2R8nBg_31_2"></a><a id="Tc_k6E52q2n2U2H2tiaWimmCg_31_5"></a><a id="Tc_evp5c4Xyskmtbjzh11MLBA_31_8"></a><a id="Tc_Xe-GOUf-U0WUQ-MPe0rQog_33_0"></a><a id="Tc_Ut-77ckk-ku7wjQZafHOTw_33_4"></a><a id="Tc__Cou2movuE6p5LYqGdP_mQ_33_7"></a><a id="Tc_5_SF344oAU6VtcEmoJdSgw_33_10"></a><a id="Tc_2Ofqdp1sb0qu5tlo9AOjMw_33_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:54.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Three and Nine Months Ended September 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance&#160;- January 1, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ddZtvRdPok-Ar8oGlz4d_g_5_2">24,978,585</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZaoKxqhAGEezqShN-KY2KQ_5_5">2,498</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kth875WnPUKg3agMaWI0Rg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_85oNl1d1n0ig6FQuur5bVQ_5_8">92,742,306</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j4B1KYQ0MEWecgQLPbVQNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_flj3AoqmRkas7v6X_hBtdA_5_11">77,440,919</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__4qFm-LH0EmcG-HgwV4Hig_5_14">15,303,885</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_btUNqS8cqEO8u58x8vC9lw_7_2">644,992</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_gsiXpCGhUUKpOTv8ss_qjw_7_5">65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_LwUNtazIRUKeu5k11Fz3xQ_7_8">1,530,925</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_D5qLIXcUIUCpYn4YW9vibQ_7_14">1,530,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_OnCKMCWKmUiSPOHA4PSyrA_9_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_g-OSBrFhkkuCOD5eyNMvDw_9_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_6cv70tXTJE6tVd3x-swFNQ_9_8">656,913</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_3AfqC5hZ7kmh1RV1ArVh8Q_9_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_qsxd1AYV7EqnUPkTjbezfQ_9_14">656,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_7fnv2bZUjkW0JF71ys6RWg_11_2">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_MmyGqiRRJ0iZCqIlfA5G_Q_11_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_BIEeMqxvdk2ZBqv6AIj1Yw_11_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_GFKBrz6Ss0qlkqRlNRv4AA_11_11">5,351,667</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_fGIH6srWIEmyE25N3BwFSA_11_14">5,351,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance - March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_J_unuOIl5062wUSe75J25w_13_2">25,623,577</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_I0uMnwUJfE6-U4TZGIDw-w_13_5">2,563</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mQSiaUfq50W0yaz5UztvLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xB2ERdGXw0S5L_Mt9S_3Xg_13_8">94,930,144</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_xmAWV6mUSKUNDQxJrP0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_i221d3KMa0GFjhnjamjwmQ_13_11">82,792,586</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_1iHEOc5UZ0iZyDD69rBDVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_oUaVSe53OUuXG9A4H6N3Ng_13_14">12,140,121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_FE3OD-pBDECzyIpiMXBgZQ_15_2">232,022</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_4Of6Hfn8W0GJdD6qusvk5w_15_5">23</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_ljER9wmlW0em5UftiH9mUg_15_8">572,978</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_g66dZkwcBkWGev1Qdc30vQ_15_14">573,001</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg" decimals="0" format="ixt:numdotdecimal" name="eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" scale="0" id="Tc_-sDPcR7KN0GQdmQDLWgs1g_17_2">91,047</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_aIXiFglvmESHgqDW6MYHKg_17_5">9</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_vrQufILv8EqRyFkDCm4SFg_17_8">130,081</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_UufV-0CdBU61ZbQH4DLVlw_17_14">130,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of SVB warrants [1]</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_kzbIalpKPk-fHEULMdpRUg_19_8">351,390</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" id="Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14">351,390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_GcHsmRSK6UCxlGDO_YQOJA_21_8">637,355</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_O81CTKW9Bke1uu25mhkDSw_21_14">637,355</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nzq8FK4mAkKZ5R2RZ9KIUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_SL2tKBoOL0uKEbgxPF7IIg_23_11">4,841,400</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_xIH7Ok6n-Eil3RIQtBQWyg_23_14">4,841,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance - June 30, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ri-21ZSjXEul7xt3vK8e3w_25_2">25,946,646</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_2RPk1ipdCE20h3piiN_bWQ_25_5">2,595</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UIjArcXu4kWTOOHrTlosoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tSeUjSF6xUS-L82W12ujZw_25_8">96,621,948</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yoZZp1S-YkSK0slqbGBuYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_3gxC-7J9SUSX-xiQCQaT5w_25_11">87,633,986</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_2iIqhP5zKUSGnKrT3fT8EA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9s18nQQn-0mLRd_S6TmuWA_25_14">8,990,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g" decimals="0" format="ixt:numdotdecimal" name="eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" scale="0" id="Tc_KnxFSpWBWkmtqXg7ZVL4Iw_27_2">16,539</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_sxOaQRRyPE2R2AlAKQIOzA_27_5">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_Ts0YkrraW0OBMA_jFs0_Fg_27_8">46,710</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc__k7ByXTwzkCCpIX17Bx98A_27_14">46,712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_xZ63D6atvUOgvtWudEME1g_29_8">777,467</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_2jb1gyXn-0qBHR4bo4fe0Q_29_14">777,467</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M_Xp5Nb4D0mDo0QoESXKLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_nXo3DElmNUyKYMLuOgMdIQ_31_11">5,568,598</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_c1vp71J5Kk-m3DYRiQDHOQ_31_14">5,568,598</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance - September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Ukrorz3GnE2hwqWAt2DEuA_33_2">25,963,185</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_nZpgCUvNQEqEGzCzG7D7VA_33_5">2,597</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_egysx-a5s0CwPDQUHEvdqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_TAei0JqbdE-0TUjzxwarJA_33_8">97,446,125</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_166ZAmZBBki2ZJaq_2i7OQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_rc1owr4LOUaJHmFOmK4_jw_33_11">93,202,584</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gRzUKDa_Xk2wV9w-EHws9Q_33_14">4,246,138</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">[1] </span><ix:footnote xml:lang="en-US" id="_fd9dc05a_1c6c_48bf_a594_db51ef746b77"><span style="font-size:9pt;">Allocated fair value of warrants of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_KrTxAk1qZ0Cku-0-7cdjhA">354,539</ix:nonFraction></span><span style="font-size:9pt;">, less allocated issuance costs of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_GkcpGqI_3ECJMVBZLg7vQQ">3,149</ix:nonFraction></span><span style="font-size:9pt;">.</span></ix:footnote></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:8.05pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">EYENOVIA,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Statements of Changes in Stockholders&#8217; Equity (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_5f9e3c77_30ab_4eb7_bd1b_57fb6c0c7353"></a><a id="Tc_5d1Vxl9vzkOT9eSqnnoDYw_1_2"></a><a id="Tc_aJ7onCKMxk2US4o3ZHJmNA_2_7"></a><a id="Tc_PZeZsR8YnE6BfQogVF_GGg_2_13"></a><a id="Tc_vvTnleggR0KFsXktB3pGWg_3_2"></a><a id="Tc_hnzE7y9dPkmHWmBLY2Hpag_3_7"></a><a id="Tc_IpJzPYGsE0el7lbkCt-R_A_3_10"></a><a id="Tc_-Tr_HFx5akiZJ4VX2FX9Pw_3_13"></a><a id="Tc_Yrnhoq3CCE-_rnkqrjrStA_4_2"></a><a id="Tc_8qgcFx7CokOzLqR17W18Ng_4_4"></a><a id="Tc_af7EI_jB-keCTjJM7P4H5Q_4_7"></a><a id="Tc_IYYdBh5UpU6Nkk0BWdLjKw_4_10"></a><a id="Tc_t_pfEeWNiEO7PdsTkAxUqQ_4_13"></a><a id="Tc_pthkFC9OCUKZirNAhrX3lg_5_0"></a><a id="Tc_S3lbTy94eUqStsZynKKsRA_5_4"></a><a id="Tc_jbg5IYazN0OhrG2zQVI-jg_5_7"></a><a id="Tc_P-nk3LA9fEW6yYZFSXTXPw_5_10"></a><a id="Tc_s-juwSnC9UCS7ku2m6DOSw_5_13"></a><a id="Tc_10450pKm_kW4vKWWEuORoA_7_0"></a><a id="Tc_4qf7M4E3QU6I5TD5BgJ0bw_9_0"></a><a id="Tc_gREoPtMg8E29f0gvV2Mygg_9_2"></a><a id="Tc_46nUyh35dUGKTltt1n2KJw_11_0"></a><a id="Tc_JARy1svCcEeDXzz0xW6NYw_11_2"></a><a id="Tc_1-0lZuIkeUioEcatdxBnIQ_13_0"></a><a id="Tc_jTXPejHAOkqZGFF6k8zOuA_15_0"></a><a id="Tc_MHlxmF0EjkWVkkLlbDdh6Q_17_0"></a><a id="Tc_jAYLZEoHcUyUHu5RhDT46Q_17_2"></a><a id="Tc_W0SJzz_tBk-qUMP5CBpwVw_19_0"></a><a id="Tc_tkYrNZ4dzUG6m60CLv90aw_19_2"></a><a id="Tc_NVW7SFOqtU2vIB4dIpj0_A_21_0"></a><a id="Tc_XhBe4oTQCkyJ3Nren-w8PA_23_0"></a><a id="Tc_QqqbJLhv4Eid6ph67s_7IA_25_0"></a><a id="Tc_nKZzN61qq0yEaFmk9nkCGA_27_0"></a><a id="Tc_2bP0rLx_x0yvWT9L4wkNbg_29_0"></a><a id="Tc_DiIDrp7biUmoJtDY2TphuA_29_2"></a><a id="Tc_0laiqE8QdUyDn6JVWW0UJQ_31_0"></a><a id="Tc_8JZVM8IKhE-hCNpzWAhNiw_31_2"></a><a id="Tc_vWU2d1l2i0-WNu33V6x4Xg_33_0"></a><a id="Tc_u9EGp4NBRUO9QVUtI-tBbA_33_4"></a><a id="Tc_eV7Pb2AavEmgMUXDWJa5oQ_33_7"></a><a id="Tc_dWyOIRd6XE-9OmohgXlZPQ_33_10"></a><a id="Tc_BHEvLWDv90ed2gANXAQxnQ_33_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:55.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Three and Nine Months Ended September 30, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;- January&#160;1, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_9sS_bKc-OUeHr4v2jhPJwA_5_2">17,100,726</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cLxLD6lP8EaZTPvKuB3qng_5_5">1,710</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HJTe8zro2Uuqwss6XoUeeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xZo48uMMiEGkSRYmP8b9kg_5_8">69,409,949</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L_q-9Sd8ckKHkP5XYRlMzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_f9FfTCexWE2V4LPlqJrAkA_5_11">57,671,052</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_YdaELA5-GUahRhUBF_xRAw_5_14">11,740,607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants in private placement [1]</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesNewIssuesTwo" scale="0" id="Tc_D0YzUAQVWE62L_TShdiWZg_7_2">2,675,293</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesTwo" scale="0" id="Tc_IitobebuVk-v9Zwz1GQADw_7_5">267</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesTwo" scale="0" id="Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8">5,451,475</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng" decimals="0" format="ixt:zerodash" name="eyen:StockIssuedDuringPeriodValueNewIssuesTwo" scale="0" id="Tc_KIDooAWzYk6H1VhhxJeQug_7_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesTwo" scale="0" id="Tc_qOmJQXwe3keWplvbtt2sSQ_7_14">5,451,742</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_bBbnjkzySUWyImtQDP5Vqg_9_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_p-NVDrQOSUa00haZpcVJZQ_9_8">583,865</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_tHmQa4W8b02RtB08iC7ApQ_9_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_RX-eAyUQAUyL0QGuPX1jWg_9_14">583,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_NqylLaamKEuGAE07liyMUQ_11_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_NiSIVy3hzE-J_-Dw2-W_oA_11_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LMXx1W_FmkKzKC7wr0_guA_11_11">5,450,910</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_4FOMk7tu1Uqrfqz_sagJdA_11_14">5,450,910</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance - March 31, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_E_DVXdZ_w0ypbq9OnisC8A_13_2">19,776,019</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_BWjQpQejwUu5RVUMFSYGYw_13_5">1,977</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QsJXwwdhUU-D4UcQ-cvUsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9wmldDzZ10yE-HZ3_BQJeQ_13_8">75,445,289</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8iU0YDKFkWOzxWgCoFXPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Da1zJNCZ0kSZa1dPy0dxMA_13_11">63,121,962</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2020_vwX5UftH6k2nB0oxeBOzmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_HSQs17FPLEqgVLf2ybQBVQ_13_14">12,325,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants" scale="0" id="Tc_CKbbVDY3nkWY4cJK1UlXpQ_15_2">167,664</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_aFQGN5v_xEmkwInfFxWDsg_15_5">17</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_F0BCkH2vTku3frlHj556dQ_15_8">376,404</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ" decimals="0" format="ixt:zerodash" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_E_s1zLMmBEeYhihbFQkXCQ_15_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_x9-BhIOHhEaxK65ZLoO65Q_15_14">376,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_HQb4258s8USXka1h-FOvug_17_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_EYFQP6ml20KyI6pCncViRQ_17_8">633,146</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_t_J8b4wNZkuWOwbTolsPYA_17_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_bm66mAgQY0-NzDWfTd7vgw_17_14">633,146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_l1QQptVmbUaVr6PQAldVPg_19_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_OIbs5jBlOEOk4xXkblEpFg_19_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_0LtgLDP4eEWwRWsEVXOu2g_19_11">5,015,565</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_HFgeEU1N4kK69wQVRy-1Ww_19_14">5,015,565</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance -June 30, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_XCMSQkFV10aeFxM3Ua02dQ_21_2">19,943,683</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_iECKN5j-u0eUgTV0UJtr1g_21_5">1,994</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aERtWPLXHE-NyWVDKwVKKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_bSaBs0MhUkWl8Q3rLrKrwA_21_8">76,454,839</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8jVnW9XRk-de3gCif1Ngg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Hv_UktBQxUKKUTV31_pNRA_21_11">68,137,527</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2020_uk3nxzgTF02apB9F1dX2kA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xn503rF6l063OwS6YrZlZA_21_14">8,319,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock in public offering [2]</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesNewIssuesThree" scale="0" id="Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2">3,833,334</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesThree" scale="0" id="Tc_aHrCmOBr3UW1GniaD9mjIg_23_5">383</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesThree" scale="0" id="Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8">12,495,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g" decimals="0" format="ixt:zerodash" name="eyen:StockIssuedDuringPeriodValueNewIssuesThree" scale="0" id="Tc_O5vsiEfkEkOvZyoF8tznfg_23_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueNewIssuesThree" scale="0" id="Tc_eC2iacNYQUmPuhllN3b-WA_23_14">12,495,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc__CCAwIYOrUCMrYLNTzj0Hw_25_2">1,080,497</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_LlydPbzlf0uTprdabBAizA_25_5">108</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_lOOtOvw-O0qUCj_JBXYRMg_25_8">2,269,562</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g" decimals="0" format="ixt:zerodash" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_Jho_7bjHTUmlpohBRWsbNw_25_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="eyen:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_Clo-haOV1U-mln3kXHr4mA_25_14">2,269,670</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" scale="0" id="Tc_KMC_kLfAekGykq2pDGqdfw_27_2">26,737</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_MVAO2_aTuUKPu3MQRnguaQ_27_5">3</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_l0Ffsi3bAUucXP0KsV1KDg_27_8">52,134</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ctZdYdIuLUOByuFm7ZP-dA_27_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_I75CLA_ZAka32_aJuE9_wA_27_14">52,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_JaQwsmSWqkS71mFuVAN1_Q_29_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_M5Dlvn0XaUi5SZqjq_Ad6A_29_8">609,930</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_2o-1XRqo10ag2UQTZ4wNEw_29_11">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_1fkqcuwJxE64O6J4aCUAfA_29_14">609,930</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_lEE6AVg8nUeKdtQDgH1X2A_31_5">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg" decimals="0" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="0" id="Tc_uR4Fa3eUmESyOkdp5TNi9Q_31_8">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Z748-Pz0UkSiK-NphFJTfA_31_11">5,096,530</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc__LIY8hv3OUi6zQjhmdrbzQ_31_14">5,096,530</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:42.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance &#8211; September&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__iuTRLPSAkW1n5O7t7j5bA_33_2">24,884,251</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yBcNE8gOUES7TJ4F4HQc4Q_33_5">2,488</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_11APGkRcvEiinWn5XMPudQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_7rpsl4R2GkKPdffQexek9A_33_8">91,881,790</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZLzQ6a3ZdkCqP8h95qZo5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_XK8BTFQhp0aLw-44zIDUrw_33_11">73,234,057</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4kjIVsxrBkmTERE5D-koeA_33_14">18,650,221</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"><a id="_d0235104_881c_4a14_8667_794e7f38029a"></a><a id="_fed9494d_ad44_48d9_bfc8_c83c86933c81"></a></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">[1]</span><span style="font-size:9pt;"> </span><ix:footnote xml:lang="en-US" id="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"><span style="font-size:9pt;">Includes gross proceeds of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA" decimals="0" format="ixt:numdotdecimal" name="eyen:ProceedsOfStockIssuedDuringPeriodGross" scale="0" id="Narr_twYTPWezSESHljdz66lP_g">5,984,931</ix:nonFraction></span><span style="font-size:9pt;">, less total issuance costs of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_hRoAoToINUm2C8PztbxY2A">533,189</ix:nonFraction></span><span style="font-size:9pt;">.</span></ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">[2] </span><ix:footnote xml:lang="en-US" id="_d37eaf7b_983e_4a30_a376_18834d02315c"><span style="font-size:9pt;">Includes gross proceeds of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="eyen:ProceedsOfStockIssuedDuringPeriodGross" scale="0" id="Narr_uukQwcXJukSvhjhnTIWTIQ">13,800,002</ix:nonFraction></span><span style="font-size:9pt;">, less total issuance costs of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Narr_lpfdHwhDLkOqPjQVds2Qzw">1,304,294</ix:nonFraction></span><span style="font-size:9pt;">.</span></ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><a id="_2ce1fc13_74e4_4295_bbd9_24fab77c465e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">EYENOVIA,&#160;INC.</p><a id="StatementsofCashFlows_626714"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b1446f7b_6159_40b9_b8fb_36a63ce8b251"></a><a id="Tc_nVLbbLAJsk-Jwr2AhmQw0g_1_2"></a><a id="Tc_H0VwCtXg-kerseOasWQy1w_2_2"></a><a id="Tc_oNjsOCVPnEy8m3OGyJyq1g_3_2"></a><a id="Tc_PjJjwgqu2EOq646A19jdvQ_3_5"></a><a id="Tc_9f73sEz57ESd1CKeRQCG-A_4_0"></a><a id="Tc_HxbSYK1ZWUSTDOP5DHnh3A_5_0"></a><a id="Tc_2UgRcykX30KDpNhwaLT5Vg_5_2"></a><a id="Tc_YbXqPGYvT0aIVCS9xq34fA_5_5"></a><a id="Tc_lrqM1qiHX0mrz6d8UtoM-w_6_0"></a><a id="Tc_h0JDh3b_tUKOiR1MbY-5og_7_0"></a><a id="Tc_wJgJ6HvcP0meWclvxTWh0Q_8_0"></a><a id="Tc_dGR0WlNE_kubM90qrwdP9w_8_6"></a><a id="Tc_SgSPU05idkyl6GtYaDcaEA_9_0"></a><a id="Tc_AUo7_JW2Nk6lk5jKDYRnPw_9_6"></a><a id="Tc_Sh5DAvZdeUengiRd6RBmpQ_10_0"></a><a id="Tc_UDtOEuJwik6jYV9eOqbEgA_11_0"></a><a id="Tc_U9P96cMdPE2XsJwmCwvsNw_12_0"></a><a id="Tc_o6SPQy7p8k2i-iHot9CcPw_13_0"></a><a id="Tc_8hInF20gbE-pC5zGUo3bMg_13_6"></a><a id="Tc_bXAWLQj9iU298K_P58j7tQ_14_0"></a><a id="Tc_qbRus1SxfUasIdnsumZAcA_15_0"></a><a id="Tc_FgzxzVaMbkmIZFVvPbjpuQ_16_0"></a><a id="Tc_uqUEJlEaLEigjdH_vZ14iw_17_0"></a><a id="Tc_94HdDgR6o0WReGyBZ--Ahw_18_0"></a><a id="Tc_smy1DVaQjEWLKfPphrlsiQ_19_0"></a><a id="Tc_ZJvCj5XpGk2GQv5_c3F0hw_19_3"></a><a id="Tc_nq-c0al3wUO3cQCsc_TYyw_20_0"></a><a id="Tc_CHF87MlrG0C7UlBtHGG-MA_22_0"></a><a id="Tc_ekYpC8mo-E6cYGe5cFw-Ag_24_0"></a><a id="Tc_gHel00LXnE2KayN7HDwuAg_25_0"></a><a id="Tc_IJlyziOUhEKJGo76cfIzhg_27_0"></a><a id="Tc_cFn076_ZsEKufssDr45pQw_29_0"></a><a id="Tc_AelmhKYmnU665dn9NVJ5wA_30_0"></a><a id="Tc_r5trsOepuUOMlTH6ujf5eQ_30_3"></a><a id="Tc_pyQY5C98cUeMysWJIeZM5Q_31_0"></a><a id="Tc_zSrBwRPDO0aNg2S7jRwjKA_31_3"></a><a id="Tc_915t9nEjR0Wxm3yW3sQPcQ_32_0"></a><a id="Tc_YTwxgLNttESeELJwcRy5wg_33_0"></a><a id="Tc_uuNobcbU1kiafBD1ge6kuw_33_3"></a><a id="Tc__Oo1g1h5o0WrZ-1izQVOUw_34_0"></a><a id="Tc_1_GPZngl_EevWUqTcJbubg_34_6"></a><a id="Tc_9OBKVdM74ECT7kOUJvhyQQ_35_0"></a><a id="Tc_lMYUOQyqqUqMKTkhWWEdCw_36_0"></a><a id="Tc_fuuMuIkHYEqUySmV4etZ6g_36_3"></a><a id="Tc_vlqkxAvogEK0UUIoBaZFUw_37_0"></a><a id="Tc_y_MVqJt48Eid15WJuAxAQA_37_6"></a><a id="Tc_IlJ1eSyvmUe3KV00raadyQ_38_0"></a><a id="Tc_7W48mBYoqE6WpdetU-6B1w_40_0"></a><a id="Tc_qVShDzL0sUq4__eKzwvtww_42_0"></a><a id="Tc_lDY5DkHxHEmb776EYPgeAg_44_0"></a><a id="Tc_GNfohtAHwkGch1oFF0ORBg_46_0"></a><a id="Tc_2cxtHZipmkOQIDoaAoTpwg_46_2"></a><a id="Tc_h26XIM6c0E2YY4EZdCa8fg_46_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Operating Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_QmKPzV8XUE2t7YhVF4AG_w_5_3">15,761,665</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_7PhSrq507kOFX_9kBMHbJQ_5_6">15,563,005</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Depreciation of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_Xe-WUK661UGc2ChkXCNJuw_7_3">148,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_LVkQXbt890yYwzqXN62JwA_7_6">71,628</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Amortization of debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="eyen:AmortizationOfDebtDiscount" scale="0" id="Tc_v67zkYZ8GEGLFxyJ9bwwKQ_8_3">41,944</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Extinguishment of PPP 7(a) Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" id="Tc_8o_KPl22HE6EMBtOpu9vFA_9_3">463,353</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_5FrBlye0ZEWGt-tzegpCwQ_10_3">2,071,735</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_yS5uqsY_z0mjnia-8xJn0Q_10_6">1,826,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_tGUuTIu-v0OyuwS5Am6S0w_12_3">35,549</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_cRe_fA_1MkeO9a11ZcY0Rw_12_6">231,194</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">License fee and expense reimbursements receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="eyen:IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" sign="-" scale="0" id="Tc_3AcHih1bFEKaqgWNoaJ82Q_13_3">2,005,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Deferred license costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCharges" sign="-" scale="0" id="Tc_Wa6gcGbUkUGffIWkxdLb2A_14_3">1,600,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="0" id="Tc_ymSNxtIeqUybXI8jq-YrAw_14_6">1,600,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_wIdnBIWbskq2-AjFLnv4dg_15_3">223,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_51SNsOezO0WKKTqtVAkGEA_15_6">76,596</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_sYxMljifL0SfMV3mvY8HNg_16_3">33,564</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc__7HZvoJZQkuPXYlhBAbh2g_16_6">172,318</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_V1mHJoahhUyKz4lO2EkpTQ_17_3">928,356</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_83bfQytB60WvXxHiEpsWww_17_6">106,471</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Deferred license fee</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="0" id="Tc_IdUVHLSwkkmE3XNvVaZ_vg_18_3">4,000,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_-RVHTP0WFkKsjAoLi5qp-w_18_6">4,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Security deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" sign="-" scale="0" id="Tc_kgkHsNV5s0qObFfXrtJLZg_19_6">1,235</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Deferred rent</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="eyen:IncreaseDecreaseInDeferredRent" sign="-" scale="0" id="Tc_NoKi1rlp5kOnKdmzvafpTA_20_3">4,397</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:IncreaseDecreaseInDeferredRent" sign="-" scale="0" id="Tc_Xmb0lEo9uUqoq1Bnmfcxug_20_6">1,119</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net Cash Used In Operating Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_FLYZQ64KcEi-v4QhDS2RKA_22_3">14,997,807</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_lkr43TyB20Ck45qTltQ44Q_22_6">11,853,369</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Investing Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_34eExlTOlEKmGb-uyq7o2w_25_3">1,165,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_IeIztb_ar0e-cBtOGxAOBA_25_6">202,046</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net Cash Used In Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_2FsGSzmfkUGMDOg3vxivmg_27_3">1,165,066</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_569ortXS2EyCep0ZoJ6nqA_27_6">202,046</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of common stock and warrants in private placement [1]</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="0" id="Tc_9MTARuC3fUqgCgb-kF9CBw_30_6">5,569,136</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from sale of common stock in public offering [2]</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc_ZDtvfvCeAke1PngL021z3g_31_6">12,734,002</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_73HZ-NqDi0is-7D5mjdUBg_32_3">2,103,991</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Tc_lscrE8Ff0Uam8xSjlvQpag_32_6">2,646,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from PPP 7(a) Loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:ProceedsFromPaycheckProtectionProgramLoan" scale="0" id="Tc_0AH37rrvp02wFLzVS6HwYw_33_6">463,353</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from SVB loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" id="Tc_hxhkobWF1UiR5MdWqDFjHA_34_3">7,500,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Repayments of notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="Tc_DJwkiEV7RkCA6VO2lGqITg_35_3">547,259</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="Tc_RU8kJXs0zECsv32Qh6Fljg_35_6">368,289</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payment of offering issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:PaymentsForRepurchaseOfPublicOffering" scale="0" id="Tc_UHHSikV_QEK236Gn0UlNIA_36_6">329,038</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Payment of loan issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Tc_OAV8IepF_ESpnOEeMbFS-Q_37_3">66,618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_Ci8vDADnfECckNlmfPQVkQ_38_3">176,802</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_aRthHd8vx023A3XLUhKGPg_38_6">52,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net Cash Provided By Financing Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_Cw_wB5E8aky1JBVxUyCTCA_40_3">9,166,916</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_UlM17XWcd0O36PmoPg3dRg_40_6">20,767,392</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Net (Decrease) Increase in Cash and Cash Equivalents</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_6DJI5rdvekCTlrN6_fYmjA_42_3">6,995,957</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_g5-AdV3T2k6i6AzyruQ1Cw_42_6">8,711,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents - Beginning of Period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_AHoEZ9m23kK42OjKp606Ng_44_3">28,371,828</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_WObSOcEsV0W4i30R9V5eQQ_44_6">14,152,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents - End of Period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ighRnSIVC0yGBJMFJibIXA_46_3">21,375,871</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_BFPxRKWOE0uYonywtrUaHg_46_6">22,864,578</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[1] <ix:footnote xml:lang="en-US" id="_979b107d_26ff_4430_be91_8b7b2590c736">Includes gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ" decimals="0" format="ixt:numdotdecimal" name="eyen:ProceedsOfStockIssuedDuringPeriodGross" scale="0" id="Narr_lYVwHtS_FkGAmxEoVbWhmA">5,984,931</ix:nonFraction>, less issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_UeTveNfUekKkaoEJY6JvSw">415,795</ix:nonFraction> deducted directly from the private placement.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">[2] Includes gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:ProceedsOfStockIssuedDuringPeriodGross" scale="0" id="Narr_qCxnzFcBDk6mYD-VwJRPqQ">13,800,002</ix:nonFraction>, less issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" id="Narr_siFoFsfSwESL6NdIzidzzA">1,066,000</ix:nonFraction> deducted directly from the offering proceeds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">EYENOVIA,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Statements of Cash Flows (Continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2288280d_780d_4d7f_bc77_1fe3123257aa"></a><a id="Tc_4i25Z-51CEyRof_wN4uWbw_1_0"></a><a id="Tc_gEJbZ5Zh2E6G-0mmp2livA_2_0"></a><a id="Tc_MnS-qQ75B0aZ1Gbe2Nksmw_2_2"></a><a id="Tc_GQffulRhVEWIQGUL4uuPzw_2_5"></a><a id="Tc_cU2-LLe0vEmWuCgqVKq5-w_3_0"></a><a id="Tc_XGrQA6NUDE6OVhhjlv1sDA_3_6"></a><a id="Tc_VyUTakZflUaP2wlP_pT4Eg_4_2"></a><a id="Tc_0Ssa_sOsE0yl1AENx2cFRA_4_5"></a><a id="Tc_x9jee97iBU-shE0fKTXoAA_5_0"></a><a id="Tc_TT3fy9EssU2Ph6jPIdyUrw_6_0"></a><a id="Tc_rXc3x_XBvUaTmBFAn2Gr8Q_7_0"></a><a id="Tc_VvIjxIuWQkGAQq7zrAQqeQ_7_2"></a><a id="Tc_3zHC4BjbHkynRNDyEuOWQQ_7_5"></a><a id="Tc_lUymXZQx_kWax9EOGbNwnw_8_0"></a><a id="Tc_JkP2vlOMREi1GKRoidaSEA_8_2"></a><a id="Tc_QM4bu2i0CESI1hB4feyfwQ_8_3"></a><a id="Tc_VThjcV-TRECCbWiKQU22VA_8_5"></a><a id="Tc_AHRhmzrI7UClCToWWC8PqA_8_6"></a><a id="Tc_uWNl3QfO1kad1__QKNXtEQ_10_0"></a><a id="Tc_pacxKJLywkuVDdw5GPppRw_11_0"></a><a id="Tc_jSmby9OAvUOLyf4RL3ZiaA_11_2"></a><a id="Tc_Cm9VHtYzJ0Scpq_Fupd5SA_11_3"></a><a id="Tc_Qpr6Tnnz2U-Kf-x0fuVkSA_11_5"></a><a id="Tc_7-ctA4pJF0-neiHy7Yta3g_12_0"></a><a id="Tc_ur1ozyQGT0iASNJwSW3Vng_12_2"></a><a id="Tc_JHDdsYQxb0ucfJcF6XIPOA_12_5"></a><a id="Tc_VSHLGflevEaB4INl-D_TZA_13_0"></a><a id="Tc_rHk9O5tnGUWPem15eAWhCQ_13_2"></a><a id="Tc_RPakHJPalUq4ftv0QpuKdQ_13_5"></a><a id="Tc_RqXT3kJWWUeTCXXEDdEmUg_13_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and restricted cash consisted of the following:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_-m1SsBeHJEqaAGoxcaFHaA_2_3">13,500,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_xyIPmubkTUK6By5enQYAww_2_6">22,864,578</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Restricted cash</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_vrsCAPnsdk2YnVxq7YtupA_3_3">7,875,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ejv9ws34rEue7u0nGGtJ_A_4_3">21,375,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ICdG4vPXzUWl-mC1wjcI6Q_4_6">22,864,578</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Disclosure of Cash Flow Information:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid during the periods for:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidCapitalized" scale="0" id="Tc_7NwLq-mxqUaK80rBcDToQQ_7_3">131,839</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidCapitalized" scale="0" id="Tc_uGPtyQB3NEqAZ7kFkeNmjg_7_6">7,961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental Disclosure of Non-Cash Investing and Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrual of public offering costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:AccrualOfPublicOfferingCosts" sign="-" scale="0" id="Tc_yzCpounE-UavJiWlnVaZwQ_11_6">26,650</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchase of insurance premium financed by note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" sign="-" scale="0" id="Tc_hAQpkWujZUOeOa_b5PXEqQ_12_3">705,360</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" sign="-" scale="0" id="Tc_aCf2FB00-0WoAtwB51XEgg_12_6">475,216</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Issuance of SVB stock warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="eyen:IssuanceOfStockWarrants" sign="-" scale="0" id="Tc_ZZTArKPl5EKSCeFuAeSXtA_13_3">351,390</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these condensed financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Note1BusinessOrganization_738474"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_u6GjaDCItEOjrOZqQAuWvg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;&#8211; Business Organization, Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Eyenovia, Inc. (&#8220;Eyenovia&#8221; or the &#8220;Company&#8221;) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP&#8482;) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system branded the Optejet<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="eyen:PercentageOfSuccessRateOfOptejet" scale="-2" id="Narr_BgLz7qxXQEa4HGNMdmdeHQ">90</ix:nonFraction>% vs. ~ <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="eyen:PercentageOfSuccessfulRateOfTraditionalEyeDrops" scale="-2" id="Narr_vFEFKj6VhkOl4Xwq8JBupA">50</ix:nonFraction>%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). Eyenovia&#8217;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October 25, 2021, the Company announced the reclassification of the Company&#8217;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, (&#8220;MydCombi&#8221; or &#8220;MicroStat&#8221;) as a drug-device combination product by the FDA in a Complete Response Letter (&#8220;CRL&#8221;) received on October 22, 2021, following a change in the agency&#8217;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. The Company believes that its other product candidates will similarly be classified by the FDA as drug-led combination products that would be subject to marketing approval via new drug applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2020 and for the year then ended, which were included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 30, 2021.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ujXUs1QEwEqeYslW-VcxNA" continuedAt="Tb_ujXUs1QEwEqeYslW-VcxNA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;&#8211; Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Since the date of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, there have been no material changes to the Company&#8217;s significant accounting policies, except as disclosed below.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:LiquidityAndGoingConcernTextBlock" id="Tb_cxoulCHZUke_AvMeB07Rxw" continuedAt="Tb_cxoulCHZUke_AvMeB07Rxw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, the Company had unrestricted cash and cash equivalents of approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_F2MrGBBIMEqkVW_4QCIeow">13.5</ix:nonFraction> million and an accumulated deficit of approximately <span style="-sec-ix-hidden:Hidden_eoq4WkYJv0u9e_1CVVO3Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$93.2</span></span> million. For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of approximately <span style="-sec-ix-hidden:Hidden_wncAopnaD0uKiQynCGwpOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.8</span></span> million and <span style="-sec-ix-hidden:Hidden_p4gZozmYS0S7balkCzNXaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.6</span></span> million, respectively, and used cash in operations of approximately <span style="-sec-ix-hidden:Hidden_ux28YaoNUkm5oVQ06xjkHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.0</span></span> million and <span style="-sec-ix-hidden:Hidden_XUae-FPTXkaSLR7npSF_nw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$11.9</span></span> million, respectively. Pursuant to the At-The-Market Offering (see Note 9 &#8211; Stockholders&#8217; Equity &#8211; At-The-Market Offering and Note 11 &#8211; Subsequent Events &#8211; At-The-Market Offering), the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_pIK--pQQT0C8bC_PClJDEQ">12.8</ix:nonFraction> million in gross proceeds and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="-5" format="ixt:numdotdecimal" name="eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="Narr_B05IdKqg-ECbepYsuU1Sgw">12.4</ix:nonFraction> million in net proceeds from the sale of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QMdUQ5Z96Ea4yA1k5U84bA">2,435,604</ix:nonFraction> shares of its common stock. The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to generate sufficient recurring revenues or the Company&#8217;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s ability to successfully commercialize its products and services, competing technological and market </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_967314cf_e497_43ec_b747_5d9b856ec43d"></a><a id="Tc_PWaXQyuHjECyj366S4Drvw_1_2"></a><a id="Tc_4r-C7RePTUC_aSh0X3a3Eg_2_2"></a><a id="Tc_cddjExirmUu5P2UJ8gtX3A_2_4"></a><a id="Tc_9RDkNCbP4Eimt7kyK9LWrg_3_0"></a><a id="Tc_bgeTArXHYEuG2am362gbkw_4_0"></a><a id="Tc_VJOD-flwVEOyXhCrA2AANA_5_0"></a><ix:continuation id="Tb_ujXUs1QEwEqeYslW-VcxNA_cont1" continuedAt="Tb_ujXUs1QEwEqeYslW-VcxNA_cont2"><ix:continuation id="Tb_cxoulCHZUke_AvMeB07Rxw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_Vuo7sfCwbUSOcdyMdr4TaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain executed agreements are recorded as Restricted Cash on the balance sheets, such as the collateralized money market account pursuant to the Loan and Security Agreement, dated May 7, 2021 with Silicon Valley Bank (&#8220;SVB&#8221;), as amended on September 29, 2021 by the First Amendment to the Loan and Security Agreement. See Note 6 - Notes Payable - Silicon Valley Bank Loan. In connection with which the Company pledged to establish and maintain a collateralized money market account in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" id="Narr_KJP8l3tFq0agojrf6sWYcA">7,875,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2021 and December 31, 2020, the Company had cash balances in excess of FDIC insurance limits of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_Uzvlf6xnpk6EBAkfDi0agQ">21,125,871</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_ZombU-NDfk623ihZZzD_ug">28,121,828</ix:nonFraction>, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_cHLQKCzD9kKQyoQ7wya9Sg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Net Loss Per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus weighted average vested but unsettled restricted stock units. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_QcfwPnAi7kig5vSGndg2yQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_4_qEKYrc8Euhf2_8V5qnGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_5sXBowAjO0q1MrzxcogoKQ_3_2">4,305,980</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_XlWzbj9LNU6tzxL4LlSTxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ukYhCaXNBUSTHpuTgV6i5Q_3_4">3,410,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_os_kMS_z0EKpasXd_445Ug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__4EPimuESUOYzU52gAMrZg_4_2">1,226,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_7Pfs622rJ02-2GjGaBo6sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_GzrSkTvZnECW7z0pMYK4Ug_4_4">2,095,993</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total potentially dilutive shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_95sTUD6b3UG-NPWzdIZFGg_5_2">5,532,163</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_g-LYzmPs3EWh2tw9VNRKYQ_5_4">5,506,533</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_6CbweD44D0qZ61A_lXka5g" continuedAt="Tb_6CbweD44D0qZ61A_lXka5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, &#8220;Collaborative Arrangements&#8221; (&#8220;ASC 808&#8221;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ujXUs1QEwEqeYslW-VcxNA_cont2" continuedAt="Tb_ujXUs1QEwEqeYslW-VcxNA_cont3"><ix:continuation id="Tb_6CbweD44D0qZ61A_lXka5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 1:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the contract with the customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 2:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 3:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 4:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Allocate the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 5:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Recognize revenue when the company satisfies a performance obligation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2020, the Company entered into a license agreement (the &#8220;Arctic Vision License Agreement&#8221;) with Arctic Vision (Hong Kong) Limited (&#8220;Arctic Vision&#8221;) and a license agreement (the &#8220;Bausch License Agreement&#8221;) with Bausch Health Companies, Inc. (&#8220;Bausch Health&#8221;). Each license has three revenue components: 1) an upfront license fee; 2) milestone payments; and 3) royalty payments. See Note 7 &#8211; Commitments and Contingencies for additional details.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_DBW5a6vom0e7vJSndHgssg" continuedAt="Tb_DBW5a6vom0e7vJSndHgssg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Recently Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13 &#8220;Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU 2018-13 effective January 1, 2021. This standard did not have a material impact on the Company&#8217;s financial position, results of operations or cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Recently Issued Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02 &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2019-01 &#8220;Leases (Topic 842) Codification Improvements&#8221; in March 2019 and ASU No. 2018-10 &#8220;Codification Improvements to Topic 842, Leases&#8221; and ASU No. 2018-11 &#8220;Leases (Topic 842) Targeted Improvements&#8221; in July 2018, and ASU No. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ujXUs1QEwEqeYslW-VcxNA_cont3"><ix:continuation id="Tb_DBW5a6vom0e7vJSndHgssg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">2018-20 &#8220;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#8221; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 3, 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2021-04, &#8220;Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&#8221; This new standard provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating ASU 2021-04 and its impact on its financial position, results of operations, and cash flows.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_5tyFTDU2bkeI_QiKpp0rhg_1_2"></a><a id="Tc_NBssKjlLT0OMmXxq9IFXsw_1_5"></a><a id="Tc_kGvxGhRIA0iFXCw0WhUqWg_2_2"></a><a id="Tc_wq0zgPU920uHo8YscKxFbg_2_5"></a><a id="Tc_R08Tz0UGUUWzcZC0n0l8rA_3_0"></a><a id="Tc_r6uHoUME40i-5IDgfdpESw_3_2"></a><a id="Tc_aYfDujzGukG_dkubJjqYLA_3_5"></a><a id="Tc__jXSAXl7WEqJXzNg_FfD-g_4_0"></a><a id="Tc_jP8Nq-QbbUis4BqszshRgQ_5_0"></a><a id="Tc_KbqUf47YM0Gw9KEnqJeHEA_6_0"></a><a id="Tc_hAmoGtHpGE-HfFY_4wW6VQ_7_0"></a><a id="Tc_IA_PPJqjpUaLXK2QxH-yZg_8_0"></a><a id="Tc_kiaMCypjeU2rBH1SqyAvsQ_9_0"></a><a id="Tc_J50bUhAfNEyEJTuijlK15w_10_0"></a><a id="Tc_447oBy9UvUOWY8Fhw2v0pg_11_0"></a><a id="Tc_6qeDp1dHf0qQof44wmDMOw_12_0"></a><a id="Tc_BNsEmqkKDk6RuQp-K-6h4g_13_0"></a><a id="Tc_BbCRo4fOXUKdAvjtJKl9og_13_2"></a><a id="Tc_5e9rHe8eC0mFCqVwooQlKQ_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" id="Tb_fy_EGjq0kUSHudWaavGlxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3&#160;&#8211; Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, prepaid expenses and other current assets consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_aQbB3kDYq0iFBnBKIk17Bg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll tax receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PayrollTaxesReceivable" scale="0" id="Tc_JY-Jetn4sES6K8ic5YRFLQ_3_3">297,494</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:PayrollTaxesReceivable" scale="0" id="Tc_NTvB8_1uTkq6zchzJzMt6w_3_6">151,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_0tpO6tBLW0Ky5DwDd5DMbA_4_3">413,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_hQutYij2JU-jObSBqCNJTw_4_6">110,094</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidResearchAndDevelopmentExpenses" scale="0" id="Tc_m9A1EYqn_E-VOBWdwTQMkQ_5_3">30,542</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:zerodash" name="eyen:PrepaidResearchAndDevelopmentExpenses" scale="0" id="Tc_HjaAaTdmtkKUb4Y5Xs3Utg_5_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid general&#160;and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidGeneralAndAdministrativeExpenses" scale="0" id="Tc_E_Lcownsv0q--kTa-Wzo6Q_6_3">105,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:zerodash" name="eyen:PrepaidGeneralAndAdministrativeExpenses" scale="0" id="Tc_dFf2s2DsokyG9kBb0TqWQQ_6_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid licenses and subscriptions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidLicensesAndSubscriptions" scale="0" id="Tc_NFKPPsxdxk-v-6jRGjZYuw_7_3">31,440</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidLicensesAndSubscriptions" scale="0" id="Tc_gOnya-smwEGU9o2KVkjDQg_7_6">57,051</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid patent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidPatentExpense" scale="0" id="Tc_t7VrfcJEckWfKJLbzyJF5g_8_3">34,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid conference expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidConferenceExpenses" scale="0" id="Tc_7Aqbo2mOGEqDptU2uHmrTA_9_3">52,041</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidConferenceExpenses" scale="0" id="Tc_f7OyrmwHTUKu8gt96MUf6A_9_6">29,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid board of directors fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidDirectorFeesCurrent" scale="0" id="Tc_qS7s5dh770aEBUfmZOXuPA_10_3">77,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidDirectorFeesCurrent" scale="0" id="Tc_e1LNuyR2D0abLsdPMe8jmg_10_6">68,250</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid rent and security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidRentAndSecurityDeposit" scale="0" id="Tc_wqH4xALj9UmMHnP0nu36tw_11_3">32,254</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:PrepaidRentAndSecurityDeposit" scale="0" id="Tc_uKcGz9bonEazyf8Z1T5GcQ_11_6">25,004</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="0" id="Tc_ppl9ZjHey0iE5WaDIsrh4Q_12_3">48,120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="0" id="Tc_QjSYXj7C10iZZeOoZ01Ptw_12_6">11,734</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_inIJBas5eUOUUiow3KlRJw_13_3">1,123,289</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_p8yoV5uM_UKJ5u5IwZFo0Q_13_6">453,478</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_g_fZyFwjRk-Ow__43m3k_g_1_2"></a><a id="Tc_4mBRBDbfi0--KQCo-0cSXg_1_5"></a><a id="Tc_kJ00TzW-MUKIbqDImN_h-A_2_2"></a><a id="Tc_0nFDCnoGO02qNS36syG2_g_2_5"></a><a id="Tc_aokvmcQGU0i9cpXu5Offhw_3_0"></a><a id="Tc_ZePNoD-P5U-WiB4ZGfWhPw_3_2"></a><a id="Tc_N2kU_oF5E0SjaNRSFVi2_Q_3_5"></a><a id="Tc_ODug3Qh0EkObdJsnCVvTOA_4_0"></a><a id="Tc_V-PQJd7S-EKPtqAd2zNaDg_5_0"></a><a id="Tc_yl9CYTjebk6OimbI4bvQFw_5_2"></a><a id="Tc_usvxr-xhgUuYGraGhglk0g_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="Tb_II-xwbm5Jk-ZKV1FEubVpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#160;&#8211; Accrued Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, accrued compensation consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:DisclosureOfAccruedCompensationTableTextBlock" id="Tb_vraJwV28EkqBBt8Dqx2rrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="0" id="Tc_GvwcjPvRX0K0RFWMxMfXZA_3_3">895,253</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="0" id="Tc_AdInod2TR06uZO22fSQ4dg_3_6">938,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="0" id="Tc_-ccNh54gbUucYHPhIR4C1Q_4_3">288,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="0" id="Tc_IktyrIrQP0GAVdKtDMB4zA_4_6">211,799</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_E898ZSaGJU2BnaiM1Rjs0w_5_3">1,184,236</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_qL95dVu6zESbvCcrd5Gqpg_5_6">1,150,672</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_TGDQSL27dUOWk7jgiRb0cQ_1_2"></a><a id="Tc_iFJJyyVh9kiMsiNa0sEh_A_1_5"></a><a id="Tc_HpOsqrDihE2SJQ_lRHFE0w_2_2"></a><a id="Tc_4jkGYhr-aUKeQSPcnKqhog_2_5"></a><a id="Tc_J3h_azfyHEyNpHoveDDqpw_3_0"></a><a id="Tc_ffPscGI_00q-MpLoPdGJwA_3_2"></a><a id="Tc_8MjgDQUVwU6bAyTYuDTDgw_3_5"></a><a id="Tc_KEY0LFKnM0aSKNMPQ_RMHg_4_0"></a><a id="Tc_eZXenJIfrUaK1SQBTNcuBQ_5_0"></a><a id="Tc_J5kGqtV4K0WdZ1He-8AMqQ_6_0"></a><a id="Tc_MQIjQ1TAyE-x1qBWQizZGw_7_0"></a><a id="Tc_yaEq---0eUa638w8BeOw0Q_8_0"></a><a id="Tc_vXP_2qUIEkSX7q_A9ol-ww_9_0"></a><a id="Tc_sB_lCQr6rk-7BM9TSf5V9w_10_0"></a><a id="Tc_s7tmlE3IzUaKGgIRG4FGiA_11_0"></a><a id="Tc_otnRyheOPk2HJQZhqm3SoA_11_2"></a><a id="Tc_xGtDsTMv3E2OiQC6ZOw81g_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_H77UyKGLYUW8Hp2nu-cv2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;&#8211; Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, accrued expenses and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_OklFVIy4-0utlZmbZdsppQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedResearchAndDevelopmentExpensesCurrent" scale="0" id="Tc_pTykd6RctEuShO3I7BdjhA_3_3">181,241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedResearchAndDevelopmentExpensesCurrent" scale="0" id="Tc_4Ydy_t5I1Emd2_w-KJzAbA_3_6">348,254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedConsultingAndProfessionalServicesCurrent" scale="0" id="Tc_tEpM_fTv1k-5XxgOr9PNYw_4_3">243,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedConsultingAndProfessionalServicesCurrent" scale="0" id="Tc_3p_fAf5gdkqqkueFpGGwMw_4_6">235,355</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit card payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:CreditCardPayable" scale="0" id="Tc_sLCqnTjn_0iBzlDWJzUKHw_5_3">44,204</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:CreditCardPayable" scale="0" id="Tc_H3d88ICpnECNzd9I740LKQ_5_6">50,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued franchise tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedFranchiseTax" scale="0" id="Tc_tfhszziNwEC6sDFMXDqY6w_6_3">39,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedFranchiseTax" scale="0" id="Tc_k99mRTcRfkmzwTSBnv2egA_6_6">32,480</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued licensing fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:zerodash" name="eyen:AccruedLicensingFees" scale="0" id="Tc_4aeaShqfm0K0b-WBqYEi7g_7_3">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedLicensingFees" scale="0" id="Tc_VuFG21m5M0uAQsaMrSByPA_7_6">804,447</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="0" id="Tc_h0lRnXSEz0qDFYSpkdAUYw_8_3">31,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="0" id="Tc_xw01zQBA2EWnzQoEbtX_wQ_8_6">3,068</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expense reimbursements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedExpenseReimbursements" scale="0" id="Tc_LQLumCC5kUqk2RX-lhmUMQ_9_3">6,441</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="eyen:AccruedExpenseReimbursements" scale="0" id="Tc_x_orM8znfkKPogdZqmMatQ_9_6">5,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_7CiWs_77bEa9arFh_Z7kGw_10_3">5,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_0nNzLFYj3U-Qzxkd0s2QCw_10_6">1,627</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" id="Tc_a2n9YvbFCESlUJMv5n9O9Q_11_3">552,336</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" id="Tc_x75WUOjmWE2f89DTeEn6SQ_11_6">1,480,692</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_20c2961c_c0e5_499e_b3e7_3c746eff7b88"></a><a id="Tc_ci2IJ_dDZESY4UoUgUqAUA_1_2"></a><a id="Tc_xBEOLaoHrEmLlFf_kQ8b5Q_1_11"></a><a id="Tc_2EZfJ8WrZkGsjF4uWHvZjQ_2_2"></a><a id="Tc_sws6YHk7T020pkrLduShWA_2_5"></a><a id="Tc_9EvP6bxqy0yDfMrDLQnrMw_2_11"></a><a id="Tc_OvGi8pbU4UC_tf82msZ5iA_2_14"></a><a id="Tc_3vMh1trk70KiqgXVq1tiAQ_3_2"></a><a id="Tc_d33ALdv1RECBRUMwRpo9jg_3_5"></a><a id="Tc_yllZNzAeBUWgkMX5WWlTaA_3_8"></a><a id="Tc_FxWvBXhQhEmmSG7ERHJIqQ_3_11"></a><a id="Tc_44-XyaeV1EOXfviu5Wnfmg_3_14"></a><a id="Tc_CtQV1sA_1kmUIQh4CjyxkA_3_17"></a><a id="Tc_66eAGEwNr02GQtqrRpLUtQ_4_0"></a><a id="Tc_3e-IOrZjf0S39EFoy3g4Xw_4_2"></a><a id="Tc_TTys76cGDESaO_Sy1VA48Q_4_5"></a><a id="Tc_XpAm1hC5GUaXpjUPNH9tNQ_4_8"></a><a id="Tc_3LIBQ4meLUeTBy1t0lz9eg_4_11"></a><a id="Tc_MQWVSBbO4U-WhHGupokWrg_4_14"></a><a id="Tc_JORHDs_JBU-BkDybocc2vg_4_17"></a><a id="Tc_gh0b6CndNEqdsHhzNf2e5g_5_0"></a><a id="Tc_b4uWO98J1UGyRjYzzDPXKw_5_3"></a><a id="Tc_StlYxF0ta0yxAwBLvP7Leg_5_9"></a><a id="Tc_xVe10wTSVEuWlgmSXkvqag_6_0"></a><a id="Tc_0wA-Qovc9UO3memsPOyiJA_7_0"></a><a id="Tc_Yf0O8gqLi027GWneR0uhXQ_7_2"></a><a id="Tc_lQHOZLHKsU6BALa95dcUIg_7_5"></a><a id="Tc_eAVQiqZLTUqAXuHZzeyrWQ_7_8"></a><a id="Tc_wCSw_Yu9ZEmMeArqwWePQA_7_11"></a><a id="Tc_yYJQeQRfmECxdn96D11Evw_7_14"></a><a id="Tc_MJGyUMLG20Cm6R9rgIvzpQ_7_17"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:NotesPayableDisclosureTextBlock" id="Tb_VdniWU9fJ0ONa73N_vJ67Q" continuedAt="Tb_VdniWU9fJ0ONa73N_vJ67Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;6&#160;&#8211; Notes Payable</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:ScheduleOfNotesPayableTableTextBlock" id="Tb_knCu734uP0m1iRLX9CLcCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of September 30, 2021 and December 31, 2020, notes payable consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BankDirect Capital Finance loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_iCv6hR3mekaUFujHwFiSGA_4_3">158,101</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_ZFQBGRRvykG310-N3RZVIw_4_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_rov2Tf1H_USV2brwf0Y7EA_4_9">158,101</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_9b7Cinf1LUaVR8q1K-FhAA_4_12">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_b-MVfMLm2UukpOTBRxAB2A_4_15">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="0" id="Tc_J-tmrPRAwEuKD9t_dQFOIg_4_18">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paycheck Protection Program loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_QoZ2KGe6NUGCeXRNsv3DqA" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_pVTPCfsTwk-60jim2FYtUA_5_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_EdGn9_JDSU-ccBu_kbMTcA_5_12">97,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_RgXbq3pYgU2vsYxP5Vkjgw_5_15">365,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_YHHlses_-0KRTAVQxOltdw_5_18">463,353</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Silicon Valley Bank loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_ps2afLhO20uU77OMLFv2MA_6_3">7,123,936</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_bKFpvbLWiEmK3fHZNt8RvQ_6_6">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_la8DkGvEIU2o9RfMrs4WDA_6_9">7,123,936</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_tWgLxSrYwUOyopWN3JUcvg_6_12">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_DiQcJQ_aa0i0m6JrPcWLGA_6_15">&#8212;</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw" decimals="0" format="ixt:zerodash" name="us-gaap:NotesPayable" scale="0" id="Tc_nQwChyE3vU24F38Wjo6D3g_6_18">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_HBJnv60ceUaHJmzXG23FxA_7_3">7,282,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:zerodash" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_5bod4KgxtkCq56X_cTPFVA_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_aq-7fBrHckyu5UiDUW5QWA_7_9">7,282,037</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="0" id="Tc_fGyIqXpM9kqToVfuY5UpYQ_7_12">97,539</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" id="Tc_XCwKRojX0k-wWxFHroe2_A_7_15">365,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_5ReVxtbS8kKuFGNroTlOyQ_7_18">463,353</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">BankDirect Capital Finance Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On February 24, 2021, the Company issued a note payable for the purchase of a directors and officers liability insurance policy. The note payable is payable in <ix:nonNumeric contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA" format="ixt-sec:durwordsen" name="eyen:NumberOfMonthlyPayments" id="Narr_5LocJUKDPEGp6iXEdRF8BA">nine month</ix:nonNumeric>ly payments consisting of principal and interest amounting to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_BGOqExXIPkKCUOa1wi_iOQ">79,343</ix:nonFraction> for an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" id="Narr_C4-Q4ROIREuKZ87jV0V4yQ">705,360</ix:nonFraction>. The note accrues interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_l_KSOZ49IUKXaQGjjD6fBg">2.96</ix:nonFraction>% per year and matures on <ix:nonNumeric contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_t-DulXLstEihpyIxUCTWjA">November 24, 2021</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Paycheck Protection Program Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On May 8, 2020, the Company received cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="0" id="Narr_BYWhWo7K_kyR4knnew0prw">463,353</ix:nonFraction> pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the &#8220;PPP Loan&#8221;). The PPP Loan provided for monthly installment payments of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_jfuug0M2L0SdXZU8GOC_ag">19,508</ix:nonFraction> beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan incurred interest at a fixed rate of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_fv_THQb6o0GG_A4a0SrB1g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_WGJKd2vD4kS22M3Za549oA">1.00</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company was eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. The Company applied for loan forgiveness on the PPP Loan in March 2021. The Company received notification in August 2021 that it had received approval for full loan forgiveness of the PPP Loan in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg" decimals="0" format="ixt:numdotdecimal" name="eyen:PaycheckProtectionProgramLoanPrincipalForgiveness" scale="0" id="Narr_xyReXVM8hkCtPCawsgXmPg">463,353</ix:nonFraction>. The Company has recorded this extinguishment as other income in the condensed statement of operations for the three and nine months ended September 30, 2021. The Company also received notification of forgiveness of accrued interest payable of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg" decimals="0" format="ixt:numdotdecimal" name="eyen:PaycheckProtectionProgramLoanAccruedInterestForgiveness" scale="0" id="Narr_6j3YAkhwqkiZfqR7GgJa2w">5,738</ix:nonFraction>, which has been reversed from interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Silicon Valley Bank Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 7, 2021 (the &#8220;Effective Date&#8221;), the Company entered into a Loan and Security Agreement (the &#8220;Loan&#8221;) with Silicon Valley Bank (&#8220;SVB&#8221;) for an aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw" decimals="-5" format="ixt:numdotdecimal" name="eyen:DebtInstrumentPrincipalAmount" scale="6" id="Narr_YOugOcNBfUuqUkQH5Revdg">25.0</ix:nonFraction> million. The Loan bears interest at an annual rate equal to the greater of (a) the sum of <ix:nonNumeric contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate" id="Narr_Z_3tITF0Xk6InIVfJdMCJA">1.25% plus the prime rate </ix:nonNumeric>as reported in The Wall Street Journal and (b) <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_uRKJn4vP4k-AIP0H3VQKtQ">5.00</ix:nonFraction>%. The Loan is secured by all of the Company&#8217;s tangible assets. The Loan matures on <ix:nonNumeric contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" id="Narr_1IE18e2f3UqX-ESPaqn00A">May 1, 2025</ix:nonNumeric>. The Loan requires monthly interest-only payments until June 1, 2022. The interest-only period can be extended to June 1, 2023, upon the occurrence of a milestone event. Upon the end of the interest-only </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ya_9x8smm0iP1Ow1sdIFjw_1_2"></a><a id="Tc_GCjL-Vy1R0avJTF5OmomMg_2_0"></a><a id="Tc_2duL5ZdZjESwj-bp9tNCtA_2_2"></a><a id="Tc_s7yMe2sdXUCyT2WW1ubsuQ_3_0"></a><a id="Tc_A1qg-McW90WOs-pSN05uzQ_4_0"></a><a id="Tc_8GYxqbllCUmD2OZJm1kCsQ_5_0"></a><a id="Tc_uHcwLEw7dEWr6TkTSjHGvw_6_0"></a><a id="Tc_koNTAdmiOE6rpWBMscHV_A_7_2"></a><ix:continuation id="Tb_VdniWU9fJ0ONa73N_vJ67Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">period, the Company will make regular monthly amortizing payments of principal and interest through the maturity date. The Loan indicates a prepayment fee of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IKbBe5b9Dk2-O_EZG5UCIQ" decimals="3" format="ixt:numdotdecimal" name="eyen:PrepaymentOfLoanFeePercentage" scale="-2" id="Narr_r6GpZFCbw0G_oWt6uuJavQ">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_ag4DlDgBVE2npGpPYLG-BA" decimals="3" format="ixt:numdotdecimal" name="eyen:PrepaymentOfLoanFeePercentage" scale="-2" id="Narr_6dJYD0z-WEGUnDhh9CUJ-w">3.0</ix:nonFraction>%, as follows: i)&#160;prepayment fee of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_FirstAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_nLEH9d3WgkSONkevFlrepw" decimals="3" format="ixt:numdotdecimal" name="eyen:PrepaymentOfLoanFeePercentage" scale="-2" id="Narr_RYq4SQNwEEC5PWoUGZ4S_g">3.0</ix:nonFraction>% of the principal balance made on or prior to the first anniversary of the Effective Date; ii)&#160;prepayment fee of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_SecondAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_Xo9_8_071Euty-FIgDxP6w" decimals="3" format="ixt:numdotdecimal" name="eyen:PrepaymentOfLoanFeePercentage" scale="-2" id="Narr_EVLV1xnDF0OsESO9sVJPlA">2.0</ix:nonFraction>% of the principal balance made on or prior to the second anniversary of the Effective Date; or iii)&#160;prepayment fee of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_ThirdAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_36SWG7orek6gpITdi6VlKA" decimals="3" format="ixt:numdotdecimal" name="eyen:PrepaymentOfLoanFeePercentage" scale="-2" id="Narr_sOmoYCV3QEeERZQ1kXhLaA">1.0</ix:nonFraction>% of the principal balance made on or prior to the third anniversary of the Effective Date. The Loan also provides for a final payment. The final payment is in addition to and not a substitution for the regular monthly payments of principal plus accrued interest due on the earliest to occur of the loan maturity date, the repayment of the loan in full or the termination of the Loan Agreement, in an amount equal to the original aggregate principal amount of the multiplied by <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ" decimals="3" format="ixt:numdotdecimal" name="eyen:OriginalPrincipalLoanPercentage" scale="-2" id="Narr_nkG2-tN1O0yuWcckAcohbw">5.0</ix:nonFraction>%.The Company is accreting the final payment as accrued interest over the term of the Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The initial tranche of the Loan, in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_pbOmGrWxa0uviYj8d4vx0g">7.5</ix:nonFraction> million was received by the Company on May 7, 2021. In connection with the Loan, the Company issued warrants to SVB to purchase <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_SM5ysAPIsEOLjg30AAUR1g">91,884</ix:nonFraction> shares of common stock at an exercise price per share equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_xf-sw9feJEqUEkZwFxJp7w">4.76</ix:nonFraction>. The warrants are exercisable for a period of <ix:nonNumeric contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ" format="ixt-sec:durwordsen" name="eyen:WarrantExercisableTerm" id="Narr_ZbFrQPgKsE-jn7sjECzO3w">ten years</ix:nonNumeric> from the date of issuance. At the Company&#8217;s option, the Company has the ability to draw down the remaining $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_9PVgnB59YkeuTvWHpKwsFw">17.5</ix:nonFraction> million in gross proceeds in two tranches over the next two years based upon the achievement of several milestones in accordance with the terms of the Loan. On September 29, 2021, the Company and SVB executed the First Amendment to the Loan and Security Agreement (the &#8220;Amendment&#8221;). In accordance with the Amendment, the Company must maintain a collateralized money market account in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_29_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_L9bBY0VpvUGL4oYGXOsvdg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_xU8PgODTB0q9v-JkgDimoA">7,875,000</ix:nonFraction>. The Company has recorded this amount as Restricted Cash. See Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash. This account must be maintained until the Release Event occurs (defined as when the Company has received approval by the FDA of the MydCombi product and achieved the minimum equity raise under the terms of the amended agreement, on or prior to November 30, 2021). Given the FDA&#8217;s recent reclassification of MydCombi as a drug-device combination and the need to resubmit a new drug application in early 2022, (See Note 11 - Subsequent Events), the restricted cash will become callable on November 30, 2021, at SVB&#8217;s election, to satisfy the Loan obligations. Therefore, the Loan has been fully classified as a current note payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">During the three and nine months ended September 30, 2021, the Company recorded interest expense relating to the Loan of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_mNTq59Ohrk--fgJKvjNTjw">95,833</ix:nonFraction></span> and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_MIZkZCxapk2rRZLoqx0LrA">150,349</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company determined that the warrants should be equity-classified and that the relative fair value was $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Narr_I36NFYdD10egO6P0rSiGfA">354,539</ix:nonFraction>, by using the Black-Scholes option pricing methodology using the following assumptions: stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_FM7GpRWW9Euozoy65TKphg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_a8qcQcX3tESW67QjDepvMA">4.76</ix:nonFraction>; expected term of <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_2RAdpzmqnESVnPrbsVNjuQ">10.0</ix:nonNumeric> years; volatility of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_2WD8Lv8rXUeF1R9C0RLl4Q">89.0</ix:nonFraction>% and a risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_p9d0P8B1qUqIdV6ZXEY1QA">1.60</ix:nonFraction>%. The Company incurred $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Narr__j3z1SYQUUGFG1CxyNv0Fg">66,618</ix:nonFraction> of debt issuance costs, of which $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DebtMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IQWi_hUUskCPeb77ph-Kwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Narr_TtZCPEIQU0qfq4Vb8b9xcA">63,469</ix:nonFraction> was allocated to the debt and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Narr_WIvdaThiTEGj477debeOIQ">3,149</ix:nonFraction> was allocated to the warrants. The relative fair value of the warrants and the issuance costs allocated to the debt were recorded as debt discount and are being amortized over the four-year term of the note. See the table below for additional details:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_WHLiDvoAz0qoOCGEPS5GgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross loan proceeds</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Tc_dUh8sQLZXE-J8EtLVaNTRg_2_3">7,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt discount:</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Tc_CaLRZkUgike2qtMqYR-IBQ_4_3">354,539</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of issuance costs</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Tc_E4oVUqfFAEG0LA6ZteGL6g_5_3">63,469</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt discount </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw" decimals="0" format="ixt:numdotdecimal" name="eyen:AmortizationOfDebtDiscount" scale="0" id="Tc_DqUupBe1UUq11hL23QRq2w_6_3">41,944</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="Tc_p6yrUpkm0UqlBUggsoVFsA_7_3">7,123,936</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_-vww2sv9Hke5TTEBsYBqFw" continuedAt="Tb_-vww2sv9Hke5TTEBsYBqFw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7&#160;&#8211; Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">See Note 8 - Related Party Transactions for certain commitments and contingencies entered into with certain related parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Litigations, Claims and Assessments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Arctic Vision License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On August 10, 2020, the Company entered into the Arctic Vision License Agreement pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-vww2sv9Hke5TTEBsYBqFw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the Arctic Vision License Agreement, the Company received a non-refundable, upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ" decimals="-5" format="ixt:numdotdecimal" name="eyen:LicenseAgreementsUpfrontPaymentsReceived" scale="6" id="Narr_2F06_kmrrkKz_PXLyOKAjQ">4.0</ix:nonFraction> million, before any payments to Senju Pharmaceutical Co., Ltd. (&#8220;Senju&#8221;), due under the Exclusive License Agreement between the Company and Senju, as amended on April 8, 2020 and a Letter Agreement dated August 10, 2020 (the &#8220;Senju License Agreement&#8221;). The Company had recorded the $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_i3TWieKEpEOqRjVjfBglLg" decimals="-5" format="ixt:numdotdecimal" name="eyen:DeferredLicenseFees" scale="6" id="Narr_rEztJhd0ikCMiWpJ8RgT0Q">4.0</ix:nonFraction> million payment as a deferred license fee until the payment is earned. The Company considers payment earned once certain trial data has been fully submitted to Arctic Vision, permitting Arctic Vision to seek regulatory approval with the National Medical Products Administration of China. The trial data for one of the two products (MicroPine) was fully submitted to Arctic Vision in March 2021. As a result, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw" decimals="-5" format="ixt:numdotdecimal" name="eyen:DeferredLicenseFees" scale="6" id="Narr_xNvlw2XN7UOmpOE0IbvG6Q">2.0</ix:nonFraction> million of deferred license fees (one-half of the $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_C3bKFFHaP0eGVFPtm44auA" decimals="-5" format="ixt:numdotdecimal" name="eyen:LicenseAgreementsUpfrontPaymentsReceived" scale="6" id="Narr_ApHZuW5PFk6b9WD_IZJ1jQ">4.0</ix:nonFraction> million upfront license fee) and recognized $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw" decimals="-5" format="ixt:numdotdecimal" name="eyen:DeferredLicenseCost" scale="6" id="Narr_b5Kl4ExpiUyJzVk3T0I2CA">0.8</ix:nonFraction> million of deferred license costs related to the Senju payment during the three months ended March 31, 2021. The trial data for the other product (MicroLine) was fully submitted to Arctic Vision in June 2021. As a result, the Company recognized the remaining $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q" decimals="-5" format="ixt:numdotdecimal" name="eyen:DeferredLicenseFees" scale="6" id="Narr_NZzzVu8Y-k6HmVdHR6jFog">2.0</ix:nonFraction> million of deferred license fees and recognized the remaining $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q" decimals="-5" format="ixt:numdotdecimal" name="eyen:DeferredLicenseCost" scale="6" id="Narr_7Kiu7xG_GkWXPTSDzCDKQA">0.8</ix:nonFraction> million of deferred license costs related to the Senju payment during the three months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In addition, the Company may receive up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA" decimals="-4" format="ixt:numdotdecimal" name="eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable" scale="6" id="Narr_VgaFaQUDkUyvK2NzsOtXZA">43.75</ix:nonFraction> million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and regulatory approvals in Greater China and South Korea (up to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA" decimals="-4" format="ixt:numdotdecimal" name="eyen:LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" scale="6" id="Narr_xmPe1vbulUWo0Wux0TuElg">39.75</ix:nonFraction> million), and development costs (up to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA" decimals="-5" format="ixt:numdotdecimal" name="eyen:LicenseAgreementThresholdDevelopmentCosts" scale="6" id="Narr_4IqeUVeALk6Ty5SNZUUM-A">4.0</ix:nonFraction> million). In December 2020, the Company satisfied a performance obligation which resulted in the Company recognizing $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w" decimals="-5" format="ixt:numdotdecimal" name="eyen:MilestoneRevenuePayments" scale="6" id="Narr_nhLl3fEcwEyTpHpKvVTHlQ">2.0</ix:nonFraction> million of milestone revenues, pursuant to the Arctic Vision License Agreement. The $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w" decimals="-5" format="ixt:numdotdecimal" name="eyen:MilestoneRevenuePayments" scale="6" id="Narr_bwXng7e83EKNmG3pSt4yKg">2.0</ix:nonFraction> million was received from Arctic Vision in December 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The milestone revenue referred to above includes $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w" decimals="-5" format="ixt:numdotdecimal" name="eyen:MilestoneRevenuePayments" scale="6" id="Narr_WvPPn2YjS0KGgNWUI-xk1w">2.0</ix:nonFraction> million related to the MicroStat product resulting from Amendment 1 to the Arctic Vision License Agreement. On September 14, 2021, the Company and Arctic Vision executed this amendment which provides for a one-time upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw" decimals="0" format="ixt:numdotdecimal" name="eyen:MilestoneUpfrontPayments" scale="0" id="Narr_W_0844GmfUCyeu7fmBxwHg">250,000</ix:nonFraction> and milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw" decimals="-5" format="ixt:numdotdecimal" name="eyen:MilestoneRevenuePaymentsReceived" scale="6" id="Narr_Zl8b08qc5keV4DLOJkn2eA">2.0</ix:nonFraction> million based on the achievement of filing for and receiving regulatory approval separately from China and South Korea for the MicroStat Product. The Company anticipates the Marketing Authorization Application (MAA) filings to occur in December 2023 and the receipt of regulatory approval to occur in December 2024. The Company didn&#8217;t recognize revenue for the $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw" decimals="0" format="ixt:numdotdecimal" name="eyen:MilestoneUpfrontPayments" scale="0" id="Narr_T1H02rasDUWdjDZVnT-nKw">250,000</ix:nonFraction> upfront payment because it was passed through to Senju. See Note 8 - Related Party Transactions for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arctic Vision also will purchase its supply of MicroPine, MicroLine and MicroStat from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_dm3PbdzDGkKl6-8dwnZVtg" decimals="0" format="ixt-sec:numwordsen" name="eyen:RoyaltyRevenuePayments" scale="0" id="Narr_8rIOWMAFckWR9UrVHH-uuQ">No</ix:nonFraction> royalty payments were earned through September 30, 2021. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Senju License Agreement. See Note 8 &#8211; Related Party Transactions- Senju License Agreement for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Bausch License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October 9, 2020, the Company entered into the Bausch License Agreement pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Bausch License Agreement, Bausch Health paid the Company a non-refundable, upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_DQU3YqFEXEeMyoIAZgkB6g" decimals="-5" format="ixt:numdotdecimal" name="eyen:LicenseAgreementsUpfrontPaymentsReceived" scale="6" id="Narr_MrV9CRMZA0q3_qxdKI4xmw">10.0</ix:nonFraction> million. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight of the ongoing MicroPine study (the CHAPERONE study). The upfront payment has not been earned as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Bausch Health could also pay the Company up to an aggregate of approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_7NBatIvU1UScUlDnCWwfjA" decimals="-5" format="ixt:numdotdecimal" name="eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable" scale="6" id="Narr_HlLBNScg2k-jozLVq8zPgg">35.0</ix:nonFraction> million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ" decimals="0" format="ixt-sec:numwordsen" name="eyen:MilestoneRevenuePayments" scale="0" id="Narr_ij4_ENHLkE-pCiAav9eRCA">No</ix:nonFraction> milestone payments were earned through September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the terms of the Bausch License Agreement, on a country-by-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration, for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed Territory. <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ" decimals="0" format="ixt-sec:numwordsen" name="eyen:RoyaltyRevenuePayments" scale="0" id="Narr_au1lN7H470qkq83R641vfA">No</ix:nonFraction> royalty payments were earned through September 30, 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_1aV3AaJsa0utYEmYuKUnVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8&#160;&#8211; Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Lease Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s Vice President of Research and Development and Manufacturing (&#8220;VP of R&amp;D&#8221;) owns a company that entered into a lease agreement with the Company on September&#160;15, 2016 to lease <ix:nonFraction unitRef="Unit_Standard_sqft_g_mpTWDoikWYZzf7J4YxvQ" contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetRentableArea" scale="0" id="Narr_Lv_LRQP2cU2reDAFLidVMw">953</ix:nonFraction> square feet of space located in Reno, NV with respect to its research and development activities. The initial&#160;monthly base rent was $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_9IMRqv6brkyXUIlqI0AdYQ" decimals="0" format="ixt:numdotdecimal" name="eyen:LeaseMonthlyBaseRent" scale="0" id="Narr_-uAiycV9D0OhMI9OtmS1-g">3,895</ix:nonFraction> per&#160;month over the term of the lease and the security deposit was $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_-6KxjfO4W0-XbcirEYaL7w">3,895</ix:nonFraction>. On September&#160;15, 2018, the Company amended the lease agreement to extend it until September&#160;14, 2020 and increase the&#160;monthly base <span style="-sec-ix-hidden:Hidden_nuJjRqoS1k-5yZXc6XLgrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_0KZL2TVKrUmrWMPejjnE0w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_V2zR9LZNy0G8EQxy9sC1uA">4,012</ix:nonFraction>. The lease agreement was amended again on April 6, 2020 to lease additional space and increase the monthly base <span style="-sec-ix-hidden:Hidden_ZGcx3U_Ha0Oyk6Kg7P3ESg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_yWodK4nHxUqdTmAUJR3I_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_VKlcVvoV90i_AcoXL1V3Bg">5,247</ix:nonFraction>. On September 15, 2020, the Company agreed to extend the lease term until September 14, 2022 and increase the monthly base <span style="-sec-ix-hidden:Hidden_D_hRu6Vn6kiVuoZDbI2E-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_4f7WqPnHVkCgD1MTwLBKxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_3FT7w9ECwk-D6fWR0dH0ZQ">5,404</ix:nonFraction>. The Company made $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember__7M2VxLcG0C8xOn47atQ4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseholdImprovementsGross" scale="0" id="Narr_Zo4c5fhb90K5zJGkMoSNew">122,298</ix:nonFraction> of leasehold improvements related to this lease which are included on the balance sheet.&#160;The Company&#8217;s rent expense amounted to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pj3iXu39uEaE-ra1uxJM1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_ZKgis5Ph4Umq08geOM4alA">16,212</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_KnS0U6aBO0mO5JTiaLy6jQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_vygP_jHwQUuYe86Rsdn0cQ">15,982</ix:nonFraction> for the three months ended September 30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pOlvfs6TQUyzUKtXgpDcEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr__PayS4D2ekqW__WUY41_pQ">48,636</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_JuJfIkOVj0CQftJ-_I1QGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_wGcBf54DM0WHrJux3ZKLMg">43,512</ix:nonFraction> for the nine months ended September 30, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Senju License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2015, the Company entered into an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q" decimals="2" format="ixt-sec:numwordsen" name="eyen:RoyaltyPercentage" scale="-2" id="Narr_QLZ1Tig8_Ui8La8DzL2R8Q">five</ix:nonFraction> percent (<ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q" decimals="2" format="ixt:numdotdecimal" name="eyen:RoyaltyPercentage" scale="-2" id="Narr_N7eRjr_C0EarNlepBH3o-A">5</ix:nonFraction>%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a former member of the Company&#8217;s Board of Directors and, together, they beneficially own greater than <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember_dyafUeHTdE6cz1HM3PEKSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_HkGGZjPr7UeGAGxQtJstoQ">5</ix:nonFraction>% of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 8, 2020, the Company entered into an amendment (the &#8220;License Amendment&#8221;) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &#8220;Senju Licensed Products&#8221;) previously licensed to Senju in China (including the People&#8217;s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &#8220;Territory&#8221;) if such a license was executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Since the Company executed a third-party license prior to April 8, 2021, the License Amendment will remain in effect for the duration of the license, subject to early termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &#8220;Letter Agreement&#8221;). Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Exclusive License Agreement was amended further by the License Amendment 2, effective September 14, 2021 (the &#8220;Amendment 2&#8221;). The Amendment 2 excludes Greater China and South Korea from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion, and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license revenue and sales revenue, including a one-time upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA" decimals="0" format="ixt:numdotdecimal" name="eyen:MilestoneUpfrontPayments" scale="0" id="Narr_RGzKIork8UiJp4Smyod_Mg">250,000</ix:nonFraction> which represented an inducement to Senju to approve Amendment 1 of the Arctic Vision License Agreement related to the MicroStat product. This upfront payment to Senju was in addition to and separate from the previously established <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA" decimals="2" format="ixt:numdotdecimal" name="eyen:PercentageOfMilestonePaymentRevenue" scale="-2" id="Narr_B1d3EtwS-Uy51egjlAbB9A">40</ix:nonFraction>% payment on milestone revenue. See Note 7 &#8211; Commitments and Contingencies &#8211; Arctic Vision License Agreement for additional details.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6696a4f7_9d61_47c8_b906_ef5ce32df339"></a><a id="Tc_wNVhEF-FvUWv9UHq9zATYg_1_2"></a><a id="Tc_IOnMHnE5VkmTN5j4acIoVw_1_6"></a><a id="Tc_BbmsSJJN1kO9tYcGq_IwHA_2_2"></a><a id="Tc_5Xo2s8pxPkmCjB8ZsKVZ9Q_2_6"></a><a id="Tc_k9XwV70ZBU2W3e2Zb5CBnw_3_2"></a><a id="Tc_oHoyRcnPC0Ws8QaQO1tGbA_3_4"></a><a id="Tc_8yc-rNvwCkaLpc7P-gJQSg_3_6"></a><a id="Tc_ouAjHDaI0Uapk8yBoYlCdg_3_8"></a><a id="Tc_A79nKmnwB0-mtbnY6NWYjA_4_0"></a><a id="Tc_BOaaQUUvbUKbCAbpEeVUzA_4_4"></a><a id="Tc_cE5IwuHxwEiMTG_srh_gPQ_4_6"></a><a id="Tc_d5KiCYCFNUST8kf3ZF5g6Q_4_8"></a><a id="Tc_w45gEemy-Ua9VeTDpbXlRQ_5_0"></a><a id="Tc_TzIYWhQ_VkyZ4KfF70ceqg_5_4"></a><a id="Tc_xIdJV9OVAkWJ6rLqWCSdaA_5_6"></a><a id="Tc_S51-EFggW0KR7tP6DQ4MZw_5_8"></a><a id="Tc_zzTHJQrsDku-2WbzT6U00w_6_0"></a><a id="Tc_VOx_lzY400GH6SrDqoXjVQ_6_4"></a><a id="Tc__f0faptBNkqNcKj1SM44BA_6_6"></a><a id="Tc_mICwDKOHC0SM2Bcrh05S0g_6_8"></a><a id="Tc_j1X0xb6njEacOcC9Qhrn5g_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_1oltRxE52U65GDV90oEJ0A" continuedAt="Tb_1oltRxE52U65GDV90oEJ0A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9&#160;&#8211; Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Securities Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 24, 2020, the Company closed on a private placement of approximately $<ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_-FgV991DL0SF93vZCSwgVw">6.0</ix:nonFraction> million of Units. Each Unit consists of (i) one share of the Company&#8217;s common stock, (ii) a <ix:nonNumeric contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_x2ajygQN6EKb6JGnk3ADLQ" format="ixt-sec:durwordsen" name="eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" id="Narr_FjX_JNBTaEm1xdq6ZfZvwg">one-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_c2IjVI1hiUyhj_jiFRUrvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_mxQwDt7brE6hu7i90XYB-Q">0.5</ix:nonFraction> of a share of common stock (&#8220;Class A Warrant&#8221;), and (iii) a <ix:nonNumeric contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9AtIdFEIokuL0HQ8uzCAsA" format="ixt-sec:durwordsen" name="eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" id="Narr_BZXpJ7ftbEK4PVOb2zVGBw">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VL8MKBI58UiYMm_viCZP0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_dozYtnjaMkuLbMsqtdHt-Q">0.75</ix:nonFraction> of a share of common stock (&#8220;Class B Warrant&#8221;) (collectively, the Class A Warrants and Class B Warrants, the &#8220;Warrants&#8221;). The Units were sold to the public at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_40ylzH8p4E6F0T980U5jPQ" decimals="5" format="ixt:numdotdecimal" name="eyen:UnitsIssuedPricePerUnit" scale="0" id="Narr_3WHIjX48okmrBykqWSE3SA">2.21425</ix:nonFraction> per Unit and to certain directors and executive officers at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_bcWFEL6RI0aDOWIz9I9cow" decimals="5" format="ixt:numdotdecimal" name="eyen:UnitsIssuedPricePerUnit" scale="0" id="Narr_pGNur5x9YUyV54DuFActBg">2.42625</ix:nonFraction> per Unit. The Company generated approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w" decimals="-4" format="ixt:numdotdecimal" name="eyen:NetProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_yEbPdVnKD0uKO5DP2RsrVA">5.45</ix:nonFraction> million of net proceeds in the offering after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_nEi_7e1obEKlZ3UD_RjwgA">0.53</ix:nonFraction> million. In the offering, the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_24_2020_To_3_24_2020_bTfSRHfxlkeROm6p3tdnwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_pD4vmsUVyk6XGfQh_wEhRQ">2,675,293</ix:nonFraction> shares of common stock, Class A Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_VN0zw8sCNECXKkjFp3cH-w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rJzqtknsXUuMjmQNmVZatA">1,337,659</ix:nonFraction> shares of common stock, and Class B Warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_hm_lAyvBM0qOeJoA1nk2ug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_a13PFUZNV0unHy_QHhfxow">2,006,495</ix:nonFraction> shares of common stock. The exercise price of the Class A Warrants issued to the public is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_aOl2qdArnUe539L8lxXVIQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_y6O0Z4QtKUO07Ld-fPsBmQ">2.058</ix:nonFraction> per share and the exercise price of the Class A Warrants issued to the directors and officers is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_txshmOfMEEmvxCweLiMsTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_2Le8lwDE6UeA9OqmkI_XFA">2.27</ix:nonFraction> per share. The exercise price of the Class B Warrants issued to the public is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_UpMsAYqFqU6-i1LSMPeaFg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_5o6eAdiVe0KhiV8AxWEcLg">2.4696</ix:nonFraction> per share and the exercise price of the Class B Warrants issued to the directors and officers is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_Am_mT9HJA0SSfr6CiMZH_A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_HsKGC-TUfUeRhWqOlpxH3Q">2.724</ix:nonFraction> per share. See &#8220;Warrants&#8221; below for additional details. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Stock Options</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_d3UJZejTx0u_-MHU1Sbykw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_WZM5kEw6tUisMBJuLyfObQ"><ix:nonNumeric contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_NHV__hqEzEmtn2Xp9lJumQ_4_2">5.85</ix:nonNumeric></ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Nuxm85SqaUGnMVZCaYXLxg">5.85</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_LPEcjtE6qEC1n4xyPdIxNg">10.00</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_RRPoTLusL0aVJIfsNYF5oA">5.85</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_iQNWWwAQP0KfcObOdYn3ug">10.00</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_PTS1FVY0Zke-CCbSi6CCTA">5.85</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Gf8tzcRN9Uiph_-If49m3Q">10.00</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_O7w0XSBOHEScZ06WDcbVUQ"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_AxoRK7KN40GL7tV_O1cpbQ_5_2">0.81</ix:nonFraction></ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_KqsB49YBM0qfMHu_MFWYFA">0.26</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_3J4UXt9Q602HYcYFHrDL9A">0.69</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_LiBLug1OWkO8fnswIIEXwA">0.45</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_U_Z7OyklgkOVZGjglTZ6nw">1.58</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_-eYVeF96-0GKwZPfHOhMKA">0.26</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_Qpcm9vfRl0KrOxuWa8Af_A">1.32</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_kfyrAhYtbk2Pue9UMPPvRw_6_2">92</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_w_Un9jcJf0y0YnOqF-GqpQ">98</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_VFt4w3OZpEKwh2n_35DDEQ">99</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_2IwNHt4I-E2sMcDFkYaUyg">92</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_86jbP5UE3Ue-l_FhUkiHjg">94</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_h7DdvVqsFEGXRQjMMnhITA">96</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_6qlMacLE1kyql987UeE6lw">99</ix:nonFraction>%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Rb6soQ5SWkKjPNWYlNaJNA_7_2">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Phhr6itN3k-uxfCUhSvZBQ_7_4">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_46heKYHJnEWhyXWnM-fZZQ_7_6">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_8Nzu7QZ0BkaTFUUGSaLrbw_7_8">0.00</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221; method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company uses a blended volatility calculation, the components of which are the Company&#8217;s historical volatility for the period from its initial public offering through the valuation date and the average peer-group data of six comparable entities to supplement the Company&#8217;s own historical data for the preceding years in computing the expected volatility. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The weighted average estimated grant date fair value of the stock options granted for the three months ended September 30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_JRmA5vMSfky7e2TsSVzjhg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_7GuJ6Fb4kEyNzWDeFm9ryg">3.56</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember__XCTy9gD4EmCBR0M73gnyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_aPv1T9I_sU-85XaHg3NiWA">2.71</ix:nonFraction> per share, respectively. The weighted average estimated grant date fair value of the stock options granted for the nine months ended September 30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_OZ8nqWdLB0CI7i4-5Qnk5w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_6REMX9HtGkaShIIfJYZXmA">4.16</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_7pE77VrTWUCPTGSIttM0Og" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_RRmRX7PUhEOiRYmcRXMZ_g">2.24</ix:nonFraction> per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June&#160;17, 2021, an employee exercised an option to purchase common shares on a cashless basis, which resulted in <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_6_17_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_72LTFu3OPkuIXbgOUgsnxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_PsomitvhQUOsyR8xLY0rIw">13,675</ix:nonFraction> shares being withheld and not issued, to cover the cost to exercise and all payroll taxes.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d139820d_8547_4ef5_934f_12befbcbdb97"></a><a id="Tc_4kvvC1k3TkSNPO1ULayIsg_1_7"></a><a id="Tc_pVfvvkre6E6eBDlmdQBj7Q_2_4"></a><a id="Tc_TLVtZ8mUYkenhTvWIWAhPA_2_7"></a><a id="Tc_2lCuuz8C40-AUlQr88e6qg_3_4"></a><a id="Tc_i04PRkXhfkakRbgyjNcGDw_3_7"></a><a id="Tc_tyCIEVX46kCgofIGV297Ng_3_9"></a><a id="Tc_vgVVhiANvEirRNO4NDlypQ_4_2"></a><a id="Tc_d17-w33xCEeHY2QGVSifRQ_4_4"></a><a id="Tc_9_UTsSNlAEOIRsDpNlSX8g_4_7"></a><a id="Tc_L-YscFPPkUauH7KtaguMnA_4_9"></a><a id="Tc_cKjGcqS19EeXaiftlrx-hA_5_2"></a><a id="Tc_TDEBfDN2UUGpTsi7UEcsHQ_5_4"></a><a id="Tc_nDlejNTZB0GobzObvCyTEw_5_7"></a><a id="Tc_bGt1hthz20WHqzvCQKKk1A_5_9"></a><a id="Tc_Hbol4eq560eh6uIAiSQCLw_6_0"></a><a id="Tc_iRJvlujMfUeYHvFgY0Oicw_6_4"></a><a id="Tc_8iwXwXTfwUeE_vf4xro8rA_7_0"></a><a id="Tc_cl2qdUo6HU2TgEblgEeWHw_8_0"></a><a id="Tc_-HRgTKnAk0abtsCQpo33Kw_9_0"></a><a id="Tc_ou8c_rK7J0SR3Zhe5qevFQ_10_0"></a><a id="Tc_bEAbZJzbXkC10wsUkPjVCQ_10_4"></a><a id="Tc_HoOPrwnL2EeHlDLY37cBoA_10_9"></a><a id="Tc_bncP3QSW00GCzerjcutb_A_11_0"></a><a id="Tc_gL1oZ4ofxkqrpOgsYyYESA_11_4"></a><a id="Tc_6wF086tYOUWdoJ1VKnTvAg_11_9"></a><a id="_d41798ec_c661_4533_ab34_b7d4c8bcd0ad"></a><a id="Tc_kNL6iOQJHUC6n8locyqwfQ_1_0"></a><a id="Tc_8wHGfIuC0ESPwLEm4fLkzg_1_5"></a><a id="Tc_qb6jWVWhiE-z6yPgFn1pRw_2_5"></a><a id="Tc_OtXLVugsH02gG20a53IXug_3_3"></a><a id="Tc_Fs_4DWL0UUSOl9Xp_q9wOw_3_5"></a><a id="Tc_OqM49LrT20mvi5ZrM5n3XA_3_7"></a><a id="Tc_hh8Dsl_4eU2XvFP6xaJDXQ_4_0"></a><a id="Tc_7R1dbsU-dESmYDWA6bMv0w_4_3"></a><a id="Tc_bGcGtGV6gUK1Esuvimd93w_4_5"></a><a id="Tc_GuviBIJGi0iq17s4X7rWYw_4_7"></a><a id="Tc_hglHaJmk9kaqeEqDgBg1ig_5_0"></a><a id="Tc_ePfmj2HxkUajUfwtQZ-GdQ_5_3"></a><a id="Tc_nhNECHMBq0e38QHXFjyutA_5_5"></a><a id="Tc_LfEFamhqwkuk5FlxvkjB9A_5_7"></a><a id="Tc_dcsDTP3dh0W_0SWrpE1w-w_6_0"></a><a id="Tc_ywuLi64f6U2Fg2wqFAY3PA_7_0"></a><a id="Tc_YR7GEMcszEaRB4YXbHx5qA_8_0"></a><a id="Tc_UmwtKLTJAEW48FHI40ZLJA_9_0"></a><a id="Tc_kYuDxnyF9kiKu2sV9l41Gw_10_0"></a><a id="Tc_Pt-_CRe4T0yDpnN0k3xMUQ_11_0"></a><a id="Tc_SJiWjghRAU6r30kwgU1vWg_12_0"></a><a id="Tc_uHKjsd6BLkGcmvT6fJW1wg_13_0"></a><a id="Tc_EbIQFRD4R0Oiq7GIHUy-uA_14_0"></a><a id="Tc_LpFsxlsF10im0ubAlQGZWw_15_0"></a><a id="Tc_1yTFk1syYEiFUNEMnzkiow_16_0"></a><a id="Tc_s6p6O9P0PUCTkYwr4tn7qQ_16_5"></a><a id="Tc_wPJzpfVvSkiah1lodNGJhQ_17_0"></a><a id="Tc_KQARZTycz0yjdocgB0LxbQ_18_0"></a><a id="Tc_LXlUSQrxZkGeg0IDPRfwcA_18_5"></a><a id="Tc_XMeF_WWZNU-Y0d6hux-5Xw_19_0"></a><a id="Tc_DSwkDuayFE-Cm7M5ZSC_6A_20_0"></a><a id="Tc_EIIoIHdTTEO5kEKddoWfKw_20_5"></a><a id="Tc_Assl6DhwaE-qdgHVFzBehQ_21_0"></a><a id="Tc_N9mufg4nRUeFaqTaJjZaBg_22_0"></a><a id="Tc_l2itCkbQe0ix-tJYTyoXug_23_0"></a><a id="Tc_pErmfZ3xHE6O7Ue0Njw8Iw_23_5"></a><a id="Tc_hv2jxUqR6USa9ep0R_fGAw_24_0"></a><a id="Tc_zxNPqSsnb0On3jspFx1-jg_24_5"></a><a id="Tc_x72WQMY1yEKgVhLcygxehQ_25_0"></a><a id="Tc_249L5xEseky9AXMf4JWShA_26_0"></a><a id="Tc_7q3jcB6YEUyjDSJpUhwttg_27_0"></a><ix:continuation id="Tb_1oltRxE52U65GDV90oEJ0A_cont1" continuedAt="Tb_1oltRxE52U65GDV90oEJ0A_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Mgh0-sfL10GriILxCtJSZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A summary of the option activity during the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_FeA5SbddTUiThZBZvHQdqA_6_2">3,427,705</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_AN4JDuOpu0aX-5kgj_0C8w_6_5">3.37</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_nQoHueLF6UWG8rqIvP_xww_7_2">1,003,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_52G4Ryq_b0mqeifuljTeVg_7_5">5.56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_qmrij3VYREuvWtaUWlgiRQ_8_2">121,261</ix:nonFraction>)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 54pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_7GXu1TV8_EOJ9FWYhSyB4g_8_5">2.07</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_b0sG45FWEU-K_3UeRKOimg_9_2">4,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_3tB_Zp41QkCnviWvfgrM3w_9_5">2.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_U9s2QazgX0K5ja2Cdr-Ztw_10_2">4,305,980</ix:nonFraction></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yBA-vSXnwkWtn5kqU4uXgA_10_5">3.89</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_BLqkm1vWO0CqKF9lUC7NXg_10_7"> 7.8</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_sRAaIXaQ0UqgMlpLcT9pTg_10_10">6,253,367</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_-Aey6c_Qb0SpqUsScPsLxA_11_2">2,364,074</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_kFyHmy7RhUWabDtqpiPSHw_11_5">3.50</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_LumsGD08ekaO3NvsdPe5Hg_11_7"><span style="font-size:9.5pt;"> 6.8</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_b-W4_7KnqkW2FWz4xZHvAA_11_10">4,448,222</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_ZUkMsVHSRUW_JWvP_PkJBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table presents information related to stock options as of September 30, 2021: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_yNyfZEDEmEeHoxufQFo6_g_6_1">1.24</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_IozVNFfXDU2UE9sRtNCfWg_6_3">260,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_pdxT137AQUSnpOvc-s2HeA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_pVKDLF_dW0C2-fy3PelVhQ_6_5"> 3.5</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_vpJOX8s5ZEuv6jFV-5D3mg_6_7">260,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_MaRnVwVVwEedVVnF11eJvw_7_1">1.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_G8I5f_yBJEa3_W7ABzjPJw_7_3">567,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_7ngFNRaQXEyNp3ttRONFSw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_2SRTh4hKzEmO1aXpEfKxDw_7_5"> 5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_-LAl-HNq1kWNKQZyw7bK5g_7_7">567,636</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_W9eyw0oj4kWUBAA6aWE_9A_8_1">2.72</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_VMZV64g6TkKHgayTDYErYg_8_3">764,419</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0pjWYEGDNkentV_xYyZQGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_aEbGDd44u0-Gm-UC6MAXOg_8_7">318,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_qJcHq2e_2kqdjviNL1Jm-A_9_1">2.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_HMpDw2vSrEyXqEn3U-tfyQ_9_3">667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_T5bwOHqjaUKS0LJJ4b5ozA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_KBCjJhiHykaPHGgvHgEdyg_9_5"> 7.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_fx38U-v2dUKZd3YHUvA4RA_9_7">0</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_k2Y3HFkV50K6Xo7PwAveYg_10_1">2.89</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_8sbmVdw1aU-WNKflweYA-g_10_3">253,251</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0rah1dwiwUKGvejQzLqdgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_TNwoex8JlU2PhUhy8eKHkg_10_7">106,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_N6E-ebZTpUSQ-oqO-rtyzA_11_1">3.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_Nx4iLlEut0WQby6q_Vcglw_11_3">656,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_LJewsOeuEk6TAXKmOshhVg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_gvAyeXMVUUiwg4Ez7tBXKg_11_5"> 7.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_ZZGsbIrTT0u64-kRSxlMkQ_11_7">468,301</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_GZIx7yB2AUqFedYNtRKezA_12_1">3.43</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_fvyLooZsG0ugR-GUhYhndQ_12_3">58,920</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_fMRMT8Kzq0GnRyxYiQBXKQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_8Xw6vCRWfk6hochEGXEWRA_12_5"> 8.9</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_Vbp4kTtKkEapijcoFdfZAA_12_7">19,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_fnVnVg9RjkC6V4uo2KhoeA_13_1">3.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_evWbAadp5kWUCeE2eAF-mQ_13_3">45,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_DIdgnF05VESFzCtSdTkV_Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_-7133u9kBUSFMIxp-uPu8w_13_5"> 8.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_33_VdJpF0UyIPm0WbBussg_13_7">15,001</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_YSMCzwYGlE6e8I1u21jEWw_14_1">3.71</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_pyqo3VYtCE6xL2-vj_M3lg_14_3">43,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_2pIbQgQQM021F_Zqq-Clqw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_WtCbROY55USW6Cs8kV0NVw_14_5"> 8.8</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_coK4lXpCsEeW6IGg6sYF-A_14_7">16,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_2X9_JNRpoUek1Y6gvGUG5Q_15_1">4.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_dFGeiRPnWkO0EdAvWUuVKw_15_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_bogZl4gZq0O_dB0iHUQz0A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_kyKuZaWBuk6RrPKI9WECZw_15_5"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_w9US1bHoP0aVXP71qoC9tg_15_7">1,890</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_foQ748P8GEG-iJl4A_G0wQ_16_1">4.53</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_wFGP8aKZ30O60ItRMdNi8g_16_3">127,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_aabBZHBAgkSpfKHOugWNFA_16_7">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_lUBiZCOGQkKDAttV7Z5gxg_17_1">4.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_WsEpMFmPg0aoypT-rkUbtQ_17_3">25,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_Mhliuin-iE-lwHos4zJZUg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_e4AEReFFkEWUhGQdJFM_1w_17_5"> 8.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_SvJDWINRhEOd76m5L7uD2A_17_7">13,196</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_TDb1sV7d00ijfjFEsPGEmg_18_1">4.81</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_tb8atf-oHE21qvfa9Yfiqw_18_3">222,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_u6QVSt8eHkOE_0TVnMGBuQ_18_7">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_S6GOCdWwYUyb__KIUbTbfQ_19_1">5.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_y0x4W37H_0mdGIVYk4OKpw_19_3">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_smJVukydaEOrt-QPyWs5Cw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_1gfis3BJ0EOHGpW-g7quGA_19_5"> 6.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_V4zU7k56cUihC5wxaDyhuQ_19_7">5,833</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_fy0izR3HyEqK1t2dPNzrpA_20_1">5.11</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_elG1z-21KEqK5T9NbN436w_20_3">1,637</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_7z26ZwmBQEq67hTGwlvkMw_20_7">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_s3zAX8Kd0USMopzRNmtsfQ_21_1">5.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_FCeHsl_HT0OO-0xhhIRnFA_21_3">16,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_Cignz6GZIEqawyto9jO6zw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_ytLCPgvoREit686yUYRvRg_21_5"> 6.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_6PKxmNBOoUWrrXnBwGgLXA_21_7">16,500</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_gor7SJZTJEWgWryE9JcJaQ_22_1">5.25</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_eO4TzcfgEUejcGmav8Ir3Q_22_3">26,668</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_t3aQtXqbMUqyY_l_s90kFA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_VAMBWBf8FU-l38vakxmwOg_22_5"> 5.0</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_RDRQ4poswEiOVXVdcLJFwg_22_7">26,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_AcOsfYaxfkC51oC9ib0Ygw_23_1">5.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_SgbHUkVkzkGenp0DzFKc1Q_23_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_sj0IDrJpXEi2kIWX2FJiTw_23_7">&#8212;</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_Og9I4Tr3jkmGZzlhHjKuFg_24_1">6.01</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_oD4RatlIeUiJ5_IWcCypBQ_24_3">652,899</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_snNJLpQzGE26AIT3q2En0w_24_7">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_wFfU8nxDi0u8BqvzuNfTAQ_25_1">6.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_0AYmhdBxBEyHWPIO0Ppwww_25_3">300,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_BHSo-xH0_02gL68u6nLG7Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_n2Soe0qa5UeNPeebyTf6YQ_25_5"> 6.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_c-ocuuQ2MU2SMkim8N0yyg_25_7">300,387</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_AcWdmmHE90OFjxDy7llfJQ_26_1">6.30</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_kKQfwc-pSkORUOEQ-1APgA_26_3">60,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_80d3KmGzV0ebsJXfreNHEQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_stW3lCrGX0KIiJNdfIvVqA_26_5"> 6.8</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_DpTyPwQ2WUyv-td12umJ5g_26_7">60,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_JIL2mBIIuEClJ-xIO_rtLQ_27_1">8.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_b0vHVaJNhEaSohWFZNU-Rg_27_3">166,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_c-dzlES2H06x3UbgBeoj7w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_UM3l-jU4xk2yFTLMtXjyPQ_27_5"> 6.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_vH5zFae3_kePB2GHsVwKxg_27_7">166,918</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_hr8EiuX7PEC5n3cggEcIJg_28_3">4,305,980</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_cDP_0W2qT0-TfPNh40Lcig_28_5"> 6.8</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_PUSlNIrmhke3d7gd6rujAQ_28_7">2,364,074</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Restricted Stock Units </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">On September 11, 2020 and March 31, 2021, the Company granted members of its Board of Directors an aggregate of </span><span style="text-decoration:none;"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_X85SIpyFOEyCHgQOqX0K3A"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_N1QMu9GoP0KcbW9Q_LTJDg">44,951</ix:nonFraction></ix:nonFraction></span><span style="text-decoration:none;"> RSUs under its Amended and Restated 2018 Omnibus Stock Incentive Plan. Each RSU is subject to settlement into </span><span style="text-decoration:none;"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA" decimals="INF" format="ixt-sec:numwordsen" name="eyen:NumberOfCommonShares" scale="0" id="Narr_-7fZjoh_g062OETu0kDx6A"><ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ" decimals="INF" format="ixt-sec:numwordsen" name="eyen:NumberOfCommonShares" scale="0" id="Narr_WJtoullk0Em_Ov-6Q7QLAA">one</ix:nonFraction></ix:nonFraction></span><span style="text-decoration:none;"> share of the Company&#8217;s common stock. The RSUs provided that vesting would occur on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The 2021 annual stockholders meeting took place on June 16, 2021 which triggered the vesting of the RSUs. The RSUs had an aggregate grant date fair value of </span><span style="text-decoration:none;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_w1sjpiHNKkuLE2e28hGLqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_CgnO5_utyUimbx0JeV_M_Q">156,200</ix:nonFraction></span><span style="text-decoration:none;">, which was recognized over the vesting period.</span><span style="text-decoration:underline;"> </span><span style="text-decoration:none;">Pursuant to the terms of the grants, vested RSUs are not issued until (a) termination of the director&#8217;s service to the Company; or (b) upon a change-of-control transaction (as specified). </span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_10bba0b7_bd62_4e45_a78d_a4bd41d844bb"></a><a id="Tc_53PLUYSPhUW6BfcW2XoPlA_1_7"></a><a id="Tc_W0GcLsBNGkmbcr2U7shpvQ_2_4"></a><a id="Tc_JsNw3PqbEkWhthpTe6jmWg_2_7"></a><a id="Tc_IPNYPM8nRE6farbmNHO6Ig_3_4"></a><a id="Tc_WlY-jWOlX0CKE68H7fraUA_3_7"></a><a id="Tc_V9dlqzBm7kOIlFquv0pZlA_3_9"></a><a id="Tc_GhWUqjic4EiIBW423-S59g_4_2"></a><a id="Tc_yyCpnSyOtkWAwI6rru6UBw_4_4"></a><a id="Tc_yjuDeyBoUUaL0ervXRjFMw_4_7"></a><a id="Tc_kFTWKTRFRkC79lCyVAU4HA_4_9"></a><a id="Tc_Essg-7sLuESawLFX15y7rg_5_2"></a><a id="Tc_bEbSHM603U6NPwMwbiEqsg_5_4"></a><a id="Tc_FeXjh5NiB0qbLz8TO2NS1w_5_7"></a><a id="Tc_Pl5LV4OYGkG9gC96p6j0rA_5_9"></a><a id="Tc_A6vUC_xM0kmt7gAFMkekSg_6_0"></a><a id="Tc_6W5QViQTk0CSYTvYxIEoxw_6_4"></a><a id="Tc_1C32Fw34Hk2punhXepdfnw_7_0"></a><a id="Tc_t0sPRPxvuUiQeM1erJaBug_8_0"></a><a id="Tc_XNFSlBF0UESrkk-WNnDz5w_9_0"></a><a id="Tc_ZkmAl-o6KU217HFfQE0bsw_9_4"></a><a id="Tc_RQjGuhBEjUOue12WtGhDrw_9_9"></a><a id="Tc_iVipELTB902AwNRNja6iPg_11_0"></a><a id="Tc_EJmjJFn74UGvbga2RezgqQ_11_4"></a><a id="Tc_O3lJK1LQm0qyXJh4sncu1g_11_9"></a><a id="_fcab51ec_4199_4851_a019_97f1c2dae78e"></a><a id="Tc_H7AcxOad-EGn3yo6XWk25A_1_0"></a><a id="Tc_x75vvqDQ4kKmf2507DSLzA_1_4"></a><a id="Tc_KqveSYLrm0ywWYk2OanQrA_2_4"></a><a id="Tc_agNUAaSXOUGKjI8cKhDDdA_3_2"></a><a id="Tc_rtFxUUSMOkWkpNbtgSSOvQ_3_4"></a><a id="Tc_PpsbcmYExUy-4e-PsN0xXQ_3_6"></a><a id="Tc_SB7LAOvvJUqe2p1EYZ0Wmg_4_0"></a><a id="Tc_Iy07L4tbrUmwEqeQlc391g_4_2"></a><a id="Tc_kSsKHSo9wUmkpzUsg9VhsQ_4_4"></a><a id="Tc_xJp_K6-2PUybqItZzNflSA_4_6"></a><a id="Tc_ENUA7SZpb0mspLUf9kNlrA_5_0"></a><a id="Tc_Ka3GFqFMLU6wVyy5ywuh7Q_5_2"></a><a id="Tc_rEI_bEKbo0WMDUFBdmR2sA_5_4"></a><a id="Tc_Qkq3Q9czxEiMND16BGIqtQ_5_6"></a><ix:continuation id="Tb_1oltRxE52U65GDV90oEJ0A_cont2" continuedAt="Tb_1oltRxE52U65GDV90oEJ0A_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense related to stock options and RSUs. During the three months ended September 30, 2021 and 2020, the Company recorded expense of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_Mt2UNJQuDUevQ67D3S9HUA">777,467</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_A7hLgIFxxUKBiuI527JBGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_DrsY-i-4YkOn2qIjZ5EgkQ">489,121</ix:nonFraction> of which was included within research and development expenses and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Jy8VhLNmEkGHN5MuNuthNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_K2vpOep-JkqXSMpEQKVDsA">288,346</ix:nonFraction> of which was included within general and administrative expenses on the condensed statement of operations) and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_NhBqyeXHLkK0Plt-cfBGVg">609,930</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rbh1OVNxSEyBxxZbh4fjoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_N5LUmxbvgEqtPGOx9AkBJw">346,294</ix:nonFraction> of which was included within research and development expenses and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_x35crJWltUqP-Ltc2GMthw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_q-S17nHXkk6sNzmnmOgtjw">263,636</ix:nonFraction> of which was included within general and administrative expenses on the condensed statement of operations), respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_XsJVwMee1kOGyVal9tvYuw">2,071,735</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ntknW_Gv5UC-DQSr8ZSQOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_a0DNfCEgtkG2kZk97xyCAw">1,138,331</ix:nonFraction> of which was included within research and development expenses and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qNX7m30BZEuTbysvLOcMQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_ZJpUKmX2WESi3cQ93AqdPQ">933,404</ix:nonFraction> was included within general and administrative expenses on the condensed statement of operations) and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_i4FDly9FsU2zqEquxxDj_w">1,826,941</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CJ4gskFkJUSoYcy73Hqa0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_X-HTu2w0t0ahB-Y_K079hg">1,002,150</ix:nonFraction> of which was included within research and development expenses and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_w6HGMgcXbEmE_fB8OrHwwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Narr_OBvHz5vQnU23-fUWGVA9Ow">824,791</ix:nonFraction> was included within general and administrative expenses on the condensed statement of operations), respectively. As of September 30, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_Km0zoa6jnUGvca-3ifn2PQ">5,787,351</ix:nonFraction> of unrecognized stock-based compensation expense which the Company expects to recognize over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_E3e47Vz9o0aU3teLS7X2Dw">2.1</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_E3t6R1n_-EiB1JfDlL5xCQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of warrant activity for the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__OBuXniExUK_I_HMsmACvw_6_2">2,011,313</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA" decimals="2" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_3OhwNhGhmUi8BAP-4IQXww_6_5">2.43</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightGranted" scale="0" id="Tc_Hj9MCWUmj0epsrsdDxqVEg_7_2">91,884</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" scale="0" id="Tc_Yx-luMtbPUa1Ymqo3CJZIQ_7_5">4.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercised" scale="0" id="Tc_DeJEVSZuxUykSPaSNVipTg_8_2">877,014</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" scale="0" id="Tc_CW0n7-A7b0uKgA0aqqVglw_8_5">2.40</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_zHMyJEInyk-BBul4GpcnTw_9_2">1,226,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="2" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_TjsysADnL0K4cZxXOUPVKA_9_5">2.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" id="Tc_p03Waz81t0qjPSAZnslVWQ_9_7"> 4.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" scale="0" id="Tc_pr_sRqQ8-E6s03k4E7jD8A_9_10">2,714,617</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_JdIbwoTBt0akbDINUOhnmQ_11_2">1,226,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="2" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" scale="0" id="Tc_i3GgZwDDh0WIHmRUdmXCfA_11_5">2.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" id="Tc_tkdFVW6Z-kKRn2ZkV6LM_g_11_7"> 4.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="0" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" scale="0" id="Tc_uwdX3Uj9WEaFEiSRtA1u2g_11_10">2,714,617</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="eyen:ScheduleOfWarrantsOutstandingTableTextBlock" id="Tb__PHcwl4o2UGAmu6goHD87g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents information related to Warrants as of September 30, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:67.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warants Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_aiRwDV9WPk6Odnl8VKQC0Q_6_0">2.4696</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_phg1TchDK0S9O44i8U8Qjw_6_2">917,919</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Im1QKFMiwEyIc4Nt8pdKyQ" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" id="Tc_2xf5Sxv5bkGvEVFA0JT4_g_6_4"> 3.5</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_yfZnSzwLk0CsV2xyHw2lIw_6_6">917,919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_cGMMiHa9y0eUlKPEfoMpKw_7_0">2.7240</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_cYzR6SLadUqrsCpJWuhFIA_7_2">216,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_s7sYagQq6kerzRAgAyzWvQ" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" id="Tc_BKgiRsXSo0inZPsEIdysog_7_4"> 3.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_1L7Yd8UUsE2jxL_K5KF7Tw_7_6">216,380</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_q_v-x_5VrE-kSdm4qMw79g_8_0">4.7600</ix:nonFraction> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_vBZWb60d4Uu0Wg9qcgPubQ_8_2">91,884</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_kdodtnQEgkKApSH7Ar3_7w" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" id="Tc_O3NVk3LxA0u_lekBbkIgug_8_4"> 9.6</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_eY2UJVJm30y1uFF_cPodtQ_8_6">91,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Xyk38DG5s0uS2aVH_qLD-A_9_2">1,226,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" format="ixt-sec:duryear" name="eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" id="Tc_W8xQ3my4DkantDK6iwEyMw_9_4"> 4.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercisable" scale="0" id="Tc_dnjfGSQ500Kos6-LEyE7rA_9_6">1,226,183</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 6 &#8211; Notes Payable &#8211; for details on the warrant issued in connection with the SVB loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended September 30, 2020, warrants for the purchase of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercised" scale="0" id="Narr_HxdKvV6G6kes6ZzOAgWHeA">1,080,497</ix:nonFraction> shares of the Company&#8217;s common stock, with exercise prices of either $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_8dZNtKxwmkiqkPx6oMKrZQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_G0f7ovIWY02mMkr6xd2L9g">2.058</ix:nonFraction> or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_whpYAzEDtkOSZXmSQSWepw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_gB8YWtk-OEGDtREEHd0BKQ">2.4696</ix:nonFraction> per share, were exercised for aggregate proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_8s2ijATZA0Cln9nOEdE5vA">2.3</ix:nonFraction> million, while <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="INF" format="ixt-sec:numwordsen" name="eyen:ClassOfWarrantOrRightExercised" scale="0" id="Narr_2XC-xGrsU0-fQ40eNSt_qg">no</ix:nonFraction> warrants were exercised during the three months ended September 30, 2021. During the nine months ended September 30, 2021 and 2020, warrants for the purchase of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercised" scale="0" id="Narr_jO2XNtKFgkezXIyhIzIXOg">877,014</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="INF" format="ixt:numdotdecimal" name="eyen:ClassOfWarrantOrRightExercised" scale="0" id="Narr_yxRQmUxt7U2Tf4uV4spZRA">1,248,161</ix:nonFraction> shares of the Company&#8217;s common stock, respectively, with exercise prices of either $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_bDqIChk0w0KvPi1evhS5nA">2.058</ix:nonFraction> or $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_o2RbATUgzEyPvfnmy9Q5rw">2.4696</ix:nonFraction> per share, were exercised for aggregate proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_3Na4LItC20q_7qqwK4DftA">2.1</ix:nonFraction> million and <span style="-sec-ix-hidden:Hidden_MimNBTPoWU-6QCm4o9Gk6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$2.6</span></span> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">At-The-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May&#160;14, 2021, the Company entered into a Sales Agreement (the &#8220;Agreement&#8221;) with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_N1KXYZq5fUuqk4TSeXUFnA" decimals="-6" format="ixt:numdotdecimal" name="eyen:FairValueOfCommonStock" scale="6" id="Narr_iZ8F4LPojU-lZTw8_kC67A">30</ix:nonFraction> million through SVB Leerink as its sales agent. Subject to the terms and conditions of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EYENOVIA, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTES TO CONDENSED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1oltRxE52U65GDV90oEJ0A_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Agreement, SVB Leerink may sell the Common Stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221;. SVB Leerink will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay SVB Leerink a commission equal to <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg" decimals="2" format="ixt-sec:numwordsen" name="eyen:PercentageOfGrossSalesOnCommonStock" scale="-2" id="Narr_PQgMo_dqF0K7_xDSdTtpnA">three</ix:nonFraction> percent (<ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg" decimals="3" format="ixt:numdotdecimal" name="eyen:PercentageOfGrossSalesOnCommonStock" scale="-2" id="Narr_GVCpEWcwcEiOdEAJKwo71g">3.0</ix:nonFraction>%) of the gross sales proceeds of any Common Stock sold through SVB Leerink under the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is not obligated to make any sales of Common Stock under the Agreement. through September 30, 2021, the Company had not sold any shares of common stock under the Agreement. See Note 11 - Subsequent Events - At-The-Market Offering for additional details.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_JrCTMvJQaEyiH4sTFaMQiQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10&#160;&#8211; Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">401(k) Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &#8220;Plan&#8221;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2021 and 2020, the Company&#8217;s Board of Directors has approved a matching contribution equal to </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_rFiZ1Q9p1kONGsVuxtB5xg">100</ix:nonFraction>%</span><span style="font-weight:normal;"> of elective deferrals up to </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" scale="-2" id="Narr_MvmFeKEHLka8clAhRiwJzA">4</ix:nonFraction>%</span><span style="font-weight:normal;"> of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three months ended September 30, 2021 and 2020, the Company recorded expense of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_imTh1wyNS0aGQwxT2SJAvg">34,076</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_8y7m2qWJqkajYHr5fCoUkA">25,535</ix:nonFraction></span><span style="font-weight:normal;"> associated with its matching contributions, respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_SemKhXcrukGc2Ykb13JUSw">144,917</ix:nonFraction></span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_8fLXKn6-GkWWWNXruTTy_A">106,021</ix:nonFraction></span><span style="font-weight:normal;"> associated with its matching contributions, respectively.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Qync8W_m8k603idNCmBMGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 11 &#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">At-The-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the At-The-Market Offering (see Note 9 &#8211; Stockholders&#8217; Equity &#8211; At-The-Market Offering) the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Oj65DkFZSkWhhIw12CyVIA">12.8</ix:nonFraction> million in gross proceeds and $<ix:nonFraction unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="-5" format="ixt:numdotdecimal" name="eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="6" id="Narr_V5qOH4qQA0-V6zRTrxgC7A">12.4</ix:nonFraction> million in net proceeds from the sale of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_qfhRvPt-Sk61rSzHbvyGJQ">2,435,604</ix:nonFraction> shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">MydCombi FDA Application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 25, 2021, the Company announced the reclassification of the Company&#8217;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, MydCombi, as a drug-device combination product by the FDA in a CRL received on October 22, 2021, following a change in the agency&#8217;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. See Note 1 &#8211; Business Organization, Nature of Operations and Basis of Presentation and Note 6 &#8211; Notes Payable &#8211; Silicon Valley Bank Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Employee Stock Options</span><span style="text-decoration:underline;text-decoration-color:#000000;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 27, 2021, the Company granted <ix:nonNumeric contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_5Xx7OP042kyHBIMWmBtS8w">ten-year</ix:nonNumeric> stock options to employees, pursuant to its Amended and Restated 2018 Omnibus Stock Incentive Plan, to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA" contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ReL8G42UUE2MjmwxfGODuA">35,000</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA" contextRef="As_Of_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_lMHKpMczF0i8b2pWYttO7Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_erhNFnU85k-J2aM3dd3-hA">4.06</ix:nonFraction> per share. The options expire on the tenth anniversary of the grant date and they vest with respect to <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tUqOu0dbMESf7ibzQiMF9g" decimals="4" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_IOwcYzLgw0KZHiqz_gq0Rw">one</ix:nonFraction>-third of the shares underlying the awards on the first anniversary of the grant date and, with respect to the remaining <ix:nonFraction unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ" contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9phIPy7ZLESGi02EKB1vbw" decimals="4" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_glsnohXaHEWyOyZ74ZEQwA">two</ix:nonFraction>-thirds of the shares underlying the awards, in equal monthly installments over the subsequent <ix:nonNumeric contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_4ETBtXlPXEmNPGz1ZuKqJw">two years</ix:nonNumeric>.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d6084b1f_ce5d_4592_883b_092d36b95f82"></a><a id="Item2ManagementsDiscussionandAnalysis_62"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of the results of operations and financial condition of Eyenovia,&#160;Inc. (&#8220;Eyenovia,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 should be read in conjunction with our unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form&#160;10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2020 as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;30, 2021.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This report contains &#8220;forward-looking statements.&#8221; Specifically, all statements other than statements of historical facts included in this report, including regarding our financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this report, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;continue&#8221; &#8220;intend,&#8221; and &#8220;plan&#8221; and words or phrases of similar import are intended to identify forward-looking statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and assumptions related to various factors that could cause actual results and the timing of events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled &#8220;Risk Factors&#8221; included in our most recent Annual report on Form&#160;10-K filed with the SEC. Furthermore, such forward-looking statements speak only as of this Quarterly Report on Form&#160;10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of advanced therapeutics based on our proprietary microdose array print (MAP&#8482;) therapeutics. We aim to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using our high-precision targeted ocular delivery system, branded the Optejet&#174; &#160;which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of &#160; traditional eye drops (~ 90% vs. ~ 50%). Our technology is designed to achieve single-digit &#181;l-volume physiologic drug delivery with up to a 75% reduction in ocular drug and preservative topical dosing and has demonstrated significant improvement in the therapeutic index in drugs used for mydriasis and IOP lowering through three Phase II and Phase III trials. Conventional eye formulations lack high-precision micro-volume delivery and expose the ocular surface to approximately 300% more medication and preservatives than are physiologically indicated leading to clinically recognized ocular and non-ocular side effects. Using the Optejet, we are developing the next generation of smart ophthalmic therapeutics which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration, (the &#8220;FDA&#8221;). Our microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Consistent with the recent FDA reclassification of MydCombi, we believe that most of our product candidates are, or will be, classified by the FDA as drug-led combination products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our pipeline is currently focused on the late-stage development of novel, potential first-in-class therapeutic indications for over an estimated five million potential patients with progressive myopia in the United States and over an estimated one hundred million potential patients with age-related near vision impairment, or presbyopia &#8211; indications where there is tremendous unmet need and no known existing FDA-approved therapies. We are also developing the first microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the estimated over 100 million annual comprehensive eye exams with pupil dilation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">MicroPine is our investigational first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. In the United States, myopia is estimated to affect approximately 25 million children, with up to five million considered to be at risk for high myopia. In February 2019, the FDA accepted our investigational new drug application, or IND, to initiate a Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. We enrolled the first patient in the CHAPERONE study in June 2019. Due to the COVID-19 pandemic, we experienced delays in trial enrollment and initiation as a result of reduced clinical trial activities and operations at investigator sites. However, we have since been able to resume enrollment in the CHAPERONE study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On October 9, 2020, we entered into a License Agreement (the &#8220;Bausch License Agreement&#8221;) with a subsidiary of Bausch Health Companies Inc. (&#8220;Bausch Health&#8221;) pursuant to which Bausch Health may develop and commercialize MicroPine in the United </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">States and Canada. Under the terms of the Bausch License Agreement, we received an upfront payment of $10.0 million and we may receive up to a total of $35.0 million in additional payments, based on the achievement of certain regulatory and launch-based milestones. Bausch Health also will pay us royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from sales of MicroPine in the United States and Canada, subject to certain adjustments. Under the terms of the Bausch License Agreement, Bausch Health is in the process of assuming oversight for, and has assumed the costs related to the ongoing CHAPERONE study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">MicroLine is our investigational pharmacologic treatment for presbyopia. Presbyopia is a non-preventable, age-related hardening of the lens, which causes the gradual loss of the eye&#8217;s ability to focus at near and impairs near visual acuity. There currently are no known FDA-approved drugs for the improvement of near vision in patients with presbyopia, although other companies have related therapies in their pipeline. We have two planned Phase III VISION trials for MicroLine, and initiated the first of these trials in December 2020. On May 25, 2021, we announced positive topline data from the Phase III VISION-1 study evaluating MicroLine for the temporary improvement of near vision in adults with presbyopia. The study achieved its primary endpoint and preparations are underway for a second Phase III registration study, VISION-2, targeted to be initiated &#160;by the end of this year. VISION-2 will be a double-masked, placebo-controlled, cross-over superiority trial designed to enroll 120 patients randomized between 2% pilocarpine and placebo cohorts. Topline data from VISION-2 is anticipated in mid-2022. These studies will serve as the basis for a planned New Drug Application (NDA) submission to FDA. VISION-1 results will be presented at a future ophthalmic-focused medical meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On August 10, 2020, we entered into a License Agreement (the &#8220;Arctic Vision License Agreement&#8221;) with Arctic Vision (Hong Kong) Limited (&#8220;Arctic Vision&#8221;), pursuant to which Arctic Vision may develop and commercialize MicroPine and MicroLine in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. Under the terms of the Arctic Vision License Agreement, we received an upfront payment of $4.0 million before any payments to Senju Pharmaceutical Co., Ltd. (&#8220;Senju&#8221;). In addition, we may receive up to a total of $43.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. Milestone revenue includes $2.0 million related to the MicroStat product resulting from Amendment 1 to the Arctic Vision License Agreement between the Company and Arctic Vision which was executed on September 14, 2021. Arctic Vision also will purchase its supply of MicroPine, MicroLine and MicroStat from us or, for such products not supplied by us, pay us a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. We will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Exclusive License Agreement with Senju dated March 8, 2015, as amended by the License Amendment dated April 8, 2020, and a Letter Agreement dated August 10, 2020 (the &#8220;Senju License Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Senju License Agreement was amended further by the License Amendment 2, effective September 14, 2021 (the &#8220;Amendment 2&#8221;). The Amendment 2 excludes Greater China and South Korea from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion, and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license revenue and sales revenue, including a one-time upfront payment of $250,000 which represented an inducement to Senju to approve Amendment 1 of the Arctic Vision License Agreement related to the MicroStat Product. This upfront payment to Senju was in addition to and separate from the previously established 40% payment on milestone revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">MydCombi&#8482; (or MicroStat) is our fixed combination formulation of phenylephrine-tropicamide for mydriasis, designed to be a novel approach for the estimated over one hundred million office-based comprehensive and diabetic eye exams performed every year in the United States. We have completed two Phase III trials for MydCombi and announced positive results from these studies, known as MIST-1 and MIST-2. In March 2021, the FDA accepted our NDA, for MydCombi &#160;for use to achieve mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. On October 25, 2021, the Company announced the reclassification of the Company&#8217;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, MydCombi, as a drug-device combination product by the FDA in a Complete Response Letter (&#8220;CRL&#8221;) received on October 22, 2021, following a change in the agency&#8217;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We have not received U.S. marketing approval for any product candidate and we have therefore not generated any revenues from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Historically, we have financed our operations principally through equity offerings, including our initial public offering, numerous public offerings in 2018, 2019 and August 2020, and our private placement that closed in March 2020. We have also generated cash through licensing arrangements and our credit facility with Silicon Valley Bank (&#8220;SVB&#8221;). However, based upon our current operating plan, there is substantial doubt about our ability to continue as a going concern for a period of at least the next twelve months. Our ability to continue as a going concern depends on our ability to raise additional capital, through the sale of equity or debt securities </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">to support our future operations. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Our net losses were $5.6 million and $15.8 million for the three and nine months ended September 30, 2021. As of September 30, 2021, we had working capital and an accumulated deficit of&#8201;$2.7 million and $93.2 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Financial Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue and Cost of Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August and October 2020, we entered into the Arctic Vision License Agreement and Bausch License Agreement, respectively. Both of these agreements provide for the Company to earn revenue from an upfront licensing fee, the achievement of various development and regulatory milestones, and royalty income on sales of licensed products. Pursuant to the Senju License Agreement, we will pay a mid-double digit percentage of such payments from the Arctic Vision License Agreement to Senju. See Note 7 &#8211; Commitments and Contingencies and Note 8 &#8211; Related Party Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses are incurred in connection with the research and development of our microdose-therapeutics and consist primarily of contract service expenses. Given where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development expenses consist of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations, contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:justify;">facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing, insurance and other supplies used in research and development activities.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We expense research and development costs as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors provide to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In addition, our license agreements with Arctic Vision and Bausch Health require them to assume or reimburse us for specified research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We expect that our research and development expenses will increase with the continuation of the aforementioned initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses consist primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development and the potential commercialization of our product candidates. We also anticipate increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements. In addition, director and officer insurance premiums and investor relations costs associated with being a public company are expected to increase in future periods.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses for the three months ended September 30, 2021 totaled $3.5 million, an increase of $0.1 million, or 3%, as compared to $3.4 million recorded for the three months ended, September 30, 2020. Research and development expenses consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Three Months&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct clinical and non-clinical expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 818,015</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,745,880</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel-related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,386,602</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 890,771</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash stock-based compensation expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 489,121</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 346,294</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Supplies and materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 496,738</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 325,517</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Facilities and other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 279,712</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 55,297</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,470,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,363,759</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">The decrease in direct clinical and non-clinical expenses was primarily due to the Vision I Study having concluded in early 2021 and significantly higher cost reimbursements from Bausch Health and Arctic Vision. The cost reimbursements are booked as contra expense. The increase in personnel-related expenses was primarily due to new hiring in preparation for commercialization. The increase in non-cash stock-based compensation was due to new option grants. The increase in supplies and materials resulted from an increase in spending on device inventory. The increase in facilities and other expenses was primarily due to rent and utilities related to the Redwood City facility. The main factor in these increases was the preparation for commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">General and administrative expenses for the three months ended September 30, 2021 totaled $2.4 million, an increase of $0.7 million, or 41%, as compared to $1.7 million recorded for the three months ended September 30, 2020. This increase was primarily attributable to a $0.3 million increase in salaries and benefits resulting from new hiring in preparation for commercialization, a $0.3 million increase in sales and marketing, primarily related to the MydCombi promotional campaign, a $0.1 million increase in insurance expense related to Directors &amp; Officer insurance and a $0.1 million increase in other G&amp;A expense, primarily due to increased travel resulting from the lifting of COVID-19 restrictions. This was slightly offset by a decrease of $0.1 million in professional services, primarily due to legal fees incurred for the Bausch Health and Arctic Vision licensing deals in 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Revenue and Cost of Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">In August 2020, we received a $4.0 million upfront payment under the Arctic Vision License Agreement, and made a related payment of $1.6 million to Senju. This upfront payment was recorded as $4.0 million of deferred license fee and $1.6 million of deferred cost of revenue. The trial data for one of the two products (MicroPine) was fully submitted to Arctic Vision in March 2021 and the trial data for the other product (MicroLine) was fully submitted to Arctic Vision in June 2021. As a result, the Company recognized the $4.0 million of deferred license fees and recognized $1.6 million of deferred license costs related to the Senju payment during the nine months ended September 30, 2021. There was no revenue for the nine months ended September 30, 2020.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Research and development expenses for the nine months ended September 30, 2021 totaled $11.3 million, an increase of $1.4 million, or 14%, as compared to $9.9 million recorded for the nine months ended September 30, 2020. Research and development expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Direct clinical and non-clinical expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,696,396</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,076,662</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,886,683</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,533,439</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-cash stock-based compensation expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,138,331</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,002,150</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplies and materials</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 936,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,108,021</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Facilities and other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 676,320</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 193,024</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,334,296</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,913,296</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The decrease in direct clinical and non-clinical expenses was primarily due to significantly higher cost reimbursements from Bausch Health and Arctic Vision which are booked as contra expense. The increase in personnel-related expenses was primarily due to new hiring in preparation of commercialization. The increase in non-cash stock-based compensation was due to new option grants. The decrease in supplies and materials resulted from higher costs incurred for the clinical cartridge supply in 2020. The increase in facilities and other expenses was primarily due to rent and utilities related to the Redwood City facility and increased travel due to the lifting of COVID-19 restrictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">General and administrative expenses for the nine months ended September 30, 2021 totaled $7.1 million, an increase of $1.4 million, or 25%, as compared to $5.7 million recorded for the nine months ended September 30, 2020. This increase was primarily attributable to a $0.8 million increase in salaries and benefits resulting from new hiring in preparation of commercialization, a $0.7 million increase in sales and marketing, primarily related to the MydCombi promotional campaign, a $0.2 million increase in insurance expense related to Directors &amp; Officer insurance and a $0.1 million increase in other G&amp;A expense, primarily due to increased travel resulting from the lifting of COVID-19 restrictions and higher director fees attributable to a new Board member. This was offset by a decrease of $0.4 million in professional services, primarily due to legal fees incurred for the Bausch Health and Arctic Vision licensing deals in 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Since inception, we have experienced negative cash flows from operations. As of September 30, 2021, our accumulated deficit since inception was $93.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, we had a cash and cash equivalents balance of $21.4 million (of which $13.5 million is unrestricted), working capital of $2.7 million and stockholders&#8217; equity of&#8201;$4.2 million. As of September 30, 2021 and December 31, 2020, we had $7.3 million and $0.5 million, respectively, of debt outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to generate sufficient recurring revenue or our ability to raise additional capital through the sale of equity or debt securities to support our future operations. Our operating needs include the planned costs to operate our business, including amounts required to fund research and development activities including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If we are unable to generate sufficient recurring revenue or secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash. During the nine months ended September 30, 2021 and 2020, our sources and uses of cash were as follows:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May 7, 2021, the Company entered into a Loan and Security Agreement (the &#8220;Loan&#8221;) with SVB for an aggregate principal amount of up to $25.0 million. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 1.25% plus the prime rate as reported in The Wall Street Journal and (b) 5.00%. The Loan is secured by all of the Company&#8217;s tangible assets. The Loan matures on May 1, 2025. The Loan requires monthly interest-only payments until June 1, 2022. The initial tranche of the Loan, in the amount of $7.5 million was received by the Company on May 7, 2021. In connection with the Loan, the Company issued to SVB warrants to purchase 91,884 shares of common stock at an exercise price per share equal to $4.76. The warrants are exercisable for a period of ten years from the date of issuance. At the Company&#8217;s option, the Company has the ability to draw down the remaining $17.5 million in gross proceeds in two tranches over the next two years based upon the achievement of several milestones in accordance with the terms of the Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On September 29, 2021, the Company and SVB executed the First Amendment to the Loan and Security Agreement (the &#8220;Amendment&#8221;). In accordance with the Amendment, the Company must maintain a collateralized money market account in the amount of $7,875,000. This account must be maintained until the Release Event occurs (defined as when the Company has received approval by the FDA of the MydCombi product and achieved the minimum equity raise under the terms of the amended agreement, on or prior to November 30, 2021). Given the FDA&#8217;s recent reclassification of MydCombi as a drug-device combination and the need to resubmit a new drug application in early 2022, the restricted cash will become callable on November 30, 2021, at SVB&#8217;s election, to satisfy the Loan obligations. Therefore, the Loan has been fully classified as a current note payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operating activities for the nine months ended September 30, 2021 was $15.0 million, which includes cash used to fund a net loss of $15.8 million, reduced by $1.8 million of non-cash expenses, plus $1.0 million of cash generated from changes in operating assets and liabilities. Net cash used in operating activities for the nine months ended September 30, 2020 was $11.9 million, which includes cash used to fund a net loss of $15.6 million, reduced by $1.9 million of non-cash expenses and $1.8 million of cash used to fund changes in operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash used in investing activities for the nine months ended September 30, 2021 was $1.2 million, which was related to purchases of property and equipment. Cash used in investing activities for the nine months ended September 30, 2020 was $0.2 million, which was related to purchases of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by financing activities for the nine months ended September 30, 2021 totaled $9.2 million, which was primarily attributable to $7.5 million of proceeds from the Loan and $2.3 million from the exercise of warrants and stock options. This was slightly offset by the repayment of notes payable and loan issuance costs of $0.6 million. Net cash provided by financing activities for the nine months ended September 30, 2020 totaled $20.8 million, which was primarily attributable to aggregate net proceeds from the sale of our common stock and warrants in our public and private offerings of $18.0 million, $2.6 million of proceeds from the exercise of stock warrants, and $0.5 million in proceeds from a loan in connection with the Paycheck Protection Program under the CARES Act. This was slightly offset by the repayment of notes payable of $0.4 million and payment of offering issuance costs of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On October 6, 2021, the Company commenced sales of its common stock pursuant to the at-the-market offering. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions, changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For a description of our critical accounting policies, see Note 2 &#8211; Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recently Adopted and Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a description of recently adopted and issued accounting pronouncements, including adoption dates and estimated effects, if any, on our condensed financial statements, see Note 2 &#8211; Summary of Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form&#160;10-Q.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_620400e1_4962_4297_910f_a3b5ee1ff961"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">We are a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), for this reporting period and are not required to provide the information required by this item.</p><a id="_c953580e_de43_4f2b_ac41_80d9e2096b8b"></a><a id="Item4ControlsandProcedures_795021"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;4. Controls and Procedures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Based on their evaluation, our principal executive officer and principal financial and accounting officer concluded that as of September 30, 2021 our disclosure controls and procedures were designed to, and were effective to, provide assurance at a reasonable level that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There has been no change in our internal control over financial reporting that occurred during the third quarter of 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ae34bbc5_8e02_4f8c_9c7b_33e785f2e509"></a><a id="PARTIIOTHERINFORMATION_210178"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART&#160;II&#160;- OTHER INFORMATION</b></p><a id="Item1LegalProceedings_458954"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;1. Legal Proceedings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_800d62d4_b947_4e5b_b0ea_91802cb555c1"></a><a id="Item1ARiskFactors_613824"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;1A. Risk Factors.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a smaller reporting company, as defined in Rule 12b-2 under the Exchange Act, for this reporting period and are not required to provide the information required by this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7ce174c8_54a3_4180_8b25_e2e1ab96992d"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_df393d28_d67a_4604_a412_8d46c4d9cf75"></a><a id="Item3DefaultsuponSeniorSecurities_662766"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;3. Defaults upon Senior Securities.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><a id="_0a7a34f9_a7ba_4a39_8cbf_e96b153d1018"></a><a id="Item4MineSafetyDisclosures_19173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;4. Mine Safety Disclosures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4bb6066d_a1db_453b_a195_eb86da946129"></a><a id="Item5OtherInformation_587983"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;5. Other Information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_2631bef7_f8e2_47e9_9a1a_c5e5c1a3d65b"></a><a id="Item6Exhibits_406166"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;6. Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:44.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Incorporated&#160;by&#160;Reference&#160;(Unless&#160;Otherwise&#160;Indicated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:40.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.79%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:11.55%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.1+</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Amendment 1 to the License Agreement between Eyenovia, Inc. and Arctic Vision (Hong Kong) Limited, dated September 14, 2021</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.2+</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Amendment 2 to the Exclusive License Agreement between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd., effective as of May 2021</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">10.3+</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">First Amendment to Loan and Security Agreement between Eyenovia, Inc. and Silicon Valley Bank, dated September 29, 2021</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;" href="eyen-20210930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">Certification of the Principal Financial and Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Filed herewith</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Inline Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Condensed Balance Sheets as of September 30, 2021 and December 31, 2020; (ii) Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020; (iii) Condensed Statements of Changes in Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2021 and 2020; Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020; and (iv) Notes to Condensed Financial Statements</p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Cover Page&#160;Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)</p></td><td style="vertical-align:top;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">+          Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bc9a112f_be3c_4752_9ff1_16531081befb"></a><a id="SIGNATURES_5708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EYENOVIA,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 12, 2021</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Gandolfo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Gandolfo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer <br />(Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>eyen-20210930xex10d1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:18 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AMENDMENT 1 TO LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="font-size:12pt;">This </font><b style="font-size:12pt;font-weight:bold;">AMENDMENT 1 TO LICENSE AGREEMENT </b><font style="font-size:12pt;">(the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Amendment</b><font style="font-size:12pt;">&#8221;) is entered into on September ___, 2021 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Amendment Effective Date</b><font style="font-size:12pt;">&#8221;) by and between </font><b style="font-size:12pt;font-weight:bold;">EYENOVIA, INC.</b><font style="font-size:12pt;">, a Delaware corporation with a place of business at 295 Madison Ave., New York, NY 10017 (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Eyenovia</b><font style="font-size:12pt;">&#8221;), and </font><b style="font-size:12pt;font-weight:bold;">ARCTIC VISION (HONG KONG) LIMITED</b><font style="font-size:12pt;">, a Hong Kong company with a registered office at 19th Floor, Three Exchange Square, 8 Connaught Place, Central, Hong Kong (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Arctic Vision</b><font style="font-size:12pt;">&#8221;). Eyenovia and Arctic Vision may be referred to herein individually as a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Party</b><font style="font-size:12pt;">&#8221; and collectively as the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Parties</b><font style="font-size:12pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Recitals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.4pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, Eyenovia and Arctic Vision entered into that certain License Agreement dated August 10, 2020 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">License Agreement</b><font style="font-size:12pt;">&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.4pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, Eyenovia and Arctic Vision desire to amend the License Agreement on the terms and conditions set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.4pt;margin:0pt 0pt 12pt 3.6pt;"><b style="font-size:12pt;font-weight:bold;">NOW THEREFORE</b><font style="font-size:12pt;">, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, Arctic Vision and Eyenovia hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">AGREEMENT</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Any capitalized terms used in this Amendment shall have the meaning assigned to them in the License Agreement, except as otherwise amended herein.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">References in the License Agreement to &#8220;either Product&#8221; are hereby deleted and replaced with references to &#8220;any Product.&#8221;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="color:#010101;font-size:12pt;text-decoration:underline;text-decoration-color:#010101;">Section 1.4</u><font style="color:#010101;font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Additional Indication</b><font style="font-size:12pt;">&#8221; means any Indication other than (a) presbyopia with respect to the MicroLine Product, (b) myopia with respect to the MicroPine Product, and (c) mydriasis with respect to the MicroStat product.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="color:#010101;font-size:12pt;text-decoration:underline;text-decoration-color:#010101;">Section 1.24</u><font style="color:#010101;font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:40.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">1.24</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">&#8220;Competitive Combination Product&#8221;</b><font style="color:#010101;font-size:12pt;"> means (a) for the MicroLine Product, pilocarpine and [***], (b) for the MicroPine Product, atropine sulfate and [***], and (c) for the MicroStat Product, </font><font style="font-size:12pt;">phenylephrine plus tropicamide fixed combination </font><font style="color:#010101;font-size:12pt;">[***].</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="color:#010101;font-size:12pt;text-decoration:underline;text-decoration-color:#010101;">Section 1.25</u><font style="color:#010101;font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">1.25</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Competitive Senju Product</b><font style="font-size:12pt;">&#8221; means a Senju Product for the treatment of (a) myopia (in the case of a MicroPine Product), (b) improvement in near vision or presbyopia (in the case of a MicroLine Product) or (c) mydriasis (in the case of a MicroStat Product).</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 1.50</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">1.50 </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">&#8220;Initial Indications</b><font style="font-size:12pt;">&#8221; means, with respect to (a) the MicroLine Product, presbyopia; (b) the MicroPine Product, myopia; and (c) the MicroStat Product, mydriasis.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 1.58</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">1.58 </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">&#8220;Licensed Know-How</b><font style="font-size:12pt;">&#8221; means, subject to Section 11.2(b), all Know-How that (a) is Controlled by Eyenovia or any of its Affiliates as of the Effective Date or at any time during the Term and (b) is necessary or reasonably useful for the Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Product in the Field, including, for the avoidance of doubt, (i) all such Know-How in any and all Improvements, (ii) Eyenovia&#8217;s and its Affiliates&#8217; interest in any Joint Invention satisfying clauses (a) and (b) above, and (iii) MicroStat Product Gen 1 and Gen 2 new drug application filings and related Know-How.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 1.76</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">1.76 </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">&#8220;Product&#8221;</b><font style="font-size:12pt;"> means (a) the MicroLine Product, (b) the MicroPine Product, and/or (c) the MicroStat Product, as the context dictates.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.6 (b)</u><font style="color:#010101;font-size:12pt;"> of the License Agreement </font><font style="font-size:12pt;">is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">directly or indirectly through a Third Party, Develop or Commercialize any pharmaceutical product for the treatment of (i) myopia (in the case of a MicroPine Product), (ii) improvement in near vision or presbyopia (in the case of a MicroLine Product), or (iii) mydriasis (in the case of a MicroStat Product), in each case in such Region, except, in each case, to the extent rights to Develop or Commercialize such product in such Region are granted under the Senju License Agreement;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.6 (d)</u><font style="color:#010101;font-size:12pt;"> of the License Agreement</font><font style="font-size:12pt;"> is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:12pt;">supply the Optejet Dispenser Base that is compatible for use with the cartridges included as a component in a Product, or the cartridge included as a component in such Product, to any Third Party in such Region to deliver a pharmaceutical product for the treatment of (i) myopia (in the case of a MicroPine Product), (ii) improvement in near vision or presbyopia (in the case of a MicroLine Product) or (iii) mydriasis (in the case of a MicroStat Product);</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 2.6 (f)</u><font style="color:#010101;font-size:12pt;"> of the License Agreement </font><font style="font-size:12pt;">is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f) </font></font><font style="font-size:12pt;">supply to any Third Party in such Region (other than a designee of Arctic Vision) (i) pilocarpine (</font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">) formulated and loaded into a cartridge for use in the treatment of improvement in near vision or presbyopia, (ii) atropine sulfate (</font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">) formulated and loaded into a cartridge for the treatment of myopia; or (iii) </font><font style="color:#010101;font-size:12pt;">phenylephrine plus tropicamide fixed combination ([***]) </font><font style="color:#010101;font-size:12pt;">formulated</font><font style="font-size:12pt;"> and loaded into a cartridge for the treatment of mydriasis; or</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.4(a)</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a) </b></font><b style="font-size:12pt;font-weight:bold;">Initial Indications</b><font style="font-size:12pt;">. &#160;Arctic Vision (either itself or through its Affiliates and Sublicensees) shall use Commercially Reasonable Efforts to Develop and Commercialize (a) the MicroLine Product for the treatment of presbyopia in the Territory and (b) the MicroPine Product for the treatment of myopia in the Territory. Arctic Vision (either itself or through its Affiliates and Sublicensees) shall use Commercially Reasonable Efforts to file for [Clinical Trial Waiver] with the CFDA not later than </font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">) months following Regulatory Approval by the FDA for the MicroStat Product in the US and thereafter use Commercially Reasonable Efforts to Develop and, once approved, Commercialize the MicroStat Product for the treatment of mydriasis in the Territory.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4.10(a)</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">(a) </b></font><b style="font-size:12pt;font-weight:bold;">Eyenovia Supply</b><font style="font-size:12pt;">. &#160;Except as provided in Section 4.10(c) below, and subject to the Parties&#8217; execution, and the terms of, the Supply Agreement, Eyenovia shall manufacture and supply, through itself, one or more of its Affiliates, or one or more Third Party CMO(s), the Products in finished, assembled form for use in the Development and Commercialization of the Products under this Agreement. &#160;Subject to Section 4.10(c), all Products supplied by Eyenovia to Arctic Vision under the Supply Agreement shall be at a price equal to the Supply Price for such Product set forth in Section 5.3, and Eyenovia shall source such Products, and the components thereof, from one or more manufacturers (which may be any combination of Eyenovia, any Affiliates thereof, or Third Party CMOs that Eyenovia or its Affiliate reasonably determines in good faith to be appropriately qualified for such manufacture), provided that within </font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">) </font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;"> after submitting the first MAA of a Product in the U.S., Eyenovia shall have at least two (2) manufacturers (which may be any combination of Eyenovia, any Affiliates thereof, or Third Parties) able (i.e., with all technology transfer reasonably necessary to be operational completed) to manufacture and supply for each stage of the manufacturing process of the Products (for example, two (2) manufacturers providing MicroLine Product, MicroPine Product and MicroStat Product drug substance, two (2) manufacturers manufacturing MicroLine Product, MicroPine Product and MicroStat Product cartridges, two (2) manufacturers performing drug-cartridge assembly, etc.).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.1</u><font style="color:#010101;font-size:12pt;"> of the License Agreement </font><font style="font-size:12pt;">is amended by adding the following new terms:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">In addition to payments already provided to Eyenovia per terms of the License Agreement, Arctic Vision shall pay to Eyenovia a one-time upfront payment of two hundred and fifty thousand dollars ($</font><font style="color:#010101;font-size:12pt;">250,000</font><font style="font-size:12pt;">) within </font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">) Business Days after the Amendment Effective Date, with Arctic Vision initiating an irrevocable wire transfer to Eyenovia therefor, and providing Eyenovia reasonable written evidence thereof.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">15.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.2</u><font style="color:#010101;font-size:12pt;"> of the License Agreement </font><font style="font-size:12pt;">is amended by adding the following new rows 10 through 13 to the chart of Milestone Events:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:4.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:53.33%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Development and Regulatory Milestone Events</b></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Payment</b></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10)</font></p></td><td style="vertical-align:top;width:53.33%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">11)</font></p></td><td style="vertical-align:top;width:53.33%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">12)</font></p></td><td style="vertical-align:top;width:53.33%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">13)</font></p></td><td style="vertical-align:top;width:53.33%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">16.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 5.5</u><font style="color:#010101;font-size:12pt;"> of the License Agreement</font><font style="font-size:12pt;"> is amended to include royalty payments applicable to the MicroStat Product on the same terms and condition as applicable to the MicroPine Product and the MicroLine Product. For clarity and in accordance with the License Agreement, the royalty payments shall be calculated by multiplying the applicable royalty rate set forth in the table below by the corresponding amounts of Net Sales of such MicroPine Products, MicroLine Products or MicroStat Products, respectively, sold in the Territory in the applicable Calendar Year.</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:bottom;width:84.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">For that portion of Net Sales of MicroPine Products, MicroLine Products or MicroStat Products in the Territory in a particular Calendar Year</b></p></td><td style="vertical-align:bottom;width:15.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1)</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">less than or equal to</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">2)</font></p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">greater than</font></p></td><td style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.83%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:42.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">but less than or equal to</font></p></td><td style="vertical-align:bottom;width:39.03%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#010101;font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td rowspan="2" style="vertical-align:top;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">3)</font></p></td><td rowspan="2" style="vertical-align:top;width:42.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">greater than <br>but less than or equal to</font></p></td><td style="vertical-align:bottom;width:39.03%;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.82%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="display:none;vertical-align:bottom;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="display:none;vertical-align:bottom;width:42.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:39.03%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:2.5%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4)</font></p></td><td style="vertical-align:bottom;width:42.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">greater than</font></p></td><td style="vertical-align:bottom;width:39.03%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">$</font><font style="color:#010101;font-size:12pt;">[***]</font></p></td><td style="vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">17.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">The introductory sentence of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8.1</u><font style="font-size:12pt;"> of the License Agreement is amended as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:left;">8.1 </b></font><b style="font-size:12pt;font-weight:bold;">Mutual Representations and Warranties</b><font style="font-size:12pt;">. Each Party hereby represents, warrants, and covenants (as applicable) to the other Party, as of the Amendment Effective Date, as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">18.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">The introductory sentence of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8.2</u><font style="font-size:12pt;"> of the License Agreement is amended as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:left;">8.2 </b></font><b style="font-size:12pt;font-weight:bold;">Additional Representations and Warranties</b><font style="font-size:12pt;">. Eyenovia hereby represents and warrants to Arctic Vision that, as of the Effective Date for the MicroLine Product and the MicroPine Product and as of the Amendment Effective Date for MicroStat Product, as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">19.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8.3(b)</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:left;">(b) </b></font><font style="font-size:12pt;">Eyenovia is, as of the Amendment Effective Date, in compliance in all material respects with the Senju License Agreement, and, to Eyenovia&#8217;s knowledge, the other party to the Senju License Agreement is, as of the Amendment Effective Date, not in breach or default in any respect of the Senju License Agreement pertaining to the Product.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">20.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8.4</u><font style="font-size:12pt;"> of the License Agreement is amended and restated in its entirety as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:left;">8.4 </b></font><b style="font-size:12pt;font-weight:bold;">Arctic Vision Representations, Warranties, and Covenants Regarding the Senju License Agreement.</b><font style="font-size:12pt;white-space:pre-wrap;">  Arctic Vision represents and warrants that, as of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">Effective Date for the MicroLine Product and the MicroPine Product and as of the Amendment Effective Date for the MicroStat Product, neither it nor any of its Affiliates is a Senju Competitor. Notwithstanding anything to the contrary, Arctic Vision shall not, and shall ensure that Sublicensees and its Affiliates do not, (i) sublicense any rights granted hereunder to any Third Party that is a Senju Competitor at the time such sublicense is granted, (ii) permit any Sublicensee to sublicense its rights to any Third Party that is a Senju Competitor at the time such sublicense is granted, or (iii) indirectly or directly sell or otherwise provide, or permit any Affiliate of Arctic Vision or Sublicensee to indirectly or directly sell or otherwise provide, any Product to any Third Party that is a Senju Competitor.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">21.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 8.6</u><font style="font-size:12pt;"> is hereby added to the License Agreement as follows:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:left;">8.6 </b></font><b style="font-size:12pt;font-weight:bold;">Updated Representations, Warranties and Covenants.</b><font style="font-size:12pt;"> The Parties hereby agree and acknowledge that the representations, warranties and covenants in this Agreement were made as of the Effective Date with respect to the MicroLine Product and the MicroPine Product. The Parties hereby agree and acknowledge that the representations, warranties and covenants in this Agreement are made as of the Amendment Effective Date with respect to the MicroStat Product and as otherwise explicitly noted in this Article 8.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">22.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11.5</u><font style="color:#010101;font-size:12pt;"> of the License Agreement </font><font style="font-size:12pt;">is hereby amended by deleting the notice information for Wyrick Robbins Yates &amp; Ponton LLP and replacing it with the following:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">with a copy (which shall not constitute notice) to:</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 3580 Carmel Mountain Road, Suite 300</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">San Diego, CA 92130</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Attn:</font></p></td><td style="vertical-align:bottom;width:93.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Fred Hernandez</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Fax:</font></p></td><td style="vertical-align:bottom;width:93.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(858) 314-1501</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">23.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">24.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">25.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">26.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***]</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">27.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">Except as amended by this Amendment, the License Agreement shall remain in full force and effect.  This Amendment may not be modified, amended, or varied in any manner unless by a written agreement duly executed by each of the Parties.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, Eyenovia and Arctic Vision have executed this Amendment by their respective duly authorized representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EYENOVIA, INC.</b></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;">&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;">ARCTIC VISION (HONG KONG) LIMITED</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:48.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Tsontcho Ianchulev</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Wu Hoi Ti</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:38.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Tsontcho Ianchulev</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Wu Hoi Ti</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:38.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CEO</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CEO</font></p></td></tr><tr><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:38.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9/14/2021</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9/10/2021</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>eyen-20210930xex10d2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:21 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#010101;font-size:12pt;font-weight:bold;">LICENSE AMENDMENT 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">This LICENSE AMENDMENT 2 (the &#8220;LA2&#8221;) by and between:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Senju Pharmaceutical Co., Ltd., a corporation duly organized and existing under the laws of Japan, having a principal place of business at 3-1-9, Kawaramachi, Chuo-ku, Osaka 541-0048, Japan (&#8220;Senju&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">Eyenovia, Inc., a corporation organized and existing under the laws of Delaware, having a principal place of business at 295 Madison Avenue, Suite 2400, New York, NY 10017, U.S.A. (&#8220;Eyenovia&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">shall be effective as of May __, 2021 (the &#8220;LA2 Effective Date&#8221;), and where Senju and Eyenovia are each individually referred to herein as a &#8220;Party&#8221; and collectively referred to as the &#8220;Parties&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">RECITALS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">WHEREAS, Senju and Eyenovia are parties to an Exclusive License Agreement dated March 18, 2015 (the &#8220;Agreement&#8221;), which remains in full force and effect; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">WHEREAS, Senju and Eyenovia are parties to a License Amendment (the &#8220;LA1&#8221;) and a letter entitled &#8220;RE: Eye Spray Exclusive License Agreement&#8221; (the &#8220;Letter&#8221;), dated April 8, 2020 and August 7, 2020 respectively, both of which remain in full force and effect; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">WHEREAS, the Parties wish to confirm their mutual understanding of the terms of the Agreement as stated in this LA2; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">WHEREAS, it is the intentions of the Parties that the terms of the Agreement be so confirmed by way of this LA2.</font></p><p style="display:none;line-height:0pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="color:#010101;font-size:12pt;">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the Parties hereby agree as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Any capitalized terms in this LA2 shall have the meaning assigned to them in the Agreement, provided that the following terms are defined by this LA2:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#010101;font-size:12pt;font-style:italic;"> &#8220;China&#8221;</i><font style="color:#010101;font-size:12pt;"> shall mean the People&#8217;s Republic of China, and also Hong Kong, Macao, and Taiwan.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#010101;font-size:12pt;font-style:italic;">&#8220;LA2 Licensed Products&#8221;</i><font style="color:#010101;font-size:12pt;"> shall mean a Licensed Product using piezo-print technology in a microdose dispenser containing: the chemical substance atropine sulfate as its sole active ingredient and that is used for the treatment of myopia in humans; the chemical substance pilocarpine as its sole active ingredient and that is used for the treatment of presbyopia in humans; the chemical substances phenylephrine and tropicamide in combination as active ingredients that are used for pharmaceutical mydriasis in humans.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(3)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#010101;font-size:12pt;font-style:italic;">&#8220;LA2 Term&#8221;</i><font style="color:#010101;font-size:12pt;"> shall mean the period of time from the LA2 Effective Date until the end of one (1) year thereafter.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(4)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="color:#010101;font-size:12pt;font-style:italic;">&#8220;Senju Licensed Know-How&#8221;</i><font style="color:#010101;font-size:12pt;"> shall mean any and all information, data, clinical studies, instructions, proprietary information, trade secrets, techniques or materials which are related to and generated by Senju&#8217;s activities (or those performed on Senju&#8217;s behalf) under the Agreement for the Licensed Product.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(5)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">&#8220;</font><i style="color:#010101;font-size:12pt;font-style:italic;">Senju Inventions</i><font style="color:#010101;font-size:12pt;">&#8221; shall mean Inventions generating from Senju&#8217;s activities (or those performed on Senju&#8217;s behalf) under the Agreement for the Licensed Product.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">LA1 shall be terminated as of the LA2 Effective Date and any rights and obligations set forth in LA1 shall be transferred to and re-stated in this LA2.  For clarification, the amount to be paid to Senju upon the execution of the arrangement with Eyenovia Designated Third Party for atropine product and pilocarpine product pursuant to Section 4.5(i)(b) has been already paid as of the LA2 Effective Date and shall not be refundable.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">For the LA2 Term and only for the LA2 Licensed Products, the Territory as stated in Section 1.15 of the Agreement shall exclude China and South Korea.  For the purpose of clarification, this exclusion shall not affect Senju&#8217;s rights to the LA2 Licensed Product outside of China and South Korea.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">If before the end of the LA2 Term, Eyenovia enters into a definitive arrangement with any third party which Eyenovia designates (&#8220;Eyenovia Designated Third Party&#8221;) for the LA2 Licensed Products in China and South Korea, then the exclusion of Section 2 of this LA2 shall continue as long as the definitive agreement with the Eyenovia Designated Third Party is in place, unless otherwise altered by agreement of the Parties.  Provided, however, that:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Eyenovia itself may not research, develop, commercialize, manufacture, or use the LA2 Licensed Products in China and South Korea (and accordingly it doing so would not extend the exclusion of Section 2 of this LA2); this restriction would not apply to the third party under terms of a license agreement; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Subject to the terms and conditions of this LA2, and without limitation of Sections 2.1.4, 6.1.1, 7.4.3, and 7.4.4 of the Agreement, Eyenovia has a right by way of sub-license to the Eyenovia Designated Third Party, to research, develop, commercialize, manufacture, or use the LA2 Licensed Products in China and South Korea, under the Senju Licensed Know-How and Senju Inventions, as applicable.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(3)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">Senju has a right, with a right to Sublicense in accordance with the Agreement, to research, develop, commercialize, manufacture, or use, under the Licensed Know-How and Inventions with respect to the Licensed Product generated from the Eyenovia Designated Third Party&#8217;s activities under this LA2, (a) the Licensed Products other than LA2 Licensed Products in China and South Korea, and (b) the Licensed Products in countries of the Territory other than China and South Korea.  For the purpose of clarification, Senju&#8217;s right to use the Licensed Know-How and Invention under this</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="color:#010101;font-size:12pt;">Section will not increase the Running Royalty in Section 6.2 of the Agreement and/or extend Royalty Term/Term under Sections 6.3 and 7.1 of the Agreement, respectively,</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(4)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Senju makes no representations or warranties that the Senju Licensed Know-How and/or Senju Inventions are sufficient to develop, manufacture or commercialize the Licensed Product, including LA2 Licensed Products, nor that any resulting patent applications for Senju Inventions will be granted or patents enforceable.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(5)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">In consideration for the exclusion of Section 2 of this LA2, Eyenovia shall pay to Senju the following compensation upon and after the execution of the arrangement with Eyenovia Designated Third Party:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Non-Royalty License Revenue:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:70.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">$250,000 representing the entirety of the lump-sum payment received from Eyenovia Designated Third Party if Eyenovia licenses the phenylephrine plus tropicamide combination product;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:70.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***] percent ([***]%) of any lump-sum payment received from Eyenovia Designated Third Party if Eyenovia licenses any other LA2 Licensed Product, including, without limitation, any signing fee and, upfront;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:70.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***] percent ([***]%) of any lump-sum payment received from Eyenovia Designated Third Party if Eyenovia licenses any LA2 Licensed Product for milestones; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:70.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***] percent ([***]%) of any net revenue obtained from contract research and/or development for the LA2 Licensed Product; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:70.55pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">[***] percent ([***]%) of any net revenue obtained from contract manufacture for the device of the LA2 Licensed Product.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 70.9pt;"><font style="color:#010101;font-size:12pt;">In the case of contract manufacturing, Net Revenue is defined as [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 70.9pt;"><font style="color:#010101;font-size:12pt;">In the case of contract research and or development, Net Revenue is defined as [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 70.9pt;"><font style="color:#010101;font-size:12pt;">Senju must receive a minimum of [***] United States Dollars (US$[***]) in payments for Non-Royalty License Revenue under this Section 3. (3) (i).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Revenue from running royalty based on sales:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 70.9pt;"><font style="color:#010101;font-size:12pt;">[***] percent ([***]%) of all sales royalty revenues received by Eyenovia for the sale or commercialization of the LA2 Licensed Product in China and South Korea by Eyenovia Designated Third Party.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">At the request of Senju, Eyenovia shall deliver to Senju a true and accurate report setting out in detail the information necessary to calculate the payments and revenues due under Section 3(3), including all deductions made under Net Revenues.  Eyenovia shall retain records pertaining to such payments and revenues, which will be open for inspection by an auditor chosen by Senju, for the purpose of verifying the amounts payable by Eyenovia hereunder.  Such inspections shall be at the expense of Senju, unless a variation or error producing an underpayment in amounts payable exceeding five percent (5%) of the amount paid for any period covered by the inspection is established, in which case, all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered shall be paid by Eyenovia.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;white-space:pre-wrap;">In the event that Eyenovia fails to enter into such a definitive arrangement with Eyenovia Designated Third Party for the LA2 Licensed Product in China and South Korea during the LA2 Term, then the exclusion of Section 2 of this LA2 shall end at the end of the LA2 Term.  In the event that such arrangement was to be entered into during the LA2 Term, but then expire or otherwise terminate thereafter, then the exclusion of Section 2 of this LA2 shall end upon such expiration or termination.  In either such case, Senju would regain and retain full rights to the LA2 License Product in China and South Korea.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">Any material breach by Eyenovia of the terms of this LA2 shall be grounds for Senju to terminate this LA2 upon notification to Eyenovia and after Eyenovia is given sixty (60) days to address any such material breach. If Eyenovia remains in such material breach after that time, Senju may terminate this LA2 and the rights and obligations stated herein.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">The Parties agree and acknowledge that &#8220;LA Licensed Product&#8221; in the Letter shall be replaced in its entirety to &#8220;LA2 Licensed Product.&#8221;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">The remaining terms and conditions of the Agreement shall remain unchanged, and in full force and effect.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="color:#010101;font-size:12pt;">This LA2 may be executed in counterparts and signature pages may be delivered by facsimile or scanned (&#8220;PDF&#8221;) form, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;white-space:pre-wrap;"> [Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, Eyenovia and Senju have executed this LA2 by their respective duly authorized representatives.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">EYENOVIA, INC.</b></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SENJU PHARMACEUTICAL CO., LTD.</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">(&#8220;Senju&#8221;)</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Tsontcho Ianchulev</font></p></td><td style="vertical-align:bottom;width:3.33%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Shuhei Yoshida</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:39.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Tsontcho Ianchulev</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Shuhei Yoshida</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:39.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CEO</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">President</font></p></td></tr><tr><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:39.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">9/14/2021</font></p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">5/14/2021</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>eyen-20210930xex10d3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:25 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INFORMATION HAS BEEN REDACTED.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FIRST AMENDMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">LOAN AND SECURITY AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This First Amendment to Loan and Security Agreement (this &#8220;Amendment&#8221;) is entered into this 29</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">day of September, 2021, by and between </font><b style="font-size:11pt;font-weight:bold;">SILICON VALLEY BANK</b><font style="font-size:11pt;"> (&#8220;Bank&#8221;) and </font><b style="font-size:11pt;font-weight:bold;">EYENOVIA, INC.</b><font style="font-size:11pt;">, a Delaware corporation (&#8220;Borrower&#8221;) whose address is 295 Madison Avenue, Suite 2400, New York, New York 10017.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">A.</b></font><font style="font-size:11pt;">Bank and Borrower have entered into that certain Loan and Security Agreement dated as of May 7, 2021 (as the same may from time to time be amended, modified, supplemented or restated, the &#8220;Loan Agreement&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">B.</b></font><font style="font-size:11pt;">Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">C.</b></font><font style="font-size:11pt;">Borrower has requested that Bank amend the Loan Agreement to make certain revisions to the Loan Agreement as more fully set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">D.</b></font><font style="font-size:11pt;">Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">NOW, THEREFORE,</b><font style="font-size:11pt;"> in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-size:11pt;font-weight:bold;">Definitions.</b><font style="font-size:11pt;"> &#160;Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 4.5pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-size:11pt;font-weight:bold;">Amendments to Loan Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">2.1</b></font><b style="font-size:11pt;font-weight:bold;">Section 5.7 (Financial Covenant).</b><font style="font-size:11pt;"> &#160;Section 5.7(a) is amended in its entirety and replaced with the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><b style="font-size:11pt;font-weight:bold;">(a)</b><font style="display:inline-block;width:23.17pt;"></font><b style="font-size:11pt;font-weight:bold;">Minimum Equity Raise</b><font style="font-size:11pt;">. Borrower shall deliver evidence to Bank, satisfactory to Bank in its sole but reasonable discretion that Borrower has received, after the Effective Date, but prior to November&#160;30, 2021, unrestricted and unencumbered net cash proceeds in an aggregate amount of at least [***] from the issuance and sale by Borrower of its equity securities to investors reasonably acceptable to Bank.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">2.2</b></font><b style="font-size:11pt;font-weight:bold;">Section 5.14 (Cash Collateralization)</b><font style="font-size:11pt;">. The following new Section 5.14 is inserted to appear immediately following Section 5.13 thereof:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">&#8220;</font></font><b style="font-size:11pt;font-weight:bold;">5.14</b><font style="display:inline-block;width:16.75pt;"></font><b style="font-size:11pt;font-weight:bold;">Cash Collateralization. </b><font style="font-size:11pt;"> At all times prior to the occurrence of the Release Event, Borrower shall maintain unrestricted and unencumbered cash in the Cash Collateral Account in an amount equal to at least $7,875,000.00. Borrower hereby authorizes and directs Bank to transfer to the Cash Collateral Account an amount equal to $7,875,000.00 on or about the First Amendment Effective Date as required under this Section 5.14 (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Cash Collateralization</b><font style="font-size:11pt;white-space:pre-wrap;">&#8221;).  If Bank determines, in its sole and absolute discretion, that the Release Event has not occurred on or prior to November 30, 2021, Borrower further authorizes Bank, at the election of Bank, in Bank&#8217;s sole and absolute discretion, upon notice thereof to Borrower, to apply the funds held in the Cash Collateral Account on account of the outstanding Obligations of Borrower to Bank (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Paydown Payment</b><font style="font-size:11pt;">&#8221;).&#160; Upon the occurrence of the Release Event, the unrestricted and unencumbered cash pledged and deposited into the Cash Collateral Account, pursuant to this Section 5.14, shall be promptly remitted to Borrower&#8217;s Designated Deposit Account. For the avoidance of doubt, the Paydown Payment shall not be subject to the Prepayment Fee.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></font><b style="font-size:11pt;font-weight:bold;">Section 12.2 (Definitions)</b><font style="font-size:11pt;">. The Loan Agreement is amended by inserting the following new terms and their respective definitions to appear alphabetically in Section 12.2 thereof:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;white-space:pre-wrap;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Cash Collateral Account</b><font style="font-size:11pt;">&#8221; means a separate segregated collateral money market account of Borrower maintained with Bank, which is subject to the Cash Pledge Agreement.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Cash Collateralization</b><font style="font-size:11pt;">&#8221; is defined in Section 5.14.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Cash Pledge Agreement</b><font style="font-size:11pt;">&#8221; is that certain cash pledge agreement dated as of the First Amendment Effective Date, executed by Borrower in favor of Bank, as amended, modified, supplemented and/or restated from time to time.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;white-space:pre-wrap;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">First Amendment Effective Date</b><font style="font-size:11pt;">&#8221; means September 29, 2021.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Paydown Payment</b><font style="font-size:11pt;">&#8221; is defined in Section 5.14.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Release Event</b><font style="font-size:11pt;">&#8221; occurs if and when (if ever) Bank confirms in writing that it has received evidence, satisfactory to Bank in its sole and absolute discretion, after the First Amendment Effective Date, but on or prior to November 30, 2021, that Borrower has (a) received FDA approval of MydCombi on or prior to November 30, 2021, and (b) achieved the minimum equity raise financial covenant set forth in Section 5.7(a) hereof.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">2.4</b></font><b style="font-size:11pt;font-weight:bold;">Section 12.2 (Definitions).</b><font style="font-size:11pt;"> The following term and its respective definition set forth in Section 12.2 is amended in its entirety and replaced with the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">&#8220;</font></font><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Loan Documents</b><font style="font-size:11pt;">&#8221; are, collectively, this Agreement and any schedules, exhibits, certificates, notices, and any other documents related to this Agreement, the Cash Pledge Agreement, the Perfection Certificate, the Warrant, any Control Agreements, any Bank Services Agreement, any subordination agreement, any note, or notes or guaranties executed by Borrower or any Guarantor, landlord waivers and consents, bailee waivers and consents, and any other present or future agreement by Borrower and/or any Guarantor</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><font style="font-size:11pt;">with or for the benefit of Bank in connection with this Agreement or Bank Services, all as amended, restated, or otherwise modified in accordance with the terms thereof.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">2.5</b></font><b style="font-size:11pt;font-weight:bold;">Exhibit A (Compliance Statement)</b><font style="font-size:11pt;">. &#160;The Compliance Statement appearing as </font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b><font style="font-size:11pt;"> to the Loan Agreement is deleted in its entirety and replaced with the Compliance Statement attached as </font><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 1</b><font style="font-size:11pt;"> attached hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-size:11pt;font-weight:bold;">Limitation of Amendments.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">3.1</b></font><font style="font-size:11pt;">The amendments set forth in Section&#160;2, above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a)&#160;be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b)&#160;otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">3.2</b></font><font style="font-size:11pt;">This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-size:11pt;font-weight:bold;">Representations and Warranties.</b><font style="font-size:11pt;"> &#160;To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.1</b></font><font style="font-size:11pt;">Immediately after giving effect to this Amendment (a)&#160;the representations and warranties contained in the Loan Documents are true, accurate, and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b)&#160;no Event of Default has occurred and is continuing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.2</b></font><font style="font-size:11pt;">Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.3</b></font><font style="font-size:11pt;">The organizational documents of Borrower delivered to Bank on the Effective Date, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.4</b></font><font style="font-size:11pt;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.5</b></font><font style="font-size:11pt;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a)&#160;any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c)&#160;any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d)&#160;the organizational documents of Borrower;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.6</b></font><font style="font-size:11pt;">The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">except as already has been obtained or made; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-align:justify;">4.7</b></font><font style="font-size:11pt;">This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-size:11pt;font-weight:bold;">Ratification of Perfection Certificate</b><font style="font-size:11pt;">. &#160;Borrower hereby ratifies, confirms and reaffirms, all and singular, the terms and disclosures contained in a certain Perfection Certificate dated as of May 7, 2021, and acknowledges, confirms and agrees that the disclosures and information Borrower provided to Bank in such Perfection Certificate have not changed, as of the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-size:11pt;font-weight:bold;">Integration</b><font style="font-size:11pt;">. &#160;This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. &#160;All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-size:11pt;font-weight:bold;">Counterparts.</b><font style="font-size:11pt;"> &#160;This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-size:11pt;font-weight:bold;">Effectiveness</b><font style="font-size:11pt;">. &#160;This Amendment shall be deemed effective upon (a) the due execution and delivery to Bank of this Amendment by each party hereto, (b) the due execution and deliver to Bank of the Cash Pledge Agreement by each party thereto, and (c)&#160;Borrower&#8217;s payment to Bank of Bank&#8217;s reasonable and documented legal fees and expenses incurred in connection with this Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">[Signature page follows.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF, </b><font style="font-size:11pt;">the parties hereto have caused this Amendment to be duly executed as a sealed instrument under the laws of the Commonwealth of Massachusetts and delivered as of the date first written above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:45.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:41.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">BANK</b></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">BORROWER</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">SILICON VALLEY BANK</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">EYENOVIA, INC.</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:middle;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:47.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:middle;width:45.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Lauren Cole</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:middle;width:41.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ John Gandolfo</font></p></td></tr><tr><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:middle;width:45.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Lauren Cole</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:middle;width:41.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">John Gandolfo</font></p></td></tr><tr><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:middle;width:45.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Director</font></p></td><td style="vertical-align:middle;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:5.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:middle;width:41.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Schedule 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">COMPLIANCE STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TO:</p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SILICON VALLEY BANK</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FROM:</p></td><td style="vertical-align:top;width:29.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EYENOVIA, INC.</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;">Under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (as amended, modified, supplemented and/or restated from time to time, the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below. &#160;Attached are the required documents evidencing such compliance, setting forth calculations prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. &#160;Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 5pt;"><b style="font-weight:bold;">Please indicate compliance status by circling Yes/No under &#8220;Complies&#8221; column.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Reporting Covenants</b></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Required</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Complies</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Monthly financial statements with <br>Compliance Statement</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Monthly within 30 days (except for the</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">months ending March 31, June 30, September 30, and December 31)</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q Report with Compliance Statement</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Q1, Q2, and Q3 within 45 days</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K Report and Annual financial statements (CPA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audited) with Compliance Statement</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FYE within 90 days</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A/R and A/P Agings</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon the Funding Date of the Term B Loan Advance, monthly within 30 days</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Filed 10-Q, 10-K and 8-K</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within 5 days after filing with</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SEC</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Board approved projections</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FYE within 30 days and as amended/updated</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">Yes   No</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Financial Covenant</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Required</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Actual</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Complies</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="font-weight:bold;margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="font-weight:bold;margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;">Maintain as indicated:</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="font-weight:bold;margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="font-weight:bold;margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;">Minimum Equity Raise</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;">[***]</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;">$_______</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Yes   No</b></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;">Commencing upon the Funding Date of the Term B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;">Loan Advance maintain as indicated:</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><font style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;">Minimum Product Revenue</p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><i style="font-style:italic;">See Section 5.7(b)</i></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.6pt;"><b style="font-weight:bold;">$_______</b></p></td><td style="vertical-align:top;width:20%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Yes   No</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following financial covenant analyses and information set forth in Schedule 1 attached hereto are true and correct as of the date of this Compliance Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following are the exceptions with respect to the statements above: (If no exceptions exist, state &#8220;No exceptions to note.&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 1 to Compliance Statement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Financial Covenants of Borrower</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event of a conflict between this Schedule and the Agreement, the terms of the Agreement shall govern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Dated:</font></font>____________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I.</font></font><b style="font-weight:bold;white-space:pre-wrap;">Minimum Equity Raise.  </b>(Section 5.7(a))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Required:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Borrower shall deliver evidence to Bank, satisfactory to Bank in its sole but reasonable discretion, that Borrower has received, after the Effective Date, but prior to November&#160;30, 2021, unrestricted and unencumbered net cash proceeds in an aggregate amount of at least [***] from the issuance and sale by Borrower of its equity securities to investors reasonably acceptable to Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual:</p></td><td style="vertical-align:top;width:54.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$________________</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:7.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:59.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No, not in compliance</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">_______Yes, in compliance</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">II.</font></font><b style="font-weight:bold;">Minimum Product Revenue</b>. (See Section 5.7(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Require:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commencing upon the Funding Date of the Term B Loan Advance, Borrower shall achieve, to be tested as of the last day of each month, minimum Product Revenue for the trailing 12 month period ending on such date, of at least:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;" align="center"><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:middle;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Minimum Product Revenue</b></p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">March 31, 2022</p></td><td style="vertical-align:middle;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">April 30, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">May 31, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">June 30, 2022</p></td><td style="vertical-align:middle;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">July 31, 2022</p></td><td style="vertical-align:middle;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">August 31, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">September 30, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">October 31, 2022</p></td><td style="vertical-align:middle;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">November 30, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr><tr><td style="vertical-align:middle;width:49.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">December 31, 2022</p></td><td style="vertical-align:top;width:50.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">*See Section 5.7(b) with respect to periods ending after December 31, 2022</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:59.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actual:</p></td><td style="vertical-align:top;width:52.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$________________</p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:59.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:59.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No, not in compliance</p></td><td style="vertical-align:top;width:32.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">_______Yes, in compliance</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Confidential Treatment Requested by Eyenovia, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to 17 C.F.R. Section 200.83</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ny-2251995</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>eyen-20210930xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:28 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">I, Tsontcho Ianchulev, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this Quarterly Report on Form 10-Q of Eyenovia, Inc. for the quarterly period ended September 30, 2021;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:10pt;"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 12, 2021</p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tsontcho Ianchulev</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tsontcho Ianchulev</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer<br>(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>eyen-20210930xex31d2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:31 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">I, John Gandolfo, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this Quarterly Report on Form 10-Q of Eyenovia, Inc. for the quarterly period ended September 30, 2021;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:39.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 12, 2021</p></td><td colspan="2" style="vertical-align:top;width:49.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Gandolfo</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:39.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Gandolfo</p></td></tr><tr><td style="vertical-align:top;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:39.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer<br>(Principal Financial and Accounting Officer)&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>eyen-20210930xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with this Quarterly Report of Eyenovia, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Tsontcho Ianchulev, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 12, 2021</p></td><td colspan="2" style="vertical-align:top;width:48.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tsontcho Ianchulev</p></td></tr><tr><td style="vertical-align:top;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tsontcho Ianchulev</p></td></tr><tr><td style="vertical-align:top;width:51.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer<br>(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>eyen-20210930xex32d2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/12/2021 11:05:38 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with this Quarterly Report of Eyenovia, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, John Gandolfo, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:33.65pt;text-indent:-33.65pt;margin:0pt 0pt 0pt 33pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:55.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 12, 2021</p></td><td colspan="2" style="vertical-align:top;width:44.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John Gandolfo</p></td></tr><tr><td style="vertical-align:top;width:55.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Gandolfo</p></td></tr><tr><td style="vertical-align:top;width:55.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer<br>(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eyen-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 11:06:05 AM-->
<!--Modified on: 11/12/2021 11:06:05 AM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" targetNamespace="http://www.eyenoviabio.com/20210930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:eyen="http://www.eyenoviabio.com/20210930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" id="StatementCondensedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" id="DisclosureAccruedCompensationDetails">
        <link:definition>40401 - Disclosure - Accrued Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" id="DisclosureNotesPayableScheduleOfNotesPayableDetails">
        <link:definition>40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity" id="StatementCondensedStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - Condensed Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" id="StatementCondensedStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails" id="DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" id="DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails">
        <link:definition>40602 - Disclosure - Notes Payable - Schedule of debt discount Note payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" id="DisclosureNotesPayableAdditionalInformationDetails">
        <link:definition>40603 - Disclosure - Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40801 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" id="DisclosureStockholdersEquityBlackScholesOptionDetails">
        <link:definition>40901 - Disclosure - Stockholders' Equity - Black Scholes option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" id="DisclosureStockholdersEquitySummaryOfOptionActivityDetails">
        <link:definition>40902 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" id="DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails">
        <link:definition>40903 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" id="DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails">
        <link:definition>40905 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>40906 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" id="DisclosureEmployeeBenefitPlansDetails">
        <link:definition>41001 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41101 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation" id="DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>10301 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" id="DisclosureAccruedCompensation">
        <link:definition>10401 - Disclosure - Accrued Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayable" id="DisclosureNotesPayable">
        <link:definition>10601 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10801 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10901 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
        <link:definition>11001 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11101 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" id="DisclosureAccruedCompensationTables">
        <link:definition>30403 - Disclosure - Accrued Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" id="DisclosureNotesPayableTables">
        <link:definition>30603 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30903 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" id="DisclosureStockholdersEquityWarrantsActivityDetails">
        <link:definition>40904 - Disclosure - Stockholders' Equity - Warrants Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" substitutionGroup="xbrli:item" />
  <xsd:element id="eyen_ProceedsOfStockIssuedDuringPeriodGross" name="ProceedsOfStockIssuedDuringPeriodGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_IncreaseDecreaseInDeferredRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element id="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_DisclosureOfAccruedCompensationTableTextBlock" name="DisclosureOfAccruedCompensationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="PrepaidRentAndSecurityDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidRentAndSecurityDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PrepaidConferenceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PrepaidConferenceExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PayrollTaxesReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_PayrollTaxesReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="eyen_AccruedResearchAndDevelopmentExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="eyen_CreditCardPayable" name="CreditCardPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="VicePresidentOfResearchAndDevelopmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_VicePresidentOfResearchAndDevelopmentMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SenjuPharmaceuticalCoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_SenjuPharmaceuticalCoMember" substitutionGroup="xbrli:item" />
  <xsd:element name="LeaseMonthlyBaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_LeaseMonthlyBaseRent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="RoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="eyen_RoyaltyPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceOneMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTwoMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceThreeMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFourMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceFiveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceFiveMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceSixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSixMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceSevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceSevenMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceEightMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceEightMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceNineMemberMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceNineMemberMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceTenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="eyen_ExercisePriceTenMember" substitutionGroup="xbrli:item" />
  <xsd:element id="eyen_AccruedFranchiseTax" name="AccruedFranchiseTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="eyen_NetProceedsFromIssuanceOfCommonStock" name="NetProceedsFromIssuanceOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" name="StockIssuedDuringPeriodValueNewIssuesTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" name="StockIssuedDuringPeriodSharesNewIssuesTwo" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" name="StockIssuedDuringPeriodSharesExercisesOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_OmnibusStockIncentivePlan2018Member" name="OmnibusStockIncentivePlan2018Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_PaymentsForRepurchaseOfPublicOffering" name="PaymentsForRepurchaseOfPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_ExercisePriceElevenMember" name="ExercisePriceElevenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_StockIssuedDuringPeriodValueNewIssuesThree" name="StockIssuedDuringPeriodValueNewIssuesThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" name="StockIssuedDuringPeriodSharesNewIssuesThree" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" name="PercentageOfSuccessfulRateOfTraditionalEyeDrops" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_LiquidityAndGoingConcernTextBlock" name="LiquidityAndGoingConcernTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassWarrantsMember" name="ClassWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_NumberOfMonthlyPayments" name="NumberOfMonthlyPayments" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" name="PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_PercentageOfSuccessRateOfOptejet" name="PercentageOfSuccessRateOfOptejet" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_PaycheckProtectionProgramLoanMember" name="PaycheckProtectionProgramLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" name="SmallBusinessAdministrationEconomicInjuryDisasterGrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ProceedsFromPaycheckProtectionProgramLoan" name="ProceedsFromPaycheckProtectionProgramLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_NotesPayableDisclosureTextBlock" name="NotesPayableDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ScheduleOfNotesPayableTableTextBlock" name="ScheduleOfNotesPayableTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_PrepaidDirectorFeesCurrent" name="PrepaidDirectorFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_BauschLicenseAgreementMember" name="BauschLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_AccrualOfPublicOfferingCosts" name="AccrualOfPublicOfferingCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_LicenseAgreementsUpfrontPaymentsReceived" name="LicenseAgreementsUpfrontPaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_ArcticVisionLicenseAgreementMember" name="ArcticVisionLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" name="LicenseAgreementsMaximumAdditionalPaymentsReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" name="ClassOfWarrantsOrRightsOutstandingRollforward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightGranted" name="ClassOfWarrantOrRightGranted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercisable" name="ClassOfWarrantOrRightExercisable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" name="ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" name="ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" name="ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" name="ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" name="ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_WarrantsAtExercisePriceOneMember" name="WarrantsAtExercisePriceOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_WarrantsAtExercisePriceTwoMember" name="WarrantsAtExercisePriceTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_WarrantsAtExercisePriceThreeMember" name="WarrantsAtExercisePriceThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_PrepaidLicensesAndSubscriptions" name="PrepaidLicensesAndSubscriptions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_AccruedExpenseReimbursements" name="AccruedExpenseReimbursements" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="eyen_AccruedLicensingFees" name="AccruedLicensingFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="eyen_AccruedConsultingAndProfessionalServicesCurrent" name="AccruedConsultingAndProfessionalServicesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="eyen_MilestoneRevenuePayments" name="MilestoneRevenuePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_RoyaltyRevenuePayments" name="RoyaltyRevenuePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" name="ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_NumberOfCommonShares" name="NumberOfCommonShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_LicenseFeeAndExpenseReimbursementsReceivables" name="LicenseFeeAndExpenseReimbursementsReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" name="IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="eyen_PrepaidGeneralAndAdministrativeExpenses" name="PrepaidGeneralAndAdministrativeExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_DeferredLicenseFees" name="DeferredLicenseFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_DeferredLicenseCost" name="DeferredLicenseCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_SenjuLicenseAgreementMember" name="SenjuLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_DirectorsAndExecutiveOfficersMember" name="DirectorsAndExecutiveOfficersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_UnitsIssuedPricePerUnit" name="UnitsIssuedPricePerUnit" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="eyen_AmortizationOfDebtDiscount" name="AmortizationOfDebtDiscount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_IssuanceOfStockWarrants" name="IssuanceOfStockWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_PrepaymentOfLoanFeePercentage" name="PrepaymentOfLoanFeePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_PeriodAxis" name="PeriodAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_PeriodTypeDomain" name="PeriodTypeDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_FirstAnniversaryMember" name="FirstAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_SecondAnniversaryMember" name="SecondAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ThirdAnniversaryMember" name="ThirdAnniversaryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_OriginalPrincipalLoanPercentage" name="OriginalPrincipalLoanPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_WarrantExercisableTerm" name="WarrantExercisableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceTwelveMember" name="ExercisePriceTwelveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceThirteenMember" name="ExercisePriceThirteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceFourteenMember" name="ExercisePriceFourteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceFifteenMember" name="ExercisePriceFifteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceSixteenMember" name="ExercisePriceSixteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceSeventeenMember" name="ExercisePriceSeventeenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceEighteenMember" name="ExercisePriceEighteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceNineteenMember" name="ExercisePriceNineteenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceTwentyMember" name="ExercisePriceTwentyMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_ExercisePriceTwentyOneMember" name="ExercisePriceTwentyOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_PercentageOfGrossSalesOnCommonStock" name="PercentageOfGrossSalesOnCommonStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="eyen_StockOptionsMember" name="StockOptionsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_BankDirectCapitalFinanceLoanMember" name="BankDirectCapitalFinanceLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="eyen_DebtInstrumentPrincipalAmount" name="DebtInstrumentPrincipalAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="eyen_FairValueOfCommonStock" name="FairValueOfCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="eyen_PrepaidPatentExpense" name="PrepaidPatentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" abstract="false" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" id="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExercisePriceTwentyTwoMember" id="eyen_ExercisePriceTwentyTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestoneUpfrontPayments" id="eyen_MilestoneUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PercentageOfMilestonePaymentRevenue" id="eyen_PercentageOfMilestonePaymentRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MilestoneRevenuePaymentsReceived" id="eyen_MilestoneRevenuePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementThresholdDevelopmentCosts" id="eyen_LicenseAgreementThresholdDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" id="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaycheckProtectionProgramLoanPrincipalForgiveness" id="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaycheckProtectionProgramLoanAccruedInterestForgiveness" id="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eyen-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 11:06:05 AM-->
<!--Modified on: 11/12/2021 11:06:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637723119635560219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637723119635560219" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119635560219" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723119635560219" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119635560219" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723119635560219" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119635570086" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723119635560219" xlink:to="us-gaap_DeferredCostsCurrent_637723119635570086" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723119635560219" xlink:to="eyen_LicenseFeeAndExpenseReimbursementsReceivables_637723119635570086" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637723119635560219" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119635570086" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637723119635570086" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_637723119635570086" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637723119635570086" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637723119635570086" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637723119635570086" xlink:to="us-gaap_LiabilitiesCurrent_637723119635570086" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="us-gaap_AccountsPayableCurrent_637723119635580254" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637723119635580254" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637723119635580254" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="us-gaap_DeferredRentCreditCurrent_637723119635580254" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637723119635580254" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637723119635570086" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637723119635580254" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637723119635570086" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637723119635580254" order="2" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637723119635580254" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637723119635570086" xlink:to="us-gaap_LongTermNotesPayable_637723119635580254" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723119635590352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637723119635590352" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637723119635590352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723119635590352" xlink:to="us-gaap_PreferredStockValue_637723119635590352" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637723119635590352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723119635590352" xlink:to="us-gaap_CommonStockValue_637723119635590352" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637723119635590352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723119635590352" xlink:to="us-gaap_AdditionalPaidInCapital_637723119635590352" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637723119635590352" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637723119635590352" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637723119635590352" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637723119635600305" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637723119635600305" xlink:to="us-gaap_GrossProfit_637723119635600305" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637723119635600305" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637723119635600305" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_637723119635600305" xlink:to="us-gaap_CostOfRevenue_637723119635600305" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637723119635600305" xlink:to="us-gaap_OperatingExpenses_637723119635600305" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637723119635600305" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637723119635600305" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637723119635600305" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637723119635600305" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637723119635600305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637723119635600305" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637723119635610186" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119635610186" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637723119635610186" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense_637723119635610186" order="6" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119635610186" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119635610186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119635610186" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_NetIncomeLoss_637723119635619944" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637723119635619944" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AmortizationOfDebtDiscount" xlink:label="eyen_AmortizationOfDebtDiscount_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="eyen_AmortizationOfDebtDiscount_637723119635619944" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119635619944" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_ShareBasedCompensation_637723119635619944" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637723119635619944" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_637723119635619944" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637723119635619944" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637723119635619944" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723119635630179" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637723119635630179" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_637723119635630179" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637723119635630179" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637723119635630179" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119635619944" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637723119635630179" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723119635630179" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723119635630179" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723119635630179" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723119635630179" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_637723119635640180" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_ProceedsFromNotesPayable_637723119635640180" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723119635640180" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637723119635640180" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723119635640180" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637723119635640180" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_RepaymentsOfNotesPayable_637723119635640180" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637723119635650177" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637723119635650177" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637723119635650177" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119635640180" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637723119635650177" order="10" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637723119635650177" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PayrollTaxesReceivable_637723119635650177" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637723119635650177" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637723119635650177" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidDirectorFeesCurrent_637723119635660186" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidConferenceExpenses_637723119635660186" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidLicensesAndSubscriptions_637723119635660186" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637723119635660186" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidGeneralAndAdministrativeExpenses" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidGeneralAndAdministrativeExpenses_637723119635660186" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssets_637723119635660186" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="eyen_PrepaidPatentExpense_637723119635660186" order="10" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637723119635660186" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637723119635660186" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_637723119635660186" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637723119635670171" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_637723119635670171" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedLicensingFees_637723119635670171" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedExpenseReimbursements_637723119635670171" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_InterestPayableCurrent_637723119635670171" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_CreditCardPayable_637723119635670171" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="eyen_AccruedFranchiseTax_637723119635670171" order="7" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637723119635670171" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637723119635670171" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637723119635680143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent_637723119635680143" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637723119635680143" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable_637723119635680143" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eyen-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 11:06:05 AM-->
<!--Modified on: 11/12/2021 11:06:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityBlackScholesOptionDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.eyenoviabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="eyen-20210930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityTypeAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodAxis" xlink:label="eyen_PeriodAxis_1" xlink:title="eyen_PeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodTypeDomain" xlink:label="eyen_PeriodTypeDomain_1" xlink:title="eyen_PeriodTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="eyen_PeriodAxis_1" xlink:to="eyen_PeriodTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:eyen_PeriodAxis_1 To eyen_PeriodTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eyen_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BankDirectCapitalFinanceLoanMember" xlink:label="eyen_BankDirectCapitalFinanceLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eyen_BankDirectCapitalFinanceLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eyen_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eyen_SiliconValleyBankLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Notes Payable - Schedule of debt discount Note payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="eyen_SiliconValleyBankLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:label="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AmortizationOfDebtDiscount" xlink:label="eyen_AmortizationOfDebtDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="eyen_AmortizationOfDebtDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_NotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Notes Payable - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="eyen_PaycheckProtectionProgramLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="eyen_SiliconValleyBankLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodAxis" xlink:label="eyen_PeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="eyen_PeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodTypeDomain" xlink:label="eyen_PeriodTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="eyen_PeriodAxis" xlink:to="eyen_PeriodTypeDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FirstAnniversaryMember" xlink:label="eyen_FirstAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="eyen_PeriodTypeDomain" xlink:to="eyen_FirstAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SecondAnniversaryMember" xlink:label="eyen_SecondAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="eyen_PeriodTypeDomain" xlink:to="eyen_SecondAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ThirdAnniversaryMember" xlink:label="eyen_ThirdAnniversaryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="eyen_PeriodTypeDomain" xlink:to="eyen_ThirdAnniversaryMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_NumberOfMonthlyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DebtInstrumentPrincipalAmount" xlink:label="eyen_DebtInstrumentPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_DebtInstrumentPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaymentOfLoanFeePercentage" xlink:label="eyen_PrepaymentOfLoanFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_PrepaymentOfLoanFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OriginalPrincipalLoanPercentage" xlink:label="eyen_OriginalPrincipalLoanPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_OriginalPrincipalLoanPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantExercisableTerm" xlink:label="eyen_WarrantExercisableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="eyen_WarrantExercisableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_BauschLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuLicenseAgreementMember" xlink:label="eyen_SenjuLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_SenjuLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseFees" xlink:label="eyen_DeferredLicenseFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_DeferredLicenseFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseCost" xlink:label="eyen_DeferredLicenseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_DeferredLicenseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdDevelopmentCosts" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LicenseAgreementThresholdDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RoyaltyRevenuePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MilestoneRevenuePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePaymentsReceived" xlink:label="eyen_MilestoneRevenuePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MilestoneRevenuePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneUpfrontPayments" xlink:label="eyen_MilestoneUpfrontPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MilestoneUpfrontPayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="eyen_SenjuPharmaceuticalCoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="eyen_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_LeaseMonthlyBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_RoyaltyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneUpfrontPayments" xlink:label="eyen_MilestoneUpfrontPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_MilestoneUpfrontPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfMilestonePaymentRevenue" xlink:label="eyen_PercentageOfMilestonePaymentRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_PercentageOfMilestonePaymentRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Black Scholes option (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceEightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceNineMemberMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceElevenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwelveMember" xlink:label="eyen_ExercisePriceTwelveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwelveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThirteenMember" xlink:label="eyen_ExercisePriceThirteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceThirteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourteenMember" xlink:label="eyen_ExercisePriceFourteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFourteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFifteenMember" xlink:label="eyen_ExercisePriceFifteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceFifteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixteenMember" xlink:label="eyen_ExercisePriceSixteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSixteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSeventeenMember" xlink:label="eyen_ExercisePriceSeventeenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceSeventeenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEighteenMember" xlink:label="eyen_ExercisePriceEighteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceEighteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineteenMember" xlink:label="eyen_ExercisePriceNineteenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceNineteenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyMember" xlink:label="eyen_ExercisePriceTwentyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwentyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyOneMember" xlink:label="eyen_ExercisePriceTwentyOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwentyOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyTwoMember" xlink:label="eyen_ExercisePriceTwentyTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="eyen_ExercisePriceTwentyTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="eyen_ClassOfWarrantOrRightExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="eyen_WarrantsAtExercisePriceThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="eyen_OmnibusStockIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eyen_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantMember" xlink:to="eyen_ClassWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantMember" xlink:to="eyen_ClassBWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockOptionsMember" xlink:label="eyen_StockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="eyen_StockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="eyen_DirectorsAndExecutiveOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NumberOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_UnitsIssuedPricePerUnit" xlink:label="eyen_UnitsIssuedPricePerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_UnitsIssuedPricePerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FairValueOfCommonStock" xlink:label="eyen_FairValueOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_FairValueOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfGrossSalesOnCommonStock" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="eyen_PercentageOfGrossSalesOnCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="eyen_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="eyen_OmnibusStockIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eyen-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 11:06:05 AM-->
<!--Modified on: 11/12/2021 11:06:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Unrestricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Amount pledged to establish and maintain a collateralized money market account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred license costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseFeeAndExpenseReimbursementsReceivables" xlink:to="eyen_LicenseFeeAndExpenseReimbursementsReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">Amount of license fee and expense reimbursements receivables classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">License Fee and Expense Reimbursements Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">License fee and expense reimbursements receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Workers' Compensation Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred license fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Notes payable - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent - non-current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable - non-current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Non-Current Portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 90,000,000 shares authorized; 25,963,185 and 24,978,585 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Operating Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss From Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income (Expense):</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Amount of small business administration economic injury disaster grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Small Business Administration Economic Injury Disaster Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_lbl" xml:lang="en-US">Small Business Administration Economic Injury Disaster Grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Extinguishment of PPP 7(a) loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Extinguishment of PPP 7(a) loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">- Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">- Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">- Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">- Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Statements of Changes in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of SVB warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock two value on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock and warrants in private placement</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock issuance of common stock one shares on public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_lbl" xml:lang="en-US">Issuance of common stock and warrants in private placement(in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">This represents Stock Issued During Period Value New Issues three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">This represents common stock issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_lbl" xml:lang="en-US">Issuance of common stock in public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Stock exercises of warrant on cashless basis shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Stock Issued During Period Shares Exercises Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_lbl" xml:lang="en-US">Exercise of warrants on a cashless basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Number of share options (or share units) exercised on cashless basis during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Exercises in Period On Cashless Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_lbl" xml:lang="en-US">Exercise of stock options on a cashless basis (in shares)</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of stock warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of shares issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of stock warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_lbl" xml:lang="en-US">Proceeds Of Stock Issued During Period Gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Relative fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property and equipment</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AmortizationOfDebtDiscount" xlink:label="eyen_AmortizationOfDebtDiscount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AmortizationOfDebtDiscount" xlink:to="eyen_AmortizationOfDebtDiscount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amount of Amortization of debt discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AmortizationOfDebtDiscount_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" xlink:to="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">Increase Decrease In License Fee And Expense Reimbursements Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_lbl" xml:lang="en-US">License fee and expense reimbursements receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred license costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred license fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IncreaseDecreaseInDeferredRent" xlink:to="eyen_IncreaseDecreaseInDeferredRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Increase Decrease in Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from sale of common stock and warrants in private placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from sale of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">The cash inflow from paycheck protection program loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Proceeds from Paycheck Protection Program Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_lbl" xml:lang="en-US">Proceeds from PPP 7(a) Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from SVB loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of notes payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaymentsForRepurchaseOfPublicOffering" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payments for Repurchase of Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_lbl" xml:lang="en-US">Payment of offering issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Payment of loan issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Relative fair value of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of private placement issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (Decrease) Increase in Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents - Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Cash and restricted cash consisted of the following:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidCapitalized" xlink:to="us-gaap_InterestPaidCapitalized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidCapitalized_lbl" xml:lang="en-US">Interest Paid, Capitalized, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidCapitalized_lbl" xml:lang="en-US">Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccrualOfPublicOfferingCosts" xlink:label="eyen_AccrualOfPublicOfferingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccrualOfPublicOfferingCosts" xlink:to="eyen_AccrualOfPublicOfferingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccrualOfPublicOfferingCosts_lbl" xml:lang="en-US">Amount of accrual of public offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccrualOfPublicOfferingCosts_lbl" xml:lang="en-US">Accrual Of Public Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccrualOfPublicOfferingCosts_lbl" xml:lang="en-US">Accrual of public offering costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:to="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">The amount of purchase of insurance premium financed by short term notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">Purchase Of Insurance Premium Financed By Short Term Note Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_lbl" xml:lang="en-US">Purchase of insurance premium financed by note payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IssuanceOfStockWarrants" xlink:label="eyen_IssuanceOfStockWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_IssuanceOfStockWarrants" xlink:to="eyen_IssuanceOfStockWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_IssuanceOfStockWarrants_lbl" xml:lang="en-US">The cash outflow of issuance of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_IssuanceOfStockWarrants_lbl" xml:lang="en-US">Issuance Of Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_IssuanceOfStockWarrants_lbl" xml:lang="en-US">Issuance of SVB stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Compensation Related Costs, General [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_lbl" xml:lang="en-US">Accrued Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NotesPayableDisclosureTextBlock" xlink:label="eyen_NotesPayableDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NotesPayableDisclosureTextBlock" xlink:to="eyen_NotesPayableDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LiquidityAndGoingConcernTextBlock" xlink:label="eyen_LiquidityAndGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LiquidityAndGoingConcernTextBlock" xlink:to="eyen_LiquidityAndGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for liquidity and going concern.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive weighted average diluted common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Disclosure of Accrued compensation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ScheduleOfNotesPayableTableTextBlock" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ScheduleOfNotesPayableTableTextBlock" xlink:to="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of Notes Payable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_lbl" xml:lang="en-US">Schedule of notes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes option pricing model to stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of the stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of information related to stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of the Warrant activity and related information</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="eyen_ScheduleOfWarrantsOutstandingTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrants Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfSuccessRateOfOptejet" xlink:label="eyen_PercentageOfSuccessRateOfOptejet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfSuccessRateOfOptejet" xlink:to="eyen_PercentageOfSuccessRateOfOptejet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_lbl" xml:lang="en-US">This refers percentage of success rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_lbl" xml:lang="en-US">Percentage Of Success Rate Of Optejet</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:to="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" xml:lang="en-US">This represents successful percentage rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_lbl" xml:lang="en-US">Percentage of Successful Rate of Traditional Eye Drops</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AtMarketOfferingMember" xlink:to="eyen_AtMarketOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Amount pledged to establish and maintain a collateralized money market account</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution net of issuance costs to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Aggregate number of shares issued including over-allotment option (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PayrollTaxesReceivable" xlink:to="eyen_PayrollTaxesReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Amount of Payroll Taxes Receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PayrollTaxesReceivable_lbl" xml:lang="en-US">Payroll tax receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidResearchAndDevelopmentExpenses" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Prepaid research and development expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidGeneralAndAdministrativeExpenses" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidGeneralAndAdministrativeExpenses" xlink:to="eyen_PrepaidGeneralAndAdministrativeExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Represents the information pertaining to Prepaid general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Prepaid general and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">Prepaid general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidLicensesAndSubscriptions" xlink:to="eyen_PrepaidLicensesAndSubscriptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">The amount of prepaid licenses and subscriptions, current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">Prepaid Licenses and Subscriptions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaidLicensesAndSubscriptions_lbl" xml:lang="en-US">Prepaid licenses and subscriptions</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidPatentExpense" xlink:to="eyen_PrepaidPatentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Amount of prepaid patent expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidPatentExpense_lbl" xml:lang="en-US">Prepaid Patent Expense</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidConferenceExpenses" xlink:to="eyen_PrepaidConferenceExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Amount of assets related to prepaid conference expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidConferenceExpenses_lbl" xml:lang="en-US">Prepaid conference expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidDirectorFeesCurrent" xlink:to="eyen_PrepaidDirectorFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of director fees prepaid, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Prepaid Director Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidDirectorFeesCurrent_lbl" xml:lang="en-US">Prepaid board of directors fees</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaidRentAndSecurityDeposit" xlink:to="eyen_PrepaidRentAndSecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid Rent and Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_PrepaidRentAndSecurityDeposit_lbl" xml:lang="en-US">Prepaid rent and security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonus expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued compensation</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Amount of accrued research and development expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and professional service, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Accrued Consulting and Professional Services, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_lbl" xml:lang="en-US">Accrued consulting and professional services</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_CreditCardPayable" xlink:to="eyen_CreditCardPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Amount of credit card expenses payable by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit Card payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_CreditCardPayable_lbl" xml:lang="en-US">Credit card payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedFranchiseTax" xlink:to="eyen_AccruedFranchiseTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Amount of accrued franchise tax expenses paid by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued Franchise Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_AccruedFranchiseTax_lbl" xml:lang="en-US">Accrued franchise tax</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedLicensingFees" xlink:to="eyen_AccruedLicensingFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">The amount of accrued licensing fees, current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">Accrued Licensing Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedLicensingFees_lbl" xml:lang="en-US">Accrued licensing fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_AccruedExpenseReimbursements" xlink:to="eyen_AccruedExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expense reimbursements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Accrued Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_AccruedExpenseReimbursements_lbl" xml:lang="en-US">Accrued expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BankDirectCapitalFinanceLoanMember" xlink:label="eyen_BankDirectCapitalFinanceLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_BankDirectCapitalFinanceLoanMember" xlink:to="eyen_BankDirectCapitalFinanceLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_BankDirectCapitalFinanceLoanMember_lbl" xml:lang="en-US">Represents member information pertaining to BankDirect Capital Finance loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_BankDirectCapitalFinanceLoanMember_lbl" xml:lang="en-US">BankDirect Capital Finance loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaycheckProtectionProgramLoanMember" xlink:to="eyen_PaycheckProtectionProgramLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to Paycheck Protection Program Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US">Paycheck Protection Program loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SiliconValleyBankLoanMember" xlink:to="eyen_SiliconValleyBankLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SiliconValleyBankLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to Silicon Valley Bank Loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SiliconValleyBankLoanMember_lbl" xml:lang="en-US">Silicon Valley Bank loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Gross loan proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:label="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:to="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_lbl" xml:lang="en-US">Debt Issuance Costs, Net, Alternative [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_lbl" xml:lang="en-US">Debt discount:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US">Notes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodAxis" xlink:label="eyen_PeriodAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PeriodAxis" xlink:to="eyen_PeriodAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PeriodAxis_lbl" xml:lang="en-US">Information about timing of debt period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PeriodAxis_lbl" xml:lang="en-US">Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodTypeDomain" xlink:label="eyen_PeriodTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PeriodTypeDomain" xlink:to="eyen_PeriodTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PeriodTypeDomain_lbl" xml:lang="en-US">Period as defined under terms of the anniversary period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PeriodTypeDomain_lbl" xml:lang="en-US">Period Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FirstAnniversaryMember" xlink:label="eyen_FirstAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_FirstAnniversaryMember" xlink:to="eyen_FirstAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_FirstAnniversaryMember_lbl" xml:lang="en-US">Prior to First Anniversary</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SecondAnniversaryMember" xlink:label="eyen_SecondAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SecondAnniversaryMember" xlink:to="eyen_SecondAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SecondAnniversaryMember_lbl" xml:lang="en-US">Second Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SecondAnniversaryMember_lbl" xml:lang="en-US">Prior to Second Anniversary</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ThirdAnniversaryMember" xlink:label="eyen_ThirdAnniversaryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ThirdAnniversaryMember" xlink:to="eyen_ThirdAnniversaryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ThirdAnniversaryMember_lbl" xml:lang="en-US">Prior to Third Anniversary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtMember" xlink:to="us-gaap_DebtMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtMember_lbl" xml:lang="en-US">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfMonthlyPayments" xlink:to="eyen_NumberOfMonthlyPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number of monthly payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number Of Monthly Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NumberOfMonthlyPayments_lbl" xml:lang="en-US">Number of monthly payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DebtInstrumentPrincipalAmount" xlink:label="eyen_DebtInstrumentPrincipalAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DebtInstrumentPrincipalAmount" xlink:to="eyen_DebtInstrumentPrincipalAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DebtInstrumentPrincipalAmount_lbl" xml:lang="en-US">Amount of the total principal payments made during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DebtInstrumentPrincipalAmount_lbl" xml:lang="en-US">Debt Instrument Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DebtInstrumentPrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Aggregate principal payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Long-term Lines of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_lbl" xml:lang="en-US">Cash proceeds from loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" xlink:to="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_lbl" xml:lang="en-US">Amount of principal forgiveness on paycheck protection program loan,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_lbl" xml:lang="en-US">Paycheck Protection Program Loan, Principal Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_lbl" xml:lang="en-US">Amount of principal forgiveness on PPP loan</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" xlink:to="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_lbl" xml:lang="en-US">Amount of  accrued interest  forgiveness on paycheck protection program loan,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_lbl" xml:lang="en-US">Paycheck Protection Program Loan, Accrued Interest Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_lbl" xml:lang="en-US">Amount of accrued interest forgiveness on PPP loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Debt instrument effective stated rate</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaymentOfLoanFeePercentage" xlink:label="eyen_PrepaymentOfLoanFeePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PrepaymentOfLoanFeePercentage" xlink:to="eyen_PrepaymentOfLoanFeePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PrepaymentOfLoanFeePercentage_lbl" xml:lang="en-US">The rate of prepayment of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PrepaymentOfLoanFeePercentage_lbl" xml:lang="en-US">Prepayment Of Loan Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PrepaymentOfLoanFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OriginalPrincipalLoanPercentage" xlink:label="eyen_OriginalPrincipalLoanPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OriginalPrincipalLoanPercentage" xlink:to="eyen_OriginalPrincipalLoanPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OriginalPrincipalLoanPercentage_lbl" xml:lang="en-US">The rate of original principal loan percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OriginalPrincipalLoanPercentage_lbl" xml:lang="en-US">Original Principal Loan Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_OriginalPrincipalLoanPercentage_lbl" xml:lang="en-US">Aggregate loan percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants for purchase of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price of Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantExercisableTerm" xlink:label="eyen_WarrantExercisableTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantExercisableTerm" xlink:to="eyen_WarrantExercisableTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantExercisableTerm_lbl" xml:lang="en-US">Period of time on warrant exercisable term, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantExercisableTerm_lbl" xml:lang="en-US">Warrant Exercisable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_WarrantExercisableTerm_lbl" xml:lang="en-US">Warrant exercisable term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Loan received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ArcticVisionLicenseAgreementMember" xlink:to="eyen_ArcticVisionLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ArcticVisionLicenseAgreementMember_lbl" xml:lang="en-US">This member stands for Arctic Vision License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ArcticVisionLicenseAgreementMember_lbl" xml:lang="en-US">Arctic Vision License Agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_BauschLicenseAgreementMember" xlink:to="eyen_BauschLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_BauschLicenseAgreementMember_lbl" xml:lang="en-US">This member stands for Bausch License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_BauschLicenseAgreementMember_lbl" xml:lang="en-US">Bausch License Agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuLicenseAgreementMember" xlink:label="eyen_SenjuLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SenjuLicenseAgreementMember" xlink:to="eyen_SenjuLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_SenjuLicenseAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to Senju License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SenjuLicenseAgreementMember_lbl" xml:lang="en-US">Senju License Agreement</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">Amount of upfront payments received by the entity, pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">License Agreements, Upfront Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_lbl" xml:lang="en-US">Upfront payment received</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseFees" xlink:label="eyen_DeferredLicenseFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredLicenseFees" xlink:to="eyen_DeferredLicenseFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredLicenseFees_lbl" xml:lang="en-US">Represents the information pertaining to deferred license fees .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredLicenseFees_lbl" xml:lang="en-US">Deferred license fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DeferredLicenseFees_lbl" xml:lang="en-US">Deferred license fees</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseCost" xlink:label="eyen_DeferredLicenseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DeferredLicenseCost" xlink:to="eyen_DeferredLicenseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DeferredLicenseCost_lbl" xml:lang="en-US">Represents the information pertaining to Deferred license cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DeferredLicenseCost_lbl" xml:lang="en-US">Deferred license cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_DeferredLicenseCost_lbl" xml:lang="en-US">Deferred license cost</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">Maximum amount of additional payments receivable by the company pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">License Agreements, Maximum Additional Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_lbl" xml:lang="en-US">Maximum additional payments receivable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" xlink:to="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_lbl" xml:lang="en-US">Maximum amount incurred by the company on clinical research and regulatory approval payments  pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_lbl" xml:lang="en-US">License Agreement, Threshold Initiation Of Clinical Research And Regulatory Approval Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_lbl" xml:lang="en-US">Initiation of clinical research and regulatory approval payments</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdDevelopmentCosts" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementThresholdDevelopmentCosts" xlink:to="eyen_LicenseAgreementThresholdDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts_lbl" xml:lang="en-US">Maximum amount of development costs incurred by the company pursuant to a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts_lbl" xml:lang="en-US">License Agreement, Threshold Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts_lbl" xml:lang="en-US">Development costs</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RoyaltyRevenuePayments" xlink:to="eyen_RoyaltyRevenuePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Amount of royalty revenue payment earned during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Royalty Revenue Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_RoyaltyRevenuePayments_lbl" xml:lang="en-US">Royalty payments earned</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_MilestoneRevenuePayments" xlink:to="eyen_MilestoneRevenuePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Amount of milestone revenue payment earned during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Milestone Revenue Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_MilestoneRevenuePayments_lbl" xml:lang="en-US">Milestone payments earned</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePaymentsReceived" xlink:label="eyen_MilestoneRevenuePaymentsReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_MilestoneRevenuePaymentsReceived" xlink:to="eyen_MilestoneRevenuePaymentsReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_MilestoneRevenuePaymentsReceived_lbl" xml:lang="en-US">Amount of milestone revenue payment received during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_MilestoneRevenuePaymentsReceived_lbl" xml:lang="en-US">Milestone Revenue Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_MilestoneRevenuePaymentsReceived_lbl" xml:lang="en-US">Milestone payments received</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneUpfrontPayments" xlink:label="eyen_MilestoneUpfrontPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_MilestoneUpfrontPayments" xlink:to="eyen_MilestoneUpfrontPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_MilestoneUpfrontPayments_lbl" xml:lang="en-US">Amount of milestone upfront payment during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_MilestoneUpfrontPayments_lbl" xml:lang="en-US">Milestone Upfront Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_MilestoneUpfrontPayments_lbl" xml:lang="en-US">Upfront payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_lbl" xml:lang="en-US">Vice President of Research and Development</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_SenjuPharmaceuticalCoMember" xlink:to="eyen_SenjuPharmaceuticalCoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_SenjuPharmaceuticalCoMember_lbl" xml:lang="en-US">Senju Pharmaceutical Co</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LicenseAgreementMember" xlink:to="eyen_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">This member stands for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetRentableArea_lbl" xml:lang="en-US">Net Rentable Area</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_LeaseMonthlyBaseRent" xlink:to="eyen_LeaseMonthlyBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">The base rent per month for lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_LeaseMonthlyBaseRent_lbl" xml:lang="en-US">Lease, Monthly Base Rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_RoyaltyPercentage" xlink:to="eyen_RoyaltyPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">It represents the percentage rate of royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_RoyaltyPercentage_lbl" xml:lang="en-US">Royalty Percentage</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfMilestonePaymentRevenue" xlink:label="eyen_PercentageOfMilestonePaymentRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfMilestonePaymentRevenue" xlink:to="eyen_PercentageOfMilestonePaymentRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfMilestonePaymentRevenue_lbl" xml:lang="en-US">Represents the percentage of milestone payment revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfMilestonePaymentRevenue_lbl" xml:lang="en-US">Percentage of Milestone Payment Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PercentageOfMilestonePaymentRevenue_lbl" xml:lang="en-US">Percentage of milestone payment revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Minority Interest Ownership Percentage In Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding | Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Granted | Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options Exercised | Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options Forfeited | Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options Exercisable | Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable | $ / Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding | $</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceOneMember" xlink:to="eyen_ExercisePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceOneMember_lbl" xml:lang="en-US">Exercise Price 1.24 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwoMember" xlink:to="eyen_ExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwoMember_lbl" xml:lang="en-US">Exercise Price 1.95 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceThreeMember" xlink:to="eyen_ExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceThreeMember_lbl" xml:lang="en-US">Exercise Price 2.72 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFourMember" xlink:to="eyen_ExercisePriceFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFourMember_lbl" xml:lang="en-US">Exercise Price 2.74 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFiveMember" xlink:to="eyen_ExercisePriceFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFiveMember_lbl" xml:lang="en-US">Exercise Price 2.89 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSixMember" xlink:to="eyen_ExercisePriceSixMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSixMember_lbl" xml:lang="en-US">Exercise Price 3.11 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSevenMember" xlink:to="eyen_ExercisePriceSevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSevenMember_lbl" xml:lang="en-US">Exercise Price 3.43 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceEightMember" xlink:to="eyen_ExercisePriceEightMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceEightMember_lbl" xml:lang="en-US">Exercise Price 3.48 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceNineMemberMember" xlink:to="eyen_ExercisePriceNineMemberMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceNineMemberMember_lbl" xml:lang="en-US">Exercise Price 3.71 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTenMember" xlink:to="eyen_ExercisePriceTenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price Ten</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTenMember_lbl" xml:lang="en-US">Exercise Price 4.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceElevenMember" xlink:to="eyen_ExercisePriceElevenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price Eleven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceElevenMember_lbl" xml:lang="en-US">Exercise Price 4.53 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwelveMember" xlink:label="eyen_ExercisePriceTwelveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwelveMember" xlink:to="eyen_ExercisePriceTwelveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price Twelve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwelveMember_lbl" xml:lang="en-US">Exercise Price 4.68 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThirteenMember" xlink:label="eyen_ExercisePriceThirteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceThirteenMember" xlink:to="eyen_ExercisePriceThirteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise Price Thirteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceThirteenMember_lbl" xml:lang="en-US">Exercise Price 4.81 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourteenMember" xlink:label="eyen_ExercisePriceFourteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFourteenMember" xlink:to="eyen_ExercisePriceFourteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price Fourteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFourteenMember_lbl" xml:lang="en-US">Exercise Price 5.10 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFifteenMember" xlink:label="eyen_ExercisePriceFifteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceFifteenMember" xlink:to="eyen_ExercisePriceFifteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceFifteenMember_lbl" xml:lang="en-US">Exercise Price 5.11 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixteenMember" xlink:label="eyen_ExercisePriceSixteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSixteenMember" xlink:to="eyen_ExercisePriceSixteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSixteenMember_lbl" xml:lang="en-US">Exercise Price Sixteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSixteenMember_lbl" xml:lang="en-US">Exercise Price 5.19 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSeventeenMember" xlink:label="eyen_ExercisePriceSeventeenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceSeventeenMember" xlink:to="eyen_ExercisePriceSeventeenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceSeventeenMember_lbl" xml:lang="en-US">Exercise Price Seventeen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceSeventeenMember_lbl" xml:lang="en-US">Exercise Price 5.25 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEighteenMember" xlink:label="eyen_ExercisePriceEighteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceEighteenMember" xlink:to="eyen_ExercisePriceEighteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceEighteenMember_lbl" xml:lang="en-US">Exercise Price Eighteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceEighteenMember_lbl" xml:lang="en-US">Exercise Price 5.77 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineteenMember" xlink:label="eyen_ExercisePriceNineteenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceNineteenMember" xlink:to="eyen_ExercisePriceNineteenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceNineteenMember_lbl" xml:lang="en-US">Exercise Price Nineteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceNineteenMember_lbl" xml:lang="en-US">Exercise Price 6.01 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyMember" xlink:label="eyen_ExercisePriceTwentyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwentyMember" xlink:to="eyen_ExercisePriceTwentyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwentyMember_lbl" xml:lang="en-US">Exercise Price Twenty [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwentyMember_lbl" xml:lang="en-US">Exercise Price 6.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyOneMember" xlink:label="eyen_ExercisePriceTwentyOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwentyOneMember" xlink:to="eyen_ExercisePriceTwentyOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwentyOneMember_lbl" xml:lang="en-US">Exercise Price Twenty One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwentyOneMember_lbl" xml:lang="en-US">Exercise Price 6.30 [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyTwoMember" xlink:label="eyen_ExercisePriceTwentyTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ExercisePriceTwentyTwoMember" xlink:to="eyen_ExercisePriceTwentyTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ExercisePriceTwentyTwoMember_lbl" xml:lang="en-US">Exercise Price Twenty Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ExercisePriceTwentyTwoMember_lbl" xml:lang="en-US">Exercise Price Twenty 8.72 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Outstanding, Outstanding Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Life In Years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:to="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">Class Of Warrants Or Rights Outstanding [Rollforward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_lbl" xml:lang="en-US">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding at ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding at beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightGranted" xlink:label="eyen_ClassOfWarrantOrRightGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightGranted" xlink:to="eyen_ClassOfWarrantOrRightGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Number of warrants or rights granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Class of Warrant or Right, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercised" xlink:to="eyen_ClassOfWarrantOrRightExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Number of warrants or rights exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Class of Warrant or Right, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisable" xlink:to="eyen_ClassOfWarrantOrRightExercisable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Number of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Exercisable Number of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisable_lbl" xml:lang="en-US">Exercisable Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:to="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Class Of Warrants Or Rights, Weighted Average Exercise Price [Rollforward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning balance</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Granted, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Exercised, , Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Weighted Average Remaining Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Weighted Average Remaining Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercisable</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:to="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:to="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants or rights exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceOneMember" xlink:to="eyen_WarrantsAtExercisePriceOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceOneMember_lbl" xml:lang="en-US">This member stands for warrants with the first exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceOneMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.4696</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceTwoMember" xlink:to="eyen_WarrantsAtExercisePriceTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_lbl" xml:lang="en-US">This member stands for warrants with the second exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_lbl" xml:lang="en-US">Warrants at exercise price of $2.7240</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_WarrantsAtExercisePriceThreeMember" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_lbl" xml:lang="en-US">This member stands for warrants with the third exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_lbl" xml:lang="en-US">Warrants at exercise price of $4.7600</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_OmnibusStockIncentivePlan2018Member" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">The member stands for omnibus stock incentive plan 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_lbl" xml:lang="en-US">Omnibus Stock Incentive Plan 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassWarrantsMember" xlink:to="eyen_ClassWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassWarrantsMember_lbl" xml:lang="en-US">Class A Warrants Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassWarrantsMember_lbl" xml:lang="en-US">Class A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassBWarrantsMember" xlink:to="eyen_ClassBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member ]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member ]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockOptionsMember" xlink:label="eyen_StockOptionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_StockOptionsMember" xlink:to="eyen_StockOptionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_StockOptionsMember_lbl" xml:lang="en-US">Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_StockOptionsMember_lbl" xml:lang="en-US">Stock Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_DirectorsAndExecutiveOfficersMember" xlink:to="eyen_DirectorsAndExecutiveOfficersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_lbl" xml:lang="en-US">This member stands for directors and executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_lbl" xml:lang="en-US">Directors And Executive Officers [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NumberOfCommonShares" xlink:to="eyen_NumberOfCommonShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Information about number of share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Number of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_NumberOfCommonShares_lbl" xml:lang="en-US">Number of common shares</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_UnitsIssuedPricePerUnit" xlink:label="eyen_UnitsIssuedPricePerUnit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_UnitsIssuedPricePerUnit" xlink:to="eyen_UnitsIssuedPricePerUnit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_UnitsIssuedPricePerUnit_lbl" xml:lang="en-US">Per share or per unit amount of equity shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_UnitsIssuedPricePerUnit_lbl" xml:lang="en-US">Units Issued Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_UnitsIssuedPricePerUnit_lbl" xml:lang="en-US">Units issued price per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_NetProceedsFromIssuanceOfCommonStock" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The cash inflow from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net Proceeds From Issuance Of Common Stock</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FairValueOfCommonStock" xlink:label="eyen_FairValueOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_FairValueOfCommonStock" xlink:to="eyen_FairValueOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_FairValueOfCommonStock_lbl" xml:lang="en-US">Purchase price of common stock expressed of its fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_FairValueOfCommonStock_lbl" xml:lang="en-US">Fair Value Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_FairValueOfCommonStock_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized stock - based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period of recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of awards granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">No. of common stock per warrant</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Information about number of years warrant to purchase share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Class Of Warrant Or Right Number Of Years Securities Called By Warrants to Purchase Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Warrant to purchase common stock in period</label>
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfGrossSalesOnCommonStock" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="eyen_PercentageOfGrossSalesOnCommonStock" xlink:to="eyen_PercentageOfGrossSalesOnCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock_lbl" xml:lang="en-US">The rate gross sale on common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock_lbl" xml:lang="en-US">Percentage Of Gross Sales On Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock_lbl" xml:lang="en-US">Percentage on gross sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Period of employees stock options granted</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eyen-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2021 11:06:05 AM-->
<!--Modified on: 11/12/2021 11:06:05 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedBalanceSheets" roleURI="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedBalanceSheetsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#StatementCondensedStatementsOfCashFlowsParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedCompensation" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayable" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayable" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSubsequentEvents" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedCompensationTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableTables" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedCompensationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableScheduleOfNotesPayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureNotesPayableAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityBlackScholesOptionDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquitySummaryOfOptionActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityWarrantsActivityDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureEmployeeBenefitPlansDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" />
  <roleRef xlink:type="simple" xlink:href="eyen-20210930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637723119636329921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637723119636329921" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637723119636329921" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637723119636329921" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637723119636329921" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637723119636329921" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637723119636329921" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637723119636329921" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637723119636329921" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637723119636329921" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637723119636329921" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637723119636340095" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637723119636340095" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637723119636340095" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637723119636340095" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637723119636340095" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637723119636340095" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637723119636340095" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637723119636340095" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637723119636340095" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637723119636340095" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637723119636340095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637723119636340095" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637723119636350491" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637723119636350491" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637723119636350491" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637723119636350491" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637723119636350491" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637723119636350491" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637723119636350491" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637723119636350491" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637723119636350491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637723119636350491" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_637723119636360342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723119636360342" xlink:to="us-gaap_AssetsCurrentAbstract_637723119636360342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636360342" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636360342" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="us-gaap_DeferredCostsCurrent_637723119636360342" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_LicenseFeeAndExpenseReimbursementsReceivables_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="eyen_LicenseFeeAndExpenseReimbursementsReceivables_637723119636360342" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119636360342" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637723119636360342" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637723119636360342" xlink:to="us-gaap_AssetsCurrent_637723119636360342" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723119636360342" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637723119636370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723119636360342" xlink:to="us-gaap_SecurityDeposit_637723119636370289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637723119636360342" xlink:to="us-gaap_Assets_637723119636370289" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_AccountsPayableCurrent_637723119636370289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_637723119636370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637723119636370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="eyen_AccruedExpensesAndOtherLiabilitiesCurrent_637723119636370289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_DeferredRentCreditCurrent_637723119636380356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637723119636380356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637723119636380356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637723119636370289" xlink:to="us-gaap_LiabilitiesCurrent_637723119636380356" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637723119636380356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" xlink:to="us-gaap_LongTermNotesPayable_637723119636380356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637723119636370289" xlink:to="us-gaap_Liabilities_637723119636380356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637723119636380356" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_CommitmentsAndContingencies_637723119636380356" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_StockholdersEquityAbstract_637723119636390331" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723119636390331" xlink:to="us-gaap_PreferredStockValue_637723119636390331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723119636390331" xlink:to="us-gaap_CommonStockValue_637723119636390331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723119636390331" xlink:to="us-gaap_AdditionalPaidInCapital_637723119636390331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723119636390331" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637723119636390331" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637723119636390331" xlink:to="us-gaap_StockholdersEquity_637723119636390331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637723119636390331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637723119636390331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_98" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637723119636399974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesAuthorized_637723119636399974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesIssued_637723119636399974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_PreferredStockSharesOutstanding_637723119636399974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723119636399974" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesAuthorized_637723119636399974" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesIssued_637723119636399974" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98" xlink:to="us-gaap_CommonStockSharesOutstanding_637723119636399974" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_143" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637723119636399974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_RevenuesAbstract_637723119636399974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637723119636399974" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637723119636410255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637723119636399974" xlink:to="us-gaap_CostOfRevenue_637723119636410255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637723119636399974" xlink:to="us-gaap_GrossProfit_637723119636410255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingExpensesAbstract_637723119636410255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723119636410255" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637723119636410255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723119636410255" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637723119636410255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637723119636410255" xlink:to="us-gaap_OperatingExpenses_637723119636410255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_OperatingIncomeLoss_637723119636410255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant" xlink:label="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" xlink:to="eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant_637723119636410255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119636410255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637723119636410255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" xlink:to="us-gaap_InterestExpense_637723119636410255" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_637723119636410255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637723119636410255" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_637723119636410255" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_NetIncomeLoss_637723119636420246" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637723119636420246" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637723119636420246" xlink:to="us-gaap_EarningsPerShareBasic_637723119636420246" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637723119636420246" xlink:to="us-gaap_EarningsPerShareDiluted_637723119636420246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_143" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637723119636420246" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637723119636420246" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637723119636420246" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637723119636420246" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_637723119636420246" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637723119636420246" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Statements of Changes in Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364255" xlink:to="us-gaap_StatementTable_637723119636430004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636430004" xlink:to="us-gaap_StatementEquityComponentsAxis_637723119636430004" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636430004" xlink:to="us-gaap_CommonStockMember_637723119636430004" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636430004" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637723119636430004" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636430004" xlink:to="us-gaap_RetainedEarningsMember_637723119636430004" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636430004" xlink:to="us-gaap_EquityComponentDomain_637723119636430004" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636430004" xlink:to="us-gaap_StatementLineItems_637723119636430004" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_StockholdersEquity_637723119636430004" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_SharesOutstanding_637723119636430004" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_637723119636430004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesTwo_637723119636430004" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesTwo" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637723119636430004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesTwo_637723119636430004" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodValueNewIssuesThree_637723119636440249" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesNewIssuesThree" xlink:label="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodSharesNewIssuesThree_637723119636440249" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants" xlink:label="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants_637723119636440249" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis" xlink:label="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis_637723119636440249" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodValueWarrantsExercised_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodValueWarrantsExercised_637723119636440249" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="eyen_StockIssuedDuringPeriodSharesWarrantsExercised_637723119636440249" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637723119636440249" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723119636440249" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_NetIncomeLoss_637723119636440249" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637723119636440249" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_StockholdersEquity_637723119636440249" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636430004" xlink:to="us-gaap_SharesOutstanding_637723119636450554" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637723119636450554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637723119636450554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_364366" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723119636450554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_247" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_NetIncomeLoss_637723119636450554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637723119636450554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637723119636450554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AmortizationOfDebtDiscount" xlink:label="eyen_AmortizationOfDebtDiscount_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="eyen_AmortizationOfDebtDiscount_637723119636460123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637723119636460123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_ShareBasedCompensation_637723119636460123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637723119636460123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables" xlink:label="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables_637723119636460123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_637723119636460123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637723119636460123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637723119636460123" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_637723119636460123" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637723119636460123" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_637723119636460123" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IncreaseDecreaseInDeferredRent" xlink:label="eyen_IncreaseDecreaseInDeferredRent_637723119636460123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637723119636460123" xlink:to="eyen_IncreaseDecreaseInDeferredRent_637723119636460123" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637723119636450554" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119636470248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723119636470248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637723119636470248" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637723119636470248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_637723119636470248" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637723119636470248" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723119636470248" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromPaycheckProtectionProgramLoan" xlink:label="eyen_ProceedsFromPaycheckProtectionProgramLoan_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="eyen_ProceedsFromPaycheckProtectionProgramLoan_637723119636470248" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_ProceedsFromNotesPayable_637723119636470248" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637723119636470248" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_RepaymentsOfNotesPayable_637723119636470248" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaymentsForRepurchaseOfPublicOffering" xlink:label="eyen_PaymentsForRepurchaseOfPublicOffering_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="eyen_PaymentsForRepurchaseOfPublicOffering_637723119636480383" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637723119636480383" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637723119636480383" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637723119636480383" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637723119636470248" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637723119636480383" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637723119636480383" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723119636480383" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723119636480383" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377231196364803831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6377231196364803831" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_637723119636490457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_637723119636490457" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636490457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_637723119636490457" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636490457" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636490457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_637723119636490457" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636490457" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723119636490457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract_637723119636490457" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637723119636490457" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637723119636490457" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637723119636490457" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidCapitalized" xlink:label="us-gaap_InterestPaidCapitalized_637723119636500486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637723119636490457" xlink:to="us-gaap_InterestPaidCapitalized_637723119636500486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637723119636500486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_247" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637723119636500486" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccrualOfPublicOfferingCosts" xlink:label="eyen_AccrualOfPublicOfferingCosts_637723119636500486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637723119636500486" xlink:to="eyen_AccrualOfPublicOfferingCosts_637723119636500486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable" xlink:label="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_637723119636500486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637723119636500486" xlink:to="eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable_637723119636500486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_IssuanceOfStockWarrants" xlink:label="eyen_IssuanceOfStockWarrants_637723119636500486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637723119636500486" xlink:to="eyen_IssuanceOfStockWarrants_637723119636500486" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_277" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636580672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_277" xlink:to="us-gaap_StatementTable_637723119636580672" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637723119636580672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636580672" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637723119636580672" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636580672" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637723119636580672" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636580672" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636580672" xlink:to="us-gaap_PrivatePlacementMember_637723119636590241" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636580672" xlink:to="us-gaap_StatementLineItems_637723119636590241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="eyen_ProceedsOfStockIssuedDuringPeriodGross_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636590241" xlink:to="eyen_ProceedsOfStockIssuedDuringPeriodGross_637723119636590241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636590241" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_637723119636590241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_285" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637723119636590241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637723119636590241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="10301 - Disclosure - Prepaid Expenses and Other Current Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637723119636590241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_5" xlink:to="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_637723119636590241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensation" xlink:type="extended" xlink:title="10401 - Disclosure - Accrued Compensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368361" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:label="us-gaap_CompensationRelatedCostsGeneralTextBlock_637723119636600241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368361" xlink:to="us-gaap_CompensationRelatedCostsGeneralTextBlock_637723119636600241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses and Other Current Liabilities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637723119636600241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_637723119636600241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayable" xlink:type="extended" xlink:title="10601 - Disclosure - Notes Payable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NotesPayableDisclosureTextBlock" xlink:label="eyen_NotesPayableDisclosureTextBlock_637723119636600241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="eyen_NotesPayableDisclosureTextBlock_637723119636600241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637723119636600241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_11" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637723119636600241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10801 - Disclosure - Related Party Transactions">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_14" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_14" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637723119636610282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10901 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_17" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_17" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637723119636610282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans" xlink:type="extended" xlink:title="11001 - Disclosure - Employee Benefit Plans">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_637723119636610282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11101 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_20" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_20" xlink:to="us-gaap_SubsequentEventsTextBlock_637723119636610282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LiquidityAndGoingConcernTextBlock" xlink:label="eyen_LiquidityAndGoingConcernTextBlock_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="eyen_LiquidityAndGoingConcernTextBlock_637723119636610282" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637723119636610282" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_637723119636610282" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637723119636620262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637723119636620262" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637723119636620262" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637723119636620262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_62" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637723119636620262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables" xlink:type="extended" xlink:title="30403 - Disclosure - Accrued Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368364" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DisclosureOfAccruedCompensationTableTextBlock" xlink:label="eyen_DisclosureOfAccruedCompensationTableTextBlock_637723119636620262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368364" xlink:to="eyen_DisclosureOfAccruedCompensationTableTextBlock_637723119636620262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_65" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_65" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637723119636630279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableTables" xlink:type="extended" xlink:title="30603 - Disclosure - Notes Payable (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ScheduleOfNotesPayableTableTextBlock" xlink:label="eyen_ScheduleOfNotesPayableTableTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="eyen_ScheduleOfNotesPayableTableTextBlock_637723119636630279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_637723119636630279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224653" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637723119636630279" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637723119636630279" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_637723119636630279" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637723119636630279" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_637723119636630279" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224653" xlink:to="eyen_ScheduleOfWarrantsOutstandingTableTextBlock_637723119636640260" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfSuccessRateOfOptejet" xlink:label="eyen_PercentageOfSuccessRateOfOptejet_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="eyen_PercentageOfSuccessRateOfOptejet_637723119636640260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops" xlink:label="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_225484" xlink:to="eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops_637723119636640260" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68" xlink:to="us-gaap_StatementTable_637723119636640260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636640260" xlink:to="us-gaap_StatementEquityComponentsAxis_637723119636640260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636640260" xlink:to="us-gaap_EquityComponentDomain_637723119636640260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637723119636640260" xlink:to="us-gaap_WarrantMember_637723119636640260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636640260" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637723119636640260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis_637723119636640260" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637723119636640260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain_637723119636640260" xlink:to="us-gaap_EmployeeStockOptionMember_637723119636640260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636640260" xlink:to="us-gaap_StatementLineItems_637723119636640260" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637723119636640260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636640260" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637723119636640260" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_83" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_83" xlink:to="us-gaap_StatementTable_637723119636650624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636650624" xlink:to="us-gaap_SubsequentEventTypeAxis_637723119636650624" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723119636650624" xlink:to="us-gaap_SubsequentEventTypeDomain_637723119636650624" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723119636650624" xlink:to="us-gaap_SubsequentEventMember_637723119636650624" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636650624" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637723119636650624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637723119636650624" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636650624" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636650624" xlink:to="eyen_AtMarketOfferingMember_637723119636650624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636650624" xlink:to="us-gaap_StatementLineItems_637723119636650624" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637723119636650624" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637723119636650624" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637723119636650624" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637723119636650624" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_NetIncomeLoss_637723119636650624" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637723119636660287" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119636660287" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637723119636660287" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119636660287" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636650624" xlink:to="us-gaap_CashUninsuredAmount_637723119636660287" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PayrollTaxesReceivable" xlink:label="eyen_PayrollTaxesReceivable_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PayrollTaxesReceivable_637723119636660287" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidInsurance_637723119636660287" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="eyen_PrepaidResearchAndDevelopmentExpenses_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidResearchAndDevelopmentExpenses_637723119636660287" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidGeneralAndAdministrativeExpenses" xlink:label="eyen_PrepaidGeneralAndAdministrativeExpenses_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidGeneralAndAdministrativeExpenses_637723119636660287" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidLicensesAndSubscriptions" xlink:label="eyen_PrepaidLicensesAndSubscriptions_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidLicensesAndSubscriptions_637723119636660287" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidPatentExpense" xlink:label="eyen_PrepaidPatentExpense_637723119636660287" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidPatentExpense_637723119636660287" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidConferenceExpenses" xlink:label="eyen_PrepaidConferenceExpenses_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidConferenceExpenses_637723119636670307" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidDirectorFeesCurrent" xlink:label="eyen_PrepaidDirectorFeesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidDirectorFeesCurrent_637723119636670307" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaidRentAndSecurityDeposit" xlink:label="eyen_PrepaidRentAndSecurityDeposit_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="eyen_PrepaidRentAndSecurityDeposit_637723119636670307" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_OtherAssets_637723119636670307" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_116" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637723119636670307" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Compensation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_368367" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedBonusesCurrent_637723119636670307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_AccruedSalariesCurrent_637723119636670307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_368367" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637723119636670307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_122" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedResearchAndDevelopmentExpensesCurrent_637723119636670307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedConsultingAndProfessionalServicesCurrent" xlink:label="eyen_AccruedConsultingAndProfessionalServicesCurrent_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedConsultingAndProfessionalServicesCurrent_637723119636670307" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_CreditCardPayable" xlink:label="eyen_CreditCardPayable_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_CreditCardPayable_637723119636670307" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedFranchiseTax" xlink:label="eyen_AccruedFranchiseTax_637723119636670307" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedFranchiseTax_637723119636670307" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedLicensingFees" xlink:label="eyen_AccruedLicensingFees_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedLicensingFees_637723119636680281" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_InterestPayableCurrent_637723119636680281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AccruedExpenseReimbursements" xlink:label="eyen_AccruedExpenseReimbursements_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="eyen_AccruedExpenseReimbursements_637723119636680281" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637723119636680281" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_122" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_637723119636680281" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_StatementTable_637723119636680281" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636680281" xlink:to="us-gaap_DebtInstrumentAxis_637723119636680281" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637723119636680281" xlink:to="us-gaap_DebtInstrumentNameDomain_637723119636680281" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BankDirectCapitalFinanceLoanMember" xlink:label="eyen_BankDirectCapitalFinanceLoanMember_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637723119636680281" xlink:to="eyen_BankDirectCapitalFinanceLoanMember_637723119636680281" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637723119636680281" xlink:to="eyen_PaycheckProtectionProgramLoanMember_637723119636680281" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637723119636680281" xlink:to="eyen_SiliconValleyBankLoanMember_637723119636680281" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636680281" xlink:to="us-gaap_StatementLineItems_637723119636680281" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637723119636680281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636680281" xlink:to="us-gaap_NotesPayableCurrent_637723119636680281" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636680281" xlink:to="us-gaap_LongTermNotesPayable_637723119636690238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636680281" xlink:to="us-gaap_NotesPayable_637723119636690238" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Notes Payable - Schedule of debt discount Note payable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_StatementTable_637723119636690238" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636690238" xlink:to="us-gaap_DebtInstrumentAxis_637723119636690238" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637723119636690238" xlink:to="us-gaap_DebtInstrumentNameDomain_637723119636690238" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637723119636690238" xlink:to="eyen_SiliconValleyBankLoanMember_637723119636690238" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636690238" xlink:to="us-gaap_StatementLineItems_637723119636690238" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636690238" xlink:to="us-gaap_LongTermDebt_637723119636690238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsNetAlternativeAbstract" xlink:label="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636690238" xlink:to="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723119636690238" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637723119636690238" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637723119636690238" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AmortizationOfDebtDiscount" xlink:label="eyen_AmortizationOfDebtDiscount_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="eyen_AmortizationOfDebtDiscount_637723119636700691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="us-gaap_NotesPayable_637723119636700691" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="us-gaap_NotesPayableCurrent_637723119636700691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtIssuanceCostsNetAlternativeAbstract_637723119636690238" xlink:to="us-gaap_LongTermNotesPayable_637723119636700691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Notes Payable - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="us-gaap_ShortTermDebtTypeAxis_637723119636700691" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637723119636700691" xlink:to="us-gaap_ShortTermDebtTypeDomain_637723119636700691" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember_637723119636700691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637723119636700691" xlink:to="us-gaap_NotesPayableOtherPayablesMember_637723119636700691" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanMember" xlink:label="eyen_PaycheckProtectionProgramLoanMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637723119636700691" xlink:to="eyen_PaycheckProtectionProgramLoanMember_637723119636710512" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SiliconValleyBankLoanMember" xlink:label="eyen_SiliconValleyBankLoanMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637723119636700691" xlink:to="eyen_SiliconValleyBankLoanMember_637723119636710512" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="srt_RangeAxis_637723119636710512" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723119636710512" xlink:to="srt_RangeMember_637723119636710512" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636710512" xlink:to="srt_MinimumMember_637723119636710512" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636710512" xlink:to="srt_MaximumMember_637723119636710512" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodAxis" xlink:label="eyen_PeriodAxis_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="eyen_PeriodAxis_637723119636710512" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PeriodTypeDomain" xlink:label="eyen_PeriodTypeDomain_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_PeriodAxis_637723119636710512" xlink:to="eyen_PeriodTypeDomain_637723119636710512" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FirstAnniversaryMember" xlink:label="eyen_FirstAnniversaryMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_PeriodTypeDomain_637723119636710512" xlink:to="eyen_FirstAnniversaryMember_637723119636710512" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SecondAnniversaryMember" xlink:label="eyen_SecondAnniversaryMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_PeriodTypeDomain_637723119636710512" xlink:to="eyen_SecondAnniversaryMember_637723119636710512" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ThirdAnniversaryMember" xlink:label="eyen_ThirdAnniversaryMember_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_PeriodTypeDomain_637723119636710512" xlink:to="eyen_ThirdAnniversaryMember_637723119636710512" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637723119636710512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="us-gaap_StatementEquityComponentsAxis_637723119636710512" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636710512" xlink:to="us-gaap_EquityComponentDomain_637723119636720275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637723119636720275" xlink:to="us-gaap_WarrantMember_637723119636720275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="us-gaap_FinancialInstrumentAxis_637723119636720275" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637723119636720275" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637723119636720275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637723119636720275" xlink:to="us-gaap_DebtMember_637723119636720275" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637723119636700691" xlink:to="us-gaap_ShortTermDebtLineItems_637723119636720275" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfMonthlyPayments" xlink:label="eyen_NumberOfMonthlyPayments_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_NumberOfMonthlyPayments_637723119636720275" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_637723119636720275" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DebtInstrumentPrincipalAmount" xlink:label="eyen_DebtInstrumentPrincipalAmount_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_DebtInstrumentPrincipalAmount_637723119636720275" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_637723119636720275" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_637723119636720275" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637723119636730270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_RepaymentsOfNotesPayable_637723119636730270" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="us-gaap_ProceedsFromLongTermLinesOfCredit_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ProceedsFromLongTermLinesOfCredit_637723119636730270" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanPrincipalForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_PaycheckProtectionProgramLoanPrincipalForgiveness_637723119636730270" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness" xlink:label="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness_637723119636730270" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_637723119636730270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_DebtInstrumentMaturityDate_637723119636730270" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_637723119636740312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_637723119636740312" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PrepaymentOfLoanFeePercentage" xlink:label="eyen_PrepaymentOfLoanFeePercentage_637723119636740312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_PrepaymentOfLoanFeePercentage_637723119636740312" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OriginalPrincipalLoanPercentage" xlink:label="eyen_OriginalPrincipalLoanPercentage_637723119636740312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_OriginalPrincipalLoanPercentage_637723119636740312" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_637723119636740312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_LongTermDebt_637723119636740312" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723119636740312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723119636740312" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119636750503" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantExercisableTerm" xlink:label="eyen_WarrantExercisableTerm_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="eyen_WarrantExercisableTerm_637723119636750503" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_637723119636750503" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_637723119636750503" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_InterestExpenseDebt_637723119636750503" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637723119636750503" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723119636750503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723119636750503" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637723119636760254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_SharePrice_637723119636760254" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723119636760254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723119636760254" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723119636760254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723119636760254" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_637723119636760254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637723119636720275" xlink:to="us-gaap_RepaymentsOfLongTermDebt_637723119636760254" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637026734627591739" xlink:to="us-gaap_StatementTable_637723119636770351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636770351" xlink:to="us-gaap_TypeOfArrangementAxis_637723119636770351" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723119636770351" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636770351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636770351" xlink:to="eyen_ArcticVisionLicenseAgreementMember_637723119636770351" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_BauschLicenseAgreementMember" xlink:label="eyen_BauschLicenseAgreementMember_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636770351" xlink:to="eyen_BauschLicenseAgreementMember_637723119636770351" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuLicenseAgreementMember" xlink:label="eyen_SenjuLicenseAgreementMember_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636770351" xlink:to="eyen_SenjuLicenseAgreementMember_637723119636770351" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636770351" xlink:to="us-gaap_StatementLineItems_637723119636770351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsUpfrontPaymentsReceived" xlink:label="eyen_LicenseAgreementsUpfrontPaymentsReceived_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_LicenseAgreementsUpfrontPaymentsReceived_637723119636770351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseFees" xlink:label="eyen_DeferredLicenseFees_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_DeferredLicenseFees_637723119636770351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DeferredLicenseCost" xlink:label="eyen_DeferredLicenseCost_637723119636770351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_DeferredLicenseCost_637723119636770351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable" xlink:label="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable_637723119636780268" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments" xlink:label="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments_637723119636780268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementThresholdDevelopmentCosts" xlink:label="eyen_LicenseAgreementThresholdDevelopmentCosts_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_LicenseAgreementThresholdDevelopmentCosts_637723119636780268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyRevenuePayments" xlink:label="eyen_RoyaltyRevenuePayments_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_RoyaltyRevenuePayments_637723119636780268" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePayments" xlink:label="eyen_MilestoneRevenuePayments_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_MilestoneRevenuePayments_637723119636780268" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneRevenuePaymentsReceived" xlink:label="eyen_MilestoneRevenuePaymentsReceived_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_MilestoneRevenuePaymentsReceived_637723119636780268" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneUpfrontPayments" xlink:label="eyen_MilestoneUpfrontPayments_637723119636780268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636770351" xlink:to="eyen_MilestoneUpfrontPayments_637723119636780268" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_161" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_161" xlink:to="us-gaap_StatementTable_637723119636790317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636790317" xlink:to="us-gaap_RelatedPartyTransactionAxis_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637723119636790317" xlink:to="us-gaap_RelatedPartyTransactionDomain_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="eyen_VicePresidentOfResearchAndDevelopmentMember_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637723119636790317" xlink:to="eyen_VicePresidentOfResearchAndDevelopmentMember_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="eyen_SenjuPharmaceuticalCoMember_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637723119636790317" xlink:to="eyen_SenjuPharmaceuticalCoMember_637723119636790317" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636790317" xlink:to="srt_OwnershipAxis_637723119636790317" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637723119636790317" xlink:to="srt_OwnershipDomain_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LicenseAgreementMember" xlink:label="eyen_LicenseAgreementMember_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637723119636790317" xlink:to="eyen_LicenseAgreementMember_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636790317" xlink:to="us-gaap_TypeOfArrangementAxis_637723119636790317" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637723119636790317" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636790317" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ArcticVisionLicenseAgreementMember" xlink:label="eyen_ArcticVisionLicenseAgreementMember_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637723119636790317" xlink:to="eyen_ArcticVisionLicenseAgreementMember_637723119636790317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636790317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636790317" xlink:to="us-gaap_StatementLineItems_637723119636790317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="us-gaap_NetRentableArea_637723119636800381" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="eyen_LeaseMonthlyBaseRent_637723119636800381" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="us-gaap_LeaseAndRentalExpense_637723119636800381" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="us-gaap_SecurityDeposit_637723119636800381" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="us-gaap_LeaseholdImprovementsGross_637723119636800381" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="eyen_LeaseMonthlyBaseRent_6377231196368003811" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="eyen_LeaseMonthlyBaseRent_6377231196368003811" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_RoyaltyPercentage" xlink:label="eyen_RoyaltyPercentage_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="eyen_RoyaltyPercentage_637723119636800381" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_MilestoneUpfrontPayments" xlink:label="eyen_MilestoneUpfrontPayments_637723119636800381" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="eyen_MilestoneUpfrontPayments_637723119636800381" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfMilestonePaymentRevenue" xlink:label="eyen_PercentageOfMilestonePaymentRevenue_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="eyen_PercentageOfMilestonePaymentRevenue_637723119636810240" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636790317" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637723119636810240" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stockholders' Equity - Black Scholes option (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224669" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224669" xlink:to="us-gaap_StatementTable_637723119636810240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636810240" xlink:to="srt_RangeAxis_637723119636810240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723119636810240" xlink:to="srt_RangeMember_637723119636810240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636810240" xlink:to="srt_MinimumMember_637723119636810240" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636810240" xlink:to="srt_MaximumMember_637723119636810240" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636810240" xlink:to="us-gaap_StatementLineItems_637723119636810240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636810240" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637723119636810240" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636810240" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637723119636810240" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723119636810240" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636810240" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637723119636810240" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636810240" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637723119636820265" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stockholders' Equity - Summary of option activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_224721" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224721" xlink:to="us-gaap_StatementTable_637723119636820265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636820265" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_637723119636820265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_637723119636820265" xlink:to="us-gaap_DerivativeContractTypeDomain_637723119636820265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_637723119636820265" xlink:to="us-gaap_StockOptionMember_637723119636820265" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636820265" xlink:to="us-gaap_StatementLineItems_637723119636820265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637723119636820265" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723119636820265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637723119636820265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637723119636820265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637723119636820265" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377231196368202651" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6377231196368202651" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637723119636830272" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637723119636830272" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723119636830272" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723119636830272" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637723119636830272" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377231196368302721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6377231196368302721" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637723119636830272" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637723119636830272" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637723119636830272" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637723119636830272" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637723119636830272" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636820265" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637723119636840365" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_225356" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_225356" xlink:to="us-gaap_StatementTable_637723119636840365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636840365" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637723119636840365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637723119636840365" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceOneMember" xlink:label="eyen_ExercisePriceOneMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceOneMember_637723119636840365" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwoMember" xlink:label="eyen_ExercisePriceTwoMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTwoMember_637723119636840365" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThreeMember" xlink:label="eyen_ExercisePriceThreeMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceThreeMember_637723119636840365" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourMember" xlink:label="eyen_ExercisePriceFourMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceFourMember_637723119636840365" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFiveMember" xlink:label="eyen_ExercisePriceFiveMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceFiveMember_637723119636840365" order="5" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixMember" xlink:label="eyen_ExercisePriceSixMember_637723119636840365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceSixMember_637723119636840365" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSevenMember" xlink:label="eyen_ExercisePriceSevenMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceSevenMember_637723119636850470" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEightMember" xlink:label="eyen_ExercisePriceEightMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceEightMember_637723119636850470" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineMemberMember" xlink:label="eyen_ExercisePriceNineMemberMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceNineMemberMember_637723119636850470" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTenMember" xlink:label="eyen_ExercisePriceTenMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTenMember_637723119636850470" order="10" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceElevenMember" xlink:label="eyen_ExercisePriceElevenMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceElevenMember_637723119636850470" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwelveMember" xlink:label="eyen_ExercisePriceTwelveMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTwelveMember_637723119636850470" order="12" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceThirteenMember" xlink:label="eyen_ExercisePriceThirteenMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceThirteenMember_637723119636850470" order="13" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFourteenMember" xlink:label="eyen_ExercisePriceFourteenMember_637723119636850470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceFourteenMember_637723119636850470" order="14" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceFifteenMember" xlink:label="eyen_ExercisePriceFifteenMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceFifteenMember_637723119636860274" order="15" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSixteenMember" xlink:label="eyen_ExercisePriceSixteenMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceSixteenMember_637723119636860274" order="16" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceSeventeenMember" xlink:label="eyen_ExercisePriceSeventeenMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceSeventeenMember_637723119636860274" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceEighteenMember" xlink:label="eyen_ExercisePriceEighteenMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceEighteenMember_637723119636860274" order="18" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceNineteenMember" xlink:label="eyen_ExercisePriceNineteenMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceNineteenMember_637723119636860274" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyMember" xlink:label="eyen_ExercisePriceTwentyMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTwentyMember_637723119636860274" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyOneMember" xlink:label="eyen_ExercisePriceTwentyOneMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTwentyOneMember_637723119636860274" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ExercisePriceTwentyTwoMember" xlink:label="eyen_ExercisePriceTwentyTwoMember_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637723119636840365" xlink:to="eyen_ExercisePriceTwentyTwoMember_637723119636860274" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636860274" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636840365" xlink:to="us-gaap_StatementLineItems_637723119636860274" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637723119636870343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636860274" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637723119636870343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637723119636870343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636860274" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637723119636870343" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637723119636870343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636860274" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637723119636870343" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637723119636870343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636860274" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637723119636870343" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stockholders' Equity - Warrants Activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantsOrRightsOutstandingRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637723119636880268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightGranted" xlink:label="eyen_ClassOfWarrantOrRightGranted_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" xlink:to="eyen_ClassOfWarrantOrRightGranted_637723119636880268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" xlink:to="eyen_ClassOfWarrantOrRightExercised_637723119636880268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6377231196368802681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6377231196368802681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsOutstandingRollforward_637723119636870343" xlink:to="eyen_ClassOfWarrantOrRightExercisable_637723119636880268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward" xlink:label="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_637723119636880268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" xlink:to="eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice_637723119636880268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" xlink:to="eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice_637723119636880268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6377231196368802681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice_6377231196368802681" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward_637723119636880268" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_637723119636880268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_637723119636880268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife_637723119636880268" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637723119636890542" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue_637723119636890542" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue" xlink:label="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue_637723119636890542" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_637723119636890542" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637723119636890542" xlink:to="srt_RangeAxis_637723119636890542" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723119636890542" xlink:to="srt_RangeMember_637723119636890542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636890542" xlink:to="srt_MinimumMember_637723119636890542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636890542" xlink:to="srt_MaximumMember_637723119636890542" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637723119636890542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637723119636890542" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637723119636890542" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637723119636890542" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637723119636900243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723119636900243" xlink:to="eyen_WarrantsAtExercisePriceOneMember_637723119636900243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceTwoMember" xlink:label="eyen_WarrantsAtExercisePriceTwoMember_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723119636900243" xlink:to="eyen_WarrantsAtExercisePriceTwoMember_637723119636900243" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723119636900243" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_637723119636900243" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_637723119636890542" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119636900243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_637723119636900243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife" xlink:label="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife_637723119636900243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercisable" xlink:label="eyen_ClassOfWarrantOrRightExercisable_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="eyen_ClassOfWarrantOrRightExercisable_637723119636900243" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightExercised" xlink:label="eyen_ClassOfWarrantOrRightExercised_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="eyen_ClassOfWarrantOrRightExercised_637723119636900243" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6377231196369002431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6377231196369002431" order="6" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723119636900243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_637723119636900243" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723119636900243" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stockholders' Equity - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_202" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_202" xlink:to="us-gaap_StatementTable_637723119636910251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637723119636910251" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637723119636910251" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceOneMember" xlink:label="eyen_WarrantsAtExercisePriceOneMember_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723119636910251" xlink:to="eyen_WarrantsAtExercisePriceOneMember_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_WarrantsAtExercisePriceThreeMember" xlink:label="eyen_WarrantsAtExercisePriceThreeMember_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637723119636910251" xlink:to="eyen_WarrantsAtExercisePriceThreeMember_637723119636910251" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_PlanNameAxis_637723119636910251" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637723119636910251" xlink:to="us-gaap_PlanNameDomain_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637723119636910251" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="srt_RangeAxis_637723119636910251" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637723119636910251" xlink:to="srt_RangeMember_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637723119636910251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636910251" xlink:to="srt_MinimumMember_637723119636910251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637723119636910251" xlink:to="srt_MaximumMember_637723119636920260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_VestingAxis_637723119636920260" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637723119636920260" xlink:to="us-gaap_VestingDomain_637723119636920260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723119636920260" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723119636920260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723119636920260" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723119636920260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637723119636920260" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637723119636920260" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636920260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636920260" xlink:to="us-gaap_IPOMember_637723119636920260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119636920260" xlink:to="eyen_AtMarketOfferingMember_637723119636920260" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_StatementEquityComponentsAxis_637723119636920260" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637723119636920260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637723119636920260" xlink:to="us-gaap_EquityComponentDomain_637723119636920260" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637723119636920260" xlink:to="us-gaap_WarrantMember_637723119636930579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassWarrantsMember" xlink:label="eyen_ClassWarrantsMember_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637723119636930579" xlink:to="eyen_ClassWarrantsMember_637723119636930579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassBWarrantsMember" xlink:label="eyen_ClassBWarrantsMember_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantMember_637723119636930579" xlink:to="eyen_ClassBWarrantsMember_637723119636930579" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_StockOptionsMember" xlink:label="eyen_StockOptionsMember_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637723119636920260" xlink:to="eyen_StockOptionsMember_637723119636930579" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637723119636920260" xlink:to="us-gaap_CommonStockMember_637723119636930579" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637723119636930579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_AwardTypeAxis_637723119636930579" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637723119636930579" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119636940292" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119636940292" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637723119636940292" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_IncomeStatementLocationAxis_637723119636940292" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637723119636940292" xlink:to="us-gaap_IncomeStatementLocationDomain_637723119636940292" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637723119636940292" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637723119636940292" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637723119636940292" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637723119636940292" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637723119636940292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="srt_TitleOfIndividualAxis_637723119636940292" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637723119636940292" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723119636950388" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_DirectorsAndExecutiveOfficersMember" xlink:label="eyen_DirectorsAndExecutiveOfficersMember_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637723119636950388" xlink:to="eyen_DirectorsAndExecutiveOfficersMember_637723119636950388" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637723119636910251" xlink:to="us-gaap_StatementLineItems_637723119636950388" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_CommonStockSharesAuthorized_637723119636950388" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637723119636950388" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637723119636950388" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_PreferredStockSharesAuthorized_637723119636950388" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637723119636960271" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637723119636960271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637723119636960271" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637723119636960271" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NumberOfCommonShares" xlink:label="eyen_NumberOfCommonShares_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_NumberOfCommonShares_637723119636960271" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119636960271" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_UnitsIssuedPricePerUnit" xlink:label="eyen_UnitsIssuedPricePerUnit_637723119636960271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_UnitsIssuedPricePerUnit_637723119636960271" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637723119636970297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_SharesIssuedPricePerShare_637723119636970297" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="eyen_NetProceedsFromIssuanceOfCommonStock_637723119636970297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_NetProceedsFromIssuanceOfCommonStock_637723119636970297" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637723119636970297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_SharePrice_637723119636970297" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119636970297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119636970297" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_FairValueOfCommonStock" xlink:label="eyen_FairValueOfCommonStock_637723119636970297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_FairValueOfCommonStock_637723119636970297" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637723119636980316" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensation_637723119636980316" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637723119636980316" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637723119636980316" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637723119636980316" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637723119636980316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637723119636980316" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723119636990291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637723119636990291" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723119636990291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723119636990291" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723119636990291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637723119636990291" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723119636990291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637723119636990291" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723119637000276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637723119637000276" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637723119637000276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ProceedsFromWarrantExercises_637723119637000276" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637723119637000276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637723119637000276" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119637000276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637723119637000276" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock" xlink:label="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_637723119637000276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock_637723119637000276" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637723119637010280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637723119637010280" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_PercentageOfGrossSalesOnCommonStock" xlink:label="eyen_PercentageOfGrossSalesOnCommonStock_637723119637010280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="eyen_PercentageOfGrossSalesOnCommonStock_637723119637010280" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637723119637010280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637723119636950388" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637723119637010280" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Employee Benefit Plans (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637723119637020378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_637723119637020378" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637723119637020378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_637723119637020378" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637723119637020378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_637723119637020378" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637723119637020378" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637723119637020378" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637723119637020378" xlink:to="us-gaap_SubsequentEventTypeAxis_637723119637030302" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637723119637030302" xlink:to="us-gaap_SubsequentEventTypeDomain_637723119637030302" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637723119637030302" xlink:to="us-gaap_SubsequentEventMember_637723119637030302" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637723119637020378" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637723119637030302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637723119637030302" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637723119637030302" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_AtMarketOfferingMember" xlink:label="eyen_AtMarketOfferingMember_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119637030302" xlink:to="eyen_AtMarketOfferingMember_637723119637030302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637723119637030302" xlink:to="us-gaap_EmployeeStockOptionMember_637723119637030302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637723119637020378" xlink:to="us-gaap_AwardTypeAxis_637723119637030302" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637723119637030302" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119637030302" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="eyen_OmnibusStockIncentivePlan2018Member_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637723119637030302" xlink:to="eyen_OmnibusStockIncentivePlan2018Member_637723119637030302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637723119637030302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637723119637020378" xlink:to="us-gaap_VestingAxis_637723119637030302" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637723119637030302" xlink:to="us-gaap_VestingDomain_637723119637040421" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723119637040421" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637723119637040421" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637723119637040421" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_637723119637040421" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637723119637020378" xlink:to="us-gaap_SubsequentEventLineItems_637723119637040421" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637723119637040421" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="eyen-20210930.xsd#eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:label="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_637723119637040421" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637723119637040421" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637723119637040421" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_SharesIssuedPricePerShare_637723119637040421" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723119637040421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637723119637040421" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637723119637050394" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637723119637040421" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637723119637050394" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>eyen-20210930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:eyen="http://www.eyenoviabio.com/20210930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eyen-20210930.xsd" xlink:type="simple"/>
    <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_VN0zw8sCNECXKkjFp3cH-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_hm_lAyvBM0qOeJoA1nk2ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2020_To_3_24_2020_bTfSRHfxlkeROm6p3tdnwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_166ZAmZBBki2ZJaq_2i7OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_egysx-a5s0CwPDQUHEvdqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yoZZp1S-YkSK0slqbGBuYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UIjArcXu4kWTOOHrTlosoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_2iIqhP5zKUSGnKrT3fT8EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_xmAWV6mUSKUNDQxJrP0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mQSiaUfq50W0yaz5UztvLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_1iHEOc5UZ0iZyDD69rBDVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j4B1KYQ0MEWecgQLPbVQNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kth875WnPUKg3agMaWI0Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZLzQ6a3ZdkCqP8h95qZo5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_11APGkRcvEiinWn5XMPudQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8jVnW9XRk-de3gCif1Ngg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aERtWPLXHE-NyWVDKwVKKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_uk3nxzgTF02apB9F1dX2kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8iU0YDKFkWOzxWgCoFXPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QsJXwwdhUU-D4UcQ-cvUsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_vwX5UftH6k2nB0oxeBOzmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L_q-9Sd8ckKHkP5XYRlMzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HJTe8zro2Uuqwss6XoUeeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_lMHKpMczF0i8b2pWYttO7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-27</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_txshmOfMEEmvxCweLiMsTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_Am_mT9HJA0SSfr6CiMZH_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_aOl2qdArnUe539L8lxXVIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_UpMsAYqFqU6-i1LSMPeaFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_FM7GpRWW9Euozoy65TKphg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_7ngFNRaQXEyNp3ttRONFSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_c-dzlES2H06x3UbgBeoj7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_80d3KmGzV0ebsJXfreNHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_BHSo-xH0_02gL68u6nLG7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_Mhliuin-iE-lwHos4zJZUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_QKy5Dk4L5U21ypNDqI_eFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_bogZl4gZq0O_dB0iHUQz0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_Cignz6GZIEqawyto9jO6zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_LJewsOeuEk6TAXKmOshhVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_t3aQtXqbMUqyY_l_s90kFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_fMRMT8Kzq0GnRyxYiQBXKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_pdxT137AQUSnpOvc-s2HeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_2pIbQgQQM021F_Zqq-Clqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_smJVukydaEOrt-QPyWs5Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_T5bwOHqjaUKS0LJJ4b5ozA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_XtjRsqCqhUWe6dM1LlWLYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_DIdgnF05VESFzCtSdTkV_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceNineMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_JRmA5vMSfky7e2TsSVzjhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_OZ8nqWdLB0CI7i4-5Qnk5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember__XCTy9gD4EmCBR0M73gnyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_7pE77VrTWUCPTGSIttM0Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_w1sjpiHNKkuLE2e28hGLqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9phIPy7ZLESGi02EKB1vbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-10-27</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tUqOu0dbMESf7ibzQiMF9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-10-27</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-10-27</endDate>
        </period>
    </context>
    <context id="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_4f7WqPnHVkCgD1MTwLBKxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="As_Of_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_yWodK4nHxUqdTmAUJR3I_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_0KZL2TVKrUmrWMPejjnE0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-15</instant>
        </period>
    </context>
    <context id="As_Of_9_29_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_L9bBY0VpvUGL4oYGXOsvdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-29</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DebtMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IQWi_hUUskCPeb77ph-Kwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-15</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M_Xp5Nb4D0mDo0QoESXKLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nzq8FK4mAkKZ5R2RZ9KIUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember_dyafUeHTdE6cz1HM3PEKSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">eyen:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_QoZ2KGe6NUGCeXRNsv3DqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:BankDirectCapitalFinanceLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:BankDirectCapitalFinanceLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember__7M2VxLcG0C8xOn47atQ4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pj3iXu39uEaE-ra1uxJM1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pOlvfs6TQUyzUKtXgpDcEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_KnS0U6aBO0mO5JTiaLy6jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_JuJfIkOVj0CQftJ-_I1QGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_fv_THQb6o0GG_A4a0SrB1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_72LTFu3OPkuIXbgOUgsnxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-17</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_c2IjVI1hiUyhj_jiFRUrvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VL8MKBI58UiYMm_viCZP0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_8dZNtKxwmkiqkPx6oMKrZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_whpYAzEDtkOSZXmSQSWepw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_os_kMS_z0EKpasXd_445Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_4_qEKYrc8Euhf2_8V5qnGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_7Pfs622rJ02-2GjGaBo6sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_XlWzbj9LNU6tzxL4LlSTxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_A7hLgIFxxUKBiuI527JBGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Jy8VhLNmEkGHN5MuNuthNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ntknW_Gv5UC-DQSr8ZSQOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qNX7m30BZEuTbysvLOcMQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rbh1OVNxSEyBxxZbh4fjoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_x35crJWltUqP-Ltc2GMthw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CJ4gskFkJUSoYcy73Hqa0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_w6HGMgcXbEmE_fB8OrHwwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_bcWFEL6RI0aDOWIz9I9cow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">eyen:DirectorsAndExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_40ylzH8p4E6F0T980U5jPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-24</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_dm3PbdzDGkKl6-8dwnZVtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IKbBe5b9Dk2-O_EZG5UCIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_ag4DlDgBVE2npGpPYLG-BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_ThirdAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_36SWG7orek6gpITdi6VlKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:ThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_SecondAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_Xo9_8_071Euty-FIgDxP6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:SecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_FirstAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_nLEH9d3WgkSONkevFlrepw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eyen:PeriodAxis">eyen:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-24</startDate>
            <endDate>2021-02-24</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-11</startDate>
            <endDate>2020-09-11</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-14</startDate>
            <endDate>2021-09-14</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-14</startDate>
            <endDate>2021-09-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_C3bKFFHaP0eGVFPtm44auA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:SenjuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_DQU3YqFEXEeMyoIAZgkB6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-09</startDate>
            <endDate>2020-10-09</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-10</startDate>
            <endDate>2020-08-10</endDate>
        </period>
    </context>
    <context id="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_7NBatIvU1UScUlDnCWwfjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:BauschLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-09</instant>
        </period>
    </context>
    <context id="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_3Zy0UOScXEaWdhOuseYwgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="Duration_4_6_2020_To_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_qW8ClKspyUqkLxfdKlUpyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-06</endDate>
        </period>
    </context>
    <context id="Duration_9_15_2018_To_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_N9ZooPSTykGh4q7NxSG9rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-15</startDate>
            <endDate>2018-09-15</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_9IMRqv6brkyXUIlqI0AdYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-15</endDate>
        </period>
    </context>
    <context id="Duration_5_14_2021_To_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_N1KXYZq5fUuqk4TSeXUFnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eyen:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_i3TWieKEpEOqRjVjfBglLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:SenjuLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-10</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eyen:ArcticVisionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-07</instant>
        </period>
    </context>
    <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_x2ajygQN6EKb6JGnk3ADLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9AtIdFEIokuL0HQ8uzCAsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">eyen:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-24</startDate>
            <endDate>2020-03-24</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_s7sYagQq6kerzRAgAyzWvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_kdodtnQEgkKApSH7Ar3_7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Im1QKFMiwEyIc4Nt8pdKyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">eyen:WarrantsAtExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eyen:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_10_2021__RwvPqpFAUaT2tpu7xbEIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <instant>2021-11-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682639</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_sqft_g_mpTWDoikWYZzf7J4YxvQ">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      id="Hidden_1RgLe8I-bkex9JfHegYumg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      id="Hidden_JskXH9EJUUeZv0DhFI7gJQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="2"
      id="Hidden_Zpy7aVwBy0-Lv8WhOHXNTA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="2"
      id="Hidden_cbG6_6ZmOk-FkJmzEa1rHw"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Hidden_pjIxGAhFRkavWEUwCGLB3Q"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="2"
      id="Hidden__pXBRFNzo02E8aJpBpfeaw"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Hidden_tkGiDTxPi0K_pGbG6MFwQw"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">26052483</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Hidden_IXhkrl1xBU6hnHIlgILgfg"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">22206195</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Hidden_TdF7yINdLEuyx2Jf6GYcGQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25773098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Hidden_9cP8NU4rWUqcVr6GzJ5YpQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">19802999</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_QKy5Dk4L5U21ypNDqI_eFg"
      id="Hidden_0pjWYEGDNkentV_xYyZQGA">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_XtjRsqCqhUWe6dM1LlWLYQ"
      id="Hidden_0rah1dwiwUKGvejQzLqdgw">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Hidden_NP4wZA_uF06ifKNMb15MNA">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_8mD3YO7KBEW8Loi88kQcsA_2_1">0001682639</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_mH3nc5s9JUOFMwo5Hd2P0A_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_rCJsXRhcNU-rnriUGGK4HA_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_ZPV7oV9piEyoeiamnz_SCA_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_AV-vx2tnL0W6x7AMNYAxxA_6_1">false</dei:AmendmentFlag>
    <eyen:LeaseMonthlyBaseRent
      contextRef="Duration_9_15_2020_To_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_3Zy0UOScXEaWdhOuseYwgQ"
      decimals="0"
      id="Hidden_D_hRu6Vn6kiVuoZDbI2E-w"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5404</eyen:LeaseMonthlyBaseRent>
    <eyen:LeaseMonthlyBaseRent
      contextRef="Duration_9_15_2018_To_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_N9ZooPSTykGh4q7NxSG9rA"
      decimals="0"
      id="Hidden_nuJjRqoS1k-5yZXc6XLgrw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4012</eyen:LeaseMonthlyBaseRent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Hidden_eoq4WkYJv0u9e_1CVVO3Uw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-93202584</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Hidden_wncAopnaD0uKiQynCGwpOA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15761665</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Hidden_p4gZozmYS0S7balkCzNXaw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15563005</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Hidden_ux28YaoNUkm5oVQ06xjkHA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-14997807</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Hidden_XUae-FPTXkaSLR7npSF_nw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-11853369</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Hidden_3MWSsXXWsESbShjb4H9pdQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Hidden_oERaqE77QE2N-3RROB8Lyw"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Hidden_3Hdz33n-GkW0wPKEq9SnqA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25963185</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Hidden_d9weVYGAekqwmy1K-j8EiQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">24978585</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Hidden_MimNBTPoWU-6QCm4o9Gk6Q"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2646091</us-gaap:ProceedsFromWarrantExercises>
    <eyen:LeaseMonthlyBaseRent
      contextRef="Duration_4_6_2020_To_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_qW8ClKspyUqkLxfdKlUpyA"
      decimals="0"
      id="Hidden_ZGcx3U_Ha0Oyk6Kg7P3ESg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5247</eyen:LeaseMonthlyBaseRent>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_9HiG0WNkEEKP9vYi-MHiDA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_sFhhA4oLjkyvRiJz0pVSQg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_qChFxaQSwkmdinBEV_GnLA">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_ojEVj5YGZ0SP5HYmtxwffQ">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_rs1O-wbxp0e29Fv_CP-LDA">001-38365</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_EFZR0frdJ0iGNZ4K7AmEfA">EYENOVIA,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_a-PyXfXiekiqOrydMknXMg_0_2">47-1178401</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_aY4QRe_o5E-t8MenffLhjA">295 Madison Avenue, Suite&#160;2400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_RuYuLC_CV02-BUtqvyG8pw">NEW YORK</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_o8pJp_qzyEOggZQBR22ocg">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_BV9yMQU5ykC9wKb25gWUHw_3_2">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_hZikFdA650eUo_VJrVnQDQ">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_BwnTNgkSsEuqUFAiFSTKjQ">289-1117</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_kxgHbwXnwUqUZkOzfs9GlA_2_0">Common Stock, $0.0001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc__Ln1PB8QdUWbnbiw4Vp3Zw_2_2">EYEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_eUxj0ngPG0a2XAlne4fGBw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_tkJb9IL1Zkeb-8dHdqTe_Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_CLGejyNCcECKUQnIqD0c7w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_IePL-r4XzEyi9ziPKhd11Q_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_Bc0vMxul002xAD_hRZn19Q_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_qI2YJ9AtsEORMOj8GCJkZw_4_3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_HmLyXqL4s06h8fzTaSQ1gg">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_967PW8RHUUSyiYf73xJyiw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_10_2021__RwvPqpFAUaT2tpu7xbEIQ"
      decimals="INF"
      id="Narr_cXWa1SIG4U276C9IqpGmWg"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">28398789</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_3-XjeG44bECB1u2eSjVOmQ_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">13500871</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_cT-nNZ74jE28tvs7UFhcKQ_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">28371828</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_kUZHmBCEREqNZ2JTjClR7g_8_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7875000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DeferredCostsCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_K91UeZGtGkGheGea0eYwfA_9_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1600000</us-gaap:DeferredCostsCurrent>
    <eyen:LicenseFeeAndExpenseReimbursementsReceivables
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_YklHRmxhF0WD29k7JaDynw_10_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">960180</eyen:LicenseFeeAndExpenseReimbursementsReceivables>
    <eyen:LicenseFeeAndExpenseReimbursementsReceivables
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_jxw8pwHTlki0hJnVFcrWfg_10_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2966039</eyen:LicenseFeeAndExpenseReimbursementsReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_1uZF7tjOC0etGEAPPiz6Zg_11_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1123289</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_SYPZxRvm80a10RETKvEmWA_11_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">453478</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_Izt1rAMoIkWirQelJEMUhw_13_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">23459340</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_U3KtfYQ4nUOCGpnmAAWRKg_13_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">33391345</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_x5OfE-YNzkaMbhlqdIcOWg_15_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1413201</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_adwOYQZEfEun_3t-vo1V1Q_15_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">396380</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_AyzLhxZK6EivkGb0dvhD7A_16_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">119035</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_zhnqdb2ZKUKmHlnEbKsKpw_16_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">119035</us-gaap:SecurityDeposit>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_EzClQXZaNkOdRXl0NU-EVg_18_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">24991576</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_pCA2uTEK6UmcGzAG7e2zrw_18_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">33906760</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_8-LVUzus70GeC-1os49LHg_23_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1684733</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_evw476ZBeUWLqWSS9eaWeA_23_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1461665</us-gaap:AccountsPayableCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_fZsXhTOyTkSSLP98K1omZw_24_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1184236</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_f9Cn-QLa60i2eqhGB0wB5Q_24_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1150672</us-gaap:WorkersCompensationLiabilityCurrent>
    <eyen:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_Qny33pAHyEmFC2S8p6c8RQ_25_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">552336</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
    <eyen:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_hfn-xCnKRkeQ2A4gdEeRJQ_25_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1480692</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_qWW2AaF1502O0N2dWQyivg_26_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">16037</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_rM_1mWqfzUC7awf5voqkog_26_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7809</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_HFR-z447fEq2bz7EiT8ZoA_27_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">10000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_ql-C_mzsW0uA96wbksnvwA_27_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">14000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_muUvt3dQHUqS0p0XcGUyxA_28_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7282037</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_yF9n__jtjkKvvljv30MFjg_28_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">97539</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_R8lU7_dXzUCQ4UMbCo1ZZA_30_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">20719379</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_LooyRWh8f0ev3Wrn2st8zw_30_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">18198377</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_3Xd22g3B1kWaZ4_hMXCOzQ_32_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">26059</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_oeSqz8kCw0iXJlQC5aQYqA_32_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">38684</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_bI71TxB0vUid-JwofD7wjw_33_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">365814</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_jvxFrugoIUqGz2OmTSFalg_35_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">20745438</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_udIi5jwV40-Eypbvd90DJQ_35_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">18602875</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_qiYh8uv0r0i29yFsRyo3LA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_LCukT05TUUWyvfdxFdPR7w"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_RR1I5ompQUmaT-ogSQUZ3g"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">6000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_ZXDCww9jU0yR8THuHLI9TQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">6000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_m-LKO2gqz0abvL1Fj_0gjA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_TNJkaMheikmRpQxrLfyL1A"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_vQN8KEUaZUuM5UU9rH_otw_40_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_9xzexkj6cESnm4cvjVIDiA_40_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_M1Zr43Jl5USoweuDQOxIcA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_v8gKGkI4o0eHVLf6H9yQEQ"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_daTa2QGTjEWyC0FkS1_vTA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_D2fBQMaYh0a_ORi6_eTsRQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Narr_3suNuEXbx0mMAO_ZCpTc0Q"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25963185</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Narr_7R6E0m60pEyyfcedNeLEEw"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">24978585</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_zVI8P9d9HEyx5IkksVOhbA_41_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2597</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_pAAZPID3EEqpdHty8f0tbQ_41_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2498</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_3OqeTv9u6EqJ4anXtTSCXQ_42_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">97446125</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_EMVDYjR7bU6SSfmU4LBTvw_42_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">92742306</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_0yRthFfhoEGtYo5CAf_P-Q_43_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-93202584</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_lC1psxqnEUSCECg6hZQDxg_43_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-77440919</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_zdIFNPEUhUiq28gIX_u2Tg_45_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4246138</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_wIdu8vuzCESkDs322D5HLA_45_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">15303885</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_2CW9u7KOfEaIW6HExM5fNA_47_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">24991576</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_b1A6v7mODk2hTyZoCDcD4w_47_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">33906760</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_o-DyEGwq5kSYNvHxk4hs4w_5_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_0V9NQ43RMUS0-m5cfwmS-A_6_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1600000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_6ApBe-2BzEuL4_kSeqH4Aw_7_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2400000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_mRmih1t3FES0HAN1WkdBBg_10_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3470188</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_bmp1oCMOWECmw1cnvvc9pg_10_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3363759</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_Q6A0vPRKVkWEvw1pvDIhjA_10_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">11334296</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_pZDMmGnb1UG7AKDE8BigPA_10_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">9913296</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_nQCPq1jOMUqSt4JQC643Mg_11_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2435141</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_3NhHtfzaVUqAxvyIEMOyXg_11_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1728366</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_BkzJ32F9OECn0FqcdGvFRQ_11_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7082659</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_fJ1gtn_gC0e1PZ9M1DpJPA_11_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5669311</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_NbdNSURPYEmyN-1CADGvuA_12_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5905329</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_cpMRaDkiAk66EBHycAHB1w_12_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5092125</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_1Uc37T82e06Cyu8OWhhFzA_12_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">18416955</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_3EzixadLQUGlIrY9YxZMbw_12_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">15582607</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_nAL-80rpkUWSxWuoR8S2XA_14_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5905329</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_pZUVOB4cckuPR_TLIzGHaQ_14_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5092125</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_V0ZpiJa6YkWMvQnloANS9Q_14_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-16016955</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_rkwNUQr4BUegXKSo6u04Kg_14_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15582607</us-gaap:OperatingIncomeLoss>
    <eyen:SmallBusinessAdministrationEconomicInjuryDisasterGrant
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_Z88jJy-5j0u3NEocP2442Q_17_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">10000</eyen:SmallBusinessAdministrationEconomicInjuryDisasterGrant>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_0yIW0LvkHE29CmrMyfZRFA_18_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_O5exew2jrk-0kipSxJfb3Q_18_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_NAlYBinpcUSOO9OLXu8WKA_19_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-8010</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_VkPauxrXU0C79nQS4UwF3A_19_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-8010</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_hMbcq1aHmkaRsmav4SVeHw_20_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">119212</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_Aql3yePTNE6VCUSLRvBJUg_20_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4945</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_xtYB19cskEK9JVPJjUtcHA_20_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">202407</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_gTc5T6D9aUCcEwEwUb3Dkw_20_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">14977</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_y87_9cNvjEKhGBPWoRsvBw_21_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">600</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_58QBlQMT30y5qL0ehUfTYg_21_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">540</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_R9ciFWu7NEqtMFUOUXoM6A_21_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2354</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_dL67z9uzM0-RvbRXSXM3Mg_21_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">24579</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_9nD-LWhTo0-nDN_iz1AJSQ_23_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5568598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_VtmAsU87CUiWJRsy1tR4NQ_23_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5096530</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_PveSerKpWEGiNbLEA5978w_23_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15761665</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_TutV0VZ9XECQOuxsJF4CmA_23_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15563005</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="2"
      id="Tc_I5Tax7rDdU22rL0PwRebKQ_26_3"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="2"
      id="Tc_SManfofD80un1wSN1LsNlw_26_6"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Tc_lPEb8vlqkES-LB8Q0foM2g_26_9"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="2"
      id="Tc_N_7g5mbomUejqA0OsmqPrQ_26_12"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_RLPQlewIj0imHN5XGiSXbQ_29_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">26053532</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_K_HBzFS0bUmL2nJAIL6bCA_29_6"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">22206195</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_h8mJaP5eN0yxu74QWfjaQA_29_9"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25773098</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_B9ZE5myytkW7rO-AEQ6hQg_29_12"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">19802999</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw"
      decimals="0"
      id="Tc_ddZtvRdPok-Ar8oGlz4d_g_5_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">24978585</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MUwt1YeEqUWTw4SeAprxmw"
      decimals="0"
      id="Tc_ZaoKxqhAGEezqShN-KY2KQ_5_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2498</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kth875WnPUKg3agMaWI0Rg"
      decimals="0"
      id="Tc_85oNl1d1n0ig6FQuur5bVQ_5_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">92742306</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_j4B1KYQ0MEWecgQLPbVQNw"
      decimals="0"
      id="Tc_flj3AoqmRkas7v6X_hBtdA_5_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-77440919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc__4qFm-LH0EmcG-HgwV4Hig_5_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">15303885</us-gaap:StockholdersEquity>
    <eyen:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_btUNqS8cqEO8u58x8vC9lw_7_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">644992</eyen:StockIssuedDuringPeriodSharesWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_gsiXpCGhUUKpOTv8ss_qjw_7_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">65</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA"
      decimals="0"
      id="Tc_LwUNtazIRUKeu5k11Fz3xQ_7_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1530925</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA"
      decimals="0"
      id="Tc_D5qLIXcUIUCpYn4YW9vibQ_7_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1530990</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_OnCKMCWKmUiSPOHA4PSyrA_9_2"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_g-OSBrFhkkuCOD5eyNMvDw_9_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA"
      decimals="0"
      id="Tc_6cv70tXTJE6tVd3x-swFNQ_9_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">656913</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA"
      decimals="0"
      id="Tc_3AfqC5hZ7kmh1RV1ArVh8Q_9_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA"
      decimals="0"
      id="Tc_qsxd1AYV7EqnUPkTjbezfQ_9_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">656913</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_7fnv2bZUjkW0JF71ys6RWg_11_2"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7iWxZwikKEWk3H3C4PxkKA"
      decimals="0"
      id="Tc_MmyGqiRRJ0iZCqIlfA5G_Q_11_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OawOlZzalE6g3psbLpknWA"
      decimals="0"
      id="Tc_BIEeMqxvdk2ZBqv6AIj1Yw_11_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_foKVPTD0Z0eo9YGPzDHNeA"
      decimals="0"
      id="Tc_GFKBrz6Ss0qlkqRlNRv4AA_11_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5351667</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_kN3c_nYo2kGqn0YHJnEMCA"
      decimals="0"
      id="Tc_fGIH6srWIEmyE25N3BwFSA_11_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5351667</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw"
      decimals="0"
      id="Tc_J_unuOIl5062wUSe75J25w_13_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25623577</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2B8LtFWs706uWLAdWArQOw"
      decimals="0"
      id="Tc_I0uMnwUJfE6-U4TZGIDw-w_13_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2563</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mQSiaUfq50W0yaz5UztvLg"
      decimals="0"
      id="Tc_xB2ERdGXw0S5L_Mt9S_3Xg_13_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">94930144</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_E_xmAWV6mUSKUNDQxJrP0A"
      decimals="0"
      id="Tc_i221d3KMa0GFjhnjamjwmQ_13_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-82792586</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_1iHEOc5UZ0iZyDD69rBDVA"
      decimals="0"
      id="Tc_oUaVSe53OUuXG9A4H6N3Ng_13_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12140121</us-gaap:StockholdersEquity>
    <eyen:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg"
      decimals="0"
      id="Tc_FE3OD-pBDECzyIpiMXBgZQ_15_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">232022</eyen:StockIssuedDuringPeriodSharesWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg"
      decimals="0"
      id="Tc_4Of6Hfn8W0GJdD6qusvk5w_15_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">23</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q"
      decimals="0"
      id="Tc_ljER9wmlW0em5UftiH9mUg_15_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">572978</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Tc_g66dZkwcBkWGev1Qdc30vQ_15_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">573001</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg"
      decimals="0"
      id="Tc_-sDPcR7KN0GQdmQDLWgs1g_17_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">91047</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4BHBv9-LjEuudA9Klw2EUg"
      decimals="0"
      id="Tc_aIXiFglvmESHgqDW6MYHKg_17_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">9</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q"
      decimals="0"
      id="Tc_vrQufILv8EqRyFkDCm4SFg_17_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">130081</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Tc_UufV-0CdBU61ZbQH4DLVlw_17_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">130090</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q"
      decimals="0"
      id="Tc_kzbIalpKPk-fHEULMdpRUg_19_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">351390</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">351390</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dnGR3CnrkSUUF2wDoTP0Q"
      decimals="0"
      id="Tc_GcHsmRSK6UCxlGDO_YQOJA_21_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">637355</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Tc_O81CTKW9Bke1uu25mhkDSw_21_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">637355</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Nzq8FK4mAkKZ5R2RZ9KIUg"
      decimals="0"
      id="Tc_SL2tKBoOL0uKEbgxPF7IIg_23_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-4841400</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Tc_xIH7Ok6n-Eil3RIQtBQWyg_23_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-4841400</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g"
      decimals="0"
      id="Tc_ri-21ZSjXEul7xt3vK8e3w_25_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25946646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nsUdj8fbXEySTgSOVSTm9g"
      decimals="0"
      id="Tc_2RPk1ipdCE20h3piiN_bWQ_25_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2595</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UIjArcXu4kWTOOHrTlosoQ"
      decimals="0"
      id="Tc_tSeUjSF6xUS-L82W12ujZw_25_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">96621948</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yoZZp1S-YkSK0slqbGBuYg"
      decimals="0"
      id="Tc_3gxC-7J9SUSX-xiQCQaT5w_25_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-87633986</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_2iIqhP5zKUSGnKrT3fT8EA"
      decimals="0"
      id="Tc_9s18nQQn-0mLRd_S6TmuWA_25_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">8990557</us-gaap:StockholdersEquity>
    <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g"
      decimals="0"
      id="Tc_KnxFSpWBWkmtqXg7ZVL4Iw_27_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">16539</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YZga2g-00Euh89Nzi8Sb_g"
      decimals="0"
      id="Tc_sxOaQRRyPE2R2AlAKQIOzA_27_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw"
      decimals="0"
      id="Tc_Ts0YkrraW0OBMA_jFs0_Fg_27_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">46710</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc__k7ByXTwzkCCpIX17Bx98A_27_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">46712</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_qWuK0aClQ0ajDjHBRZuQOw"
      decimals="0"
      id="Tc_xZ63D6atvUOgvtWudEME1g_29_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">777467</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_2jb1gyXn-0qBHR4bo4fe0Q_29_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">777467</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_M_Xp5Nb4D0mDo0QoESXKLA"
      decimals="0"
      id="Tc_nXo3DElmNUyKYMLuOgMdIQ_31_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5568598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Tc_c1vp71J5Kk-m3DYRiQDHOQ_31_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5568598</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg"
      decimals="0"
      id="Tc_Ukrorz3GnE2hwqWAt2DEuA_33_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25963185</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ENf9Kw8I-kWw5DQlzXGezg"
      decimals="0"
      id="Tc_nZpgCUvNQEqEGzCzG7D7VA_33_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2597</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_egysx-a5s0CwPDQUHEvdqQ"
      decimals="0"
      id="Tc_TAei0JqbdE-0TUjzxwarJA_33_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">97446125</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_166ZAmZBBki2ZJaq_2i7OQ"
      decimals="0"
      id="Tc_rc1owr4LOUaJHmFOmK4_jw_33_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-93202584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_gRzUKDa_Xk2wV9w-EHws9Q_33_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4246138</us-gaap:StockholdersEquity>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Narr_KrTxAk1qZ0Cku-0-7cdjhA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">354539</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg"
      decimals="0"
      id="Narr_GkcpGqI_3ECJMVBZLg7vQQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3149</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw"
      decimals="0"
      id="Tc_9sS_bKc-OUeHr4v2jhPJwA_5_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">17100726</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw"
      decimals="0"
      id="Tc_cLxLD6lP8EaZTPvKuB3qng_5_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1710</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HJTe8zro2Uuqwss6XoUeeQ"
      decimals="0"
      id="Tc_xZo48uMMiEGkSRYmP8b9kg_5_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">69409949</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_L_q-9Sd8ckKHkP5XYRlMzg"
      decimals="0"
      id="Tc_f9FfTCexWE2V4LPlqJrAkA_5_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-57671052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w"
      decimals="0"
      id="Tc_YdaELA5-GUahRhUBF_xRAw_5_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">11740607</us-gaap:StockholdersEquity>
    <eyen:StockIssuedDuringPeriodSharesNewIssuesTwo
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ"
      decimals="0"
      id="Tc_D0YzUAQVWE62L_TShdiWZg_7_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2675293</eyen:StockIssuedDuringPeriodSharesNewIssuesTwo>
    <eyen:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ"
      decimals="0"
      id="Tc_IitobebuVk-v9Zwz1GQADw_7_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">267</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
    <eyen:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw"
      decimals="0"
      id="Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5451475</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
    <eyen:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng"
      decimals="0"
      id="Tc_KIDooAWzYk6H1VhhxJeQug_7_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
    <eyen:StockIssuedDuringPeriodValueNewIssuesTwo
      contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"
      decimals="0"
      id="Tc_qOmJQXwe3keWplvbtt2sSQ_7_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5451742</eyen:StockIssuedDuringPeriodValueNewIssuesTwo>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ"
      decimals="0"
      id="Tc_bBbnjkzySUWyImtQDP5Vqg_9_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw"
      decimals="0"
      id="Tc_p-NVDrQOSUa00haZpcVJZQ_9_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">583865</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng"
      decimals="0"
      id="Tc_tHmQa4W8b02RtB08iC7ApQ_9_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"
      decimals="0"
      id="Tc_RX-eAyUQAUyL0QGuPX1jWg_9_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">583865</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ"
      decimals="0"
      id="Tc_NqylLaamKEuGAE07liyMUQ_11_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bOxHU20yc0WWP5DHZhFVLw"
      decimals="0"
      id="Tc_NiSIVy3hzE-J_-Dw2-W_oA_11_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AF9i4xf450aNIzxGViZMng"
      decimals="0"
      id="Tc_LMXx1W_FmkKzKC7wr0_guA_11_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5450910</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"
      decimals="0"
      id="Tc_4FOMk7tu1Uqrfqz_sagJdA_11_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5450910</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ"
      decimals="0"
      id="Tc_E_DVXdZ_w0ypbq9OnisC8A_13_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">19776019</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Nceu5-Vaj0KL_tkWokCNIQ"
      decimals="0"
      id="Tc_BWjQpQejwUu5RVUMFSYGYw_13_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1977</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QsJXwwdhUU-D4UcQ-cvUsg"
      decimals="0"
      id="Tc_9wmldDzZ10yE-HZ3_BQJeQ_13_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">75445289</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t8iU0YDKFkWOzxWgCoFXPw"
      decimals="0"
      id="Tc_Da1zJNCZ0kSZa1dPy0dxMA_13_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-63121962</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_vwX5UftH6k2nB0oxeBOzmA"
      decimals="0"
      id="Tc_HSQs17FPLEqgVLf2ybQBVQ_13_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12325304</us-gaap:StockholdersEquity>
    <eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA"
      decimals="0"
      id="Tc_CKbbVDY3nkWY4cJK1UlXpQ_15_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">167664</eyen:StockIssuedDuringPeriodSharesExercisesOfWarrants>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA"
      decimals="0"
      id="Tc_aFQGN5v_xEmkwInfFxWDsg_15_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">17</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw"
      decimals="0"
      id="Tc_F0BCkH2vTku3frlHj556dQ_15_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">376404</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ"
      decimals="0"
      id="Tc_E_s1zLMmBEeYhihbFQkXCQ_15_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g"
      decimals="0"
      id="Tc_x9-BhIOHhEaxK65ZLoO65Q_15_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">376421</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA"
      decimals="0"
      id="Tc_HQb4258s8USXka1h-FOvug_17_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw"
      decimals="0"
      id="Tc_EYFQP6ml20KyI6pCncViRQ_17_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">633146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ"
      decimals="0"
      id="Tc_t_J8b4wNZkuWOwbTolsPYA_17_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g"
      decimals="0"
      id="Tc_bm66mAgQY0-NzDWfTd7vgw_17_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">633146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yaatnlilqU-RH_dLrx0TNA"
      decimals="0"
      id="Tc_l1QQptVmbUaVr6PQAldVPg_19_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Aco2k86DlUChLO4f2RjPFw"
      decimals="0"
      id="Tc_OIbs5jBlOEOk4xXkblEpFg_19_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rMACdL4EWUe9Fzwn1ODVLQ"
      decimals="0"
      id="Tc_0LtgLDP4eEWwRWsEVXOu2g_19_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5015565</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_ZRQb--af0kqA_v5KzUIj-g"
      decimals="0"
      id="Tc_HFgeEU1N4kK69wQVRy-1Ww_19_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5015565</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw"
      decimals="0"
      id="Tc_XCMSQkFV10aeFxM3Ua02dQ_21_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">19943683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yPXbKxolekml2TZPSWxEAw"
      decimals="0"
      id="Tc_iECKN5j-u0eUgTV0UJtr1g_21_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aERtWPLXHE-NyWVDKwVKKw"
      decimals="0"
      id="Tc_bSaBs0MhUkWl8Q3rLrKrwA_21_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">76454839</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__8jVnW9XRk-de3gCif1Ngg"
      decimals="0"
      id="Tc_Hv_UktBQxUKKUTV31_pNRA_21_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-68137527</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_uk3nxzgTF02apB9F1dX2kA"
      decimals="0"
      id="Tc_xn503rF6l063OwS6YrZlZA_21_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">8319306</us-gaap:StockholdersEquity>
    <eyen:StockIssuedDuringPeriodSharesNewIssuesThree
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">3833334</eyen:StockIssuedDuringPeriodSharesNewIssuesThree>
    <eyen:StockIssuedDuringPeriodValueNewIssuesThree
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_aHrCmOBr3UW1GniaD9mjIg_23_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">383</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
    <eyen:StockIssuedDuringPeriodValueNewIssuesThree
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"
      decimals="0"
      id="Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12495325</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
    <eyen:StockIssuedDuringPeriodValueNewIssuesThree
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"
      decimals="0"
      id="Tc_O5vsiEfkEkOvZyoF8tznfg_23_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
    <eyen:StockIssuedDuringPeriodValueNewIssuesThree
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_eC2iacNYQUmPuhllN3b-WA_23_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12495708</eyen:StockIssuedDuringPeriodValueNewIssuesThree>
    <eyen:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc__CCAwIYOrUCMrYLNTzj0Hw_25_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1080497</eyen:StockIssuedDuringPeriodSharesWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_LlydPbzlf0uTprdabBAizA_25_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">108</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"
      decimals="0"
      id="Tc_lOOtOvw-O0qUCj_JBXYRMg_25_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2269562</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"
      decimals="0"
      id="Tc_Jho_7bjHTUmlpohBRWsbNw_25_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_Clo-haOV1U-mln3kXHr4mA_25_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2269670</eyen:StockIssuedDuringPeriodValueWarrantsExercised>
    <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_KMC_kLfAekGykq2pDGqdfw_27_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">26737</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_MVAO2_aTuUKPu3MQRnguaQ_27_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"
      decimals="0"
      id="Tc_l0Ffsi3bAUucXP0KsV1KDg_27_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">52134</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"
      decimals="0"
      id="Tc_ctZdYdIuLUOByuFm7ZP-dA_27_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_I75CLA_ZAka32_aJuE9_wA_27_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">52137</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_JaQwsmSWqkS71mFuVAN1_Q_29_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"
      decimals="0"
      id="Tc_M5Dlvn0XaUi5SZqjq_Ad6A_29_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">609930</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"
      decimals="0"
      id="Tc_2o-1XRqo10ag2UQTZ4wNEw_29_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc_1fkqcuwJxE64O6J4aCUAfA_29_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">609930</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GMs_0UF6G0qIdOe8SSdrdg"
      decimals="0"
      id="Tc_lEE6AVg8nUeKdtQDgH1X2A_31_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_H3pnRHFNlku6TUpNdAorZg"
      decimals="0"
      id="Tc_uR4Fa3eUmESyOkdp5TNi9Q_31_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_tW--kHlHR0qUsk3NgFii3g"
      decimals="0"
      id="Tc_Z748-Pz0UkSiK-NphFJTfA_31_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5096530</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Tc__LIY8hv3OUi6zQjhmdrbzQ_31_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-5096530</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ"
      decimals="0"
      id="Tc__iuTRLPSAkW1n5O7t7j5bA_33_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">24884251</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yiqXQhBpUEu0ixBMFWeYxQ"
      decimals="0"
      id="Tc_yBcNE8gOUES7TJ4F4HQc4Q_33_5"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2488</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_11APGkRcvEiinWn5XMPudQ"
      decimals="0"
      id="Tc_7rpsl4R2GkKPdffQexek9A_33_8"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">91881790</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZLzQ6a3ZdkCqP8h95qZo5g"
      decimals="0"
      id="Tc_XK8BTFQhp0aLw-44zIDUrw_33_11"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-73234057</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"
      decimals="0"
      id="Tc_4kjIVsxrBkmTERE5D-koeA_33_14"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">18650221</us-gaap:StockholdersEquity>
    <eyen:ProceedsOfStockIssuedDuringPeriodGross
      contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"
      decimals="0"
      id="Narr_twYTPWezSESHljdz66lP_g"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5984931</eyen:ProceedsOfStockIssuedDuringPeriodGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2020_To_3_31_2020_KlFqTWrXWk6G-4Qm-crkeA"
      decimals="0"
      id="Narr_hRoAoToINUm2C8PztbxY2A"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">533189</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <eyen:ProceedsOfStockIssuedDuringPeriodGross
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Narr_uukQwcXJukSvhjhnTIWTIQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">13800002</eyen:ProceedsOfStockIssuedDuringPeriodGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Narr_lpfdHwhDLkOqPjQVds2Qzw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1304294</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_QmKPzV8XUE2t7YhVF4AG_w_5_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15761665</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_7PhSrq507kOFX_9kBMHbJQ_5_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-15563005</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_Xe-WUK661UGc2ChkXCNJuw_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">148245</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_LVkQXbt890yYwzqXN62JwA_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">71628</us-gaap:DepreciationDepletionAndAmortization>
    <eyen:AmortizationOfDebtDiscount
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_v67zkYZ8GEGLFxyJ9bwwKQ_8_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">41944</eyen:AmortizationOfDebtDiscount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_8o_KPl22HE6EMBtOpu9vFA_9_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_5FrBlye0ZEWGt-tzegpCwQ_10_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2071735</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_yS5uqsY_z0mjnia-8xJn0Q_10_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1826941</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_tGUuTIu-v0OyuwS5Am6S0w_12_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-35549</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_cRe_fA_1MkeO9a11ZcY0Rw_12_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">231194</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <eyen:IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_3AcHih1bFEKaqgWNoaJ82Q_13_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-2005859</eyen:IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_Wa6gcGbUkUGffIWkxdLb2A_14_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-1600000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_ymSNxtIeqUybXI8jq-YrAw_14_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1600000</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_wIdnBIWbskq2-AjFLnv4dg_15_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">223068</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_51SNsOezO0WKKTqtVAkGEA_15_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-76596</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_sYxMljifL0SfMV3mvY8HNg_16_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">33564</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc__7HZvoJZQkuPXYlhBAbh2g_16_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-172318</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_V1mHJoahhUyKz4lO2EkpTQ_17_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-928356</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_83bfQytB60WvXxHiEpsWww_17_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-106471</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_IdUVHLSwkkmE3XNvVaZ_vg_18_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-4000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_-RVHTP0WFkKsjAoLi5qp-w_18_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_kgkHsNV5s0qObFfXrtJLZg_19_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-1235</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <eyen:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_NoKi1rlp5kOnKdmzvafpTA_20_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-4397</eyen:IncreaseDecreaseInDeferredRent>
    <eyen:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_Xmb0lEo9uUqoq1Bnmfcxug_20_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-1119</eyen:IncreaseDecreaseInDeferredRent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_FLYZQ64KcEi-v4QhDS2RKA_22_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-14997807</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_lkr43TyB20Ck45qTltQ44Q_22_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-11853369</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_34eExlTOlEKmGb-uyq7o2w_25_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1165066</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_IeIztb_ar0e-cBtOGxAOBA_25_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">202046</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_2FsGSzmfkUGMDOg3vxivmg_27_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-1165066</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_569ortXS2EyCep0ZoJ6nqA_27_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-202046</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_9MTARuC3fUqgCgb-kF9CBw_30_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5569136</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_ZDtvfvCeAke1PngL021z3g_31_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12734002</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_73HZ-NqDi0is-7D5mjdUBg_32_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2103991</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_lscrE8Ff0Uam8xSjlvQpag_32_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2646091</us-gaap:ProceedsFromWarrantExercises>
    <eyen:ProceedsFromPaycheckProtectionProgramLoan
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_0AH37rrvp02wFLzVS6HwYw_33_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</eyen:ProceedsFromPaycheckProtectionProgramLoan>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_hxhkobWF1UiR5MdWqDFjHA_34_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_DJwkiEV7RkCA6VO2lGqITg_35_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">547259</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_RU8kJXs0zECsv32Qh6Fljg_35_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">368289</us-gaap:RepaymentsOfNotesPayable>
    <eyen:PaymentsForRepurchaseOfPublicOffering
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_UHHSikV_QEK236Gn0UlNIA_36_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">329038</eyen:PaymentsForRepurchaseOfPublicOffering>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_OAV8IepF_ESpnOEeMbFS-Q_37_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">66618</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_Ci8vDADnfECckNlmfPQVkQ_38_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">176802</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_aRthHd8vx023A3XLUhKGPg_38_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">52137</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_Cw_wB5E8aky1JBVxUyCTCA_40_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">9166916</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_UlM17XWcd0O36PmoPg3dRg_40_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">20767392</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_6DJI5rdvekCTlrN6_fYmjA_42_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-6995957</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_g5-AdV3T2k6i6AzyruQ1Cw_42_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">8711977</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_AHoEZ9m23kK42OjKp606Ng_44_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">28371828</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_KmmkdZ0_8k2ExEJ_m8NT8w"
      decimals="0"
      id="Tc_WObSOcEsV0W4i30R9V5eQQ_44_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">14152601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_ighRnSIVC0yGBJMFJibIXA_46_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">21375871</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"
      decimals="0"
      id="Tc_BFPxRKWOE0uYonywtrUaHg_46_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">22864578</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <eyen:ProceedsOfStockIssuedDuringPeriodGross
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ"
      decimals="0"
      id="Narr_lYVwHtS_FkGAmxEoVbWhmA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5984931</eyen:ProceedsOfStockIssuedDuringPeriodGross>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_8lu08wJ-BUqjmzmYspc_hQ"
      decimals="0"
      id="Narr_UeTveNfUekKkaoEJY6JvSw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">415795</us-gaap:PaymentsOfDebtIssuanceCosts>
    <eyen:ProceedsOfStockIssuedDuringPeriodGross
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Narr_qCxnzFcBDk6mYD-VwJRPqQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">13800002</eyen:ProceedsOfStockIssuedDuringPeriodGross>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Narr_siFoFsfSwESL6NdIzidzzA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1066000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_-m1SsBeHJEqaAGoxcaFHaA_2_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">13500871</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"
      decimals="0"
      id="Tc_xyIPmubkTUK6By5enQYAww_2_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">22864578</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_vrsCAPnsdk2YnVxq7YtupA_3_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7875000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_ejv9ws34rEue7u0nGGtJ_A_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">21375871</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"
      decimals="0"
      id="Tc_ICdG4vPXzUWl-mC1wjcI6Q_4_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">22864578</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidCapitalized
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_7NwLq-mxqUaK80rBcDToQQ_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">131839</us-gaap:InterestPaidCapitalized>
    <us-gaap:InterestPaidCapitalized
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_uGPtyQB3NEqAZ7kFkeNmjg_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7961</us-gaap:InterestPaidCapitalized>
    <eyen:AccrualOfPublicOfferingCosts
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_yzCpounE-UavJiWlnVaZwQ_11_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-26650</eyen:AccrualOfPublicOfferingCosts>
    <eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_hAQpkWujZUOeOa_b5PXEqQ_12_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-705360</eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable>
    <eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Tc_aCf2FB00-0WoAtwB51XEgg_12_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-475216</eyen:PurchaseOfInsurancePremiumFinancedByShortTermNotePayable>
    <eyen:IssuanceOfStockWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Tc_ZZTArKPl5EKSCeFuAeSXtA_13_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">-351390</eyen:IssuanceOfStockWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_u6GjaDCItEOjrOZqQAuWvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;1&#160;&#x2013; Business Organization, Nature of Operations and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Eyenovia, Inc. (&#x201c;Eyenovia&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP&#x2122;) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system branded the Optejet&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). Eyenovia&#x2019;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On October 25, 2021, the Company announced the reclassification of the Company&#x2019;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, (&#x201c;MydCombi&#x201d; or &#x201c;MicroStat&#x201d;) as a drug-device combination product by the FDA in a Complete Response Letter (&#x201c;CRL&#x201d;) received on October 22, 2021, following a change in the agency&#x2019;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. The Company believes that its other product candidates will similarly be classified by the FDA as drug-led combination products that would be subject to marketing approval via new drug applications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2020 and for the year then ended, which were included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 30, 2021.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <eyen:PercentageOfSuccessRateOfOptejet
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Narr_BgLz7qxXQEa4HGNMdmdeHQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.90</eyen:PercentageOfSuccessRateOfOptejet>
    <eyen:PercentageOfSuccessfulRateOfTraditionalEyeDrops
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Narr_vFEFKj6VhkOl4Xwq8JBupA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.50</eyen:PercentageOfSuccessfulRateOfTraditionalEyeDrops>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_ujXUs1QEwEqeYslW-VcxNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;2&#160;&#x2013; Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Since the date of the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, there have been no material changes to the Company&#x2019;s significant accounting policies, except as disclosed below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2021, the Company had unrestricted cash and cash equivalents of approximately $13.5 million and an accumulated deficit of approximately &lt;span style="-sec-ix-hidden:Hidden_eoq4WkYJv0u9e_1CVVO3Uw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$93.2&lt;/span&gt;&lt;/span&gt; million. For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of approximately &lt;span style="-sec-ix-hidden:Hidden_wncAopnaD0uKiQynCGwpOA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.8&lt;/span&gt;&lt;/span&gt; million and &lt;span style="-sec-ix-hidden:Hidden_p4gZozmYS0S7balkCzNXaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.6&lt;/span&gt;&lt;/span&gt; million, respectively, and used cash in operations of approximately &lt;span style="-sec-ix-hidden:Hidden_ux28YaoNUkm5oVQ06xjkHA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.0&lt;/span&gt;&lt;/span&gt; million and &lt;span style="-sec-ix-hidden:Hidden_XUae-FPTXkaSLR7npSF_nw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$11.9&lt;/span&gt;&lt;/span&gt; million, respectively. Pursuant to the At-The-Market Offering (see Note 9 &#x2013; Stockholders&#x2019; Equity &#x2013; At-The-Market Offering and Note 11 &#x2013; Subsequent Events &#x2013; At-The-Market Offering), the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock. The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to generate sufficient recurring revenues or the Company&#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s ability to successfully commercialize its products and services, competing technological and market &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents in the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain executed agreements are recorded as Restricted Cash on the balance sheets, such as the collateralized money market account pursuant to the Loan and Security Agreement, dated May 7, 2021 with Silicon Valley Bank (&#x201c;SVB&#x201d;), as amended on September 29, 2021 by the First Amendment to the Loan and Security Agreement. See Note 6 - Notes Payable - Silicon Valley Bank Loan. In connection with which the Company pledged to establish and maintain a collateralized money market account in the amount of $7,875,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2021 and December 31, 2020, the Company had cash balances in excess of FDIC insurance limits of $21,125,871 and $28,121,828, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus weighted average vested but unsettled restricted stock units. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,305,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,410,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,095,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total potentially dilutive shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,532,163&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &#x201c;Collaborative Arrangements&#x201d; (&#x201c;ASC 808&#x201d;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 1:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Identify the contract with the customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 2:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Identify the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 3:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Determine the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 4:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 5:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Recognize revenue when the company satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During 2020, the Company entered into a license agreement (the &#x201c;Arctic Vision License Agreement&#x201d;) with Arctic Vision (Hong Kong) Limited (&#x201c;Arctic Vision&#x201d;) and a license agreement (the &#x201c;Bausch License Agreement&#x201d;) with Bausch Health Companies, Inc. (&#x201c;Bausch Health&#x201d;). Each license has three revenue components: 1) an upfront license fee; 2) milestone payments; and 3) royalty payments. See Note 7 &#x2013; Commitments and Contingencies for additional details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In August 2018, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13 &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201d; (&#x201c;ASU 2018-13&#x201d;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU 2018-13 effective January 1, 2021. This standard did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02 &#x201c;Leases (Topic 842)&#x201d; (&#x201c;ASU 2016-02&#x201d;). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2019-01 &#x201c;Leases (Topic 842) Codification Improvements&#x201d; in March 2019 and ASU No. 2018-10 &#x201c;Codification Improvements to Topic 842, Leases&#x201d; and ASU No. 2018-11 &#x201c;Leases (Topic 842) Targeted Improvements&#x201d; in July 2018, and ASU No. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;2018-20 &#x201c;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201d; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 3, 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2021-04, &#x201c;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&#x201d; This new standard provides clarification and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating ASU 2021-04 and its impact on its financial position, results of operations, and cash flows.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <eyen:LiquidityAndGoingConcernTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_cxoulCHZUke_AvMeB07Rxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;As of September 30, 2021, the Company had unrestricted cash and cash equivalents of approximately $13.5 million and an accumulated deficit of approximately &lt;span style="-sec-ix-hidden:Hidden_eoq4WkYJv0u9e_1CVVO3Uw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$93.2&lt;/span&gt;&lt;/span&gt; million. For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of approximately &lt;span style="-sec-ix-hidden:Hidden_wncAopnaD0uKiQynCGwpOA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.8&lt;/span&gt;&lt;/span&gt; million and &lt;span style="-sec-ix-hidden:Hidden_p4gZozmYS0S7balkCzNXaw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.6&lt;/span&gt;&lt;/span&gt; million, respectively, and used cash in operations of approximately &lt;span style="-sec-ix-hidden:Hidden_ux28YaoNUkm5oVQ06xjkHA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$15.0&lt;/span&gt;&lt;/span&gt; million and &lt;span style="-sec-ix-hidden:Hidden_XUae-FPTXkaSLR7npSF_nw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$11.9&lt;/span&gt;&lt;/span&gt; million, respectively. Pursuant to the At-The-Market Offering (see Note 9 &#x2013; Stockholders&#x2019; Equity &#x2013; At-The-Market Offering and Note 11 &#x2013; Subsequent Events &#x2013; At-The-Market Offering), the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock. The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to generate sufficient recurring revenues or the Company&#x2019;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#x2019;s ability to successfully commercialize its products and services, competing technological and market &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/p&gt;</eyen:LiquidityAndGoingConcernTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="-5"
      id="Narr_F2MrGBBIMEqkVW_4QCIeow"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">13500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="-5"
      id="Narr_pIK--pQQT0C8bC_PClJDEQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="-5"
      id="Narr_B05IdKqg-ECbepYsuU1Sgw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12400000</eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="INF"
      id="Narr_QMdUQ5Z96Ea4yA1k5U84bA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2435604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_Vuo7sfCwbUSOcdyMdr4TaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents in the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain executed agreements are recorded as Restricted Cash on the balance sheets, such as the collateralized money market account pursuant to the Loan and Security Agreement, dated May 7, 2021 with Silicon Valley Bank (&#x201c;SVB&#x201d;), as amended on September 29, 2021 by the First Amendment to the Loan and Security Agreement. See Note 6 - Notes Payable - Silicon Valley Bank Loan. In connection with which the Company pledged to establish and maintain a collateralized money market account in the amount of $7,875,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2021 and December 31, 2020, the Company had cash balances in excess of FDIC insurance limits of $21,125,871 and $28,121,828, respectively.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Narr_KJP8l3tFq0agojrf6sWYcA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7875000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Narr_Uzvlf6xnpk6EBAkfDi0agQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">21125871</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Narr_ZombU-NDfk623ihZZzD_ug"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">28121828</us-gaap:CashUninsuredAmount>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_cHLQKCzD9kKQyoQ7wya9Sg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus weighted average vested but unsettled restricted stock units. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,305,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,410,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,095,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total potentially dilutive shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,532,163&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_QcfwPnAi7kig5vSGndg2yQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,305,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,410,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,095,993&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total potentially dilutive shares&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,532,163&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,506,533&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_4_qEKYrc8Euhf2_8V5qnGA"
      decimals="INF"
      id="Tc_5sXBowAjO0q1MrzxcogoKQ_3_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">4305980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_OptionIndexedToIssuersEquityTypeAxis_us-gaap_EmployeeStockOptionMember_XlWzbj9LNU6tzxL4LlSTxQ"
      decimals="INF"
      id="Tc_ukYhCaXNBUSTHpuTgV6i5Q_3_4"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">3410540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_os_kMS_z0EKpasXd_445Ug"
      decimals="INF"
      id="Tc__4EPimuESUOYzU52gAMrZg_4_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1226183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_7Pfs622rJ02-2GjGaBo6sA"
      decimals="INF"
      id="Tc_GzrSkTvZnECW7z0pMYK4Ug_4_4"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2095993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="INF"
      id="Tc_95sTUD6b3UG-NPWzdIZFGg_5_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">5532163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="INF"
      id="Tc_g-LYzmPs3EWh2tw9VNRKYQ_5_4"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">5506533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_6CbweD44D0qZ61A_lXka5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &#x201c;Collaborative Arrangements&#x201d; (&#x201c;ASC 808&#x201d;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 1:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Identify the contract with the customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 2:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Identify the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 3:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Determine the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 4:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;"&gt;Step 5:&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Recognize revenue when the company satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During 2020, the Company entered into a license agreement (the &#x201c;Arctic Vision License Agreement&#x201d;) with Arctic Vision (Hong Kong) Limited (&#x201c;Arctic Vision&#x201d;) and a license agreement (the &#x201c;Bausch License Agreement&#x201d;) with Bausch Health Companies, Inc. (&#x201c;Bausch Health&#x201d;). Each license has three revenue components: 1) an upfront license fee; 2) milestone payments; and 3) royalty payments. See Note 7 &#x2013; Commitments and Contingencies for additional details.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_DBW5a6vom0e7vJSndHgssg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In August 2018, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13 &#x201c;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement&#x201d; (&#x201c;ASU 2018-13&#x201d;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU 2018-13 effective January 1, 2021. This standard did not have a material impact on the Company&#x2019;s financial position, results of operations or cash flow.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02 &#x201c;Leases (Topic 842)&#x201d; (&#x201c;ASU 2016-02&#x201d;). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2019-01 &#x201c;Leases (Topic 842) Codification Improvements&#x201d; in March 2019 and ASU No. 2018-10 &#x201c;Codification Improvements to Topic 842, Leases&#x201d; and ASU No. 2018-11 &#x201c;Leases (Topic 842) Targeted Improvements&#x201d; in July 2018, and ASU No. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;2018-20 &#x201c;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#x201d; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 3, 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued ASU No. 2021-04, &#x201c;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&#x201d; This new standard provides clarification and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating ASU 2021-04 and its impact on its financial position, results of operations, and cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_fy_EGjq0kUSHudWaavGlxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;3&#160;&#x2013; Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September 30, 2021 and December 31, 2020, prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll tax receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 297,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 413,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,542&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid general&#160;and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid licenses and subscriptions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,440&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid patent expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid conference expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid board of directors fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid rent and security deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,254&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,123,289&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 453,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_aQbB3kDYq0iFBnBKIk17Bg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll tax receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 297,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 151,942&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 413,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110,094&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,542&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid general&#160;and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,941&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid licenses and subscriptions&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,440&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,051&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid patent expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid conference expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,041&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid board of directors fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid rent and security deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,254&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,004&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,123,289&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 453,478&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <eyen:PayrollTaxesReceivable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_JY-Jetn4sES6K8ic5YRFLQ_3_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">297494</eyen:PayrollTaxesReceivable>
    <eyen:PayrollTaxesReceivable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_NTvB8_1uTkq6zchzJzMt6w_3_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">151942</eyen:PayrollTaxesReceivable>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_0tpO6tBLW0Ky5DwDd5DMbA_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">413648</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_hQutYij2JU-jObSBqCNJTw_4_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">110094</us-gaap:PrepaidInsurance>
    <eyen:PrepaidResearchAndDevelopmentExpenses
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_m9A1EYqn_E-VOBWdwTQMkQ_5_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">30542</eyen:PrepaidResearchAndDevelopmentExpenses>
    <eyen:PrepaidResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_HjaAaTdmtkKUb4Y5Xs3Utg_5_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:PrepaidResearchAndDevelopmentExpenses>
    <eyen:PrepaidGeneralAndAdministrativeExpenses
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_E_Lcownsv0q--kTa-Wzo6Q_6_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">105941</eyen:PrepaidGeneralAndAdministrativeExpenses>
    <eyen:PrepaidGeneralAndAdministrativeExpenses
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_dFf2s2DsokyG9kBb0TqWQQ_6_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:PrepaidGeneralAndAdministrativeExpenses>
    <eyen:PrepaidLicensesAndSubscriptions
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_NFKPPsxdxk-v-6jRGjZYuw_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">31440</eyen:PrepaidLicensesAndSubscriptions>
    <eyen:PrepaidLicensesAndSubscriptions
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_gOnya-smwEGU9o2KVkjDQg_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">57051</eyen:PrepaidLicensesAndSubscriptions>
    <eyen:PrepaidPatentExpense
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_t7VrfcJEckWfKJLbzyJF5g_8_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">34809</eyen:PrepaidPatentExpense>
    <eyen:PrepaidConferenceExpenses
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_7Aqbo2mOGEqDptU2uHmrTA_9_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">52041</eyen:PrepaidConferenceExpenses>
    <eyen:PrepaidConferenceExpenses
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_f7OyrmwHTUKu8gt96MUf6A_9_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">29403</eyen:PrepaidConferenceExpenses>
    <eyen:PrepaidDirectorFeesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_qS7s5dh770aEBUfmZOXuPA_10_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">77000</eyen:PrepaidDirectorFeesCurrent>
    <eyen:PrepaidDirectorFeesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_e1LNuyR2D0abLsdPMe8jmg_10_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">68250</eyen:PrepaidDirectorFeesCurrent>
    <eyen:PrepaidRentAndSecurityDeposit
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_wqH4xALj9UmMHnP0nu36tw_11_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">32254</eyen:PrepaidRentAndSecurityDeposit>
    <eyen:PrepaidRentAndSecurityDeposit
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_uKcGz9bonEazyf8Z1T5GcQ_11_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">25004</eyen:PrepaidRentAndSecurityDeposit>
    <us-gaap:OtherAssets
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_ppl9ZjHey0iE5WaDIsrh4Q_12_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">48120</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_QjSYXj7C10iZZeOoZ01Ptw_12_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">11734</us-gaap:OtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_inIJBas5eUOUUiow3KlRJw_13_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1123289</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_p8yoV5uM_UKJ5u5IwZFo0Q_13_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">453478</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_II-xwbm5Jk-ZKV1FEubVpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;4&#160;&#x2013; Accrued Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September 30, 2021 and December 31, 2020, accrued compensation consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonus expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 895,253&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 938,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 288,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,184,236&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,150,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <eyen:DisclosureOfAccruedCompensationTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_vraJwV28EkqBBt8Dqx2rrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued bonus expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 895,253&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 938,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 288,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 211,799&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,184,236&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,150,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:DisclosureOfAccruedCompensationTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_GvwcjPvRX0K0RFWMxMfXZA_3_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">895253</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_AdInod2TR06uZO22fSQ4dg_3_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">938873</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_-ccNh54gbUucYHPhIR4C1Q_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">288983</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_IktyrIrQP0GAVdKtDMB4zA_4_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">211799</us-gaap:AccruedSalariesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_E898ZSaGJU2BnaiM1Rjs0w_5_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1184236</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_qL95dVu6zESbvCcrd5Gqpg_5_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1150672</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_H77UyKGLYUW8Hp2nu-cv2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;5&#160;&#x2013; Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of September 30, 2021 and December 31, 2020, accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 348,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 243,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit card payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,204&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued franchise tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued licensing fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expense reimbursements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,441&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 552,336&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,480,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_OklFVIy4-0utlZmbZdsppQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181,241&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 348,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued consulting and professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 243,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Credit card payable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,204&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50,002&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued franchise tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued licensing fees&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804,447&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued expense reimbursements&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,441&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 552,336&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,480,692&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <eyen:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_pTykd6RctEuShO3I7BdjhA_3_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">181241</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
    <eyen:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_4Ydy_t5I1Emd2_w-KJzAbA_3_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">348254</eyen:AccruedResearchAndDevelopmentExpensesCurrent>
    <eyen:AccruedConsultingAndProfessionalServicesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_tEpM_fTv1k-5XxgOr9PNYw_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">243979</eyen:AccruedConsultingAndProfessionalServicesCurrent>
    <eyen:AccruedConsultingAndProfessionalServicesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_3p_fAf5gdkqqkueFpGGwMw_4_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">235355</eyen:AccruedConsultingAndProfessionalServicesCurrent>
    <eyen:CreditCardPayable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_sLCqnTjn_0iBzlDWJzUKHw_5_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">44204</eyen:CreditCardPayable>
    <eyen:CreditCardPayable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_H3d88ICpnECNzd9I740LKQ_5_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">50002</eyen:CreditCardPayable>
    <eyen:AccruedFranchiseTax
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_tfhszziNwEC6sDFMXDqY6w_6_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">39300</eyen:AccruedFranchiseTax>
    <eyen:AccruedFranchiseTax
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_k99mRTcRfkmzwTSBnv2egA_6_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">32480</eyen:AccruedFranchiseTax>
    <eyen:AccruedLicensingFees
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_4aeaShqfm0K0b-WBqYEi7g_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:AccruedLicensingFees>
    <eyen:AccruedLicensingFees
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_VuFG21m5M0uAQsaMrSByPA_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">804447</eyen:AccruedLicensingFees>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_h0lRnXSEz0qDFYSpkdAUYw_8_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">31250</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_xw01zQBA2EWnzQoEbtX_wQ_8_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3068</us-gaap:InterestPayableCurrent>
    <eyen:AccruedExpenseReimbursements
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_LQLumCC5kUqk2RX-lhmUMQ_9_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">6441</eyen:AccruedExpenseReimbursements>
    <eyen:AccruedExpenseReimbursements
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_x_orM8znfkKPogdZqmMatQ_9_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5459</eyen:AccruedExpenseReimbursements>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_7CiWs_77bEa9arFh_Z7kGw_10_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5921</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_0nNzLFYj3U-Qzxkd0s2QCw_10_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1627</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_a2n9YvbFCESlUJMv5n9O9Q_11_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">552336</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_x75WUOjmWE2f89DTeEn6SQ_11_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1480692</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <eyen:NotesPayableDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_VdniWU9fJ0ONa73N_vJ67Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note&#160;6&#160;&#x2013; Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of September 30, 2021 and December 31, 2020, notes payable consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BankDirect Capital Finance loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158,101&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158,101&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Paycheck Protection Program loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Silicon Valley Bank loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,282,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,282,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;BankDirect Capital Finance Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On February 24, 2021, the Company issued a note payable for the purchase of a directors and officers liability insurance policy. The note payable is payable in nine monthly payments consisting of principal and interest amounting to $79,343 for an aggregate principal amount of $705,360. The note accrues interest at a rate of 2.96% per year and matures on November 24, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the &#x201c;PPP Loan&#x201d;). The PPP Loan provided for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan incurred interest at a fixed rate of 1.00% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company was eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. The Company applied for loan forgiveness on the PPP Loan in March 2021. The Company received notification in August 2021 that it had received approval for full loan forgiveness of the PPP Loan in the amount of $463,353. The Company has recorded this extinguishment as other income in the condensed statement of operations for the three and nine months ended September 30, 2021. The Company also received notification of forgiveness of accrued interest payable of $5,738, which has been reversed from interest expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Silicon Valley Bank Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 7, 2021 (the &#x201c;Effective Date&#x201d;), the Company entered into a Loan and Security Agreement (the &#x201c;Loan&#x201d;) with Silicon Valley Bank (&#x201c;SVB&#x201d;) for an aggregate principal amount of up to $25.0 million. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 1.25% plus the prime rate as reported in The Wall Street Journal and (b) 5.00%. The Loan is secured by all of the Company&#x2019;s tangible assets. The Loan matures on May 1, 2025. The Loan requires monthly interest-only payments until June 1, 2022. The interest-only period can be extended to June 1, 2023, upon the occurrence of a milestone event. Upon the end of the interest-only &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;period, the Company will make regular monthly amortizing payments of principal and interest through the maturity date. The Loan indicates a prepayment fee of 1.0% to 3.0%, as follows: i)&#160;prepayment fee of 3.0% of the principal balance made on or prior to the first anniversary of the Effective Date; ii)&#160;prepayment fee of 2.0% of the principal balance made on or prior to the second anniversary of the Effective Date; or iii)&#160;prepayment fee of 1.0% of the principal balance made on or prior to the third anniversary of the Effective Date. The Loan also provides for a final payment. The final payment is in addition to and not a substitution for the regular monthly payments of principal plus accrued interest due on the earliest to occur of the loan maturity date, the repayment of the loan in full or the termination of the Loan Agreement, in an amount equal to the original aggregate principal amount of the multiplied by 5.0%.The Company is accreting the final payment as accrued interest over the term of the Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The initial tranche of the Loan, in the amount of $7.5 million was received by the Company on May 7, 2021. In connection with the Loan, the Company issued warrants to SVB to purchase 91,884 shares of common stock at an exercise price per share equal to $4.76. The warrants are exercisable for a period of ten years from the date of issuance. At the Company&#x2019;s option, the Company has the ability to draw down the remaining $17.5 million in gross proceeds in two tranches over the next two years based upon the achievement of several milestones in accordance with the terms of the Loan. On September 29, 2021, the Company and SVB executed the First Amendment to the Loan and Security Agreement (the &#x201c;Amendment&#x201d;). In accordance with the Amendment, the Company must maintain a collateralized money market account in the amount of $7,875,000. The Company has recorded this amount as Restricted Cash. See Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash. This account must be maintained until the Release Event occurs (defined as when the Company has received approval by the FDA of the MydCombi product and achieved the minimum equity raise under the terms of the amended agreement, on or prior to November 30, 2021). Given the FDA&#x2019;s recent reclassification of MydCombi as a drug-device combination and the need to resubmit a new drug application in early 2022, (See Note 11 - Subsequent Events), the restricted cash will become callable on November 30, 2021, at SVB&#x2019;s election, to satisfy the Loan obligations. Therefore, the Loan has been fully classified as a current note payable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;During the three and nine months ended September 30, 2021, the Company recorded interest expense relating to the Loan of $95,833&lt;/span&gt; and $150,349, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company determined that the warrants should be equity-classified and that the relative fair value was $354,539, by using the Black-Scholes option pricing methodology using the following assumptions: stock price of $4.76; expected term of 10.0 years; volatility of 89.0% and a risk-free interest rate of 1.60%. The Company incurred $66,618 of debt issuance costs, of which $63,469 was allocated to the debt and $3,149 was allocated to the warrants. The relative fair value of the warrants and the issuance costs allocated to the debt were recorded as debt discount and are being amortized over the four-year term of the note. See the table below for additional details:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross loan proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Debt discount:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Relative fair value of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (354,539)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Relative fair value of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (63,469)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</eyen:NotesPayableDisclosureTextBlock>
    <eyen:ScheduleOfNotesPayableTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_knCu734uP0m1iRLX9CLcCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of September 30, 2021 and December 31, 2020, notes payable consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Portion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BankDirect Capital Finance loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158,101&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158,101&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Paycheck Protection Program loan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Silicon Valley Bank loan&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,282,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,282,037&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97,539&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 365,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 463,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:ScheduleOfNotesPayableTableTextBlock>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q"
      decimals="0"
      id="Tc_iCv6hR3mekaUFujHwFiSGA_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">158101</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q"
      decimals="0"
      id="Tc_ZFQBGRRvykG310-N3RZVIw_4_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q"
      decimals="0"
      id="Tc_rov2Tf1H_USV2brwf0Y7EA_4_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">158101</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ"
      decimals="0"
      id="Tc_9b7Cinf1LUaVR8q1K-FhAA_4_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ"
      decimals="0"
      id="Tc_b-MVfMLm2UukpOTBRxAB2A_4_15"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_N7F8TCtRv0CDcG_rnK7IjQ"
      decimals="0"
      id="Tc_J-tmrPRAwEuKD9t_dQFOIg_4_18"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_QoZ2KGe6NUGCeXRNsv3DqA"
      decimals="0"
      id="Tc_pVTPCfsTwk-60jim2FYtUA_5_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w"
      decimals="0"
      id="Tc_EdGn9_JDSU-ccBu_kbMTcA_5_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">97539</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w"
      decimals="0"
      id="Tc_RgXbq3pYgU2vsYxP5Vkjgw_5_15"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">365814</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_PaycheckProtectionProgramLoanMember_kYIIIOETGk-nWaBtW0dT8w"
      decimals="0"
      id="Tc_YHHlses_-0KRTAVQxOltdw_5_18"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"
      decimals="0"
      id="Tc_ps2afLhO20uU77OMLFv2MA_6_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7123936</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"
      decimals="0"
      id="Tc_bKFpvbLWiEmK3fHZNt8RvQ_6_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"
      decimals="0"
      id="Tc_la8DkGvEIU2o9RfMrs4WDA_6_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7123936</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw"
      decimals="0"
      id="Tc_tWgLxSrYwUOyopWN3JUcvg_6_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw"
      decimals="0"
      id="Tc_DiQcJQ_aa0i0m6JrPcWLGA_6_15"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2020_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_240pT7lOhUigkNAjw4zmPw"
      decimals="0"
      id="Tc_nQwChyE3vU24F38Wjo6D3g_6_18"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_HBJnv60ceUaHJmzXG23FxA_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7282037</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_5bod4KgxtkCq56X_cTPFVA_7_6"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_aq-7fBrHckyu5UiDUW5QWA_7_9"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7282037</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_fGyIqXpM9kqToVfuY5UpYQ_7_12"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">97539</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_XCwKRojX0k-wWxFHroe2_A_7_15"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">365814</us-gaap:LongTermNotesPayable>
    <us-gaap:NotesPayable
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="0"
      id="Tc_5ReVxtbS8kKuFGNroTlOyQ_7_18"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:NotesPayable>
    <eyen:NumberOfMonthlyPayments
      contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA"
      id="Narr_5LocJUKDPEGp6iXEdRF8BA">P9M</eyen:NumberOfMonthlyPayments>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA"
      decimals="0"
      id="Narr_BGOqExXIPkKCUOa1wi_iOQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">79343</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A"
      decimals="0"
      id="Narr_C4-Q4ROIREuKZ87jV0V4yQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">705360</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_izPMI-iExkCPLkxoG5CL4A"
      decimals="4"
      id="Narr_l_KSOZ49IUKXaQGjjD6fBg"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0296</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_2_24_2021_To_2_24_2021_us-gaap_ShortTermDebtTypeAxis_us-gaap_NotesPayableOtherPayablesMember_y5GQKEcX_0Gny-gsFKsSbA"
      id="Narr_t-DulXLstEihpyIxUCTWjA">2021-11-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA"
      decimals="0"
      id="Narr_BYWhWo7K_kyR4knnew0prw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_5_8_2020_To_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_h4kkyJQ_S0-CmL6B6pU_oA"
      decimals="0"
      id="Narr_jfuug0M2L0SdXZU8GOC_ag"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">19508</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_8_2020_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_fv_THQb6o0GG_A4a0SrB1g"
      decimals="4"
      id="Narr_WGJKd2vD4kS22M3Za549oA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <eyen:PaycheckProtectionProgramLoanPrincipalForgiveness
      contextRef="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg"
      decimals="0"
      id="Narr_xyReXVM8hkCtPCawsgXmPg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">463353</eyen:PaycheckProtectionProgramLoanPrincipalForgiveness>
    <eyen:PaycheckProtectionProgramLoanAccruedInterestForgiveness
      contextRef="As_Of_8_31_2021_us-gaap_ShortTermDebtTypeAxis_eyen_PaycheckProtectionProgramLoanMember_BgcxdUM1_Uq3npoE-3GAyg"
      decimals="0"
      id="Narr_6j3YAkhwqkiZfqR7GgJa2w"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5738</eyen:PaycheckProtectionProgramLoanAccruedInterestForgiveness>
    <eyen:DebtInstrumentPrincipalAmount
      contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"
      decimals="-5"
      id="Narr_YOugOcNBfUuqUkQH5Revdg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">25000000.0</eyen:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"
      id="Narr_Z_3tITF0Xk6InIVfJdMCJA">1.25% plus the prime rate </us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"
      decimals="4"
      id="Narr_uRKJn4vP4k-AIP0H3VQKtQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"
      id="Narr_1IE18e2f3UqX-ESPaqn00A">2025-05-01</us-gaap:DebtInstrumentMaturityDate>
    <eyen:PrepaymentOfLoanFeePercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IKbBe5b9Dk2-O_EZG5UCIQ"
      decimals="3"
      id="Narr_r6GpZFCbw0G_oWt6uuJavQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.010</eyen:PrepaymentOfLoanFeePercentage>
    <eyen:PrepaymentOfLoanFeePercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_ag4DlDgBVE2npGpPYLG-BA"
      decimals="3"
      id="Narr_6dJYD0z-WEGUnDhh9CUJ-w"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.030</eyen:PrepaymentOfLoanFeePercentage>
    <eyen:PrepaymentOfLoanFeePercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_FirstAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_nLEH9d3WgkSONkevFlrepw"
      decimals="3"
      id="Narr_RYq4SQNwEEC5PWoUGZ4S_g"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.030</eyen:PrepaymentOfLoanFeePercentage>
    <eyen:PrepaymentOfLoanFeePercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_SecondAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_Xo9_8_071Euty-FIgDxP6w"
      decimals="3"
      id="Narr_EVLV1xnDF0OsESO9sVJPlA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.020</eyen:PrepaymentOfLoanFeePercentage>
    <eyen:PrepaymentOfLoanFeePercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_eyen_PeriodAxis_eyen_ThirdAnniversaryMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_36SWG7orek6gpITdi6VlKA"
      decimals="3"
      id="Narr_sOmoYCV3QEeERZQ1kXhLaA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.010</eyen:PrepaymentOfLoanFeePercentage>
    <eyen:OriginalPrincipalLoanPercentage
      contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"
      decimals="3"
      id="Narr_nkG2-tN1O0yuWcckAcohbw"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.050</eyen:OriginalPrincipalLoanPercentage>
    <us-gaap:LongTermDebt
      contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"
      decimals="-5"
      id="Narr_pbOmGrWxa0uviYj8d4vx0g"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7500000</us-gaap:LongTermDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"
      decimals="INF"
      id="Narr_SM5ysAPIsEOLjg30AAUR1g"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">91884</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_39khr2_-zUm4gbhy8sBrOw"
      decimals="2"
      id="Narr_xf-sw9feJEqUEkZwFxJp7w"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <eyen:WarrantExercisableTerm
      contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"
      id="Narr_ZbFrQPgKsE-jn7sjECzO3w">P10Y</eyen:WarrantExercisableTerm>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_5_7_2021_To_5_7_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_egrbX-E_iEeuYaux1Z2tqQ"
      decimals="-5"
      id="Narr_9PVgnB59YkeuTvWHpKwsFw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">17500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_29_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_L9bBY0VpvUGL4oYGXOsvdg"
      decimals="0"
      id="Narr_xU8PgODTB0q9v-JkgDimoA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7875000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A"
      decimals="0"
      id="Narr_mNTq59Ohrk--fgJKvjNTjw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">95833</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Narr_MIZkZCxapk2rRZLoqx0LrA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">150349</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"
      decimals="0"
      id="Narr_I36NFYdD10egO6P0rSiGfA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">354539</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_FM7GpRWW9Euozoy65TKphg"
      decimals="2"
      id="Narr_a8qcQcX3tESW67QjDepvMA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.76</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"
      id="Narr_2RAdpzmqnESVnPrbsVNjuQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"
      decimals="3"
      id="Narr_2WD8Lv8rXUeF1R9C0RLl4Q"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"
      decimals="4"
      id="Narr_p9d0P8B1qUqIdV6ZXEY1QA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_gBP6bAVusk254R-jxaDM7A"
      decimals="0"
      id="Narr__j3z1SYQUUGFG1CxyNv0Fg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">66618</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_FinancialInstrumentAxis_us-gaap_DebtMember_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_IQWi_hUUskCPeb77ph-Kwg"
      decimals="0"
      id="Narr_TtZCPEIQU0qfq4Vb8b9xcA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">63469</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShortTermDebtTypeAxis_eyen_SiliconValleyBankLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_baqwqr6Ut0qcuua_7ntSPg"
      decimals="0"
      id="Narr_WIvdaThiTEGj477debeOIQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3149</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_WHLiDvoAz0qoOCGEPS5GgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gross loan proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Debt discount:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Relative fair value of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (354,539)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Relative fair value of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (63,469)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt discount &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123,936&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"
      decimals="0"
      id="Tc_dUh8sQLZXE-J8EtLVaNTRg_2_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7500000</us-gaap:LongTermDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw"
      decimals="0"
      id="Tc_CaLRZkUgike2qtMqYR-IBQ_4_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">354539</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw"
      decimals="0"
      id="Tc_E4oVUqfFAEG0LA6ZteGL6g_5_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">63469</us-gaap:RepaymentsOfLongTermDebt>
    <eyen:AmortizationOfDebtDiscount
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_uxlKvYDbyU6CV4ubKP-7Rw"
      decimals="0"
      id="Tc_DqUupBe1UUq11hL23QRq2w_6_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">41944</eyen:AmortizationOfDebtDiscount>
    <us-gaap:NotesPayable
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ"
      decimals="0"
      id="Tc_p6yrUpkm0UqlBUggsoVFsA_7_3"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">7123936</us-gaap:NotesPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_-vww2sv9Hke5TTEBsYBqFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;7&#160;&#x2013; Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:none;"&gt;See Note 8 - Related Party Transactions for certain commitments and contingencies entered into with certain related parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Litigations, Claims and Assessments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Arctic Vision License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On August 10, 2020, the Company entered into the Arctic Vision License Agreement pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under the terms of the Arctic Vision License Agreement, the Company received a non-refundable, upfront payment of $4.0 million, before any payments to Senju Pharmaceutical Co., Ltd. (&#x201c;Senju&#x201d;), due under the Exclusive License Agreement between the Company and Senju, as amended on April 8, 2020 and a Letter Agreement dated August 10, 2020 (the &#x201c;Senju License Agreement&#x201d;). The Company had recorded the $4.0 million payment as a deferred license fee until the payment is earned. The Company considers payment earned once certain trial data has been fully submitted to Arctic Vision, permitting Arctic Vision to seek regulatory approval with the National Medical Products Administration of China. The trial data for one of the two products (MicroPine) was fully submitted to Arctic Vision in March 2021. As a result, the Company recognized $2.0 million of deferred license fees (one-half of the $4.0 million upfront license fee) and recognized $0.8 million of deferred license costs related to the Senju payment during the three months ended March 31, 2021. The trial data for the other product (MicroLine) was fully submitted to Arctic Vision in June 2021. As a result, the Company recognized the remaining $2.0 million of deferred license fees and recognized the remaining $0.8 million of deferred license costs related to the Senju payment during the three months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In addition, the Company may receive up to a total of $43.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and regulatory approvals in Greater China and South Korea (up to $39.75 million), and development costs (up to $4.0 million). In December 2020, the Company satisfied a performance obligation which resulted in the Company recognizing $2.0 million of milestone revenues, pursuant to the Arctic Vision License Agreement. The $2.0 million was received from Arctic Vision in December 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The milestone revenue referred to above includes $2.0 million related to the MicroStat product resulting from Amendment 1 to the Arctic Vision License Agreement. On September 14, 2021, the Company and Arctic Vision executed this amendment which provides for a one-time upfront payment of $250,000 and milestone payments of $2.0 million based on the achievement of filing for and receiving regulatory approval separately from China and South Korea for the MicroStat Product. The Company anticipates the Marketing Authorization Application (MAA) filings to occur in December 2023 and the receipt of regulatory approval to occur in December 2024. The Company didn&#x2019;t recognize revenue for the $250,000 upfront payment because it was passed through to Senju. See Note 8 - Related Party Transactions for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Arctic Vision also will purchase its supply of MicroPine, MicroLine and MicroStat from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. No royalty payments were earned through September 30, 2021. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Senju License Agreement. See Note 8 &#x2013; Related Party Transactions- Senju License Agreement for additional details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Bausch License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On October 9, 2020, the Company entered into the Bausch License Agreement pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed Territory.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In connection with the Bausch License Agreement, Bausch Health paid the Company a non-refundable, upfront payment of $10.0 million. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight of the ongoing MicroPine study (the CHAPERONE study). The upfront payment has not been earned as of September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Bausch Health could also pay the Company up to an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. No milestone payments were earned through September 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Under the terms of the Bausch License Agreement, on a country-by-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration, for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed Territory. No royalty payments were earned through September 30, 2021.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <eyen:LicenseAgreementsUpfrontPaymentsReceived
      contextRef="Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ"
      decimals="-5"
      id="Narr_2F06_kmrrkKz_PXLyOKAjQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000.0</eyen:LicenseAgreementsUpfrontPaymentsReceived>
    <eyen:DeferredLicenseFees
      contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_i3TWieKEpEOqRjVjfBglLg"
      decimals="-5"
      id="Narr_rEztJhd0ikCMiWpJ8RgT0Q"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000.0</eyen:DeferredLicenseFees>
    <eyen:DeferredLicenseFees
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw"
      decimals="-5"
      id="Narr_xNvlw2XN7UOmpOE0IbvG6Q"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:DeferredLicenseFees>
    <eyen:LicenseAgreementsUpfrontPaymentsReceived
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_SenjuLicenseAgreementMember_C3bKFFHaP0eGVFPtm44auA"
      decimals="-5"
      id="Narr_ApHZuW5PFk6b9WD_IZJ1jQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000.0</eyen:LicenseAgreementsUpfrontPaymentsReceived>
    <eyen:DeferredLicenseCost
      contextRef="As_Of_3_31_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_abT8MOD3VU-JfADf_-FTiw"
      decimals="-5"
      id="Narr_b5Kl4ExpiUyJzVk3T0I2CA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">800000</eyen:DeferredLicenseCost>
    <eyen:DeferredLicenseFees
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q"
      decimals="-5"
      id="Narr_NZzzVu8Y-k6HmVdHR6jFog"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:DeferredLicenseFees>
    <eyen:DeferredLicenseCost
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_LT4SOXm1OUSDQJoMg_9C1Q"
      decimals="-5"
      id="Narr_7Kiu7xG_GkWXPTSDzCDKQA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">800000</eyen:DeferredLicenseCost>
    <eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable
      contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA"
      decimals="-4"
      id="Narr_VgaFaQUDkUyvK2NzsOtXZA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">43750000</eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable>
    <eyen:LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments
      contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA"
      decimals="-4"
      id="Narr_xmPe1vbulUWo0Wux0TuElg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">39750000</eyen:LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments>
    <eyen:LicenseAgreementThresholdDevelopmentCosts
      contextRef="As_Of_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_rUf-Bb2AakiW9GDGSxSvgA"
      decimals="-5"
      id="Narr_4IqeUVeALk6Ty5SNZUUM-A"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4000000.0</eyen:LicenseAgreementThresholdDevelopmentCosts>
    <eyen:MilestoneRevenuePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w"
      decimals="-5"
      id="Narr_nhLl3fEcwEyTpHpKvVTHlQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:MilestoneRevenuePayments>
    <eyen:MilestoneRevenuePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w"
      decimals="-5"
      id="Narr_bwXng7e83EKNmG3pSt4yKg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:MilestoneRevenuePayments>
    <eyen:MilestoneRevenuePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_Gb2EbOO0RkCzUyJl5Wio3w"
      decimals="-5"
      id="Narr_WvPPn2YjS0KGgNWUI-xk1w"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:MilestoneRevenuePayments>
    <eyen:MilestoneUpfrontPayments
      contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw"
      decimals="0"
      id="Narr_W_0844GmfUCyeu7fmBxwHg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">250000</eyen:MilestoneUpfrontPayments>
    <eyen:MilestoneRevenuePaymentsReceived
      contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw"
      decimals="-5"
      id="Narr_Zl8b08qc5keV4DLOJkn2eA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2000000.0</eyen:MilestoneRevenuePaymentsReceived>
    <eyen:MilestoneUpfrontPayments
      contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_a5OgCz1X_kuy6jGIjKGoHw"
      decimals="0"
      id="Narr_T1H02rasDUWdjDZVnT-nKw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">250000</eyen:MilestoneUpfrontPayments>
    <eyen:RoyaltyRevenuePayments
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_dm3PbdzDGkKl6-8dwnZVtg"
      decimals="0"
      id="Narr_8rIOWMAFckWR9UrVHH-uuQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:RoyaltyRevenuePayments>
    <eyen:LicenseAgreementsUpfrontPaymentsReceived
      contextRef="Duration_10_9_2020_To_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_DQU3YqFEXEeMyoIAZgkB6g"
      decimals="-5"
      id="Narr_MrV9CRMZA0q3_qxdKI4xmw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">10000000.0</eyen:LicenseAgreementsUpfrontPaymentsReceived>
    <eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable
      contextRef="As_Of_10_9_2020_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_7NBatIvU1UScUlDnCWwfjA"
      decimals="-5"
      id="Narr_HlLBNScg2k-jozLVq8zPgg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">35000000.0</eyen:LicenseAgreementsMaximumAdditionalPaymentsReceivable>
    <eyen:MilestoneRevenuePayments
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ"
      decimals="0"
      id="Narr_ij4_ENHLkE-pCiAav9eRCA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:MilestoneRevenuePayments>
    <eyen:RoyaltyRevenuePayments
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_eyen_BauschLicenseAgreementMember_mc25dmFAi0KfL9lpdkyIBQ"
      decimals="0"
      id="Narr_au1lN7H470qkq83R641vfA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">0</eyen:RoyaltyRevenuePayments>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_1aV3AaJsa0utYEmYuKUnVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;8&#160;&#x2013; Related Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s Vice President of Research and Development and Manufacturing (&#x201c;VP of R&amp;amp;D&#x201d;) owns a company that entered into a lease agreement with the Company on September&#160;15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial&#160;monthly base rent was $3,895 per&#160;month over the term of the lease and the security deposit was $3,895. On September&#160;15, 2018, the Company amended the lease agreement to extend it until September&#160;14, 2020 and increase the&#160;monthly base &lt;span style="-sec-ix-hidden:Hidden_nuJjRqoS1k-5yZXc6XLgrw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;rent&lt;/span&gt;&lt;/span&gt; and security deposit to $4,012. The lease agreement was amended again on April 6, 2020 to lease additional space and increase the monthly base &lt;span style="-sec-ix-hidden:Hidden_ZGcx3U_Ha0Oyk6Kg7P3ESg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;rent&lt;/span&gt;&lt;/span&gt; and security deposit to $5,247. On September 15, 2020, the Company agreed to extend the lease term until September 14, 2022 and increase the monthly base &lt;span style="-sec-ix-hidden:Hidden_D_hRu6Vn6kiVuoZDbI2E-w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;rent&lt;/span&gt;&lt;/span&gt; and security deposit to $5,404. The Company made $122,298 of leasehold improvements related to this lease which are included on the balance sheet.&#160;The Company&#x2019;s rent expense amounted to $16,212 and $15,982 for the three months ended September 30, 2021 and 2020, respectively, and $48,636 and $43,512 for the nine months ended September 30, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Senju License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During 2015, the Company entered into an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a former member of the Company&#x2019;s Board of Directors and, together, they beneficially own greater than 5% of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On April 8, 2020, the Company entered into an amendment (the &#x201c;License Amendment&#x201d;) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &#x201c;Senju Licensed Products&#x201d;) previously licensed to Senju in China (including the People&#x2019;s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &#x201c;Territory&#x201d;) if such a license was executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Since the Company executed a third-party license prior to April 8, 2021, the License Amendment will remain in effect for the duration of the license, subject to early termination.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &#x201c;Letter Agreement&#x201d;). Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Exclusive License Agreement was amended further by the License Amendment 2, effective September 14, 2021 (the &#x201c;Amendment 2&#x201d;). The Amendment 2 excludes Greater China and South Korea from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion, and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license revenue and sales revenue, including a one-time upfront payment of $250,000 which represented an inducement to Senju to approve Amendment 1 of the Arctic Vision License Agreement related to the MicroStat product. This upfront payment to Senju was in addition to and separate from the previously established 40% payment on milestone revenue. See Note 7 &#x2013; Commitments and Contingencies &#x2013; Arctic Vision License Agreement for additional details.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ"
      decimals="0"
      id="Narr_Lv_LRQP2cU2reDAFLidVMw"
      unitRef="Unit_Standard_sqft_g_mpTWDoikWYZzf7J4YxvQ">953</us-gaap:NetRentableArea>
    <eyen:LeaseMonthlyBaseRent
      contextRef="Duration_9_1_2016_To_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_9IMRqv6brkyXUIlqI0AdYQ"
      decimals="0"
      id="Narr_-uAiycV9D0OhMI9OtmS1-g"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3895</eyen:LeaseMonthlyBaseRent>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_15_2016_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_63zQj61nn0eJSrGSimD5iQ"
      decimals="0"
      id="Narr_-6KxjfO4W0-XbcirEYaL7w"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">3895</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_15_2018_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_0KZL2TVKrUmrWMPejjnE0w"
      decimals="0"
      id="Narr_V2zR9LZNy0G8EQxy9sC1uA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4012</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_4_6_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_yWodK4nHxUqdTmAUJR3I_w"
      decimals="0"
      id="Narr_VKlcVvoV90i_AcoXL1V3Bg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5247</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_15_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_4f7WqPnHVkCgD1MTwLBKxg"
      decimals="0"
      id="Narr_3FT7w9ECwk-D6fWR0dH0ZQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5404</us-gaap:SecurityDeposit>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="As_Of_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember__7M2VxLcG0C8xOn47atQ4g"
      decimals="0"
      id="Narr_Zo4c5fhb90K5zJGkMoSNew"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">122298</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pj3iXu39uEaE-ra1uxJM1A"
      decimals="0"
      id="Narr_ZKgis5Ph4Umq08geOM4alA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">16212</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_KnS0U6aBO0mO5JTiaLy6jQ"
      decimals="0"
      id="Narr_vygP_jHwQUuYe86Rsdn0cQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">15982</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_pOlvfs6TQUyzUKtXgpDcEQ"
      decimals="0"
      id="Narr__PayS4D2ekqW__WUY41_pQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">48636</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_RelatedPartyTransactionAxis_eyen_VicePresidentOfResearchAndDevelopmentMember_JuJfIkOVj0CQftJ-_I1QGQ"
      decimals="0"
      id="Narr_wGcBf54DM0WHrJux3ZKLMg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">43512</us-gaap:LeaseAndRentalExpense>
    <eyen:RoyaltyPercentage
      contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q"
      decimals="2"
      id="Narr_QLZ1Tig8_Ui8La8DzL2R8Q"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.05</eyen:RoyaltyPercentage>
    <eyen:RoyaltyPercentage
      contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_DHSq-vbrLEyNyWb4619E0Q"
      decimals="2"
      id="Narr_N7eRjr_C0EarNlepBH3o-A"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.05</eyen:RoyaltyPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember_dyafUeHTdE6cz1HM3PEKSA"
      decimals="2"
      id="Narr_HkGGZjPr7UeGAGxQtJstoQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <eyen:MilestoneUpfrontPayments
      contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA"
      decimals="0"
      id="Narr_RGzKIork8UiJp4Smyod_Mg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">250000</eyen:MilestoneUpfrontPayments>
    <eyen:PercentageOfMilestonePaymentRevenue
      contextRef="Duration_9_14_2021_To_9_14_2021_us-gaap_RelatedPartyTransactionAxis_eyen_SenjuPharmaceuticalCoMember_Cux1nMXjXk-TlrlFCPHGyA"
      decimals="2"
      id="Narr_B1d3EtwS-Uy51egjlAbB9A"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.40</eyen:PercentageOfMilestonePaymentRevenue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_1oltRxE52U65GDV90oEJ0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;9&#160;&#x2013; Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Securities Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company&#x2019;s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (&#x201c;Class A Warrant&#x201d;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&#x201c;Class B Warrant&#x201d;) (collectively, the Class A Warrants and Class B Warrants, the &#x201c;Warrants&#x201d;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.45 million of net proceeds in the offering after deducting placement agent fees and offering expenses of $0.53 million. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share. See &#x201c;Warrants&#x201d; below for additional details. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:none;"&gt;In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.81%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.26% - 0.69%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.45% - 1.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.26% - 1.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;92%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;98% - 99%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;92% - 94%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;96% - 99%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#x201c;simplified&#x201d; method to develop an estimate of the expected term of &#x201c;plain vanilla&#x201d; employee option grants. The Company uses a blended volatility calculation, the components of which are the Company&#x2019;s historical volatility for the period from its initial public offering through the valuation date and the average peer-group data of six comparable entities to supplement the Company&#x2019;s own historical data for the preceding years in computing the expected volatility. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The weighted average estimated grant date fair value of the stock options granted for the three months ended September 30, 2021 and 2020 was approximately $3.56 and $2.71 per share, respectively. The weighted average estimated grant date fair value of the stock options granted for the nine months ended September 30, 2021 and 2020 was approximately $4.16 and $2.24 per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On June&#160;17, 2021, an employee exercised an option to purchase common shares on a cashless basis, which resulted in 13,675 shares being withheld and not issued, to cover the cost to exercise and all payroll taxes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A summary of the option activity during the nine months ended September 30, 2021 is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,427,705&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.37&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,003,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; (121,261)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 54pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 2.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 4,305,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.89&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 6,253,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 2,364,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;3.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,448,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table presents information related to stock options as of September 30, 2021: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.24&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.72&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 764,419&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0pjWYEGDNkentV_xYyZQGA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 318,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.89&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 253,251&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0rah1dwiwUKGvejQzLqdgw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 656,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,920&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.81&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 222,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,637&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,668&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 652,899&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,387&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,305,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,364,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Restricted Stock Units &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:none;"&gt;On September 11, 2020 and March 31, 2021, the Company granted members of its Board of Directors an aggregate of &lt;/span&gt;&lt;span style="text-decoration:none;"&gt;44,951&lt;/span&gt;&lt;span style="text-decoration:none;"&gt; RSUs under its Amended and Restated 2018 Omnibus Stock Incentive Plan. Each RSU is subject to settlement into &lt;/span&gt;&lt;span style="text-decoration:none;"&gt;one&lt;/span&gt;&lt;span style="text-decoration:none;"&gt; share of the Company&#x2019;s common stock. The RSUs provided that vesting would occur on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The 2021 annual stockholders meeting took place on June 16, 2021 which triggered the vesting of the RSUs. The RSUs had an aggregate grant date fair value of &lt;/span&gt;&lt;span style="text-decoration:none;"&gt;$156,200&lt;/span&gt;&lt;span style="text-decoration:none;"&gt;, which was recognized over the vesting period.&lt;/span&gt;&lt;span style="text-decoration:underline;"&gt; &lt;/span&gt;&lt;span style="text-decoration:none;"&gt;Pursuant to the terms of the grants, vested RSUs are not issued until (a) termination of the director&#x2019;s service to the Company; or (b) upon a change-of-control transaction (as specified). &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration:underline;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded stock-based compensation expense related to stock options and RSUs. During the three months ended September 30, 2021 and 2020, the Company recorded expense of $777,467 ($489,121 of which was included within research and development expenses and $288,346 of which was included within general and administrative expenses on the condensed statement of operations) and $609,930 ($346,294 of which was included within research and development expenses and $263,636 of which was included within general and administrative expenses on the condensed statement of operations), respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of $2,071,735 ($1,138,331 of which was included within research and development expenses and $933,404 was included within general and administrative expenses on the condensed statement of operations) and $1,826,941 ($1,002,150 of which was included within research and development expenses and $824,791 was included within general and administrative expenses on the condensed statement of operations), respectively. As of September 30, 2021, there was $5,787,351 of unrecognized stock-based compensation expense which the Company expects to recognize over a weighted average period of 2.1 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A summary of warrant activity for the nine months ended September 30, 2021 is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,011,313&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (877,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.40&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents information related to Warrants as of September 30, 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;width:67.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warants Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$2.4696 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 917,919&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 917,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$2.7240 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$4.7600 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 6 &#x2013; Notes Payable &#x2013; for details on the warrant issued in connection with the SVB loan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the three months ended September 30, 2020, warrants for the purchase of 1,080,497 shares of the Company&#x2019;s common stock, with exercise prices of either $2.058 or $2.4696 per share, were exercised for aggregate proceeds of approximately $2.3 million, while no warrants were exercised during the three months ended September 30, 2021. During the nine months ended September 30, 2021 and 2020, warrants for the purchase of 877,014 and 1,248,161 shares of the Company&#x2019;s common stock, respectively, with exercise prices of either $2.058 or $2.4696 per share, were exercised for aggregate proceeds of approximately $2.1 million and &lt;span style="-sec-ix-hidden:Hidden_MimNBTPoWU-6QCm4o9Gk6Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;$2.6&lt;/span&gt;&lt;/span&gt; million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;At-The-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May&#160;14, 2021, the Company entered into a Sales Agreement (the &#x201c;Agreement&#x201d;) with SVB Leerink LLC (&#x201c;SVB Leerink&#x201d;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $30 million through SVB Leerink as its sales agent. Subject to the terms and conditions of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the Agreement, SVB Leerink may sell the Common Stock by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d;. SVB Leerink will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay SVB Leerink a commission equal to three percent (3.0%) of the gross sales proceeds of any Common Stock sold through SVB Leerink under the Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company is not obligated to make any sales of Common Stock under the Agreement. through September 30, 2021, the Company had not sold any shares of common stock under the Agreement. See Note 11 - Subsequent Events - At-The-Market Offering for additional details.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w"
      decimals="-5"
      id="Narr_-FgV991DL0SF93vZCSwgVw"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">6000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_x2ajygQN6EKb6JGnk3ADLQ"
      id="Narr_FjX_JNBTaEm1xdq6ZfZvwg">P1Y</eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_c2IjVI1hiUyhj_jiFRUrvw"
      decimals="INF"
      id="Narr_mxQwDt7brE6hu7i90XYB-Q"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_9AtIdFEIokuL0HQ8uzCAsA"
      id="Narr_BZXpJ7ftbEK4PVOb2zVGBw">P5Y</eyen:ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_VL8MKBI58UiYMm_viCZP0g"
      decimals="INF"
      id="Narr_dozYtnjaMkuLbMsqtdHt-Q"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <eyen:UnitsIssuedPricePerUnit
      contextRef="As_Of_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_40ylzH8p4E6F0T980U5jPQ"
      decimals="5"
      id="Narr_3WHIjX48okmrBykqWSE3SA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.21425</eyen:UnitsIssuedPricePerUnit>
    <eyen:UnitsIssuedPricePerUnit
      contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_bcWFEL6RI0aDOWIz9I9cow"
      decimals="5"
      id="Narr_pGNur5x9YUyV54DuFActBg"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.42625</eyen:UnitsIssuedPricePerUnit>
    <eyen:NetProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w"
      decimals="-4"
      id="Narr_yEbPdVnKD0uKO5DP2RsrVA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5450000</eyen:NetProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_zXIiJVMbz0OBTYwawcrR7w"
      decimals="-4"
      id="Narr_nEi_7e1obEKlZ3UD_RjwgA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">530000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_24_2020_To_3_24_2020_bTfSRHfxlkeROm6p3tdnwQ"
      decimals="0"
      id="Narr_pD4vmsUVyk6XGfQh_wEhRQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2675293</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_VN0zw8sCNECXKkjFp3cH-w"
      decimals="0"
      id="Narr_rJzqtknsXUuMjmQNmVZatA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1337659</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_24_2020_To_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_hm_lAyvBM0qOeJoA1nk2ug"
      decimals="0"
      id="Narr_a13PFUZNV0unHy_QHhfxow"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2006495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_aOl2qdArnUe539L8lxXVIQ"
      decimals="3"
      id="Narr_y6O0Z4QtKUO07Ld-fPsBmQ"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.058</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassWarrantsMember_txshmOfMEEmvxCweLiMsTA"
      decimals="2"
      id="Narr_2Le8lwDE6UeA9OqmkI_XFA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.27</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_24_2020_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_UpMsAYqFqU6-i1LSMPeaFg"
      decimals="4"
      id="Narr_5o6eAdiVe0KhiV8AxWEcLg"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.4696</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_24_2020_srt_TitleOfIndividualAxis_eyen_DirectorsAndExecutiveOfficersMember_us-gaap_StatementEquityComponentsAxis_eyen_ClassBWarrantsMember_Am_mT9HJA0SSfr6CiMZH_A"
      decimals="3"
      id="Narr_HsKGC-TUfUeRhWqOlpxH3Q"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.724</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_d3UJZejTx0u_-MHU1Sbykw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.85 - 10.00&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.81%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.26% - 0.69%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.45% - 1.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.26% - 1.32%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;92%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;98% - 99%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;92% - 94%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;96% - 99%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA"
      id="Narr_WZM5kEw6tUisMBJuLyfObQ">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      id="Tc_NHV__hqEzEmtn2Xp9lJumQ_4_2">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g"
      id="Narr_Nuxm85SqaUGnMVZCaYXLxg">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A"
      id="Narr_LPEcjtE6qEC1n4xyPdIxNg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ"
      id="Narr_RRPoTLusL0aVJIfsNYF5oA">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg"
      id="Narr_iQNWWwAQP0KfcObOdYn3ug">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw"
      id="Narr_PTS1FVY0Zke-CCbSi6CCTA">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ"
      id="Narr_Gf8tzcRN9Uiph_-If49m3Q">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_5GQbgtnDgkiDV9RlpnnpRA"
      decimals="4"
      id="Narr_O7w0XSBOHEScZ06WDcbVUQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="4"
      id="Tc_AxoRK7KN40GL7tV_O1cpbQ_5_2"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g"
      decimals="4"
      id="Narr_KqsB49YBM0qfMHu_MFWYFA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A"
      decimals="4"
      id="Narr_3J4UXt9Q602HYcYFHrDL9A"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ"
      decimals="4"
      id="Narr_LiBLug1OWkO8fnswIIEXwA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg"
      decimals="4"
      id="Narr_U_Z7OyklgkOVZGjglTZ6nw"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw"
      decimals="4"
      id="Narr_-eYVeF96-0GKwZPfHOhMKA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ"
      decimals="4"
      id="Narr_Qpcm9vfRl0KrOxuWa8Af_A"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="2"
      id="Tc_kfyrAhYtbk2Pue9UMPPvRw_6_2"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_lD0RCOzcv0G_0PapV17q2g"
      decimals="2"
      id="Narr_w_Un9jcJf0y0YnOqF-GqpQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_rh8KY2d1NUy4p-MtPR7a_A"
      decimals="2"
      id="Narr_VFt4w3OZpEKwh2n_35DDEQ"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MinimumMember_BSCDzZXC3EuWXHk0laj1MQ"
      decimals="2"
      id="Narr_2IwNHt4I-E2sMcDFkYaUyg"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_RangeAxis_srt_MaximumMember_p2WuPoy4wEumKyckSTCsYg"
      decimals="2"
      id="Narr_86jbP5UE3Ue-l_FhUkiHjg"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MinimumMember_UOg0-VQqY06Btav2wUAqLw"
      decimals="2"
      id="Narr_h7DdvVqsFEGXRQjMMnhITA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_RangeAxis_srt_MaximumMember_KmpxKeudFUqBEtPmBOT9HQ"
      decimals="2"
      id="Narr_6qlMacLE1kyql987UeE6lw"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="4"
      id="Tc_Rb6soQ5SWkKjPNWYlNaJNA_7_2"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="4"
      id="Tc_Phhr6itN3k-uxfCUhSvZBQ_7_4"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="4"
      id="Tc_46heKYHJnEWhyXWnM-fZZQ_7_6"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="4"
      id="Tc_8Nzu7QZ0BkaTFUUGSaLrbw_7_8"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_JRmA5vMSfky7e2TsSVzjhg"
      decimals="2"
      id="Narr_7GuJ6Fb4kEyNzWDeFm9ryg"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember__XCTy9gD4EmCBR0M73gnyQ"
      decimals="2"
      id="Narr_aPv1T9I_sU-85XaHg3NiWA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_OZ8nqWdLB0CI7i4-5Qnk5w"
      decimals="2"
      id="Narr_6REMX9HtGkaShIIfJYZXmA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_7pE77VrTWUCPTGSIttM0Og"
      decimals="2"
      id="Narr_RRmRX7PUhEOiRYmcRXMZ_g"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_6_17_2021_us-gaap_StatementEquityComponentsAxis_eyen_StockOptionsMember_72LTFu3OPkuIXbgOUgsnxA"
      decimals="INF"
      id="Narr_PsomitvhQUOsyR8xLY0rIw"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">13675</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_Mgh0-sfL10GriILxCtJSZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A summary of the option activity during the nine months ended September 30, 2021 is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January&#160;1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,427,705&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.37&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,003,536&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; (121,261)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 54pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 2.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 4,305,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.89&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 6,253,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 2,364,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt;3.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9.5pt;"&gt; 6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,448,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA"
      decimals="0"
      id="Tc_FeA5SbddTUiThZBZvHQdqA_6_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">3427705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA"
      decimals="2"
      id="Tc_AN4JDuOpu0aX-5kgj_0C8w_6_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="0"
      id="Tc_nQoHueLF6UWG8rqIvP_xww_7_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1003536</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="2"
      id="Tc_52G4Ryq_b0mqeifuljTeVg_7_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="0"
      id="Tc_qmrij3VYREuvWtaUWlgiRQ_8_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">121261</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="2"
      id="Tc_7GXu1TV8_EOJ9FWYhSyB4g_8_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="0"
      id="Tc_b0sG45FWEU-K_3UeRKOimg_9_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      decimals="2"
      id="Tc_3tB_Zp41QkCnviWvfgrM3w_9_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="0"
      id="Tc_U9s2QazgX0K5ja2Cdr-Ztw_10_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">4305980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="2"
      id="Tc_yBA-vSXnwkWtn5kqU4uXgA_10_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      id="Tc_BLqkm1vWO0CqKF9lUC7NXg_10_7">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="0"
      id="Tc_sRAaIXaQ0UqgMlpLcT9pTg_10_10"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">6253367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="0"
      id="Tc_-Aey6c_Qb0SpqUsScPsLxA_11_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2364074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="2"
      id="Tc_kFyHmy7RhUWabDtqpiPSHw_11_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_m0G94rM0A0WNjtYAPdgw2g"
      id="Tc_LumsGD08ekaO3NvsdPe5Hg_11_7">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_AOZOTsg0dU2Mi7xzjjVRgQ"
      decimals="0"
      id="Tc_b-W4_7KnqkW2FWz4xZHvAA_11_10"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">4448222</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_ZUkMsVHSRUW_JWvP_PkJBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table presents information related to stock options as of September 30, 2021: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.24&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 567,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.72&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 764,419&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0pjWYEGDNkentV_xYyZQGA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 318,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.89&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 253,251&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_0rah1dwiwUKGvejQzLqdgw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"&gt; 8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 656,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 468,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,920&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3.71&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"&gt; 8.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,723&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.53&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 127,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.81&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 222,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,637&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.25&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,668&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 652,899&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,387&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300,387&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,305,980&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,364,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA"
      decimals="2"
      id="Tc_yNyfZEDEmEeHoxufQFo6_g_6_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">1.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA"
      decimals="0"
      id="Tc_IozVNFfXDU2UE9sRtNCfWg_6_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_pdxT137AQUSnpOvc-s2HeA"
      id="Tc_pVKDLF_dW0C2-fy3PelVhQ_6_5">P3Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceOneMember_xlDHYIoDzkmiMclqIO85IA"
      decimals="0"
      id="Tc_vpJOX8s5ZEuv6jFV-5D3mg_6_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw"
      decimals="2"
      id="Tc_MaRnVwVVwEedVVnF11eJvw_7_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">1.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw"
      decimals="0"
      id="Tc_G8I5f_yBJEa3_W7ABzjPJw_7_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">567636</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_7ngFNRaQXEyNp3ttRONFSw"
      id="Tc_2SRTh4hKzEmO1aXpEfKxDw_7_5">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwoMember_aswxDSTbGkaeMD-z86cSYw"
      decimals="0"
      id="Tc_-LAl-HNq1kWNKQZyw7bK5g_7_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">567636</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g"
      decimals="2"
      id="Tc_W9eyw0oj4kWUBAA6aWE_9A_8_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g"
      decimals="0"
      id="Tc_VMZV64g6TkKHgayTDYErYg_8_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">764419</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThreeMember_5DCHoLBUFUSBsVReaJ2z4g"
      decimals="0"
      id="Tc_aEbGDd44u0-Gm-UC6MAXOg_8_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">318509</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA"
      decimals="2"
      id="Tc_qJcHq2e_2kqdjviNL1Jm-A_9_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA"
      decimals="0"
      id="Tc_HMpDw2vSrEyXqEn3U-tfyQ_9_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">667</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_T5bwOHqjaUKS0LJJ4b5ozA"
      id="Tc_KBCjJhiHykaPHGgvHgEdyg_9_5">P7Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourMember_-2gQgXvAwUemfHQYt-wvkA"
      decimals="0"
      id="Tc_fx38U-v2dUKZd3YHUvA4RA_9_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw"
      decimals="2"
      id="Tc_k2Y3HFkV50K6Xo7PwAveYg_10_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw"
      decimals="0"
      id="Tc_8sbmVdw1aU-WNKflweYA-g_10_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">253251</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFiveMember_ls9AzJaZSkiFlqpw-hLOjw"
      decimals="0"
      id="Tc_TNwoex8JlU2PhUhy8eKHkg_10_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">106868</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g"
      decimals="2"
      id="Tc_N6E-ebZTpUSQ-oqO-rtyzA_11_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g"
      decimals="0"
      id="Tc_Nx4iLlEut0WQby6q_Vcglw_11_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">656078</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_LJewsOeuEk6TAXKmOshhVg"
      id="Tc_gvAyeXMVUUiwg4Ez7tBXKg_11_5">P7Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixMember_yjGGde0NFkOIG0quEQy78g"
      decimals="0"
      id="Tc_ZZGsbIrTT0u64-kRSxlMkQ_11_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">468301</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew"
      decimals="2"
      id="Tc_GZIx7yB2AUqFedYNtRKezA_12_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew"
      decimals="0"
      id="Tc_fvyLooZsG0ugR-GUhYhndQ_12_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">58920</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_fMRMT8Kzq0GnRyxYiQBXKQ"
      id="Tc_8Xw6vCRWfk6hochEGXEWRA_12_5">P8Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSevenMember_1EMEFlMI60msISSk-4R2ew"
      decimals="0"
      id="Tc_Vbp4kTtKkEapijcoFdfZAA_12_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">19644</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww"
      decimals="2"
      id="Tc_fnVnVg9RjkC6V4uo2KhoeA_13_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww"
      decimals="0"
      id="Tc_evWbAadp5kWUCeE2eAF-mQ_13_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">45000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_DIdgnF05VESFzCtSdTkV_Q"
      id="Tc_-7133u9kBUSFMIxp-uPu8w_13_5">P8Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEightMember_U-xD3rTTZ0qAvKyAXj9aww"
      decimals="0"
      id="Tc_33_VdJpF0UyIPm0WbBussg_13_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">15001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q"
      decimals="2"
      id="Tc_YSMCzwYGlE6e8I1u21jEWw_14_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">3.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q"
      decimals="0"
      id="Tc_pyqo3VYtCE6xL2-vj_M3lg_14_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">43000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_2pIbQgQQM021F_Zqq-Clqw"
      id="Tc_WtCbROY55USW6Cs8kV0NVw_14_5">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineMemberMember_Xs4lwWcls0aD68Xcw6v-5Q"
      decimals="0"
      id="Tc_coK4lXpCsEeW6IGg6sYF-A_14_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">16723</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g"
      decimals="2"
      id="Tc_2X9_JNRpoUek1Y6gvGUG5Q_15_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.00</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g"
      decimals="0"
      id="Tc_dFGeiRPnWkO0EdAvWUuVKw_15_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_bogZl4gZq0O_dB0iHUQz0A"
      id="Tc_kyKuZaWBuk6RrPKI9WECZw_15_5">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTenMember_GaZsbSRAs0qyDoidNbbt8g"
      decimals="0"
      id="Tc_w9US1bHoP0aVXP71qoC9tg_15_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1890</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A"
      decimals="2"
      id="Tc_foQ748P8GEG-iJl4A_G0wQ_16_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A"
      decimals="0"
      id="Tc_wFGP8aKZ30O60ItRMdNi8g_16_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">127000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceElevenMember_bIfRO4SuH0uzbpE0uMcV5A"
      decimals="0"
      id="Tc_aabBZHBAgkSpfKHOugWNFA_16_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA"
      decimals="2"
      id="Tc_lUBiZCOGQkKDAttV7Z5gxg_17_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.68</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA"
      decimals="0"
      id="Tc_WsEpMFmPg0aoypT-rkUbtQ_17_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">25000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_Mhliuin-iE-lwHos4zJZUg"
      id="Tc_e4AEReFFkEWUhGQdJFM_1w_17_5">P8Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwelveMember_uAwXr-uhMUahFyoH-rAuBA"
      decimals="0"
      id="Tc_SvJDWINRhEOd76m5L7uD2A_17_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">13196</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw"
      decimals="2"
      id="Tc_TDb1sV7d00ijfjFEsPGEmg_18_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.81</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw"
      decimals="0"
      id="Tc_tb8atf-oHE21qvfa9Yfiqw_18_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">222000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceThirteenMember_O_cUZ05RVUSAKe2WosuSCw"
      decimals="0"
      id="Tc_u6QVSt8eHkOE_0TVnMGBuQ_18_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg"
      decimals="2"
      id="Tc_S6GOCdWwYUyb__KIUbTbfQ_19_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg"
      decimals="0"
      id="Tc_y0x4W37H_0mdGIVYk4OKpw_19_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">6000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_smJVukydaEOrt-QPyWs5Cw"
      id="Tc_1gfis3BJ0EOHGpW-g7quGA_19_5">P6Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFourteenMember_l5iutEN-gka08xus0te2lg"
      decimals="0"
      id="Tc_V4zU7k56cUihC5wxaDyhuQ_19_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">5833</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ"
      decimals="2"
      id="Tc_fy0izR3HyEqK1t2dPNzrpA_20_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ"
      decimals="0"
      id="Tc_elG1z-21KEqK5T9NbN436w_20_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1637</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceFifteenMember_qQrXsu76zEu_PRH5-IQspQ"
      decimals="0"
      id="Tc_7z26ZwmBQEq67hTGwlvkMw_20_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw"
      decimals="2"
      id="Tc_s3zAX8Kd0USMopzRNmtsfQ_21_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw"
      decimals="0"
      id="Tc_FCeHsl_HT0OO-0xhhIRnFA_21_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">16500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_Cignz6GZIEqawyto9jO6zw"
      id="Tc_ytLCPgvoREit686yUYRvRg_21_5">P6Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSixteenMember_ht5KTUUaOUuNROUNqgvEDw"
      decimals="0"
      id="Tc_6PKxmNBOoUWrrXnBwGgLXA_21_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">16500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ"
      decimals="2"
      id="Tc_gor7SJZTJEWgWryE9JcJaQ_22_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ"
      decimals="0"
      id="Tc_eO4TzcfgEUejcGmav8Ir3Q_22_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_t3aQtXqbMUqyY_l_s90kFA"
      id="Tc_VAMBWBf8FU-l38vakxmwOg_22_5">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceSeventeenMember_dGUkWJwwtUOQwjKOjfnlFQ"
      decimals="0"
      id="Tc_RDRQ4poswEiOVXVdcLJFwg_22_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA"
      decimals="2"
      id="Tc_AcOsfYaxfkC51oC9ib0Ygw_23_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">5.77</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA"
      decimals="0"
      id="Tc_SgbHUkVkzkGenp0DzFKc1Q_23_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">50000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceEighteenMember_GuT8WkHErUyvvufAHihZNA"
      decimals="0"
      id="Tc_sj0IDrJpXEi2kIWX2FJiTw_23_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA"
      decimals="2"
      id="Tc_Og9I4Tr3jkmGZzlhHjKuFg_24_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">6.01</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA"
      decimals="0"
      id="Tc_oD4RatlIeUiJ5_IWcCypBQ_24_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">652899</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceNineteenMember_KSnxHqGH-k2yyVufiI5HhA"
      decimals="0"
      id="Tc_snNJLpQzGE26AIT3q2En0w_24_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ"
      decimals="2"
      id="Tc_wFfU8nxDi0u8BqvzuNfTAQ_25_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">6.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ"
      decimals="0"
      id="Tc_0AYmhdBxBEyHWPIO0Ppwww_25_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">300387</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_BHSo-xH0_02gL68u6nLG7Q"
      id="Tc_n2Soe0qa5UeNPeebyTf6YQ_25_5">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyMember_LBPPBmp6dESNuu98x_I-kQ"
      decimals="0"
      id="Tc_c-ocuuQ2MU2SMkim8N0yyg_25_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">300387</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw"
      decimals="2"
      id="Tc_AcWdmmHE90OFjxDy7llfJQ_26_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">6.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw"
      decimals="0"
      id="Tc_kKQfwc-pSkORUOEQ-1APgA_26_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_80d3KmGzV0ebsJXfreNHEQ"
      id="Tc_stW3lCrGX0KIiJNdfIvVqA_26_5">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyOneMember_rFbFTN6kuk--AsPpeoYLDw"
      decimals="0"
      id="Tc_DpTyPwQ2WUyv-td12umJ5g_26_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">60000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw"
      decimals="2"
      id="Tc_JIL2mBIIuEClJ-xIO_rtLQ_27_1"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">8.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw"
      decimals="0"
      id="Tc_b0vHVaJNhEaSohWFZNU-Rg_27_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">166918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_c-dzlES2H06x3UbgBeoj7w"
      id="Tc_UM3l-jU4xk2yFTLMtXjyPQ_27_5">P6Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_eyen_ExercisePriceTwentyTwoMember_Na-XOc747EqqCeMtOaF9Qw"
      decimals="0"
      id="Tc_vH5zFae3_kePB2GHsVwKxg_27_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">166918</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_hr8EiuX7PEC5n3cggEcIJg_28_3"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">4305980</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_cDP_0W2qT0-TfPNh40Lcig_28_5">P6Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_PUSlNIrmhke3d7gd6rujAQ_28_7"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2364074</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA"
      decimals="INF"
      id="Narr_X85SIpyFOEyCHgQOqX0K3A"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">44951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ"
      decimals="INF"
      id="Narr_N1QMu9GoP0KcbW9Q_LTJDg"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">44951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <eyen:NumberOfCommonShares
      contextRef="Duration_9_11_2020_To_9_11_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_8ySDcn9M10ej4qSDW6T5BA"
      decimals="INF"
      id="Narr_-7fZjoh_g062OETu0kDx6A"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1</eyen:NumberOfCommonShares>
    <eyen:NumberOfCommonShares
      contextRef="Duration_3_31_2021_To_3_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_eyen_OmnibusStockIncentivePlan2018Member_Nok1-cKtrkCxE5pzH-raNQ"
      decimals="INF"
      id="Narr_WJtoullk0Em_Ov-6Q7QLAA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1</eyen:NumberOfCommonShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_w1sjpiHNKkuLE2e28hGLqg"
      decimals="0"
      id="Narr_CgnO5_utyUimbx0JeV_M_Q"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">156200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Narr_Mt2UNJQuDUevQ67D3S9HUA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">777467</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_A7hLgIFxxUKBiuI527JBGQ"
      decimals="0"
      id="Narr_DrsY-i-4YkOn2qIjZ5EgkQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">489121</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Jy8VhLNmEkGHN5MuNuthNg"
      decimals="0"
      id="Narr_K2vpOep-JkqXSMpEQKVDsA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">288346</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Narr_NhBqyeXHLkK0Plt-cfBGVg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">609930</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_rbh1OVNxSEyBxxZbh4fjoQ"
      decimals="0"
      id="Narr_N5LUmxbvgEqtPGOx9AkBJw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">346294</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_x35crJWltUqP-Ltc2GMthw"
      decimals="0"
      id="Narr_q-S17nHXkk6sNzmnmOgtjw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">263636</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Narr_XsJVwMee1kOGyVal9tvYuw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2071735</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ntknW_Gv5UC-DQSr8ZSQOg"
      decimals="0"
      id="Narr_a0DNfCEgtkG2kZk97xyCAw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1138331</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qNX7m30BZEuTbysvLOcMQQ"
      decimals="0"
      id="Narr_ZJpUKmX2WESi3cQ93AqdPQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">933404</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Narr_i4FDly9FsU2zqEquxxDj_w"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1826941</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_CJ4gskFkJUSoYcy73Hqa0A"
      decimals="0"
      id="Narr_X-HTu2w0t0ahB-Y_K079hg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">1002150</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_w6HGMgcXbEmE_fB8OrHwwA"
      decimals="0"
      id="Narr_OBvHz5vQnU23-fUWGVA9Ow"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">824791</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Narr_Km0zoa6jnUGvca-3ifn2PQ"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">5787351</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Narr_E3e47Vz9o0aU3teLS7X2Dw">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_E3t6R1n_-EiB1JfDlL5xCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A summary of warrant activity for the nine months ended September 30, 2021 is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,011,313&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.43&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (877,014)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.40&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable September 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,714,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="INF"
      id="Tc__OBuXniExUK_I_HMsmACvw_6_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2011313</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA"
      decimals="2"
      id="Tc_3OhwNhGhmUi8BAP-4IQXww_6_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.43</eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <eyen:ClassOfWarrantOrRightGranted
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="INF"
      id="Tc_Hj9MCWUmj0epsrsdDxqVEg_7_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">91884</eyen:ClassOfWarrantOrRightGranted>
    <eyen:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Tc_Yx-luMtbPUa1Ymqo3CJZIQ_7_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.76</eyen:ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice>
    <eyen:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="INF"
      id="Tc_DeJEVSZuxUykSPaSNVipTg_8_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">877014</eyen:ClassOfWarrantOrRightExercised>
    <eyen:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Tc_CW0n7-A7b0uKgA0aqqVglw_8_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.40</eyen:ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Tc_zHMyJEInyk-BBul4GpcnTw_9_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1226183</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="2"
      id="Tc_TjsysADnL0K4cZxXOUPVKA_9_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.69</eyen:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
    <eyen:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_p03Waz81t0qjPSAZnslVWQ_9_7">P4Y</eyen:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_pr_sRqQ8-E6s03k4E7jD8A_9_10"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2714617</eyen:ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue>
    <eyen:ClassOfWarrantOrRightExercisable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Tc_JdIbwoTBt0akbDINUOhnmQ_11_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1226183</eyen:ClassOfWarrantOrRightExercisable>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="2"
      id="Tc_i3GgZwDDh0WIHmRUdmXCfA_11_5"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.69</eyen:ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_tkdFVW6Z-kKRn2ZkV6LM_g_11_7">P4Y</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightExercisableAggregateIntrinsicValue
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="0"
      id="Tc_uwdX3Uj9WEaFEiSRtA1u2g_11_10"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2714617</eyen:ClassOfWarrantOrRightExercisableAggregateIntrinsicValue>
    <eyen:ScheduleOfWarrantsOutstandingTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb__PHcwl4o2UGAmu6goHD87g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents information related to Warrants as of September 30, 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;width:67.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warants Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;In&#160;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$2.4696 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 917,919&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 917,919&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$2.7240 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 216,380&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;$4.7600 &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.6&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91,884&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,226,183&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:10pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</eyen:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ"
      decimals="4"
      id="Tc_aiRwDV9WPk6Odnl8VKQC0Q_6_0"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ"
      decimals="INF"
      id="Tc_phg1TchDK0S9O44i8U8Qjw_6_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">917919</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Im1QKFMiwEyIc4Nt8pdKyQ"
      id="Tc_2xf5Sxv5bkGvEVFA0JT4_g_6_4">P3Y6M</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightExercisable
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_n14wA-cyVE6zdXcDERSYaQ"
      decimals="INF"
      id="Tc_yfZnSzwLk0CsV2xyHw2lIw_6_6"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">917919</eyen:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA"
      decimals="4"
      id="Tc_cGMMiHa9y0eUlKPEfoMpKw_7_0"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.7240</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA"
      decimals="INF"
      id="Tc_cYzR6SLadUqrsCpJWuhFIA_7_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">216380</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_s7sYagQq6kerzRAgAyzWvQ"
      id="Tc_BKgiRsXSo0inZPsEIdysog_7_4">P3Y6M</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightExercisable
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceTwoMember_uUNZbMkZOU-MGLrViEgFiA"
      decimals="INF"
      id="Tc_1L7Yd8UUsE2jxL_K5KF7Tw_7_6"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">216380</eyen:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA"
      decimals="4"
      id="Tc_q_v-x_5VrE-kSdm4qMw79g_8_0"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.7600</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA"
      decimals="INF"
      id="Tc_vBZWb60d4Uu0Wg9qcgPubQ_8_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">91884</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_kdodtnQEgkKApSH7Ar3_7w"
      id="Tc_O3NVk3LxA0u_lekBbkIgug_8_4">P9Y7M6D</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightExercisable
      contextRef="As_Of_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceThreeMember_N7I2rMf5VUKYDvnV_eynuA"
      decimals="INF"
      id="Tc_eY2UJVJm30y1uFF_cPodtQ_8_6"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">91884</eyen:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Tc_Xyk38DG5s0uS2aVH_qLD-A_9_2"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1226183</us-gaap:ClassOfWarrantOrRightOutstanding>
    <eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tc_W8xQ3my4DkantDK6iwEyMw_9_4">P4Y</eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife>
    <eyen:ClassOfWarrantOrRightExercisable
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="INF"
      id="Tc_dnjfGSQ500Kos6-LEyE7rA_9_6"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1226183</eyen:ClassOfWarrantOrRightExercisable>
    <eyen:ClassOfWarrantOrRightExercised
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="INF"
      id="Narr_HxdKvV6G6kes6ZzOAgWHeA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1080497</eyen:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MinimumMember_8dZNtKxwmkiqkPx6oMKrZQ"
      decimals="3"
      id="Narr_G0f7ovIWY02mMkr6xd2L9g"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.058</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2020_srt_RangeAxis_srt_MaximumMember_whpYAzEDtkOSZXmSQSWepw"
      decimals="4"
      id="Narr_gB8YWtk-OEGDtREEHd0BKQ"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="-5"
      id="Narr_8s2ijATZA0Cln9nOEdE5vA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2300000</us-gaap:ProceedsFromWarrantExercises>
    <eyen:ClassOfWarrantOrRightExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="INF"
      id="Narr_2XC-xGrsU0-fQ40eNSt_qg"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">0</eyen:ClassOfWarrantOrRightExercised>
    <eyen:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="INF"
      id="Narr_jO2XNtKFgkezXIyhIzIXOg"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">877014</eyen:ClassOfWarrantOrRightExercised>
    <eyen:ClassOfWarrantOrRightExercised
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="INF"
      id="Narr_yxRQmUxt7U2Tf4uV4spZRA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">1248161</eyen:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA"
      decimals="3"
      id="Narr_bDqIChk0w0KvPi1evhS5nA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.058</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2020_8tscoojBSUCMjtVH--OdCg"
      decimals="4"
      id="Narr_o2RbATUgzEyPvfnmy9Q5rw"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">2.4696</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="-5"
      id="Narr_3Na4LItC20q_7qqwK4DftA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">2100000</us-gaap:ProceedsFromWarrantExercises>
    <eyen:FairValueOfCommonStock
      contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_N1KXYZq5fUuqk4TSeXUFnA"
      decimals="-6"
      id="Narr_iZ8F4LPojU-lZTw8_kC67A"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">30000000</eyen:FairValueOfCommonStock>
    <eyen:PercentageOfGrossSalesOnCommonStock
      contextRef="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg"
      decimals="2"
      id="Narr_PQgMo_dqF0K7_xDSdTtpnA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.03</eyen:PercentageOfGrossSalesOnCommonStock>
    <eyen:PercentageOfGrossSalesOnCommonStock
      contextRef="As_Of_5_14_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GUViAl6ug0C6xhqy0gegjg"
      decimals="3"
      id="Narr_GVCpEWcwcEiOdEAJKwo71g"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.030</eyen:PercentageOfGrossSalesOnCommonStock>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_JrCTMvJQaEyiH4sTFaMQiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note&#160;10&#160;&#x2013; Employee Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;401(k) Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &#x201c;Plan&#x201d;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2021 and 2020, the Company&#x2019;s Board of Directors has approved a matching contribution equal to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;100%&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; of elective deferrals up to &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;4%&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three months ended September 30, 2021 and 2020, the Company recorded expense of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$34,076&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$25,535&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; associated with its matching contributions, respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$144,917&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$106,021&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; associated with its matching contributions, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Narr_rFiZ1Q9p1kONGsVuxtB5xg"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="2"
      id="Narr_MvmFeKEHLka8clAhRiwJzA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.04</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g"
      decimals="0"
      id="Narr_imTh1wyNS0aGQwxT2SJAvg"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">34076</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg"
      decimals="0"
      id="Narr_8y7m2qWJqkajYHr5fCoUkA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">25535</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      decimals="0"
      id="Narr_SemKhXcrukGc2Ykb13JUSw"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">144917</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw"
      decimals="0"
      id="Narr_8fLXKn6-GkWWWNXruTTy_A"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">106021</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg"
      id="Tb_Qync8W_m8k603idNCmBMGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Note 11 &#x2013; Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;At-The-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Pursuant to the At-The-Market Offering (see Note 9 &#x2013; Stockholders&#x2019; Equity &#x2013; At-The-Market Offering) the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;MydCombi FDA Application&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 25, 2021, the Company announced the reclassification of the Company&#x2019;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, MydCombi, as a drug-device combination product by the FDA in a CRL received on October 22, 2021, following a change in the agency&#x2019;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. See Note 1 &#x2013; Business Organization, Nature of Operations and Basis of Presentation and Note 6 &#x2013; Notes Payable &#x2013; Silicon Valley Bank Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt;Employee Stock Options&lt;/span&gt;&lt;span style="text-decoration:underline;text-decoration-color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 27, 2021, the Company granted ten-year stock options to employees, pursuant to its Amended and Restated 2018 Omnibus Stock Incentive Plan, to purchase an aggregate of 35,000 shares of the Company&#x2019;s common stock at an exercise price of $4.06 per share. The options expire on the tenth anniversary of the grant date and they vest with respect to one-third of the shares underlying the awards on the first anniversary of the grant date and, with respect to the remaining two-thirds of the shares underlying the awards, in equal monthly installments over the subsequent two years.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="-5"
      id="Narr_Oj65DkFZSkWhhIw12CyVIA"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="-5"
      id="Narr_V5qOH4qQA0-V6zRTrxgC7A"
      unitRef="Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ">12400000</eyen:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_6_2021_To_10_6_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_eyen_AtMarketOfferingMember_GD6Gv-ZXJU67KmZyo8upgg"
      decimals="INF"
      id="Narr_qfhRvPt-Sk61rSzHbvyGJQ"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">2435604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw"
      id="Narr_5Xx7OP042kyHBIMWmBtS8w">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw"
      decimals="INF"
      id="Narr_ReL8G42UUE2MjmwxfGODuA"
      unitRef="Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA">35000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_lMHKpMczF0i8b2pWYttO7Q"
      decimals="2"
      id="Narr_erhNFnU85k-J2aM3dd3-hA"
      unitRef="Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA">4.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_tUqOu0dbMESf7ibzQiMF9g"
      decimals="4"
      id="Narr_IOwcYzLgw0KZHiqz_gq0Rw"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9phIPy7ZLESGi02EKB1vbw"
      decimals="4"
      id="Narr_glsnohXaHEWyOyZ74ZEQwA"
      unitRef="Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ">0.02</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw"
      id="Narr_4ETBtXlPXEmNPGz1ZuKqJw">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2"
          xlink:label="Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2"
          xlink:type="locator"/>
        <link:footnote id="_d37eaf7b_983e_4a30_a376_18834d02315c" xlink:label="_d37eaf7b_983e_4a30_a376_18834d02315c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:9pt;">Includes gross proceeds of </xhtml:span><xhtml:span style="font-size:9pt;">$13,800,002</xhtml:span><xhtml:span style="font-size:9pt;">, less total issuance costs of </xhtml:span><xhtml:span style="font-size:9pt;">$1,304,294</xhtml:span><xhtml:span style="font-size:9pt;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_yyOsTfH8s0K6VBqu7x0GXg_23_2"
          xlink:to="_d37eaf7b_983e_4a30_a376_18834d02315c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_eC2iacNYQUmPuhllN3b-WA_23_14"
          xlink:label="Tc_eC2iacNYQUmPuhllN3b-WA_23_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_eC2iacNYQUmPuhllN3b-WA_23_14"
          xlink:to="_d37eaf7b_983e_4a30_a376_18834d02315c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8"
          xlink:label="Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_R4iZJDgrRk6hpXKPz6O2Jw_23_8"
          xlink:to="_d37eaf7b_983e_4a30_a376_18834d02315c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_aHrCmOBr3UW1GniaD9mjIg_23_5"
          xlink:label="Tc_aHrCmOBr3UW1GniaD9mjIg_23_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_aHrCmOBr3UW1GniaD9mjIg_23_5"
          xlink:to="_d37eaf7b_983e_4a30_a376_18834d02315c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_O5vsiEfkEkOvZyoF8tznfg_23_11"
          xlink:label="Tc_O5vsiEfkEkOvZyoF8tznfg_23_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_O5vsiEfkEkOvZyoF8tznfg_23_11"
          xlink:to="_d37eaf7b_983e_4a30_a376_18834d02315c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_D0YzUAQVWE62L_TShdiWZg_7_2"
          xlink:label="Tc_D0YzUAQVWE62L_TShdiWZg_7_2"
          xlink:type="locator"/>
        <link:footnote id="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" xlink:label="_f8d33325_e923_4cd2_82c3_ee63ff5b5490" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:9pt;">Includes gross proceeds of </xhtml:span><xhtml:span style="font-size:9pt;">$5,984,931</xhtml:span><xhtml:span style="font-size:9pt;">, less total issuance costs of </xhtml:span><xhtml:span style="font-size:9pt;">$533,189</xhtml:span><xhtml:span style="font-size:9pt;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_D0YzUAQVWE62L_TShdiWZg_7_2"
          xlink:to="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_qOmJQXwe3keWplvbtt2sSQ_7_14"
          xlink:label="Tc_qOmJQXwe3keWplvbtt2sSQ_7_14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_qOmJQXwe3keWplvbtt2sSQ_7_14"
          xlink:to="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8"
          xlink:label="Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_B9FsmU_vZEaB3dfQPUP1hQ_7_8"
          xlink:to="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_IitobebuVk-v9Zwz1GQADw_7_5"
          xlink:label="Tc_IitobebuVk-v9Zwz1GQADw_7_5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_IitobebuVk-v9Zwz1GQADw_7_5"
          xlink:to="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_KIDooAWzYk6H1VhhxJeQug_7_11"
          xlink:label="Tc_KIDooAWzYk6H1VhhxJeQug_7_11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_KIDooAWzYk6H1VhhxJeQug_7_11"
          xlink:to="_f8d33325_e923_4cd2_82c3_ee63ff5b5490"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14"
          xlink:label="Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14"
          xlink:type="locator"/>
        <link:footnote id="_fd9dc05a_1c6c_48bf_a594_db51ef746b77" xlink:label="_fd9dc05a_1c6c_48bf_a594_db51ef746b77" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size:9pt;">Allocated fair value of warrants of </xhtml:span><xhtml:span style="font-size:9pt;">$354,539</xhtml:span><xhtml:span style="font-size:9pt;">, less allocated issuance costs of </xhtml:span><xhtml:span style="font-size:9pt;">$3,149</xhtml:span><xhtml:span style="font-size:9pt;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_7EC2N4lkWUmVEK7rIHfL9Q_19_14"
          xlink:to="_fd9dc05a_1c6c_48bf_a594_db51ef746b77"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kzbIalpKPk-fHEULMdpRUg_19_8"
          xlink:label="Tc_kzbIalpKPk-fHEULMdpRUg_19_8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kzbIalpKPk-fHEULMdpRUg_19_8"
          xlink:to="_fd9dc05a_1c6c_48bf_a594_db51ef746b77"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9MTARuC3fUqgCgb-kF9CBw_30_6"
          xlink:label="Tc_9MTARuC3fUqgCgb-kF9CBw_30_6"
          xlink:type="locator"/>
        <link:footnote id="_979b107d_26ff_4430_be91_8b7b2590c736" xlink:label="_979b107d_26ff_4430_be91_8b7b2590c736" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9MTARuC3fUqgCgb-kF9CBw_30_6"
          xlink:to="_979b107d_26ff_4430_be91_8b7b2590c736"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147193009336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EYENOVIA,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1178401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">295 Madison Avenue, Suite&#160;2400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">NEW YORK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">289-1117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,398,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194431896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Unrestricted cash and cash equivalents</a></td>
<td class="nump">$ 13,500,871<span></span>
</td>
<td class="nump">$ 28,371,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred license costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseFeeAndExpenseReimbursementsReceivables', window );">License fee and expense reimbursements receivables</a></td>
<td class="nump">960,180<span></span>
</td>
<td class="nump">2,966,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,123,289<span></span>
</td>
<td class="nump">453,478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">23,459,340<span></span>
</td>
<td class="nump">33,391,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,413,201<span></span>
</td>
<td class="nump">396,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">119,035<span></span>
</td>
<td class="nump">119,035<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">24,991,576<span></span>
</td>
<td class="nump">33,906,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,684,733<span></span>
</td>
<td class="nump">1,461,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,184,236<span></span>
</td>
<td class="nump">1,150,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">552,336<span></span>
</td>
<td class="nump">1,480,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent - current portion</a></td>
<td class="nump">16,037<span></span>
</td>
<td class="nump">7,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred license fee</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Notes payable - current portion</a></td>
<td class="nump">7,282,037<span></span>
</td>
<td class="nump">97,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">20,719,379<span></span>
</td>
<td class="nump">18,198,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent - non-current portion</a></td>
<td class="nump">26,059<span></span>
</td>
<td class="nump">38,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - non-current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">20,745,438<span></span>
</td>
<td class="nump">18,602,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 90,000,000 shares authorized; 25,963,185 and 24,978,585 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">2,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">97,446,125<span></span>
</td>
<td class="nump">92,742,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(93,202,584)<span></span>
</td>
<td class="num">(77,440,919)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">4,246,138<span></span>
</td>
<td class="nump">15,303,885<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 24,991,576<span></span>
</td>
<td class="nump">$ 33,906,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseFeeAndExpenseReimbursementsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of license fee and expense reimbursements receivables classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseFeeAndExpenseReimbursementsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192931944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">25,963,185<span></span>
</td>
<td class="nump">24,978,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">25,963,185<span></span>
</td>
<td class="nump">24,978,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194008536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Operating Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,470,188<span></span>
</td>
<td class="nump">$ 3,363,759<span></span>
</td>
<td class="nump">11,334,296<span></span>
</td>
<td class="nump">$ 9,913,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,435,141<span></span>
</td>
<td class="nump">1,728,366<span></span>
</td>
<td class="nump">7,082,659<span></span>
</td>
<td class="nump">5,669,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">5,905,329<span></span>
</td>
<td class="nump">5,092,125<span></span>
</td>
<td class="nump">18,416,955<span></span>
</td>
<td class="nump">15,582,607<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(5,905,329)<span></span>
</td>
<td class="num">(5,092,125)<span></span>
</td>
<td class="num">(16,016,955)<span></span>
</td>
<td class="num">(15,582,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant', window );">Small Business Administration Economic Injury Disaster Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of PPP 7(a) loan</a></td>
<td class="nump">463,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(8,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(119,212)<span></span>
</td>
<td class="num">(4,945)<span></span>
</td>
<td class="num">(202,407)<span></span>
</td>
<td class="num">(14,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">2,354<span></span>
</td>
<td class="nump">24,579<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (5,568,598)<span></span>
</td>
<td class="num">$ (5,096,530)<span></span>
</td>
<td class="num">$ (15,761,665)<span></span>
</td>
<td class="num">$ (15,563,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- Basic</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- Diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.61)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- Basic</a></td>
<td class="nump">26,053,532<span></span>
</td>
<td class="nump">22,206,195<span></span>
</td>
<td class="nump">25,773,098<span></span>
</td>
<td class="nump">19,802,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- Diluted</a></td>
<td class="nump">26,052,483<span></span>
</td>
<td class="nump">22,206,195<span></span>
</td>
<td class="nump">25,773,098<span></span>
</td>
<td class="nump">19,802,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of small business administration economic injury disaster grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147197893688">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">$ 69,409,949<span></span>
</td>
<td class="num">$ (57,671,052)<span></span>
</td>
<td class="nump">$ 11,740,607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,100,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo', window );">Issuance of common stock and warrants in private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">5,451,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,451,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo', window );">Issuance of common stock and warrants in private placement(in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">583,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">583,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,450,910)<span></span>
</td>
<td class="num">(5,450,910)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">75,445,289<span></span>
</td>
<td class="num">(63,121,962)<span></span>
</td>
<td class="nump">12,325,304<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,776,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">69,409,949<span></span>
</td>
<td class="num">(57,671,052)<span></span>
</td>
<td class="nump">11,740,607<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,100,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,563,005)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,488<span></span>
</td>
<td class="nump">91,881,790<span></span>
</td>
<td class="num">(73,234,057)<span></span>
</td>
<td class="nump">18,650,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,884,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">75,445,289<span></span>
</td>
<td class="num">(63,121,962)<span></span>
</td>
<td class="nump">12,325,304<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,776,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants', window );">Exercise of warrants on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">376,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">376,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">633,146<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">633,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,015,565)<span></span>
</td>
<td class="num">(5,015,565)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="nump">76,454,839<span></span>
</td>
<td class="num">(68,137,527)<span></span>
</td>
<td class="nump">8,319,306<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,943,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree', window );">Issuance of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">12,495,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,495,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree', window );">Issuance of common stock in public offering (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,833,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis', window );">Exercise of stock options on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">2,269,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,269,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of stock warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,080,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">52,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,930<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">609,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,096,530)<span></span>
</td>
<td class="num">(5,096,530)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,488<span></span>
</td>
<td class="nump">91,881,790<span></span>
</td>
<td class="num">(73,234,057)<span></span>
</td>
<td class="nump">18,650,221<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,884,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">92,742,306<span></span>
</td>
<td class="num">(77,440,919)<span></span>
</td>
<td class="nump">15,303,885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,978,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">1,530,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of stock warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">644,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">656,913<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">656,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,351,667)<span></span>
</td>
<td class="num">(5,351,667)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,563<span></span>
</td>
<td class="nump">94,930,144<span></span>
</td>
<td class="num">(82,792,586)<span></span>
</td>
<td class="nump">12,140,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,623,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,498<span></span>
</td>
<td class="nump">92,742,306<span></span>
</td>
<td class="num">(77,440,919)<span></span>
</td>
<td class="nump">15,303,885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,978,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,761,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,597<span></span>
</td>
<td class="nump">97,446,125<span></span>
</td>
<td class="num">(93,202,584)<span></span>
</td>
<td class="nump">4,246,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,963,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,563<span></span>
</td>
<td class="nump">94,930,144<span></span>
</td>
<td class="num">(82,792,586)<span></span>
</td>
<td class="nump">12,140,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,623,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of SVB warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis', window );">Exercise of stock options on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">572,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of stock warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">130,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,841,400)<span></span>
</td>
<td class="num">(4,841,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,595<span></span>
</td>
<td class="nump">96,621,948<span></span>
</td>
<td class="num">(87,633,986)<span></span>
</td>
<td class="nump">8,990,557<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,946,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis', window );">Exercise of stock options on a cashless basis (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">46,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,568,598)<span></span>
</td>
<td class="num">(5,568,598)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,597<span></span>
</td>
<td class="nump">$ 97,446,125<span></span>
</td>
<td class="num">$ (93,202,584)<span></span>
</td>
<td class="nump">$ 4,246,138<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,963,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">Includes gross proceeds of </span><span style="font-size:9pt;">$5,984,931</span><span style="font-size:9pt;">, less total issuance costs of </span><span style="font-size:9pt;">$533,189</span><span style="font-size:9pt;">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">Includes gross proceeds of </span><span style="font-size:9pt;">$13,800,002</span><span style="font-size:9pt;">, less total issuance costs of </span><span style="font-size:9pt;">$1,304,294</span><span style="font-size:9pt;">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size:9pt;">Allocated fair value of warrants of </span><span style="font-size:9pt;">$354,539</span><span style="font-size:9pt;">, less allocated issuance costs of </span><span style="font-size:9pt;">$3,149</span><span style="font-size:9pt;">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised on cashless basis during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock exercises of warrant on cashless basis shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents common stock issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock one shares on public offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents Stock Issued During Period Value New Issues three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueNewIssuesTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance of common stock two value on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueNewIssuesTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190907448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Condensed Statements of Changes in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,002<span></span>
</td>
<td class="nump">$ 5,984,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 3,149<span></span>
</td>
<td class="nump">$ 1,304,294<span></span>
</td>
<td class="nump">$ 533,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 354,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194517368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (15,761,665)<span></span>
</td>
<td class="num">$ (15,563,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,245<span></span>
</td>
<td class="nump">71,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of PPP 7(a) loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(463,353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,071,735<span></span>
</td>
<td class="nump">1,826,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,549<span></span>
</td>
<td class="num">(231,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables', window );">License fee and expense reimbursements receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,005,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred license costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">223,068<span></span>
</td>
<td class="num">(76,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,564<span></span>
</td>
<td class="num">(172,318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(928,356)<span></span>
</td>
<td class="num">(106,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred license fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,397)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,997,807)<span></span>
</td>
<td class="num">(11,853,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,165,066)<span></span>
</td>
<td class="num">(202,046)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,165,066)<span></span>
</td>
<td class="num">(202,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of common stock and warrants in private placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,569,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,734,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,103,991<span></span>
</td>
<td class="nump">2,646,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsFromPaycheckProtectionProgramLoan', window );">Proceeds from PPP 7(a) Loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from SVB loan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(547,259)<span></span>
</td>
<td class="num">(368,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaymentsForRepurchaseOfPublicOffering', window );">Payment of offering issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(329,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of loan issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(66,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">176,802<span></span>
</td>
<td class="nump">52,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,166,916<span></span>
</td>
<td class="nump">20,767,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,995,957)<span></span>
</td>
<td class="nump">8,711,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - Beginning of Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,371,828<span></span>
</td>
<td class="nump">14,152,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - End of Period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,375,871<span></span>
</td>
<td class="nump">22,864,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract', window );"><strong>Cash and restricted cash consisted of the following:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,500,871<span></span>
</td>
<td class="nump">22,864,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,375,871<span></span>
</td>
<td class="nump">22,864,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidCapitalized', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131,839<span></span>
</td>
<td class="nump">7,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccrualOfPublicOfferingCosts', window );">Accrual of public offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable', window );">Purchase of insurance premium financed by note payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(705,360)<span></span>
</td>
<td class="num">$ (475,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IssuanceOfStockWarrants', window );">Issuance of SVB stock warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (351,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $5,984,931, less issuance costs of $415,795 deducted directly from the private placement.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccrualOfPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrual of public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccrualOfPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Amortization of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IssuanceOfStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow of issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IssuanceOfStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaymentsForRepurchaseOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaymentsForRepurchaseOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsFromPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from paycheck protection program loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsFromPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase of insurance premium financed by short term notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest capitalized, classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194472536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 13,800,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">1,066,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">5,984,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="nump">$ 415,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190741560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization, Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Organization, Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;1&#160;&#8211; Business Organization, Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Eyenovia, Inc. (&#8220;Eyenovia&#8221; or the &#8220;Company&#8221;) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP&#8482;) therapeutics. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system branded the Optejet<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, the Optejet has demonstrated the ability to horizontally deliver ophthalmic medication with a success rate significantly higher than that of traditional eye drops (~ 90% vs. ~ 50%). Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations where there are currently no comparable drug therapies approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). Eyenovia&#8217;s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October 25, 2021, the Company announced the reclassification of the Company&#8217;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, (&#8220;MydCombi&#8221; or &#8220;MicroStat&#8221;) as a drug-device combination product by the FDA in a Complete Response Letter (&#8220;CRL&#8221;) received on October 22, 2021, following a change in the agency&#8217;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. The Company believes that its other product candidates will similarly be classified by the FDA as drug-led combination products that would be subject to marketing approval via new drug applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed financial statements of the Company as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020. The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of the operating results for the full year ending December 31, 2021 or any other period. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and related disclosures of the Company as of December 31, 2020 and for the year then ended, which were included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192161864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;2&#160;&#8211; Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Since the date of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, there have been no material changes to the Company&#8217;s significant accounting policies, except as disclosed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, the Company had unrestricted cash and cash equivalents of approximately $13.5 million and an accumulated deficit of approximately <span style="-sec-ix-hidden:Hidden_eoq4WkYJv0u9e_1CVVO3Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$93.2</span></span> million. For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of approximately <span style="-sec-ix-hidden:Hidden_wncAopnaD0uKiQynCGwpOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.8</span></span> million and <span style="-sec-ix-hidden:Hidden_p4gZozmYS0S7balkCzNXaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.6</span></span> million, respectively, and used cash in operations of approximately <span style="-sec-ix-hidden:Hidden_ux28YaoNUkm5oVQ06xjkHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.0</span></span> million and <span style="-sec-ix-hidden:Hidden_XUae-FPTXkaSLR7npSF_nw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$11.9</span></span> million, respectively. Pursuant to the At-The-Market Offering (see Note 9 &#8211; Stockholders&#8217; Equity &#8211; At-The-Market Offering and Note 11 &#8211; Subsequent Events &#8211; At-The-Market Offering), the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock. The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to generate sufficient recurring revenues or the Company&#8217;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s ability to successfully commercialize its products and services, competing technological and market </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain executed agreements are recorded as Restricted Cash on the balance sheets, such as the collateralized money market account pursuant to the Loan and Security Agreement, dated May 7, 2021 with Silicon Valley Bank (&#8220;SVB&#8221;), as amended on September 29, 2021 by the First Amendment to the Loan and Security Agreement. See Note 6 - Notes Payable - Silicon Valley Bank Loan. In connection with which the Company pledged to establish and maintain a collateralized money market account in the amount of $7,875,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2021 and December 31, 2020, the Company had cash balances in excess of FDIC insurance limits of $21,125,871 and $28,121,828, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Net Loss Per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus weighted average vested but unsettled restricted stock units. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,305,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,410,540</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,095,993</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total potentially dilutive shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,532,163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506,533</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, &#8220;Collaborative Arrangements&#8221; (&#8220;ASC 808&#8221;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 1:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the contract with the customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 2:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 3:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 4:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Allocate the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 5:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Recognize revenue when the company satisfies a performance obligation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2020, the Company entered into a license agreement (the &#8220;Arctic Vision License Agreement&#8221;) with Arctic Vision (Hong Kong) Limited (&#8220;Arctic Vision&#8221;) and a license agreement (the &#8220;Bausch License Agreement&#8221;) with Bausch Health Companies, Inc. (&#8220;Bausch Health&#8221;). Each license has three revenue components: 1) an upfront license fee; 2) milestone payments; and 3) royalty payments. See Note 7 &#8211; Commitments and Contingencies for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Recently Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13 &#8220;Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU 2018-13 effective January 1, 2021. This standard did not have a material impact on the Company&#8217;s financial position, results of operations or cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Recently Issued Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02 &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2019-01 &#8220;Leases (Topic 842) Codification Improvements&#8221; in March 2019 and ASU No. 2018-10 &#8220;Codification Improvements to Topic 842, Leases&#8221; and ASU No. 2018-11 &#8220;Leases (Topic 842) Targeted Improvements&#8221; in July 2018, and ASU No. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">2018-20 &#8220;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#8221; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 3, 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2021-04, &#8220;Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&#8221; This new standard provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating ASU 2021-04 and its impact on its financial position, results of operations, and cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192171144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;3&#160;&#8211; Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll tax receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151,942</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 413,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid general&#160;and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid licenses and subscriptions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,051</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid patent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid conference expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,403</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid board of directors fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,250</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid rent and security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,004</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,123,289</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 453,478</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192621880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Accrued Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;4&#160;&#8211; Accrued Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, accrued compensation consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 895,253</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 938,873</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 288,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,799</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,184,236</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,150,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190654056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;5&#160;&#8211; Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2021 and December 31, 2020, accrued expenses and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,254</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235,355</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit card payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,204</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,002</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued franchise tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,480</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued licensing fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804,447</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expense reimbursements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,459</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,627</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 552,336</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480,692</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192039768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NotesPayableDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Note&#160;6&#160;&#8211; Notes Payable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of September 30, 2021 and December 31, 2020, notes payable consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BankDirect Capital Finance loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,101</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,101</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paycheck Protection Program loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,353</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Silicon Valley Bank loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,282,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,282,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,353</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">BankDirect Capital Finance Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On February 24, 2021, the Company issued a note payable for the purchase of a directors and officers liability insurance policy. The note payable is payable in nine monthly payments consisting of principal and interest amounting to $79,343 for an aggregate principal amount of $705,360. The note accrues interest at a rate of 2.96% per year and matures on November 24, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Paycheck Protection Program Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On May 8, 2020, the Company received cash proceeds of $463,353 pursuant to a loan provided in connection with the Paycheck Protection Program under the CARES Act (the &#8220;PPP Loan&#8221;). The PPP Loan provided for monthly installment payments of $19,508 beginning in August 2021 with the remaining balance due on May 3, 2022, the maturity date. The PPP Loan incurred interest at a fixed rate of 1.00% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the CARES Act, as amended by the Paycheck Protection Program Flexibility Act of 2020, the Company was eligible to apply for and receive forgiveness for all or a portion of its PPP Loan. The Company applied for loan forgiveness on the PPP Loan in March 2021. The Company received notification in August 2021 that it had received approval for full loan forgiveness of the PPP Loan in the amount of $463,353. The Company has recorded this extinguishment as other income in the condensed statement of operations for the three and nine months ended September 30, 2021. The Company also received notification of forgiveness of accrued interest payable of $5,738, which has been reversed from interest expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Silicon Valley Bank Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 7, 2021 (the &#8220;Effective Date&#8221;), the Company entered into a Loan and Security Agreement (the &#8220;Loan&#8221;) with Silicon Valley Bank (&#8220;SVB&#8221;) for an aggregate principal amount of up to $25.0 million. The Loan bears interest at an annual rate equal to the greater of (a) the sum of 1.25% plus the prime rate as reported in The Wall Street Journal and (b) 5.00%. The Loan is secured by all of the Company&#8217;s tangible assets. The Loan matures on May 1, 2025. The Loan requires monthly interest-only payments until June 1, 2022. The interest-only period can be extended to June 1, 2023, upon the occurrence of a milestone event. Upon the end of the interest-only </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">period, the Company will make regular monthly amortizing payments of principal and interest through the maturity date. The Loan indicates a prepayment fee of 1.0% to 3.0%, as follows: i)&#160;prepayment fee of 3.0% of the principal balance made on or prior to the first anniversary of the Effective Date; ii)&#160;prepayment fee of 2.0% of the principal balance made on or prior to the second anniversary of the Effective Date; or iii)&#160;prepayment fee of 1.0% of the principal balance made on or prior to the third anniversary of the Effective Date. The Loan also provides for a final payment. The final payment is in addition to and not a substitution for the regular monthly payments of principal plus accrued interest due on the earliest to occur of the loan maturity date, the repayment of the loan in full or the termination of the Loan Agreement, in an amount equal to the original aggregate principal amount of the multiplied by 5.0%.The Company is accreting the final payment as accrued interest over the term of the Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The initial tranche of the Loan, in the amount of $7.5 million was received by the Company on May 7, 2021. In connection with the Loan, the Company issued warrants to SVB to purchase 91,884 shares of common stock at an exercise price per share equal to $4.76. The warrants are exercisable for a period of ten years from the date of issuance. At the Company&#8217;s option, the Company has the ability to draw down the remaining $17.5 million in gross proceeds in two tranches over the next two years based upon the achievement of several milestones in accordance with the terms of the Loan. On September 29, 2021, the Company and SVB executed the First Amendment to the Loan and Security Agreement (the &#8220;Amendment&#8221;). In accordance with the Amendment, the Company must maintain a collateralized money market account in the amount of $7,875,000. The Company has recorded this amount as Restricted Cash. See Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash. This account must be maintained until the Release Event occurs (defined as when the Company has received approval by the FDA of the MydCombi product and achieved the minimum equity raise under the terms of the amended agreement, on or prior to November 30, 2021). Given the FDA&#8217;s recent reclassification of MydCombi as a drug-device combination and the need to resubmit a new drug application in early 2022, (See Note 11 - Subsequent Events), the restricted cash will become callable on November 30, 2021, at SVB&#8217;s election, to satisfy the Loan obligations. Therefore, the Loan has been fully classified as a current note payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">During the three and nine months ended September 30, 2021, the Company recorded interest expense relating to the Loan of $95,833</span> and $150,349, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company determined that the warrants should be equity-classified and that the relative fair value was $354,539, by using the Black-Scholes option pricing methodology using the following assumptions: stock price of $4.76; expected term of 10.0 years; volatility of 89.0% and a risk-free interest rate of 1.60%. The Company incurred $66,618 of debt issuance costs, of which $63,469 was allocated to the debt and $3,149 was allocated to the warrants. The relative fair value of the warrants and the issuance costs allocated to the debt were recorded as debt discount and are being amortized over the four-year term of the note. See the table below for additional details:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross loan proceeds</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt discount:</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (354,539)</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of issuance costs</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,469)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt discount </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,944</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192113224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;7&#160;&#8211; Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">See Note 8 - Related Party Transactions for certain commitments and contingencies entered into with certain related parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Litigations, Claims and Assessments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Arctic Vision License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On August 10, 2020, the Company entered into the Arctic Vision License Agreement pursuant to which Arctic Vision may develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under the terms of the Arctic Vision License Agreement, the Company received a non-refundable, upfront payment of $4.0 million, before any payments to Senju Pharmaceutical Co., Ltd. (&#8220;Senju&#8221;), due under the Exclusive License Agreement between the Company and Senju, as amended on April 8, 2020 and a Letter Agreement dated August 10, 2020 (the &#8220;Senju License Agreement&#8221;). The Company had recorded the $4.0 million payment as a deferred license fee until the payment is earned. The Company considers payment earned once certain trial data has been fully submitted to Arctic Vision, permitting Arctic Vision to seek regulatory approval with the National Medical Products Administration of China. The trial data for one of the two products (MicroPine) was fully submitted to Arctic Vision in March 2021. As a result, the Company recognized $2.0 million of deferred license fees (one-half of the $4.0 million upfront license fee) and recognized $0.8 million of deferred license costs related to the Senju payment during the three months ended March 31, 2021. The trial data for the other product (MicroLine) was fully submitted to Arctic Vision in June 2021. As a result, the Company recognized the remaining $2.0 million of deferred license fees and recognized the remaining $0.8 million of deferred license costs related to the Senju payment during the three months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In addition, the Company may receive up to a total of $43.75 million in additional payments, based on various development and regulatory milestones, including the initiation of clinical research and regulatory approvals in Greater China and South Korea (up to $39.75 million), and development costs (up to $4.0 million). In December 2020, the Company satisfied a performance obligation which resulted in the Company recognizing $2.0 million of milestone revenues, pursuant to the Arctic Vision License Agreement. The $2.0 million was received from Arctic Vision in December 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The milestone revenue referred to above includes $2.0 million related to the MicroStat product resulting from Amendment 1 to the Arctic Vision License Agreement. On September 14, 2021, the Company and Arctic Vision executed this amendment which provides for a one-time upfront payment of $250,000 and milestone payments of $2.0 million based on the achievement of filing for and receiving regulatory approval separately from China and South Korea for the MicroStat Product. The Company anticipates the Marketing Authorization Application (MAA) filings to occur in December 2023 and the receipt of regulatory approval to occur in December 2024. The Company didn&#8217;t recognize revenue for the $250,000 upfront payment because it was passed through to Senju. See Note 8 - Related Party Transactions for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Arctic Vision also will purchase its supply of MicroPine, MicroLine and MicroStat from the Company or, for such products not supplied by the Company, pay the Company a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. No royalty payments were earned through September 30, 2021. The Company will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to Senju pursuant to the Senju License Agreement. See Note 8 &#8211; Related Party Transactions- Senju License Agreement for additional details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Bausch License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On October 9, 2020, the Company entered into the Bausch License Agreement pursuant to which Bausch Health may develop and commercialize the Bausch Licensed Product in the Licensed Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In connection with the Bausch License Agreement, Bausch Health paid the Company a non-refundable, upfront payment of $10.0 million. The Company has recorded this payment as a deferred license fee until the payment is earned. The Company will consider payment earned once certain administrative functions are transferred to Bausch Health, permitting Bausch Health to assume supervisory oversight of the ongoing MicroPine study (the CHAPERONE study). The upfront payment has not been earned as of September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Bausch Health could also pay the Company up to an aggregate of approximately $35.0 million in additional payments, depending on the achievement of certain regulatory and launch-based milestones. No milestone payments were earned through September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under the terms of the Bausch License Agreement, on a country-by-country basis and Bausch Licensed Product-by- Bausch Licensed Product basis, Bausch Health will pay the Company royalties on a tiered basis (ranging from mid-single digit to mid-teen percentages) on gross profits from the sales of the Bausch Licensed Product in the Licensed Territory, subject to certain adjustments in the event of generic entry, negative gross profits or patent expiration, for a period of the later to occur of the 10th anniversary of the first commercial sale of a Bausch Licensed Product in such country in the Licensed Territory or the expiration of the last valid patent claim for a Bausch Licensed Product in such country in the Licensed Territory. No royalty payments were earned through September 30, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192196216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;8&#160;&#8211; Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Lease Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s Vice President of Research and Development and Manufacturing (&#8220;VP of R&amp;D&#8221;) owns a company that entered into a lease agreement with the Company on September&#160;15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial&#160;monthly base rent was $3,895 per&#160;month over the term of the lease and the security deposit was $3,895. On September&#160;15, 2018, the Company amended the lease agreement to extend it until September&#160;14, 2020 and increase the&#160;monthly base <span style="-sec-ix-hidden:Hidden_nuJjRqoS1k-5yZXc6XLgrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $4,012. The lease agreement was amended again on April 6, 2020 to lease additional space and increase the monthly base <span style="-sec-ix-hidden:Hidden_ZGcx3U_Ha0Oyk6Kg7P3ESg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $5,247. On September 15, 2020, the Company agreed to extend the lease term until September 14, 2022 and increase the monthly base <span style="-sec-ix-hidden:Hidden_D_hRu6Vn6kiVuoZDbI2E-w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">rent</span></span> and security deposit to $5,404. The Company made $122,298 of leasehold improvements related to this lease which are included on the balance sheet.&#160;The Company&#8217;s rent expense amounted to $16,212 and $15,982 for the three months ended September 30, 2021 and 2020, respectively, and $48,636 and $43,512 for the nine months ended September 30, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Senju License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2015, the Company entered into an Exclusive License Agreement with Senju whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its microdose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the microdose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement will continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a microdose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a microdose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a former member of the Company&#8217;s Board of Directors and, together, they beneficially own greater than 5% of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 8, 2020, the Company entered into an amendment (the &#8220;License Amendment&#8221;) to the Exclusive License Agreement. Pursuant to the License Amendment, the Company can license to any third party the right to research, develop, commercialize, manufacture or use certain products identified below (the &#8220;Senju Licensed Products&#8221;) previously licensed to Senju in China (including the People&#8217;s Republic of China, Hong Kong, Macao, and Taiwan) and South Korea (the &#8220;Territory&#8221;) if such a license was executed by the Company by April 8, 2021. The Senju Licensed Products are those using piezo-print technology in a microdose dispenser with (i) atropine sulfate as its sole active ingredient to treat myopia in humans and (ii) pilocarpine as its sole active ingredient to treat presbyopia in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Pursuant to the License Amendment, the Company must pay Senju (a) close to a mid-double digit percentage of revenue on any lump-sum payments the Company receives from the third party, revenue (net of costs) obtained by the Company from contract research and/or development of the Senju Licensed Product in the Territory, and revenue (net of costs) obtained by the Company from contract manufacture for the device of the Senju Licensed Product in the Territory, the aggregate of which must be at least a high seven figure dollar amount minimum payment to Senju; and (b) a lower-double digit percentage of any sales royalty revenue the Company receives from the third party. Since the Company executed a third-party license prior to April 8, 2021, the License Amendment will remain in effect for the duration of the license, subject to early termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Exclusive License Agreement was further amended in a Letter Agreement by and between the Company and Senju on August 10, 2020 (the &#8220;Letter Agreement&#8221;). Pursuant to the Letter Agreement, the Company will pay a mid-double digit percentage of certain payments, royalties, or net proceeds received from Arctic Vision in connection with the Arctic Vision License Agreement to Senju. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Exclusive License Agreement was amended further by the License Amendment 2, effective September 14, 2021 (the &#8220;Amendment 2&#8221;). The Amendment 2 excludes Greater China and South Korea from the territory in which Senju was granted an exclusive royalty-bearing license from the Company. In consideration for this exclusion, and upon and after the execution of Amendment 1 with Arctic Vision, the Company must make payments to Senju based on non-royalty license revenue and sales revenue, including a one-time upfront payment of $250,000 which represented an inducement to Senju to approve Amendment 1 of the Arctic Vision License Agreement related to the MicroStat product. This upfront payment to Senju was in addition to and separate from the previously established 40% payment on milestone revenue. See Note 7 &#8211; Commitments and Contingencies &#8211; Arctic Vision License Agreement for additional details.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190531832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;9&#160;&#8211; Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Securities Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 24, 2020, the Company closed on a private placement of approximately $6.0 million of Units. Each Unit consists of (i) one share of the Company&#8217;s common stock, (ii) a one-year warrant to purchase 0.5 of a share of common stock (&#8220;Class A Warrant&#8221;), and (iii) a five-year warrant to purchase 0.75 of a share of common stock (&#8220;Class B Warrant&#8221;) (collectively, the Class A Warrants and Class B Warrants, the &#8220;Warrants&#8221;). The Units were sold to the public at a price of $2.21425 per Unit and to certain directors and executive officers at a price of $2.42625 per Unit. The Company generated approximately $5.45 million of net proceeds in the offering after deducting placement agent fees and offering expenses of $0.53 million. In the offering, the Company issued an aggregate of 2,675,293 shares of common stock, Class A Warrants to purchase up to 1,337,659 shares of common stock, and Class B Warrants to purchase up to 2,006,495 shares of common stock. The exercise price of the Class A Warrants issued to the public is $2.058 per share and the exercise price of the Class A Warrants issued to the directors and officers is $2.27 per share. The exercise price of the Class B Warrants issued to the public is $2.4696 per share and the exercise price of the Class B Warrants issued to the directors and officers is $2.724 per share. See &#8220;Warrants&#8221; below for additional details. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">In connection with the private placement, on March 23, 2020, the Company also entered into a Registration Rights Agreement with the investors. Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC, no later than 30 days following the date on which the Company files its Form 10-K for the year ended December 31, 2019 with the SEC, a registration statement on Form S-3 covering the shares of common stock issued in the offering and the shares of common stock underlying the Warrants. The Company timely filed the registration statement on Form S-3 (Registration Statement No. 333-237790), which was declared and has remained effective with the SEC since May 13, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.81%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.26% - 0.69%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.45% - 1.58%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.26% - 1.32%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">92%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">98% - 99%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">92% - 94%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">96% - 99%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221; method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company uses a blended volatility calculation, the components of which are the Company&#8217;s historical volatility for the period from its initial public offering through the valuation date and the average peer-group data of six comparable entities to supplement the Company&#8217;s own historical data for the preceding years in computing the expected volatility. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The weighted average estimated grant date fair value of the stock options granted for the three months ended September 30, 2021 and 2020 was approximately $3.56 and $2.71 per share, respectively. The weighted average estimated grant date fair value of the stock options granted for the nine months ended September 30, 2021 and 2020 was approximately $4.16 and $2.24 per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June&#160;17, 2021, an employee exercised an option to purchase common shares on a cashless basis, which resulted in 13,675 shares being withheld and not issued, to cover the cost to exercise and all payroll taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A summary of the option activity during the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,427,705</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.37</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,003,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> (121,261)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 54pt;"><span style="font-size:9.5pt;"> 2.07</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 4,305,980</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.89</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 6,253,367</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 2,364,074</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;">3.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 6.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,448,222</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table presents information related to stock options as of September 30, 2021: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,636</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.72</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 764,419</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0pjWYEGDNkentV_xYyZQGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 318,509</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.89</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0rah1dwiwUKGvejQzLqdgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,868</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 656,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,301</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,920</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,644</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,001</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"> 8.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,723</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,890</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,196</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 222,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,833</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,637</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,668</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.01</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 652,899</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,387</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,918</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,305,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,364,074</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Restricted Stock Units </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:none;">On September 11, 2020 and March 31, 2021, the Company granted members of its Board of Directors an aggregate of </span><span style="text-decoration:none;">44,951</span><span style="text-decoration:none;"> RSUs under its Amended and Restated 2018 Omnibus Stock Incentive Plan. Each RSU is subject to settlement into </span><span style="text-decoration:none;">one</span><span style="text-decoration:none;"> share of the Company&#8217;s common stock. The RSUs provided that vesting would occur on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2021 annual stockholders meeting, subject to the grantee remaining on the Board until then. The 2021 annual stockholders meeting took place on June 16, 2021 which triggered the vesting of the RSUs. The RSUs had an aggregate grant date fair value of </span><span style="text-decoration:none;">$156,200</span><span style="text-decoration:none;">, which was recognized over the vesting period.</span><span style="text-decoration:underline;"> </span><span style="text-decoration:none;">Pursuant to the terms of the grants, vested RSUs are not issued until (a) termination of the director&#8217;s service to the Company; or (b) upon a change-of-control transaction (as specified). </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Stock-Based Compensation Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded stock-based compensation expense related to stock options and RSUs. During the three months ended September 30, 2021 and 2020, the Company recorded expense of $777,467 ($489,121 of which was included within research and development expenses and $288,346 of which was included within general and administrative expenses on the condensed statement of operations) and $609,930 ($346,294 of which was included within research and development expenses and $263,636 of which was included within general and administrative expenses on the condensed statement of operations), respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of $2,071,735 ($1,138,331 of which was included within research and development expenses and $933,404 was included within general and administrative expenses on the condensed statement of operations) and $1,826,941 ($1,002,150 of which was included within research and development expenses and $824,791 was included within general and administrative expenses on the condensed statement of operations), respectively. As of September 30, 2021, there was $5,787,351 of unrecognized stock-based compensation expense which the Company expects to recognize over a weighted average period of 2.1 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of warrant activity for the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,011,313</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (877,014)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.40</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714,617</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents information related to Warrants as of September 30, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:67.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warants Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$2.4696 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 917,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 917,919</p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$2.7240 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,380</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$4.7600 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 6 &#8211; Notes Payable &#8211; for details on the warrant issued in connection with the SVB loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended September 30, 2020, warrants for the purchase of 1,080,497 shares of the Company&#8217;s common stock, with exercise prices of either $2.058 or $2.4696 per share, were exercised for aggregate proceeds of approximately $2.3 million, while no warrants were exercised during the three months ended September 30, 2021. During the nine months ended September 30, 2021 and 2020, warrants for the purchase of 877,014 and 1,248,161 shares of the Company&#8217;s common stock, respectively, with exercise prices of either $2.058 or $2.4696 per share, were exercised for aggregate proceeds of approximately $2.1 million and <span style="-sec-ix-hidden:Hidden_MimNBTPoWU-6QCm4o9Gk6Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$2.6</span></span> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">At-The-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May&#160;14, 2021, the Company entered into a Sales Agreement (the &#8220;Agreement&#8221;) with SVB Leerink LLC (&#8220;SVB Leerink&#8221;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $30 million through SVB Leerink as its sales agent. Subject to the terms and conditions of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Agreement, SVB Leerink may sell the Common Stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221;. SVB Leerink will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay SVB Leerink a commission equal to three percent (3.0%) of the gross sales proceeds of any Common Stock sold through SVB Leerink under the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is not obligated to make any sales of Common Stock under the Agreement. through September 30, 2021, the Company had not sold any shares of common stock under the Agreement. See Note 11 - Subsequent Events - At-The-Market Offering for additional details.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190746984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note&#160;10&#160;&#8211; Employee Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">401(k) Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;">In April 2019, the Company adopted the Eyenovia 401(k) Plan (the &#8220;Plan&#8221;), which went into effect in May 2019. All Company employees are able to participate in the Plan, subject to eligibility requirements as outlined in the Plan documents. Under the terms of the Plan, eligible employees are able to defer a percentage of their pay every pay period up to annual limitations set by Congress and the Internal Revenue Service under Section 401(k) of the Internal Revenue Code. For 2021 and 2020, the Company&#8217;s Board of Directors has approved a matching contribution equal to </span><span style="font-weight:normal;">100%</span><span style="font-weight:normal;"> of elective deferrals up to </span><span style="font-weight:normal;">4%</span><span style="font-weight:normal;"> of eligible earnings with the matching contribution subject to certain vesting requirements as outlined in the Plan documents. During the three months ended September 30, 2021 and 2020, the Company recorded expense of </span><span style="font-weight:normal;">$34,076</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$25,535</span><span style="font-weight:normal;"> associated with its matching contributions, respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded expense of </span><span style="font-weight:normal;">$144,917</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$106,021</span><span style="font-weight:normal;"> associated with its matching contributions, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192129528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 11 &#8211; Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">At-The-Market Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the At-The-Market Offering (see Note 9 &#8211; Stockholders&#8217; Equity &#8211; At-The-Market Offering) the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">MydCombi FDA Application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 25, 2021, the Company announced the reclassification of the Company&#8217;s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, MydCombi, as a drug-device combination product by the FDA in a CRL received on October 22, 2021, following a change in the agency&#8217;s legal interpretation of its authorities imposed by a recent court ruling. The Company is preparing the necessary documents for expedited resubmission of the new drug application for MydCombi in response to the CRL. See Note 1 &#8211; Business Organization, Nature of Operations and Basis of Presentation and Note 6 &#8211; Notes Payable &#8211; Silicon Valley Bank Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Employee Stock Options</span><span style="text-decoration:underline;text-decoration-color:#000000;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 27, 2021, the Company granted ten-year stock options to employees, pursuant to its Amended and Restated 2018 Omnibus Stock Incentive Plan, to purchase an aggregate of 35,000 shares of the Company&#8217;s common stock at an exercise price of $4.06 per share. The options expire on the tenth anniversary of the grant date and they vest with respect to one-third of the shares underlying the awards on the first anniversary of the grant date and, with respect to the remaining two-thirds of the shares underlying the awards, in equal monthly installments over the subsequent two years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192102472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Liquidity and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of September 30, 2021, the Company had unrestricted cash and cash equivalents of approximately $13.5 million and an accumulated deficit of approximately <span style="-sec-ix-hidden:Hidden_eoq4WkYJv0u9e_1CVVO3Uw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$93.2</span></span> million. For the nine months ended September 30, 2021 and 2020, the Company incurred net losses of approximately <span style="-sec-ix-hidden:Hidden_wncAopnaD0uKiQynCGwpOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.8</span></span> million and <span style="-sec-ix-hidden:Hidden_p4gZozmYS0S7balkCzNXaw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.6</span></span> million, respectively, and used cash in operations of approximately <span style="-sec-ix-hidden:Hidden_ux28YaoNUkm5oVQ06xjkHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$15.0</span></span> million and <span style="-sec-ix-hidden:Hidden_XUae-FPTXkaSLR7npSF_nw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$11.9</span></span> million, respectively. Pursuant to the At-The-Market Offering (see Note 9 &#8211; Stockholders&#8217; Equity &#8211; At-The-Market Offering and Note 11 &#8211; Subsequent Events &#8211; At-The-Market Offering), the Company commenced sales of its common stock on October 6, 2021. As of the filing date, the Company has received approximately $12.8 million in gross proceeds and $12.4 million in net proceeds from the sale of 2,435,604 shares of its common stock. The Company does not have recurring revenue and has not yet achieved profitability. The Company expects to continue to incur cash outflows from operations. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, it will eventually need to generate significant product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern for at least one year from the date that these financial statements are issued. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to generate sufficient recurring revenues or the Company&#8217;s ability to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s ability to successfully commercialize its products and services, competing technological and market </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its product and service offerings. If the Company is unable to generate sufficient recurring revenues or secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less to be cash equivalents in the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain executed agreements are recorded as Restricted Cash on the balance sheets, such as the collateralized money market account pursuant to the Loan and Security Agreement, dated May 7, 2021 with Silicon Valley Bank (&#8220;SVB&#8221;), as amended on September 29, 2021 by the First Amendment to the Loan and Security Agreement. See Note 6 - Notes Payable - Silicon Valley Bank Loan. In connection with which the Company pledged to establish and maintain a collateralized money market account in the amount of $7,875,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company has cash deposits in a financial institution which, at times, may be in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2021 and December 31, 2020, the Company had cash balances in excess of FDIC insurance limits of $21,125,871 and $28,121,828, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Net Loss Per Common Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period, plus weighted average vested but unsettled restricted stock units. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,305,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,410,540</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,095,993</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total potentially dilutive shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,532,163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506,533</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our revenues are generated primarily through research, development and commercialization agreements. The terms of such agreements may contain multiple promised goods and services, which may include (i) licenses to our intellectual property, and (ii) in certain cases, payment in connection with the manufacturing and delivery of clinical supply materials. Payments to us under these arrangements typically include one or more of the following: non-refundable, upfront license fees; milestone payments; payments for clinical product supply, and royalties on future product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We analyze our arrangements to assess whether such arrangements involve joint operating activities. For collaboration arrangements that are deemed to be within the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, &#8220;Collaborative Arrangements&#8221; (&#8220;ASC 808&#8221;), we allocate the contract consideration between such joint operating activities and elements that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;). Our policy is to recognize amounts allocated to joint operating activities as a reduction in research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under ASC 606, we recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 1:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the contract with the customer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 2:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Identify the performance obligations in the contract;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 3:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Determine the transaction price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 4:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Allocate the transaction price to the performance obligations in the contract; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;text-decoration:underline;text-decoration-color:#000000;">Step 5:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Recognize revenue when the company satisfies a performance obligation.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We must make significant judgments in our revenue recognition process, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation. In addition, arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered discretionary purchase options. We assess if these options provide a material right to the customer and if so, they are considered performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For upfront license fees, we must consider how many performance obligations are in the contract and, if more than one, how to allocate the fee to those performance obligations upon satisfaction of the performance obligation(s). Milestone payments represent variable consideration that will be recognized when the performance obligation is achieved. Sales-based royalty payments derived from usage of intellectual property are recognized when those sales occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2020, the Company entered into a license agreement (the &#8220;Arctic Vision License Agreement&#8221;) with Arctic Vision (Hong Kong) Limited (&#8220;Arctic Vision&#8221;) and a license agreement (the &#8220;Bausch License Agreement&#8221;) with Bausch Health Companies, Inc. (&#8220;Bausch Health&#8221;). Each license has three revenue components: 1) an upfront license fee; 2) milestone payments; and 3) royalty payments. See Note 7 &#8211; Commitments and Contingencies for additional details.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="text-decoration:underline;text-decoration-color:#000000;">Recently Adopted Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In August 2018, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13 &#8220;Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement&#8221; (&#8220;ASU 2018-13&#8221;). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the FASB Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. The Company adopted ASU 2018-13 effective January 1, 2021. This standard did not have a material impact on the Company&#8217;s financial position, results of operations or cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration:underline;">Recently Issued Accounting Standards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02 &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. ASU 2016-02, as amended, is now effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The FASB issued ASU No. 2019-01 &#8220;Leases (Topic 842) Codification Improvements&#8221; in March 2019 and ASU No. 2018-10 &#8220;Codification Improvements to Topic 842, Leases&#8221; and ASU No. 2018-11 &#8220;Leases (Topic 842) Targeted Improvements&#8221; in July 2018, and ASU No. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">2018-20 &#8220;Leases (Topic 842) - Narrow Scope Improvements for Lessors&#8221; in December 2018. ASU 2019-01, ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 3, 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2021-04, &#8220;Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.&#8221; This new standard provides clarification and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating ASU 2021-04 and its impact on its financial position, results of operations, and cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190493896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive weighted average diluted common shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,305,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,410,540</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,095,993</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total potentially dilutive shares</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,532,163</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,506,533</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192635000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll tax receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 151,942</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 413,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110,094</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,542</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid general&#160;and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid licenses and subscriptions</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,440</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,051</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid patent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid conference expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,041</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,403</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid board of directors fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,250</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid rent and security deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,254</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,004</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,734</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,123,289</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 453,478</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190780024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DisclosureOfAccruedCompensationTableTextBlock', window );">Schedule of accrued compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued bonus expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 895,253</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 938,873</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 288,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,799</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,184,236</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,150,672</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DisclosureOfAccruedCompensationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DisclosureOfAccruedCompensationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192107528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181,241</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 348,254</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued consulting and professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 243,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235,355</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Credit card payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,204</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50,002</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued franchise tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,480</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued licensing fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804,447</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,068</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued expense reimbursements</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,441</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,459</p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,627</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses and other current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 552,336</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,480,692</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147190558024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ScheduleOfNotesPayableTableTextBlock', window );">Schedule of notes payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of September 30, 2021 and December 31, 2020, notes payable consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Portion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BankDirect Capital Finance loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,101</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,101</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paycheck Protection Program loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,353</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Silicon Valley Bank loan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,282,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,282,037</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 365,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 463,353</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gross loan proceeds</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Debt discount:</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (354,539)</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Relative fair value of issuance costs</p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (63,469)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt discount </p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,944</p></td></tr><tr><td style="vertical-align:bottom;width:82.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123,936</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ScheduleOfNotesPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ScheduleOfNotesPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192171144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option pricing model to stock options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.85 - 10.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.81%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.26% - 0.69%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.45% - 1.58%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.26% - 1.32%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">92%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">98% - 99%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">92% - 94%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">96% - 99%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.00%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of the stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A summary of the option activity during the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January&#160;1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,427,705</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.37</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,003,536</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> (121,261)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:middle;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 54pt;"><span style="font-size:9.5pt;"> 2.07</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 4,305,980</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.89</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 6,253,367</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 2,364,074</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;">3.50</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:9.5pt;"> 6.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,448,222</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of information related to stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table presents information related to stock options as of September 30, 2021: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;width:49.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.24</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 567,636</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.72</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 764,419</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0pjWYEGDNkentV_xYyZQGA;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 318,509</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.89</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 253,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0rah1dwiwUKGvejQzLqdgw;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:right;"> 8.7</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,868</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 656,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468,301</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,920</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,644</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,001</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 3.75pt 0.05pt 0pt;"> 8.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,723</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,890</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.53</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 127,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,196</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.81</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 222,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,833</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,637</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,500</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.25</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,668</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.0</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,668</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.01</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 652,899</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,387</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300,387</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,918</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,305,980</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,364,074</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Warrant activity and related information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of warrant activity for the nine months ended September 30, 2021 is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,011,313</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.43</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (877,014)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.40</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714,617</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable September 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,714,617</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents information related to Warrants as of September 30, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:67.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warants Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:top;width:51.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">In&#160;Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$2.4696 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 917,919</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 917,919</p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$2.7240 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 216,380</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">$4.7600 </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.6</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91,884</p></td></tr><tr><td style="vertical-align:top;width:51.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,226,183</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192639784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization, Nature of Operations and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfSuccessRateOfOptejet', window );">Percentage Of Success Rate Of Optejet</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops', window );">Percentage of Successful Rate of Traditional Eye Drops</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfSuccessRateOfOptejet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This refers percentage of success rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfSuccessRateOfOptejet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents successful percentage rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192693560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">5,532,163<span></span>
</td>
<td class="nump">5,506,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">4,305,980<span></span>
</td>
<td class="nump">3,410,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="nump">1,226,183<span></span>
</td>
<td class="nump">2,095,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147197913256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Unrestricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,864,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,871<span></span>
</td>
<td class="nump">$ 22,864,578<span></span>
</td>
<td class="nump">$ 28,371,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Amount pledged to establish and maintain a collateralized money market account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,202,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,202,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,440,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,568,598)<span></span>
</td>
<td class="num">$ (4,841,400)<span></span>
</td>
<td class="num">$ (5,351,667)<span></span>
</td>
<td class="num">$ (5,096,530)<span></span>
</td>
<td class="num">$ (5,015,565)<span></span>
</td>
<td class="num">$ (5,450,910)<span></span>
</td>
<td class="num">(15,761,665)<span></span>
</td>
<td class="num">(15,563,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,997,807)<span></span>
</td>
<td class="num">$ (11,853,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,125,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,125,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,121,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | At Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">2,435,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution net of issuance costs to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147286545208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PayrollTaxesReceivable', window );">Payroll tax receivable</a></td>
<td class="nump">$ 297,494<span></span>
</td>
<td class="nump">$ 151,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">413,648<span></span>
</td>
<td class="nump">110,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">30,542<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidGeneralAndAdministrativeExpenses', window );">Prepaid general and administrative expenses</a></td>
<td class="nump">105,941<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidLicensesAndSubscriptions', window );">Prepaid licenses and subscriptions</a></td>
<td class="nump">31,440<span></span>
</td>
<td class="nump">57,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidPatentExpense', window );">Prepaid Patent Expense</a></td>
<td class="nump">34,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidConferenceExpenses', window );">Prepaid conference expenses</a></td>
<td class="nump">52,041<span></span>
</td>
<td class="nump">29,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidDirectorFeesCurrent', window );">Prepaid board of directors fees</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">68,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidRentAndSecurityDeposit', window );">Prepaid rent and security deposit</a></td>
<td class="nump">32,254<span></span>
</td>
<td class="nump">25,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other</a></td>
<td class="nump">48,120<span></span>
</td>
<td class="nump">11,734<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,123,289<span></span>
</td>
<td class="nump">$ 453,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PayrollTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Payroll Taxes Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PayrollTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidConferenceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets related to prepaid conference expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidConferenceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidDirectorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of director fees prepaid, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidDirectorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Prepaid general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidLicensesAndSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid licenses and subscriptions, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidLicensesAndSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid patent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidRentAndSecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidRentAndSecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192642136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Accrued Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expenses</a></td>
<td class="nump">$ 895,253<span></span>
</td>
<td class="nump">$ 938,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll expenses</a></td>
<td class="nump">288,983<span></span>
</td>
<td class="nump">211,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total accrued compensation</a></td>
<td class="nump">$ 1,184,236<span></span>
</td>
<td class="nump">$ 1,150,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194192536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 181,241<span></span>
</td>
<td class="nump">$ 348,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedConsultingAndProfessionalServicesCurrent', window );">Accrued consulting and professional services</a></td>
<td class="nump">243,979<span></span>
</td>
<td class="nump">235,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_CreditCardPayable', window );">Credit card payable</a></td>
<td class="nump">44,204<span></span>
</td>
<td class="nump">50,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedFranchiseTax', window );">Accrued franchise tax</a></td>
<td class="nump">39,300<span></span>
</td>
<td class="nump">32,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedLicensingFees', window );">Accrued licensing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">804,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">31,250<span></span>
</td>
<td class="nump">3,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpenseReimbursements', window );">Accrued expense reimbursements</a></td>
<td class="nump">6,441<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5,921<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 552,336<span></span>
</td>
<td class="nump">$ 1,480,692<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedConsultingAndProfessionalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and professional service, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedConsultingAndProfessionalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expense reimbursements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedFranchiseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued franchise tax expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedFranchiseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedLicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued licensing fees, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedLicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_CreditCardPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of credit card expenses payable by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_CreditCardPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147281219144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Schedule of notes payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="nump">$ 7,282,037<span></span>
</td>
<td class="nump">$ 97,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">7,282,037<span></span>
</td>
<td class="nump">463,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eyen_BankDirectCapitalFinanceLoanMember', window );">BankDirect Capital Finance loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="nump">158,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">158,101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current Portion</a></td>
<td class="nump">7,123,936<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-Current Portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="nump">$ 7,123,936<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eyen_BankDirectCapitalFinanceLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eyen_BankDirectCapitalFinanceLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eyen_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147193412184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Schedule of debt discount Note payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsNetAlternativeAbstract', window );"><strong>Debt discount:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Relative fair value of warrants</a></td>
<td class="num">$ (354,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Relative fair value of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (66,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,282,037<span></span>
</td>
<td class="nump">$ 463,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,282,037<span></span>
</td>
<td class="nump">97,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Gross loan proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsNetAlternativeAbstract', window );"><strong>Debt discount:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Relative fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(354,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Relative fair value of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,123,936<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,123,936<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable - non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Amortization of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsNetAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsNetAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eyen_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147183710584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 07, 2021</div></th>
<th class="th"><div>Feb. 24, 2021</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 547,259<span></span>
</td>
<td class="nump">$ 368,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amount pledged to establish and maintain a collateralized money market account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfMonthlyPayments', window );">Number of monthly payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Aggregate principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 24,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember', window );">Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Cash proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaycheckProtectionProgramLoanPrincipalForgiveness', window );">Amount of principal forgiveness on PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 463,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness', window );">Amount of accrued interest forgiveness on PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DebtInstrumentPrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">May  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Debt instrument effective stated rate</a></td>
<td class="text">1.25% plus the prime rate <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OriginalPrincipalLoanPercentage', window );">Aggregate loan percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants for purchase of common stock</a></td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_WarrantExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Loan received</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amount pledged to establish and maintain a collateralized money market account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Prior to First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaymentOfLoanFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Prior to Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaymentOfLoanFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Prior to Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaymentOfLoanFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaymentOfLoanFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember', window );">Silicon Valley Bank loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaymentOfLoanFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfMonthlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of monthly payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfMonthlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OriginalPrincipalLoanPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of original principal loan percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OriginalPrincipalLoanPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of  accrued interest  forgiveness on paycheck protection program loan,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PaycheckProtectionProgramLoanPrincipalForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal forgiveness on paycheck protection program loan,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PaycheckProtectionProgramLoanPrincipalForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaymentOfLoanFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of prepayment of loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaymentOfLoanFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_WarrantExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time on warrant exercisable term, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_WarrantExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=eyen_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=eyen_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PeriodAxis=eyen_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PeriodAxis=eyen_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PeriodAxis=eyen_SecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PeriodAxis=eyen_SecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PeriodAxis=eyen_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PeriodAxis=eyen_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194533928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 14, 2021</div></th>
<th class="th"><div>Oct. 09, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember', window );">Arctic Vision License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredLicenseFees', window );">Deferred license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredLicenseCost', window );">Deferred license cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments', window );">Initiation of clinical research and regulatory approval payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementThresholdDevelopmentCosts', window );">Development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyRevenuePayments', window );">Royalty payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneRevenuePayments', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneRevenuePaymentsReceived', window );">Milestone payments received</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneUpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember', window );">Bausch License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable', window );">Maximum additional payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyRevenuePayments', window );">Royalty payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneRevenuePayments', window );">Milestone payments earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_SenjuLicenseAgreementMember', window );">Senju License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementsUpfrontPaymentsReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_DeferredLicenseFees', window );">Deferred license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredLicenseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Deferred license cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredLicenseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_DeferredLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to deferred license fees .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_DeferredLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementThresholdDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of development costs incurred by the company pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementThresholdDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount incurred by the company on clinical research and regulatory approval payments  pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional payments receivable by the company pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementsUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received by the entity, pursuant to a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementsUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MilestoneRevenuePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone revenue payment earned during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MilestoneRevenuePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MilestoneRevenuePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone revenue payment received during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MilestoneRevenuePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MilestoneUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone upfront payment during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MilestoneUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyRevenuePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty revenue payment earned during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyRevenuePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_BauschLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_SenjuLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_SenjuLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194554392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember', window );">Arctic Vision License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneUpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=eyen_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority Interest Ownership Percentage In Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember', window );">Vice President of Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,212<span></span>
</td>
<td class="nump">$ 15,982<span></span>
</td>
<td class="nump">48,636<span></span>
</td>
<td class="nump">$ 43,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,404<span></span>
</td>
<td class="nump">5,247<span></span>
</td>
<td class="nump">4,012<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="nump">$ 5,247<span></span>
</td>
<td class="nump">$ 4,012<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember', window );">Senju Pharmaceutical Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyPercentage', window );">Royalty Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MilestoneUpfrontPayments', window );">Upfront payments</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfMilestonePaymentRevenue', window );">Percentage of milestone payment revenue</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base rent per month for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MilestoneUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone upfront payment during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MilestoneUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfMilestonePaymentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of milestone payment revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfMilestonePaymentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the percentage rate of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eyen_ArcticVisionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eyen_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eyen_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192659208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Black Scholes option (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.81%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.45%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
<td class="nump">1.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147281278632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of option activity (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="nump">3,427,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted | Shares</a></td>
<td class="nump">1,003,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Exercised | Shares</a></td>
<td class="num">(121,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options Forfeited | Shares</a></td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding | Shares</a></td>
<td class="nump">4,305,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Exercisable | Shares</a></td>
<td class="nump">2,364,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="nump">$ 3.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / Shares</a></td>
<td class="nump">5.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / Shares</a></td>
<td class="nump">2.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / Shares</a></td>
<td class="nump">2.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / Shares</a></td>
<td class="nump">3.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / Shares</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 6,253,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 4,448,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194676888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of information related to stock options (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">4,305,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">2,364,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember', window );">Exercise Price 1.24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember', window );">Exercise Price 1.95 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">567,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">567,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember', window );">Exercise Price 2.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">764,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">318,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember', window );">Exercise Price 2.74 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember', window );">Exercise Price 2.89 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">253,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">106,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember', window );">Exercise Price 3.11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">656,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">468,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember', window );">Exercise Price 3.43 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">58,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">19,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember', window );">Exercise Price 3.48 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">15,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember', window );">Exercise Price 3.71 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">16,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember', window );">Exercise Price 4.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember', window );">Exercise Price 4.53 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwelveMember', window );">Exercise Price 4.68 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">13,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThirteenMember', window );">Exercise Price 4.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourteenMember', window );">Exercise Price 5.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">5,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFifteenMember', window );">Exercise Price 5.11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixteenMember', window );">Exercise Price 5.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSeventeenMember', window );">Exercise Price 5.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEighteenMember', window );">Exercise Price 5.77 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineteenMember', window );">Exercise Price 6.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">652,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyMember', window );">Exercise Price 6.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">300,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">300,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyOneMember', window );">Exercise Price 6.30 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyTwoMember', window );">Exercise Price Twenty 8.72 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Outstanding, Outstanding Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">166,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">166,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147194527976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,011,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightGranted', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercised', window );">Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,080,497)<span></span>
</td>
<td class="num">(877,014)<span></span>
</td>
<td class="num">(1,248,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding at ending balance</a></td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of warrants</a></td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding at ending balance</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 2,714,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,714,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 2,714,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,714,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147281280728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional information related to Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,011,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercised', window );">Number of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,080,497<span></span>
</td>
<td class="nump">877,014<span></span>
</td>
<td class="nump">1,248,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,103,991<span></span>
</td>
<td class="nump">$ 2,646,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember', window );">Warrants at exercise price of $2.4696</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">917,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">917,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember', window );">Warrants at exercise price of $2.7240</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 2.7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 2.7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember', window );">Warrants at exercise price of $4.7600</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding Number of Warrants</a></td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife', window );">Weighted Average Remaining Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightExercisable', window );">Exercisable Number of Warrants</a></td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147183259656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 11, 2020</div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 777,467<span></span>
</td>
<td class="nump">$ 637,355<span></span>
</td>
<td class="nump">$ 656,913<span></span>
</td>
<td class="nump">$ 609,930<span></span>
</td>
<td class="nump">$ 633,146<span></span>
</td>
<td class="nump">$ 583,865<span></span>
</td>
<td class="nump">$ 2,071,735<span></span>
</td>
<td class="nump">$ 1,826,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071,735<span></span>
</td>
<td class="nump">1,826,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock - based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,787,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,787,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,802<span></span>
</td>
<td class="nump">52,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,103,991<span></span>
</td>
<td class="nump">$ 2,646,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,138,331<span></span>
</td>
<td class="nump">$ 1,002,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933,404<span></span>
</td>
<td class="nump">$ 824,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember', window );">Class A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember', window );">Class A Warrants [Member] | Directors And Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember', window );">Class B Warrants [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,006,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember', window );">Class B Warrants [Member ] | Directors And Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=eyen_StockOptionsMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate number of shares issued including over-allotment option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_UnitsIssuedPricePerUnit', window );">Units issued price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.21425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfCommonStock', window );">Net Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Directors And Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_UnitsIssuedPricePerUnit', window );">Units issued price per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.42625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Class A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">No. of common stock per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock', window );">Warrant to purchase common stock in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Class B Warrants [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">No. of common stock per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock', window );">Warrant to purchase common stock in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember', window );">At Market Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_FairValueOfCommonStock', window );">Aggregate offering price</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PercentageOfGrossSalesOnCommonStock', window );">Percentage on gross sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member', window );">Omnibus Stock Incentive Plan 2018 [Member] | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NumberOfCommonShares', window );">Number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,951<span></span>
</td>
<td class="nump">44,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember', window );">Warrants at exercise price of $2.4696</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember', window );">Warrants at exercise price of $4.7600</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about number of years warrant to purchase share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_FairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_FairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about number of share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PercentageOfGrossSalesOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate gross sale on common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PercentageOfGrossSalesOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_UnitsIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_UnitsIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=eyen_DirectorsAndExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=eyen_DirectorsAndExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=eyen_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=eyen_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=eyen_WarrantsAtExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147192127000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</a></td>
<td class="nump">$ 34,076<span></span>
</td>
<td class="nump">$ 25,535<span></span>
</td>
<td class="nump">$ 144,917<span></span>
</td>
<td class="nump">$ 106,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140147281246408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Oct. 27, 2021</div></th>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Mar. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | At Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock in public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,435,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock Options | Omnibus Stock Incentive Plan 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Period of employees stock options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock Options | Omnibus Stock Incentive Plan 2018 [Member] | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Employee Stock Options | Omnibus Stock Incentive Plan 2018 [Member] | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting rights</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution net of issuance costs to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eyen_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eyen_OmnibusStockIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eyen_OmnibusStockIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M.8)L4P\)>0Y%!0  (A8  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
M6%USXC84?=[^"@WM=-J9$-LRX6-+F"$D:9G=$!+2[*1OPA;8L[;$RG((_[Y7
M-M@D8Z[=OH"_[M'1U=4YDH9;J;XG >>:O,612"Y;@=:;SY:5> &/67(N-US
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MX]EJAPF^_H T 7A_(X1^G9@#MGFA"E\ 4$L#!!0    ( #F";%/;U$US0@4
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M(WFZGVM8!!^]D=!OB1%TZQ5N)% A;>;$(?HKKL&?<)L\(9+3F$;Z68NM#+A
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M>KSEXED6  J]EI3)B5,H5=VXKLP**+&\YA4PO;/BHL1*3\7:E94 G%M02=W
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M8Q4:_ N4NXQ! K#.3<RR$OM[FVP+U3EUG47-'NX.#'T_7H[IAT5J>YFGN;9
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M>JMTF:N_.=IX[R!Q5:I;S_K!UL!L\*M!R@58SE535L;7E<UJ4,ZT7S(U_F!
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MS9G9Q12(0;:9@TA)'JI\#6OP(2+$?BBJEQKFKDCAK3":#R'.\DIO0 I'-][
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MO(6/F:DWA$VLL,.Z82N9XJDB NX3<]1X(Y^4N:M.9=AF*.8%3/W2KHE$F%[
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M6_''I='(I;0 W\^=J^,?=$#[_S1>_0M02P,$%     @ .8)L4^3$IW=' P
MO @  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&ULM5;?;]LV$/Y7"&W8
MDQ!1%!7;J6T@23ML#UV-9EN?:>ED$95(C:3CY+_?D9)EI7:" MU>3/%X]]UW
M/\CS\J#-5UL#./+4-LJNHMJY[B9);%%#*^R5[D#A2:5-*QQNS2ZQG0%1!J.V
M21BEUTDKI(K6RR#;F/52[UTC%6P,L?NV%>;Y#AI]6$5I=!1\EKO:>4&R7G9B
M!P_@_NHV!G?)B%+*%I256A$#U2JZ36_NN-</"G]+.-C)-_&1;+7^ZC>_EZN(
M>D+00.$\@L#E$>ZA:3P0TOAGP(Q&E]YP^GU$_S7$CK%LA85[W7R1I:M7T3PB
M)51BW[C/^O ;#/'D'J_0C0V_Y-#K<A:18F^=;@=C9-!*U:_B:<C#Q&!.7S%@
M@P$+O'M'@>5[X<1Z:?2!&*^-:/XCA!JLD9Q4OB@/SN"I1#NWWACHA"S)AR<L
MLP5+A"K))U>#(?=[8T Y<FLM.+M,'+KS1DDQ0-_UT.P5Z 7YJ)6K+?F@2BA?
MVB=(<^3*CESOV)N #]!=D8S&A%&6OH&7C;%G 2_[;V-_X8N/OGCPQ?^//+\-
M_8=V0#+RRT]SEJ;OR'=[PH7HBF!6';1;/#ZF-EB\AV*0ID&*9]V #%-D'9"+
M 5GTR(7&6VL=E-X!*I!*-WC]I=K=!)XT>_?#ZTO>+^@>54(PGCO9B&>#%(@3
M3_B4%" ?Q;:!4?%GPA:SF"_X1)+F:;S@;,RG5'9OA"K@%/^WE'B:Q==\?B9/
M4QI3!#]"&; @3%&'!);PB$]CU_KTG2%C:#ERF *F[%3C'2@PH@DXHL3G 9-N
MA'_G7B>9TASC2B_F=8K=R.)49;O?VL+(SK^DYY"8<\[IF3B?Q31/1\!.N(LQ
MCB@\GM/%J_4^PF!O58#-]E8A<A;3"R&R1<QI-B)MM3"A0TN)/>&TL:2""V@S
MC(.>AW<]CUE.)T7U_>]S!7@;I'O&RG;:2G<*D*'!J<58CK!\N)IC"\WCE-%)
MY\2SC),_M<,J?__]FW0QPF4QFR\F,IYG,9^-;7KI=4LF$Z4%LPMST]_KO7+]
M<!FEXVB^[2?22;V?ZQ^%V>'=(0U4:$JO9GE$3#\K^XW379A/6^UPVH7/&O]>
M@/$*>%YI?."&C7<P_F%9_PM02P,$%     @ .8)L4S/*=_9H @  ]04  !D
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M_[O,$]K)2#OQM),W=N]UEF_*(DS@P[N,)<DE/$<*:P.J!&J+Q6:+>NP-<%G
M1\P';^*]=,<'DOR8)%<T3,:2F[ALA5 J05-9R]V%SQZGEV]^GTH\478(\;J=
MS+'4K9*= 7QP4M&,@>\AFT]#-DV///,T"[-9.D);_JBIBG_!+,O">?8$I=Z&
ML_D<OBO+Q?/]><J2A$DV"5EZ?NJ;QN'YC!U\S_U T=$H-JAW?N$82M-)VT_E
MZ!UWVKH?Y:?P?B%><[VKI0&!)4'CL]DT -TOF=ZPJO6#O566UH0_5K274;L
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ME2N$S$R9\Y["B,[E+!J.ABPWU);+I55+2<<VQ+R?&'8N>^-H..FUI)-Q;$M
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M<X/([8V0G0NK:5H8J!=*31%,4P-SQ-KF 3YWP,]8-"0,52_B+:=)F1;:MQ<
M+4#:JVZ[ &JON_(]^X'-Y1'3H+-N5&C+'A (_B%1:>98J?:&Z$C3<-D=AUK
MO59=C*L&+@AJ=@IB5_QZO*/VQQR9I3;20B X'R9$X:)+/4?-^M%T.A)N)1F;
M%^"<(6C0>1ATCKX0J2=E8^W8T#1*P0:\OW%,9]2]G'@;U(?Q!D]9CW RP#)9
M!CW"ENL>-P@D=U*UOR0WI5U77!='JXQ9D^J[RE+CP0:NVEJ(E5BY$8G9Y'O]
M>Z??-CT<L[0&?4X]VI"K-B:XT35NSU%'^)$7G%[")DT%D?%*HU:$\'?4 ,$^
M=2'Q21Q30\B@4GMNIZ?WX80FJ&G@!K-CDS(W-7 GC!R7!;>8"M,VX>\U30(L
M1Y4UW]L%U83-:/7K<9GKG;M"9=1LDYT+2<HBG-*4FA69ZK\A(D(+K50F[0.:
M#F)+N7 D,Z+IY3CJ]7K?:J@K&JQ_AHT1GF2'6\RIZ"^!Z_R2<R#.Q;U_T\]O
M-?4RYU87=-=> HJ).WI! *S#9J*/^*_X@)8$LP%#)YGOX)0O*P\C+ 8K/U>U
M_A0<W*R0>I]5JBCC/CQR?!":.G&:J 7O@P:;E<H/(OIP3*G X>/[ZQ QG[8)
M2.:: C@IXX(EK8+11P7@5F=H$:G#@N^MI&PNC\^488J4#1KO%;[Z!4,8+! E
MO]"P$ 2K\Y2DA[*XI.@'=P:,6FC"661JN3Q/U"/A2TS+57D@37SB^=X-(%7.
M,TUU+U<;)O,C9#/P4<W:5L/X:1T$_3Y'P=S!!"02>\&=A:I5>Y7?<7#/-E<\
MD\5H=OVDDQ\J'A%"5K, *QR^\40DK(-,;K%M$M#,,4W[$8X#VRJ 8E4Y>4,]
M/%&YW(I@-1\?2*;J?7#[!597O$="5Q7LQ^;!@]<\/K'V1S4\00I7+[8:79"F
MLW$T'0YW4C11OKISX$F/WG5)<"M3I@GWXQR(YVT%\Q:%/Y%>+DAM!:*^5%PA
M.\/QB-Y)1I0%I0MJWZ0R?CB_CU<F5:$X<+&B#9DJ5B8QJ5FV2>I/$C2HE!F3
MH!/V9<_7.9[K4=>NV! <':'L]WL8X[@&7(E'0[)RR<&3Z8SZ2$Y 8;5[.%^0
M1VJ3-B]X)F&^JHMU>#'4F4RB27]*VQ(U+^IJB,1PA8MHW8_:G<DP&DUF;!E$
MJ:'6/PE.8E*2HS.,^J-G-@7/>$F.6;T"A::J5PFY*]0SQV^@=!-7$(!7$^T\
M7+*5L&.NV ]^'**O1J'<+C"5GO,KSG:_1='OX9U#GI-S3M]T?8M1-<E 2L2B
MU*G[\8].1S[Z_,(=0GBSZ=N$]MOS<:]']4J\;VMX>/+GXR:NS1OVG5:!?O8<
MQ9[]:SH?$F<HSVS-&FYW+5]_X.A'L]'A=X_.X6>)8Q\L+UH?>S-EE_Q)F]Z6
MXPC_W;=>K;^:7_N/Q<UV_\G]D[3HZF%@M0!IKWLY/D'Z\&=L?U.8-7\ZGINB
M,!G_7"D,998VX/G"("JJ&SJ@_K\$[_X+4$L#!!0    ( #F";%-(KWEH:0D
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MBQ;@4NQB)W:CV 9/#>X%.LR%*"0#-G !,*5HRWK)^*(#ZF X>I ?/(^@!+<
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M4)Z/3D<BIT(V.MS:[7OJXSEFO,QJ'W_%MI.=0SAK?+!5KPP/*F6Z?_G8Y^%
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M 9M8?"RQ^I)C 7PO+!JI?V$#PS)]\3=02P,$%     @ .8)L4U_W66@$$@
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M%BF40OW.!V9?4GSQ]EOH#.@U"?3;[5V^''5\1XE2,LJO%2790MU1^/E+WF%
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M'T': '.^%T*?#9N@?W&7?P!02P,$%     @ .8)L4[247(X% P  @@<  !D
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MKA)BIHX_39P>0I<]:(<]._QV^$B"\0ZXWFKMSA-/$)_=_=]02P,$%     @
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M]8?H>J'DPGS\O9-*R=R\SD6<B%(+ '\JI6H6VD'[WX#S?P%02P,$%     @
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M7-@5]/TD"FF<O!6\&:KQ=JC&.X=@$L0D\5\%WW@MZ+P6]'KMI+#-!JUR/EN
MWXQ$X$3VF(O6?W::@ X#>S:"?I<SPQ7+Q2\0+63)?\)W]00#"VN:ELN[S?IT
M@WF<Q. ,O.6S]^7>&!AV!H;]!F995526^,R."-!/G2S#G=4/TP RDR;A%L_!
MDG<.R3@.0YR2U&T3[6RBO3;] Q[/I78F,]U=E-(HH>E61EW0G8PZ#).0A-N!
MN70(TH"2*(JWRL,EB-.(!EL:KYR"!&C2MX+7+L$0=)+MY'%836@< <DME;=.
M21H%&%-W4*(N*%%O4,YLIZDTI!E4"XSJJMZA73&ZB1P<PC2-$[SETMMHUP&$
M)#0(HCTI%'=LXUZVUUI7K,RXG3XR64 Q(QAYLB=T .SUDD$O=4T29_$.=3^*
MJ9\&;CI)1R=YUWD?T4,I2ETI<&'3EESYG>PV0D*@^+9;Z\U0P3N'8$+\_:TU
M[6Q*>VV:5H\:=A[8==#%L_W]#YT8]+EIF%_F<ZY@QNO9^ A^'21Q[TKW2F:<
MSS2:*UD@#3O=3E@AJJL*VGH&7UPKMW,BWMVX_ 3CO5V8; R[Y-V>M6IY.I<F
MCJ7#OJ5?!P/2/QG\9JZ?MFK?)'L8T B'6XR\C4. /4!#C!>0R2CG<T#BHQA4
MJ.9,VCP8N:K/!8_2P#FCOEW".9XK*P#?YU*:EP=[U.C^&9C\#U!+ P04
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MNOH]%$:=.'7\6CTT@0_1TR%ZZNQ%OQO]%5_1X"MRON)+OMB3%%6%-'LTY[\
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MK99G;'E,;^V2:!J2T(_Q;EB5]VE3/XHFKVEO9 :]S.!#,FOZ(CAC5X6V3.%
M 8FB:70J]$R:YTVFT_-"PUYH>%7H3ZXHT\W=RDTO7E8K-7Q7+,^+ N*/3[2>
MRPO=\82<B,6#1C*/V \JMD4E$8.-1KJCB282[</0!HK7MK?67.E.M=-<OZ4@
M3(+>WW"NCH%IU_YU3OX"4$L#!!0    ( #F";%/55);'+@,  .D)   9
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ML-_8#G/[#]A!^&,O9N$O ><6!::4+L*$Q418W$3(.P.VQ4R(K9B7)B'9)5_
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M ,X7$LRCW)B)K)K 1_\ 4$L#!!0    ( #F";%,>>=*7D ,  &4-   9
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MB5TT9_JFHWAE3[D;KO29V3;W^AY$A G0[[=<9Z+MF &ZF]7B?U!+ P04
M"  Y@FQ3&YC;E-H(  #K,0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6RUFUESXS82@)^SOP*EVE1-JA*)%WA,V:[R,;8T$T]4X\WD&:8@B6M> 2C;
MVMH?'X"B!<H"&Y2BO-@ZT(U&H_%U Z#.7@KVQ)>45N@U2W-^/EA65?EQ-.+Q
MDF:$#XN2YN*;><$R4HFW;#'B):-D5@MEZ<BQ+'^4D20?7)S5GTW9Q5FQJM(D
MIU.&^"K+"%M?T;1X.1_8@[</OB6+924_&%V<E61!'VCU>SEEXMUHJV669#3G
M29$C1N?G@TO[XY<@E )UB^\)?>&MUT@.Y;$HGN2;R>Q\8$F+:$KC2JH@XM\S
MO:9I*C4)._YLE ZV?4K!]NLW[;?UX,5@'@FGUT7Z1S*KEN>#<(!F=$Y6:?6M
M>!G39D!8ZHN+E-=_T<NF;1 -4+SB59$UPL*"+,DW_\EKXXB6@!-T"#B-@/-.
MP/8[!-Q&P'TOX'8(>(V ]]XDW"& &P'\O@>O0\!O!/R^/02-0-!7(&P$PKX"
M42,0]1V#;;W-G-5;9#O9FZ#;1$D=8C>D(A=GK'A!3+87^N2+.DYK>1%922Z7
MU$/%Q+>)D*LNOA85Y6A*UN0QI>@7=#F;)3+628HF^6;%RLC_<$,KDJ3\)]'D
M]X<;].'?/YV-*M&_U#**F[ZN-GTY'7W=DS6R@I^18SFV1OH:EKZECT/D>)WB
M-STZ#VMI2R/]"99^H.40N59GY[>P^.=5#HK?]>]=9_SX[QD_^7N]?^XA[D2=
MO7^!Q2]7"]&[K1,?B5C?!KRS#7BGUN?V"7A G[O5Y];ZO Y]WVA)UB+'5!P5
M<Y06)-=-T$:'7^N06>[Y GN!@Z.ST7-[(O:;N7[HA*K9CHG>UD0/-/'3*V5Q
MPBF:LB2FTLP_"&-$FOS;JN(5R6=)OM MBHW>J&6/,[1PN&OUW:95L-/*\R-_
MM]FXE[*)4=F."_#6!1ATP656K/(*E2F=+>@,506B8MR/:<*72 P?R>)# $ZD
M>"2(FI**,I(F_Q--LR*G:_$]>Q+U#8ECJ4?G*KPW=4$88,NRWGG!W&YG@/YV
M@#XXP$DN3!9C0O155%N<ZH)PHP&WNK:QY7H=T15L>P[ GF])PM!WDJZH2![_
M%3E++H9VD.EP&>P'.O:PVV%*N#4EA-=BPI_0G%&*DC=W,#&5NNF"%5G#T/X1
M@$.T-2@RK+Q2E(XRX"C+T(<U)8SK$N<G6 U&M22R+1F.U9(C'\W(F@,6VI8J
M *Q^-CX7(NZ3-*G6VOP(:XG$6K8@E]FMBL0&5=W0QPHEG*](+F@5%UP;0N-&
M2SN&?-^W0WT(V2H_V [8_7V2)]DJ@X:B<H/MGB39V KE]C_$\CN['W^-S78-
M5P"V80(?L#8-FC2+LQFA2<[Q=7)CHYR'=7*3P_O;]9UBNPW#O3=&#'KZ<:1Q
MYLE4C4^G:G(25;NSH/*<#2>Z?J"\,VB)PGU0-FXR"&H(VSC%(.B;T*SRJPWG
MQ7OR:F*C2HUV=!(V.BJ3.:9,=BP;&\6F$G9B;K=KNLIY#ISS^M/QSJ#)&OJ1
M-KP,<O80A]KH,LJY#A1<3FMC!B?>OI2[,^@1B[^6U3KA:-')4:*[KE!U@P-O
M*GNBQJ EBKI08Q+TNE!S1(^[+E"%C@,7.AL\E&8\J K$P:<!CLK+#IQNOJZR
M1\HD:.ILDZ[1VUF [GC+H"QJ4A9DF<I5#LS\NH:>Y+QB*VG/SVA*65+,DEB.
M7WZB-7!_5Q9$KN=VP$UE#0?.&I>+!:,+@3-4LB2/DY*DL*/"?3LL[/H=6V1'
MI1P'WD=-VFQ%'P@7V_U2Y QAB XTUP9USC ""SQ792X7SESWI%HQL<A%L:*%
M_K5!_FOQ7)^-_NN''PS'9*Y*22X,=A$H\9+&3R*;BH6SN0 1+Q>,9)ICKMU.
M%//=$YW&M8[C8 0=$_DW[O[!FQUAJV/3XRJ(N3#$#@RX&X,ZVT!75['0A?<F
MUX0OQ6HL8DIG7!0>A6Y.&YOV3ZP\WW5Q!Q9<14\7!EYS)B?HJ; P+]@B>:8Y
MY1S)>)M.N^SZTFCO;9=BIPNS4]E%XIBM1!;>UF2'F+</4QRX71&E6.K"+'T0
MQ4 LNOY.TI2NT17)GXRK4?'1/4U)[BFP>3"8=.@G6<<9ZE6CK.TS1QZ-=IZ.
M>HIF'DRS U?BE4$=-JQ$3Q'0,QPW&=!_991?([L!/X8L4@3U>A TV1(4T?F<
MUA??2&RA9%':L3.Y@O7*AP,^\I+$]'Q0BJF@[)D.!-(<_",JTQ5'U;*.DHQN
MY@@:2^OF R:FBC^Y2-YFG"ST]L.ZC'.NZ.O!]/VUR!>_U+L<Z6NM*9IK @PM
M!$5=#Z;N=DLL6(;*%8N7A-=[Y;C(1 $JYKB(G[0F[5\?1'88>AT&*=QZIF.5
M(W?M5XWBL)T!AD''7MQ3B/5@Q#;=([HQK+X8EY.E-0%6U6-3Z"DZ>W"Y^:N,
M8$9C*I;B3&M,M%_%@%&#%<>Q@>/_]/W99[S/?O!B#"OTXY[H!Z[&\/YE0H1#
MMZ.6P(KN&*9SS[N,1DM[;0%W&5BA',,H[ZH6T/\UY-GM0R$6>R<I&G#KKA;&
M8U^GX7VGN9[?<8>(%2$Q3$C :?HKS=U^%/AP<!K'*7)A&#?'7,6.\?YN&[J+
MQ8I7&.95_S/-L4&3/?3!S.LKCODPQQYD=I-51JR]>6JD.S-*<X]N:+5KF^*4
M#W.J[_GGV*"G1]+Q%<#\GH>RX$GDV* E-)T+^@II?I_JU @'7_,HC=WUJ(.O
M8.?#-2# !E&^B(I*9,;;A(E0O\QSD:<9)VP-C5M!T3_-Z:7?>F($YMR4O3VZ
MA.9BD<*UL4&7:YI?144?+@?[>/B!BA:SOBY6^/3#T[A8(="'P768BTVGC;"+
M P7!P #!'B[^SS)A?3T<*,0%]DD\'"@^!3!9#O*P09?I>"U0D J.KKO,CY<$
MBD;!:4JO0%$F@$NOP]P)ZS*Z4Y$J.+HB,]](!ZT'V4Y3D 6** %<D!WF3EA7
M)V)'K:>_Y<\@[@E;)#E'*9T+1=903A/;_+)@\Z8JROJ!\,>BJHJL?KFD9$:9
M;""^GQ?"$<T;^8SY]O<=%W\!4$L#!!0    ( #F";%-B$\YDS@,  'P/   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)U777.;.!3]*QIF']J978,P
M^*-C>R:QFR:=[6PFGG2?%;BVM07$2L*.__U*H( ;0,6;AQB!SCU'NE<'[N+$
M^ ]Q )#H-4TRL70.4N:?7%=$!TB)&+$<,O5DQWA*I!KRO2MR#B0N06GB^IXW
M<5-",V>U*.\]\M6"%3*A&3QR)(HT)?Q\"PD[+1WLO-UXHON#U#?<U2(G>]B"
M?,X?N1JY=928II )RC+$8;=T;O"G>]_3@'+&=PHG<7&-]%)>&/NA!P_QTO&T
M(D@@DCH$43]'6$.2Z$A*Q[\FJ%-S:N#E]5OTNW+Q:C$O1,":)7_36!Z6SLQ!
M,>Q(D<@G=KH'LZ!0QXM8(LK_Z%3-G88.B@HA66K 2D%*L^J7O)J-N #@H ?@
M&X#_'M#',#: \5"&P ""H8#0 ,*A@(D!3(8"I@8P'0J8&<"LS&Z5CC*7&R+)
M:L'9"7$]6T73%V5!E&B50IKIVMU*KIY2A9.K-4M3*E4Q2H%(%J,URR3-]I!%
M% 3Z ]W$,=5%1A+TD%5'19?<APU(0A/Q44UYWF[0A]\^+ERI].BH;F2X;RMN
MOX=["_D(X>!WY'L^[H"O[?"_(CE"WKR$>QWPC1U^4^P5N]<+_VR'?R-\A,:X
M5_S=@+6/O5[X%SM\ U'-WB7^W@[_6F1][*XJH+J*_+J*_#)>T+>77%E0A+[3
MTM+^I)$R-T W>PZ@2\O",*X9QE:&YWS'56FBG)QU1&6;$2C3B[OR7D6:E)&T
M=Q]7@5?^+=QCAX2@EA!8)6Q@!YQ#C!*SOAV Z"J<H,7OO^.O<O3K>3_I#&N=
MX74Z(R9DE\XJ3'C!/^N2&;9DSBPJ)[7*B57E-_)*TR)%I#$8DUMADDM>$NA*
M[Z0E.QA/PWY%TUK1U*KH(5-"*GMC.Q2IQS12JC@((#PZE/;(85\D1#)^1B3/
M.3M>R.[2.FUI'<]M6F>UUMDO<GQ4GQUY>11T>CO)9^V-LM77O.:>6[F?V)DD
M\MRD2VU/UGD2[^:MTNGAQE[SOO+L=4,34&_%# ;P?S&Q!A\Q?/':Q-?*L%C2
MK8DV7$CCO-ANO>^,L:L0;DV(G]@M18@;4\9V5[XEA?J:OLKP<6.WV.ZW5UC^
M&K>]%'O6#6[<%-OM]'\;U1JWG7,<6D4UYHGM[GG%&<1MO^RC;YP2VZWRFD-X
M9V(-<8'&_K#=_[:0_5-<5W>-O6&[OUU1=Y]QV^&L'NLW/N?;?6[HU\;&;WM<
MMP3WHDO0?:GZ@MW33* $=@KIC70CQZM6KQI(EI>-PPN3J@TI+P^J/0:N)ZCG
M.\;DVT#W(G7#O?H/4$L#!!0    ( #F";%-H%],27@0  +@1   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;*U8:V_B.!3]*Q;[T*Q4D3@D(<Q2I+;T
M-=/N(+KM?G:#(=Y)XHQM2I'VQ\^-">%E3$8[_5#RN.?<E^UCI[_@XJM,*%7H
M/4MS>=Y*E"H^.HZ,$YH1V>8%S>'-E(N,*+@5,T<6@I*)!F6IX[ENZ&2$Y:U!
M7S\;B4&?SU7*<CH22,ZSC(CE)4WYXKR%6^L'8S9+5/G &?0+,J-/5#T7(P%W
M3LTR81G-)>,Y$G1ZWKK 'Q]PMP1HBQ=&%W+K&I6IO'+^M;RYGYRWW#(BFM)8
ME10$?M[H%4W3D@GB^%:1MFJ?)7#[>LU^HY.'9%Z)I%<\_8=-5'+>BEIH0J=D
MGJHQ7]S1*J&@Y(MY*O5_M%C9!FX+Q7.I>%:!(8*,Y:M?\EX58@O@X2, KP)X
M30&="M!I"O K@-\4$%2 8!_@'P&$%2!LZJ%; ;I- 5$%B)H">A6@UQ2 W77G
MW#T(/I8VKIO=N-MXW6ZL^^VL!I8>E4.BR* O^ *)TA[XR@L]M#4>!B/+RUGX
MI 2\98!3@S%-B:(3-")"+='?@N22Z/DAT8<A582E\H^^H\!3:>_$%>OEBM4[
MPOI$BS;"_AGR7 \_/PW1AU]-+%=-6 +-XAYG&=I9+@K11FYXBN6Z<2PX.LYR
MTYPEK%BFZO=?<#?ZT\!VVX"MXYZJ\EUS%DM][G]*+)]^2BR?[2Q#&@,+UE4.
M#/"'QO C03@PR>J9YM4SS=.T_M'<XKE@,,F&M."2*5._5PRA9BCU\VV <<_M
M0!)OVZUH9O9PTFPGCTZ=1\>:QX6 ]2%&+TP+\0.+09(INI@)2D&=E:52?NW!
MMWIX+J:"YPH59%DR2M/ZXQ_DY@4N_)ES"VK/@=7SCV03UIRAE?.1Y5SW_3Y7
M5%"IT)=%3H5,6(%&5(!#!=L=>(NN>%:0?&D:\'870=MU?[.$VJU#[5IY7B!]
M-((8V02B0GR*QE12(N($D7P" _<-=FW%B;I$M;/(ZNPOV&*.R^1?4R@X["#1
M?\BR%MZLV(*MCO>"CKG=O3J$GKW=%/9O9^@1!EN2+M$EW.F03%+5.QAP@>_Z
MNS-N:##R_.ZNT?6AD>]B;]?HYM"H$_6.S%SL;L3>M2;\I:""*);/D$Y=GNET
MT?5[40Y[HP*Y!V7'H;<?[EUEMK/6!+UHS^S>P.9'82?<-?MD8/,[P9;3W?2W
M]CKX_R[!5Q5%8&^TR>JPTP8K0ZL-5I9>;^0&V_5&=SCAZ03=9X7@;WH]@X[?
M"BY-2^HM-NB%YWF]:+^))^UV(]X("[8KRX],QXKJQ'PT61G:=&AE:M.AE:5-
M&ZW#=K%[HOF_<S1*"!PI8SH':24I*(%E@<4;-<-V.1OS)4EAN&]DQKB9LI.<
M$A>\$4)LEZDFNEY1-!5VO)$V;->V+:D%7<M8"DK,<[H.!@D0MWQN*M#E"6;?
M/58A9^M<5G[3>"1BQN!DE=(I,+GM+E1>K#X3K&X4+_11[94K./KIRX22"16E
M ;R?<J[6-^7IK_Y8,_@.4$L#!!0    ( #F";%/:7Z=03@,  )(/   9
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MP(H7Y/,EI>(P* S4;?CD#U!+ P04    "  Y@FQ3$D8GB)0#  "!#0  &0
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M3$($GV,<DA "$"'B(J(U)[MCSA,$X(.(P0?A\H%ZDT$ 'D1D/(S8.UQ#-,F
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M=,+9#O#<6J+E7XKE*KQE@Z,TGZP[P>6OD?03TSO!EH]K%H>49[^!Q<]M)%[
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ME.<&\O<58V)_D >H-I6GOP!02P,$%     @ .8)L4]S7GVLP"0  8RX  !D
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MX,4;S<5%QO;YRYL/+,M8G'_<T6!-N100?]\PEATOY/N@U7OE%_\#4$L#!!0
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MR\),>Y#6P9ROA=#[C0W0?C^,?@-02P,$%     @ .8)L4XN>!S6@ P  M0T
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  Y@FQ3F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M #F";%,/"7D.104  "(6   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  Y@FQ305^C6O0%  !6%P  &
M            @(&'#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ .8)L4S+ZSB.Q @  7 D  !@              ("!L1,  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #F";%/;U$US0@4  /X4
M   8              " @9@6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  Y@FQ3=7.8A24*  !-.0  &               @($0'
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ .8)L4\/$)"#/
M @  2@<  !@              ("!:R8  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( #F";%/T)W7'4 @  '0A   8              "
M@7 I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  Y@FQ3
MAT&2:VD"   8!@  &               @('V,0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ .8)L4XP$X>9?!@  . \  !@
M     ("!E30  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M #F";%/U5K,K#A(  +,Q   9              " @2H[  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ .8)L4^3$IW=' P  O @  !D
M             ("!;TT  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  Y@FQ3,\IW]F@"  #U!0  &0              @('M4   >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #F";%-IVWS<'@,
M "X(   9              " @8Q3  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ .8)L4X&-P9QP"P  5R   !D              ("!
MX58  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  Y@FQ3
M2*]Y:&D)  ##&P  &0              @(&(8@  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( #F";%,Q/893M @  -,6   9
M      " @2AL  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ .8)L4R4)\5%D$   #S8  !D              ("!$W4  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  Y@FQ3&6V&_JL#  "Y"
M&0              @(&NA0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( #F";%/'0%.K# 4  %@+   9              " @9")  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ .8)L4U_W66@$
M$@  VC(  !D              ("!TXX  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  Y@FQ39TLT K$"   (!@  &0
M@($.H0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #F"
M;%- U+UL+0,  !H(   9              " @?:C  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ .8)L4PZY58Y. @  ?04  !D
M         ("!6J<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  Y@FQ3M)1<C@4#  ""!P  &0              @('?J0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #F";%-I$*,%0P,  "T*
M   9              " @1NM  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ .8)L4P/E@-:!!@  &1@  !D              ("!E;
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  Y@FQ3*7@S
ME3<"  !Q!0  &0              @(%-MP  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( #F";%,R+0_\FP(   4'   9
M  " @;NY  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M.8)L4XP7J*IC!   )1   !D              ("!C;P  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  Y@FQ3R=U-(' #   Q"P  &0
M            @($GP0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( #F";%/&(<AN,P(  *D%   9              " @<[$  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ .8)L4]54EL<N P
MZ0D  !D              ("!.,<  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  Y@FQ3W23K[1(#  "-"P  &0              @(&=
MR@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #F";%,>
M>=*7D ,  &4-   9              " @>;-  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ .8)L4QN8VY3:"   ZS$  !D
M     ("!K=$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #F";%-M9F:=00@  /A$   9              "
M@:CJ  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ .8)L
M4QKM[K:M P  :PX  !D              ("!(/,  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  Y@FQ3!VE0IV\%  !@'@  &0
M        @($$]P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( #F";%/<UY]K, D  &,N   9              " @:K\  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ .8)L4^:@S.6S @  2P@
M !D              ("!$08! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  Y@FQ3BYX'-: #  "U#0  &0              @('[" $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( #F";%-%F]K_
M6@,  -P6   -              "  =(, 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ .8)L4Y>*NQS     $P(   L              ( !5Q ! %]R96QS
M+RYR96QS4$L! A0#%     @ .8)L4\CTO53Z P  @1X   \
M ( !0!$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #F";%.X-L3<J0$
M "X;   :              "  6<5 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( #F";%-3V2LIL@$  %,;   3              "
M 4@7 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U #4 :@X  "L9 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>343</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Business Organization, Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Accrued Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</Role>
      <ShortName>Accrued Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Accrued Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</Role>
      <ShortName>Accrued Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureNotesPayable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails</Role>
      <ShortName>Business Organization, Nature of Operations and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Accrued Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails</Role>
      <ShortName>Accrued Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails</Role>
      <ShortName>Notes Payable - Schedule of notes payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Notes Payable - Schedule of debt discount Note payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails</Role>
      <ShortName>Notes Payable - Schedule of debt discount Note payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails</Role>
      <ShortName>Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stockholders' Equity - Black Scholes option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails</Role>
      <ShortName>Stockholders' Equity - Black Scholes option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stockholders' Equity - Summary of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails</Role>
      <ShortName>Stockholders' Equity - Summary of information related to stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stockholders' Equity - Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Additional information related to Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="eyen-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="eyen-20210930x10q.htm">eyen-20210930x10q.htm</File>
    <File>eyen-20210930.xsd</File>
    <File>eyen-20210930_cal.xml</File>
    <File>eyen-20210930_def.xml</File>
    <File>eyen-20210930_lab.xml</File>
    <File>eyen-20210930_pre.xml</File>
    <File>eyen-20210930xex10d1.htm</File>
    <File>eyen-20210930xex10d2.htm</File>
    <File>eyen-20210930xex10d3.htm</File>
    <File>eyen-20210930xex31d1.htm</File>
    <File>eyen-20210930xex31d2.htm</File>
    <File>eyen-20210930xex32d1.htm</File>
    <File>eyen-20210930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eyen-20210930x10q.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 210,
   "dts": {
    "calculationLink": {
     "local": [
      "eyen-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eyen-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "eyen-20210930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eyen-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eyen-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eyen-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 423,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 22,
    "http://www.eyenoviabio.com/20210930": 3,
    "http://xbrl.sec.gov/dei/2021": 6,
    "total": 31
   },
   "keyCustom": 80,
   "keyStandard": 263,
   "memberCustom": 43,
   "memberStandard": 18,
   "nsprefix": "eyen",
   "nsuri": "http://www.eyenoviabio.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Accrued Compensation",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensation",
     "shortName": "Accrued Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:NotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Notes Payable",
     "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:NotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Related Party Transactions",
     "role": "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stockholders' Equity",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Employee Benefit Plans",
     "role": "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Subsequent Events",
     "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Balance Sheets",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:DisclosureOfAccruedCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Accrued Compensation (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables",
     "shortName": "Accrued Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:DisclosureOfAccruedCompensationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "eyen:NotesPayableDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:ScheduleOfNotesPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "eyen:NotesPayableDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "eyen:ScheduleOfNotesPayableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "eyen:PercentageOfSuccessRateOfOptejet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails",
     "shortName": "Business Organization, Nature of Operations and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "eyen:PercentageOfSuccessRateOfOptejet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails",
     "shortName": "Summary of Significant Accounting Policies - Anti-dilutive weighted average diluted common shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:PayrollTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:PayrollTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "eyen:DisclosureOfAccruedCompensationTableTextBlock",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Accrued Compensation (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails",
     "shortName": "Accrued Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "eyen:DisclosureOfAccruedCompensationTableTextBlock",
       "us-gaap:CompensationRelatedCostsGeneralTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:AccruedResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "eyen:ScheduleOfNotesPayableTableTextBlock",
       "eyen:NotesPayableDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Notes Payable - Schedule of notes payable (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails",
     "shortName": "Notes Payable - Schedule of notes payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "eyen:ScheduleOfNotesPayableTableTextBlock",
       "eyen:NotesPayableDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_BankDirectCapitalFinanceLoanMember_nJiqVwToTkuvXBEe14Cp5Q",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_kSSw8sBQgUqtYLlD6h8Gmg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Notes Payable - Schedule of debt discount Note payable (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
     "shortName": "Notes Payable - Schedule of debt discount Note payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_eyen_SiliconValleyBankLoanMember_1OK1_7uWI0ODrG89Tc5ikQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfNotesPayable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Notes Payable - Additional Information (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
     "shortName": "Notes Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyen:LicenseAgreementsUpfrontPaymentsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_8_10_2020_To_8_10_2020_us-gaap_TypeOfArrangementAxis_eyen_ArcticVisionLicenseAgreementMember_x1QG4wiB9U6lcmo_E277nQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "eyen:LicenseAgreementsUpfrontPaymentsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2015_srt_OwnershipAxis_eyen_LicenseAgreementMember_dyafUeHTdE6cz1HM3PEKSA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stockholders' Equity - Black Scholes option (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
     "shortName": "Stockholders' Equity - Black Scholes option (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_L2IyzNjT2Eeyl0K4pnAV9g",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stockholders' Equity - Summary of option activity (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_StockOptionMember_e-81JENDk0m_aL8GCn-TFA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Statements of Operations",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations",
     "shortName": "Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stockholders' Equity - Summary of information related to stock options (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
     "shortName": "Stockholders' Equity - Summary of information related to stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2020_1NM_R39maE6VWBP7sgxYZA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Stockholders' Equity - Warrants Activity (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails",
     "shortName": "Stockholders' Equity - Warrants Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "INF",
      "lang": null,
      "name": "eyen:ClassOfWarrantOrRightGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_nloC6KPu4UqcfiDd88y7mA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Stockholders' Equity - Additional information related to Warrants (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
     "shortName": "Stockholders' Equity - Additional information related to Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "eyen:ScheduleOfWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_ClassOfWarrantOrRightAxis_eyen_WarrantsAtExercisePriceOneMember_Im1QKFMiwEyIc4Nt8pdKyQ",
      "decimals": null,
      "lang": "en-US",
      "name": "eyen:ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_KnGdRfKOP0CDIiI2ijpkxA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_wTip1WJhwUmlhfmYaFuPiQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_3_24_2020_To_3_24_2020_bTfSRHfxlkeROm6p3tdnwQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_2EWWk3Aj4Emg8jieW8ISEA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_10_27_2021_To_10_27_2021_us-gaap_AwardTypeAxis_eyen_OmnibusStockIncentivePlan2018Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockOptionMember_iFn-7Azb506FQ9HAzDy_hw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0uJR4VXW306rVhRswZPkDw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Statements of Changes in Stockholders' Equity",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uRd-xT5vk0e9wrngV3sMnQ",
      "decimals": "0",
      "lang": null,
      "name": "eyen:StockIssuedDuringPeriodValueNewIssuesTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:ProceedsOfStockIssuedDuringPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Condensed Statements of Changes in Stockholders' Equity (Parenthetical)",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_7_1_2020_To_9_30_2020_VwRRLsSHVkmkSsGhzqQCHg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:ProceedsOfStockIssuedDuringPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Statements of Cash Flows",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:ProceedsOfStockIssuedDuringPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00405 - Statement - Condensed Statements of Cash Flows (Parenthetical)",
     "role": "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical",
     "shortName": "Condensed Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2020_To_9_30_2020_YGu_zP_w-ku1JJ3C01y4Mw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "eyen:ProceedsOfStockIssuedDuringPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD__JOw7kJfvUigDPzA_E4ukQ",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation",
     "role": "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation",
     "shortName": "Business Organization, Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "eyen-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_LvARya8Yukq4Zy0pePybvg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.eyenoviabio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "eyen_AccrualOfPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrual of public offering costs.",
        "label": "Accrual Of Public Offering Costs",
        "terseLabel": "Accrual of public offering costs"
       }
      }
     },
     "localname": "AccrualOfPublicOfferingCosts",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedConsultingAndProfessionalServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and professional service, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Consulting and Professional Services, Current",
        "terseLabel": "Accrued consulting and professional services"
       }
      }
     },
     "localname": "AccruedConsultingAndProfessionalServicesCurrent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedExpenseReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expense reimbursements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Expense Reimbursements",
        "terseLabel": "Accrued expense reimbursements"
       }
      }
     },
     "localname": "AccruedExpenseReimbursements",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.",
        "label": "Accrued expenses and other liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedFranchiseTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued franchise tax expenses paid by the entity.",
        "label": "Accrued Franchise Tax",
        "verboseLabel": "Accrued franchise tax"
       }
      }
     },
     "localname": "AccruedFranchiseTax",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedLicensingFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued licensing fees, current.",
        "label": "Accrued Licensing Fees",
        "terseLabel": "Accrued licensing fees"
       }
      }
     },
     "localname": "AccruedLicensingFees",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development expenses paid by the entity.",
        "label": "Accrued research and development expenses, Current",
        "verboseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_AmortizationOfDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Amortization of debt discount.",
        "label": "Amortization of debt discount",
        "terseLabel": "Amortization of debt discount",
        "verboseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscount",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ArcticVisionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Arctic Vision License Agreement.",
        "label": "Arctic Vision License Agreement"
       }
      }
     },
     "localname": "ArcticVisionLicenseAgreementMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Offering [Member]",
        "label": "At Market Offering"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_BankDirectCapitalFinanceLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents member information pertaining to BankDirect Capital Finance loan.",
        "label": "BankDirect Capital Finance loan"
       }
      }
     },
     "localname": "BankDirectCapitalFinanceLoanMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_BauschLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Bausch License Agreement.",
        "label": "Bausch License Agreement"
       }
      }
     },
     "localname": "BauschLicenseAgreementMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ClassBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B Warrants [Member ]",
        "label": "Class B Warrants [Member ]"
       }
      }
     },
     "localname": "ClassBWarrantsMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Exercisable Number of warrants",
        "verboseLabel": "Exercisable Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_ClassOfWarrantOrRightExercisableAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate intrinsic value of warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableAggregateIntrinsicValue",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of warrants or rights exercisable.",
        "label": "Class of Warrant or Right, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyen_ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining life of warrants or rights exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Right, Exercisable, Weighted Average Remaining Life",
        "terseLabel": "Weighted Average Remaining Life, Exercisable",
        "verboseLabel": "Weighted Average Remaining Life, Exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyen_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right, Exercised",
        "negatedLabel": "Exercised",
        "verboseLabel": "Number of warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right, Exercised, , Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyen_ClassOfWarrantOrRightGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right, Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGranted",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyen_ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of years warrant to purchase share of common stock.",
        "label": "Class Of Warrant Or Right Number Of Years Securities Called By Warrants to Purchase Common Stock",
        "terseLabel": "Warrant to purchase common stock in period"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfYearsSecuritiesCalledByWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyen_ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate intrinsic value of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at ending balance",
        "periodStartLabel": "Outstanding at beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyen_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining life of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Right, Outstanding, Weighted Average Remaining Life",
        "terseLabel": "Weighted Average Remaining Life, Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyen_ClassOfWarrantsOrRightsOutstandingRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Class Of Warrants Or Rights Outstanding [Rollforward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsOutstandingRollforward",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eyen_ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Class Of Warrants Or Rights, Weighted Average Exercise Price [Rollforward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsWeightedAverageExercisePriceRollforward",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eyen_ClassWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Warrants Member",
        "label": "Class A Warrants [Member]"
       }
      }
     },
     "localname": "ClassWarrantsMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_CreditCardPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of credit card expenses payable by the entity.",
        "label": "Credit Card payable",
        "verboseLabel": "Credit card payable"
       }
      }
     },
     "localname": "CreditCardPayable",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_DebtInstrumentPrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the reporting period.",
        "label": "Debt Instrument Principal Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAmount",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_DeferredLicenseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Deferred license cost.",
        "label": "Deferred license cost",
        "terseLabel": "Deferred license cost"
       }
      }
     },
     "localname": "DeferredLicenseCost",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_DeferredLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to deferred license fees .",
        "label": "Deferred license fees",
        "terseLabel": "Deferred license fees"
       }
      }
     },
     "localname": "DeferredLicenseFees",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_DirectorsAndExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for directors and executive officers.",
        "label": "Directors And Executive Officers [Member]"
       }
      }
     },
     "localname": "DirectorsAndExecutiveOfficersMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_DisclosureOfAccruedCompensationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued compensation.",
        "label": "Disclosure of Accrued compensation [Table Text Block]",
        "verboseLabel": "Schedule of accrued compensation"
       }
      }
     },
     "localname": "DisclosureOfAccruedCompensationTableTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_ExercisePriceEightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price",
        "label": "Exercise Price 3.48 [Member]"
       }
      }
     },
     "localname": "ExercisePriceEightMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eighteen [Member]",
        "label": "Exercise Price 5.77 [Member]"
       }
      }
     },
     "localname": "ExercisePriceEighteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceElevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Eleven.",
        "label": "Exercise Price 4.53 [Member]"
       }
      }
     },
     "localname": "ExercisePriceElevenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fifteen [Member]",
        "label": "Exercise Price 5.11 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFifteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Five",
        "label": "Exercise Price 2.89 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFiveMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Four",
        "label": "Exercise Price 2.74 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Fourteen [Member]",
        "label": "Exercise Price 5.10 [Member]"
       }
      }
     },
     "localname": "ExercisePriceFourteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceNineMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price 3.71 [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineMemberMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Nineteen [Member]",
        "label": "Exercise Price 6.01 [Member]"
       }
      }
     },
     "localname": "ExercisePriceNineteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price One",
        "label": "Exercise Price 1.24 [Member]"
       }
      }
     },
     "localname": "ExercisePriceOneMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceSevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price",
        "label": "Exercise Price 3.43 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSevenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceSeventeenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Seventeen [Member]",
        "label": "Exercise Price 5.25 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSeventeenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Six",
        "label": "Exercise Price 3.11 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceSixteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Sixteen [Member]",
        "label": "Exercise Price 5.19 [Member]"
       }
      }
     },
     "localname": "ExercisePriceSixteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Ten",
        "label": "Exercise Price 4.00 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Thirteen [Member]",
        "label": "Exercise Price 4.81 [Member]"
       }
      }
     },
     "localname": "ExercisePriceThirteenMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Three",
        "label": "Exercise Price 2.72 [Member]"
       }
      }
     },
     "localname": "ExercisePriceThreeMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTwelveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twelve [Member]",
        "label": "Exercise Price 4.68 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwelveMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twenty [Member]",
        "label": "Exercise Price 6.20 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwentyMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twenty One [Member]",
        "label": "Exercise Price 6.30 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwentyOneMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Twenty Two [Member]",
        "label": "Exercise Price Twenty 8.72 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwentyTwoMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Two",
        "label": "Exercise Price 1.95 [Member]"
       }
      }
     },
     "localname": "ExercisePriceTwoMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_FairValueOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed of its fair value.",
        "label": "Fair Value Of Common Stock",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "FairValueOfCommonStock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_FirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Anniversary [Member]",
        "label": "Prior to First Anniversary"
       }
      }
     },
     "localname": "FirstAnniversaryMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of deferred rent that provides economic benefits in future periods.",
        "label": "Increase Decrease in Deferred Rent",
        "verboseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of license fee and expense reimbursements receivables.",
        "label": "Increase Decrease In License Fee And Expense Reimbursements Receivables",
        "negatedLabel": "License fee and expense reimbursements receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_IssuanceOfStockWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow of issuance of warrants.",
        "label": "Issuance Of Stock Warrants",
        "terseLabel": "Issuance of SVB stock warrants"
       }
      }
     },
     "localname": "IssuanceOfStockWarrants",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base rent per month for lease.",
        "label": "Lease, Monthly Base Rent"
       }
      }
     },
     "localname": "LeaseMonthlyBaseRent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for license agreement.",
        "label": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_LicenseAgreementThresholdDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of development costs incurred by the company pursuant to a license agreement.",
        "label": "License Agreement, Threshold Development Costs",
        "terseLabel": "Development costs"
       }
      }
     },
     "localname": "LicenseAgreementThresholdDevelopmentCosts",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount incurred by the company on clinical research and regulatory approval payments  pursuant to a license agreement.",
        "label": "License Agreement, Threshold Initiation Of Clinical Research And Regulatory Approval Payments",
        "terseLabel": "Initiation of clinical research and regulatory approval payments"
       }
      }
     },
     "localname": "LicenseAgreementThresholdInitiationOfClinicalResearchAndRegulatoryApprovalPayments",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LicenseAgreementsMaximumAdditionalPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of additional payments receivable by the company pursuant to a license agreement.",
        "label": "License Agreements, Maximum Additional Payments Receivable",
        "terseLabel": "Maximum additional payments receivable"
       }
      }
     },
     "localname": "LicenseAgreementsMaximumAdditionalPaymentsReceivable",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LicenseAgreementsUpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments received by the entity, pursuant to a license agreement.",
        "label": "License Agreements, Upfront Payments Received",
        "verboseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "LicenseAgreementsUpfrontPaymentsReceived",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LicenseFeeAndExpenseReimbursementsReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license fee and expense reimbursements receivables classified as current.",
        "label": "License Fee and Expense Reimbursements Receivables",
        "terseLabel": "License fee and expense reimbursements receivables"
       }
      }
     },
     "localname": "LicenseFeeAndExpenseReimbursementsReceivables",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_LiquidityAndGoingConcernTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for liquidity and going concern.",
        "label": "Liquidity and Going Concern [Text Block]",
        "verboseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_MilestoneRevenuePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone revenue payment earned during period.",
        "label": "Milestone Revenue Payments",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestoneRevenuePayments",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_MilestoneRevenuePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone revenue payment received during period.",
        "label": "Milestone Revenue Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestoneRevenuePaymentsReceived",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_MilestoneUpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone upfront payment during period.",
        "label": "Milestone Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "MilestoneUpfrontPayments",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_NetProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of common stock.",
        "label": "Net Proceeds From Issuance Of Common Stock"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_NotesPayableDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of notes payable.",
        "label": "Notes Payable Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayableDisclosureTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_NumberOfCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of share of common stock.",
        "label": "Number of Common Shares",
        "terseLabel": "Number of common shares"
       }
      }
     },
     "localname": "NumberOfCommonShares",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_NumberOfMonthlyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of monthly payments.",
        "label": "Number Of Monthly Payments",
        "terseLabel": "Number of monthly payments"
       }
      }
     },
     "localname": "NumberOfMonthlyPayments",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyen_OmnibusStockIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for omnibus stock incentive plan 2018.",
        "label": "Omnibus Stock Incentive Plan 2018 [Member]"
       }
      }
     },
     "localname": "OmnibusStockIncentivePlan2018Member",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_OriginalPrincipalLoanPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of original principal loan percentage.",
        "label": "Original Principal Loan Percentage",
        "terseLabel": "Aggregate loan percentage"
       }
      }
     },
     "localname": "OriginalPrincipalLoanPercentage",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_PaycheckProtectionProgramLoanAccruedInterestForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of  accrued interest  forgiveness on paycheck protection program loan,",
        "label": "Paycheck Protection Program Loan, Accrued Interest Forgiveness",
        "terseLabel": "Amount of accrued interest forgiveness on PPP loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanAccruedInterestForgiveness",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Paycheck Protection Program Loan.",
        "label": "Paycheck Protection Program loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_PaycheckProtectionProgramLoanPrincipalForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of principal forgiveness on paycheck protection program loan,",
        "label": "Paycheck Protection Program Loan, Principal Forgiveness",
        "terseLabel": "Amount of principal forgiveness on PPP loan"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanPrincipalForgiveness",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PaymentsForRepurchaseOfPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's offering of stock to the public.",
        "label": "Payments for Repurchase of Public Offering",
        "negatedLabel": "Payment of offering issuance costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfPublicOffering",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PayrollTaxesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Payroll Taxes Receivable.",
        "label": "Payroll Taxes Receivable",
        "verboseLabel": "Payroll tax receivable"
       }
      }
     },
     "localname": "PayrollTaxesReceivable",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PercentageOfGrossSalesOnCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate gross sale on common stock.",
        "label": "Percentage Of Gross Sales On Common Stock",
        "terseLabel": "Percentage on gross sale"
       }
      }
     },
     "localname": "PercentageOfGrossSalesOnCommonStock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_PercentageOfMilestonePaymentRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of milestone payment revenue.",
        "label": "Percentage of Milestone Payment Revenue",
        "terseLabel": "Percentage of milestone payment revenue"
       }
      }
     },
     "localname": "PercentageOfMilestonePaymentRevenue",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_PercentageOfSuccessRateOfOptejet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This refers percentage of success rate.",
        "label": "Percentage Of Success Rate Of Optejet"
       }
      }
     },
     "localname": "PercentageOfSuccessRateOfOptejet",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_PercentageOfSuccessfulRateOfTraditionalEyeDrops": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents successful percentage rate.",
        "label": "Percentage of Successful Rate of Traditional Eye Drops"
       }
      }
     },
     "localname": "PercentageOfSuccessfulRateOfTraditionalEyeDrops",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt period.",
        "label": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "eyen_PeriodTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the anniversary period.",
        "label": "Period Type [Domain]"
       }
      }
     },
     "localname": "PeriodTypeDomain",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_PrepaidConferenceExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets related to prepaid conference expenses.",
        "label": "Prepaid conference Expenses",
        "verboseLabel": "Prepaid conference expenses"
       }
      }
     },
     "localname": "PrepaidConferenceExpenses",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidDirectorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of director fees prepaid, classified as current.",
        "label": "Prepaid Director Fees, Current",
        "verboseLabel": "Prepaid board of directors fees"
       }
      }
     },
     "localname": "PrepaidDirectorFeesCurrent",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_PrepaidGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Prepaid general and administrative expenses.",
        "label": "Prepaid general and administrative expenses",
        "terseLabel": "Prepaid general and administrative expenses"
       }
      }
     },
     "localname": "PrepaidGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidLicensesAndSubscriptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prepaid licenses and subscriptions, current.",
        "label": "Prepaid Licenses and Subscriptions",
        "terseLabel": "Prepaid licenses and subscriptions"
       }
      }
     },
     "localname": "PrepaidLicensesAndSubscriptions",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidPatentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prepaid patent expense.",
        "label": "Prepaid Patent Expense"
       }
      }
     },
     "localname": "PrepaidPatentExpense",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidRentAndSecurityDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent and security deposits that provides economic benefits within a future period of one year or the normal operating cycle.",
        "label": "Prepaid Rent and Security Deposit",
        "verboseLabel": "Prepaid rent and security deposit"
       }
      }
     },
     "localname": "PrepaidRentAndSecurityDeposit",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaidResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development Expenses",
        "label": "Prepaid Research And Development Expenses",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PrepaymentOfLoanFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of prepayment of loan.",
        "label": "Prepayment Of Loan Fee Percentage",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentOfLoanFeePercentage",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution net of issuance costs to the entity.",
        "label": "Proceeds from Issuance of Common Stock Net of Issuance Costs",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ProceedsFromPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from paycheck protection program loan.",
        "label": "Proceeds from Paycheck Protection Program Loan",
        "terseLabel": "Proceeds from PPP 7(a) Loan"
       }
      }
     },
     "localname": "ProceedsFromPaycheckProtectionProgramLoan",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ProceedsOfStockIssuedDuringPeriodGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds Of Stock Issued During Period Gross"
       }
      }
     },
     "localname": "ProceedsOfStockIssuedDuringPeriodGross",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_PurchaseOfInsurancePremiumFinancedByShortTermNotePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchase of insurance premium financed by short term notes payable.",
        "label": "Purchase Of Insurance Premium Financed By Short Term Note Payable",
        "terseLabel": "Purchase of insurance premium financed by note payable"
       }
      }
     },
     "localname": "PurchaseOfInsurancePremiumFinancedByShortTermNotePayable",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the percentage rate of royalty.",
        "label": "Royalty Percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "eyen_RoyaltyRevenuePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty revenue payment earned during period.",
        "label": "Royalty Revenue Payments",
        "terseLabel": "Royalty payments earned"
       }
      }
     },
     "localname": "RoyaltyRevenuePayments",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_ScheduleOfNotesPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of notes payable.",
        "label": "Schedule of Notes Payable [Table Text Block]",
        "terseLabel": "Schedule of notes payable"
       }
      }
     },
     "localname": "ScheduleOfNotesPayableTableTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of warrants outstanding.",
        "label": "Schedule Of Warrants Outstanding [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "eyen_SecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Anniversary [Member]",
        "label": "Prior to Second Anniversary"
       }
      }
     },
     "localname": "SecondAnniversaryMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_SenjuLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Senju License Agreement.",
        "label": "Senju License Agreement"
       }
      }
     },
     "localname": "SenjuLicenseAgreementMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_SenjuPharmaceuticalCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senju Pharmaceutical Co"
       }
      }
     },
     "localname": "SenjuPharmaceuticalCoMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised on cashless basis during the current period.",
        "label": "Share based Compensation Arrangement by Share based Payment Award Options Exercises in Period On Cashless Basis",
        "verboseLabel": "Exercise of stock options on a cashless basis (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodOnCashlessBasis",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_SiliconValleyBankLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Silicon Valley Bank Loan.",
        "label": "Silicon Valley Bank loan"
       }
      }
     },
     "localname": "SiliconValleyBankLoanMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_SmallBusinessAdministrationEconomicInjuryDisasterGrant": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of small business administration economic injury disaster grant.",
        "label": "Small Business Administration Economic Injury Disaster Grant",
        "terseLabel": "Small Business Administration Economic Injury Disaster Grant"
       }
      }
     },
     "localname": "SmallBusinessAdministrationEconomicInjuryDisasterGrant",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_StockIssuedDuringPeriodSharesExercisesOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exercises of warrant on cashless basis shares.",
        "label": "Stock Issued During Period Shares Exercises Of Warrants",
        "verboseLabel": "Exercise of warrants on a cashless basis (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExercisesOfWarrants",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_StockIssuedDuringPeriodSharesNewIssuesThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents common stock issued during period.",
        "label": "Stock Issued During Period Shares New Issues Three",
        "terseLabel": "Issuance of common stock in public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesThree",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_StockIssuedDuringPeriodSharesNewIssuesTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance of common stock one shares on public offering",
        "label": "Stock Issued During Period Shares New Issues Two",
        "verboseLabel": "Issuance of common stock and warrants in private placement(in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesTwo",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "eyen_StockIssuedDuringPeriodValueNewIssuesThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Stock Issued During Period Value New Issues three.",
        "label": "Stock Issued During Period Value New Issues Three",
        "terseLabel": "Issuance of common stock in public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesThree",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_StockIssuedDuringPeriodValueNewIssuesTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance of common stock two value on public offering.",
        "label": "Stock Issued During Period Value New Issues Two",
        "verboseLabel": "Issuance of common stock and warrants in private placement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesTwo",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "eyen_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Option"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_ThirdAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Anniversary [Member]",
        "label": "Prior to Third Anniversary"
       }
      }
     },
     "localname": "ThirdAnniversaryMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_UnitsIssuedPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity shares issued.",
        "label": "Units Issued Price Per Unit",
        "terseLabel": "Units issued price per unit"
       }
      }
     },
     "localname": "UnitsIssuedPricePerUnit",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "eyen_VicePresidentOfResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vice President of Research and Development"
       }
      }
     },
     "localname": "VicePresidentOfResearchAndDevelopmentMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_WarrantExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time on warrant exercisable term, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Warrant Exercisable Term",
        "terseLabel": "Warrant exercisable term"
       }
      }
     },
     "localname": "WarrantExercisableTerm",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "eyen_WarrantsAtExercisePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants with the first exercise price.",
        "label": "Warrants at exercise price of $2.4696"
       }
      }
     },
     "localname": "WarrantsAtExercisePriceOneMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_WarrantsAtExercisePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants with the third exercise price.",
        "label": "Warrants at exercise price of $4.7600"
       }
      }
     },
     "localname": "WarrantsAtExercisePriceThreeMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "eyen_WarrantsAtExercisePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants with the second exercise price.",
        "label": "Warrants at exercise price of $2.7240"
       }
      }
     },
     "localname": "WarrantsAtExercisePriceTwoMember",
     "nsuri": "http://www.eyenoviabio.com/20210930",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r171",
      "r198",
      "r235",
      "r236",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r355",
      "r383",
      "r384",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r171",
      "r198",
      "r235",
      "r236",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r355",
      "r383",
      "r384",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r171",
      "r198",
      "r233",
      "r235",
      "r236",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r355",
      "r383",
      "r384",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r171",
      "r198",
      "r233",
      "r235",
      "r236",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r355",
      "r383",
      "r384",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r127",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "verboseLabel": "Accrued bonus expenses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r270",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r267",
      "r268",
      "r269",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r238",
      "r240",
      "r272",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r211",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r167",
      "r211",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Issuance of SVB warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potentially dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r113",
      "r116",
      "r122",
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r279",
      "r281",
      "r296",
      "r319",
      "r321",
      "r361",
      "r373"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r46",
      "r81",
      "r134",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r279",
      "r281",
      "r296",
      "r319",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r29",
      "r73"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash",
        "verboseLabel": "Unrestricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Cash and restricted cash consisted of the following:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r12",
      "r74",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r68",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - End of Period",
        "periodStartLabel": "Cash and cash equivalents - Beginning of Period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r297"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase in Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r214",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise Price of Warrants Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "No. of common stock per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants for purchase of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding at ending balance",
        "periodStartLabel": "Outstanding at beginning balance",
        "verboseLabel": "Outstanding Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r214",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r154",
      "r365",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r155",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r84",
      "r85",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 90,000,000 shares authorized; 25,963,185 and 24,978,585 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r231",
      "r232",
      "r237",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items.  Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "verboseLabel": "Accrued Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r216",
      "r217",
      "r228"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred license fee"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r58",
      "r81",
      "r134",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r296"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Aggregate principal payments"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r80",
      "r82",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r308",
      "r362",
      "r363",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r38",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "verboseLabel": "Debt instrument effective stated rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r39",
      "r171",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r80",
      "r82",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r40",
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "verboseLabel": "Debt Instrument, Periodic Payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsNetAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net, Alternative [Abstract]",
        "verboseLabel": "Debt discount:"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.",
        "label": "Debt"
       }
      }
     },
     "localname": "DebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "verboseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred license costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r17",
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent - current portion"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r19",
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "verboseLabel": "Deferred rent - non-current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r71",
      "r112"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r47",
      "r284",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r97",
      "r99",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r293",
      "r294",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "- Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted Average Number of Common Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r99",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r293",
      "r294",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "- Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Total accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Unrecognized stock - based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r108",
      "r135",
      "r211",
      "r213",
      "r267",
      "r268",
      "r269",
      "r276",
      "r277",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r385",
      "r386",
      "r387",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r71",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Relative fair value of warrants",
        "verboseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r185",
      "r209",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r71",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Extinguishment of PPP 7(a) loan",
        "terseLabel": "Extinguishment of PPP 7(a) loan"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r57",
      "r81",
      "r113",
      "r115",
      "r118",
      "r121",
      "r123",
      "r134",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r296"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross Profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r70",
      "r356"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred license fee"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.",
        "label": "Increase (Decrease) in Deferred Charges",
        "negatedLabel": "Deferred license costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "verboseLabel": "Security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r111",
      "r305",
      "r307",
      "r368"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r60",
      "r182",
      "r187",
      "r190",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidCapitalized": {
     "auth_ref": [
      "r62",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest capitalized, classified as investing activity.",
        "label": "Interest Paid, Capitalized, Investing Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r8",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements, Gross"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r81",
      "r117",
      "r134",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r280",
      "r281",
      "r282",
      "r296",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r81",
      "r134",
      "r296",
      "r321",
      "r364",
      "r377"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r81",
      "r134",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r280",
      "r281",
      "r282",
      "r296",
      "r319",
      "r320",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r176",
      "r186",
      "r188",
      "r189",
      "r363",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Gross loan proceeds"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      },
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Notes payable - non-current portion",
        "verboseLabel": "Non-Current Portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Minority Interest Ownership Percentage In Company"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided By Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used In Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Cash used in operations",
        "totalLabel": "Net Cash Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r49",
      "r52",
      "r54",
      "r72",
      "r81",
      "r87",
      "r89",
      "r90",
      "r91",
      "r92",
      "r95",
      "r96",
      "r100",
      "r113",
      "r115",
      "r118",
      "r121",
      "r123",
      "r134",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r294",
      "r296",
      "r366",
      "r381"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other Income (Expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r18",
      "r363",
      "r374"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable.",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current Portion",
        "verboseLabel": "Note payable - current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r115",
      "r118",
      "r121",
      "r123"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss From Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r195",
      "r288",
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureBusinessOrganizationNatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r15",
      "r360",
      "r372"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of private placement issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r241",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r6",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "verboseLabel": "Prepaid insurance expenses"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from sale of common stock in public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock in public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Loan received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from sale of common stock and warrants in private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Cash proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "verboseLabel": "Proceeds from SVB loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r63",
      "r266"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock warrants",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationRelatedToWarrantsDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r148",
      "r321",
      "r369",
      "r378"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r234",
      "r313",
      "r314",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r311",
      "r312",
      "r314",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Payment of loan issuance costs",
        "negatedTerseLabel": "Relative fair value of issuance costs",
        "verboseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayments of notes payable",
        "terseLabel": "Repayments of loan"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r275",
      "r357",
      "r393"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r12",
      "r73",
      "r76",
      "r359",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Amount pledged to establish and maintain a collateralized money market account"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r12",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Amount pledged to establish and maintain a collateralized money market account"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r213",
      "r270",
      "r321",
      "r376",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r135",
      "r267",
      "r268",
      "r269",
      "r276",
      "r277",
      "r292",
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r109",
      "r110",
      "r114",
      "r119",
      "r120",
      "r124",
      "r125",
      "r126",
      "r226",
      "r227",
      "r358"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Operating Income"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of anti-dilutive weighted average diluted common shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range Table Text Block",
        "verboseLabel": "Schedule of information related to stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r245",
      "r253",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "verboseLabel": "Schedule of the stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Black-Scholes option pricing model to stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r214",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "verboseLabel": "Summary of the Warrant activity and related information"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "verboseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Number of Options Exercisable | Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercisable | $ / Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options Forfeited | Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of Options Granted | Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Outstanding | $"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r247",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options Outstanding | Shares",
        "periodStartLabel": "Number of Options Outstanding | Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding | $ / Shares",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding | $ / Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r239",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Exercised | $ / Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited | $ / Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Granted | $ / Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "verboseLabel": "Options Exercisable, Exercisable Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "verboseLabel": "Options Outstanding, Outstanding Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price",
        "verboseLabel": "Price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting rights"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Period of employees stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r259",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Life In Years, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted Average Remaining Life In Years, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "verboseLabel": "Options Outstanding, Outstanding Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options Exercisable, Weighted Average Remaining Life In Years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r31",
      "r380"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-term Bank Loans and Notes Payable",
        "verboseLabel": "Notes payable - current portion"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r43",
      "r50",
      "r51",
      "r52",
      "r84",
      "r85",
      "r86",
      "r88",
      "r94",
      "r96",
      "r108",
      "r135",
      "r211",
      "r213",
      "r267",
      "r268",
      "r269",
      "r276",
      "r277",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r385",
      "r386",
      "r387",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock option activity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Changes in Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r108",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfDebtDiscountNotePayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableScheduleOfNotesPayableDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityBlackScholesOptionDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfInformationRelatedToStockOptionsDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Aggregate number of shares issued including over-allotment option (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r211",
      "r213",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options Exercised | Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r211",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquitySummaryOfOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r81",
      "r128",
      "r134",
      "r296",
      "r321"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r213",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r304",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r304",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r304",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r304",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r322",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r185",
      "r209",
      "r290",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/DisclosureNotesPayableAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.eyenoviabio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAntiDilutiveWeightedAverageDilutedCommonSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "- Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r97",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "- Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers' Compensation Liability, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.eyenoviabio.com/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r394": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r395": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r396": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r397": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r398": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r399": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r401": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r402": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r403": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r404": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r405": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r406": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r407": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001104659-21-138092-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-138092-xbrl.zip
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M.W9OJ,2@*7*+UC%QZ&(;18_ 1J]"_O@_4$L#!!0    ( #F";%.HSY=B4 T
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M(+T*C"QU]==:8:T[63T7>QA5HJ3X0VI$^(UZB#^ -_#D(MGD.[Z+[B?Q3ZM
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M31^@L8S^0=E/T=3$5R B>[QETZM1LD5<ET5;_VA-,:=6++_D-KC%"K> T1H
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M'66%@&[XPLN\OB_8@+.RV3.SSTLKT#H&"\#,C0;6_.+EI'S.>@'SBK:.QE*
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M<X0(-U[%#%3Z+G6V-8B1"%#.*!4(/1$]S0@JML7*X9QZ^@IZ&P\O00N"!_^
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M!X1U'';#>[ ;YJEYTRC@_^,1F">F@_QX(#GW"%DSC=+E[EJVW9_=K"5!X)(
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MZR8.?9L1)@]5Q4?SY*$G!8*$*IAIYPP%+)1IPD;7BM)1D -!*OEID':&J,!
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M,:( Z(P#/SH5ZJ&N$$-&18D$ 40I!-.KV^33Y88L6>DVY4DLR^*AA8?2)8L
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M2IC![^$_O9+!YGOW?@SZD14CC[ZL@$$<*-R2_X"SS.;W^T!@"[Z"U<%Z+T%
M+/>CX;6K/84,Z,D_X/6A) .__/;N-JTS53IO#!+^.^O8;+[R\/>@WU@]^-B.
MZ6^HV**7WWYU]S5JL )^Y->?U@^$(ZPI4%*#P7UL%;O##R[#@'ST,0.C#]^
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M4[,JVUH?(KB=J88?!W@,"/W1@"UC7@XJZ\$MN'Z*E(B3FHY@(;55P_A8:0>
M0+JKY$*C%*NVMC4677;CON&:X_P,J-OG2?5PEF_H_[S^YR%]3#+"5W56GR=E
M>4SS^]^2[*"+@QUQ873?2S#9%IP0@]N&!U=C;2-(K D9^X>$OD))C1H*B)&
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M\O>PXM$GA3 VI9)0HM"L$3_.ZB5AQG$BY1F6.6&"GUOY!&0.:)"G6YZA6/_
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MO3IV(-?)D;TY2?C<7.U9A]]6T,N<RW^5GPN^:>VYVD,M/B:$1PLTD9T'7'A
M((\91*KQM?*V )V9&"HX-?1548J_'/*TKKYNG?!&X7E%D%<_8+0^E+3%!U#
M!S.'C":="C(Y\L!(&AG='9$,)T9';'@DQI><//%YPO]?T8,W,=V,"QBG#S.U
M\B(A\IYBJ@*N%(:]>;/&-7P.#\VG$(@G*C6+Z)0R&V%'%8^:6!SI(D\6M8HH
M-KA)1?20\'S(6!=0Z@.Q(K*)(RSUDE<?DZYXXJPM!.@<5^"[2K/).O8SX:H
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MA&TKU@Z&QL]]D9\C<TJ^R=:@4UFV4YF+%[/H7^F_:5T;.O")0]TSL$D[T,^
M_NV"YO;6*<L=DG]GF%4"YINS75'6Z;]4.44_5!C_XR.6[$]<\(+[!W>F1DHJ
MHZY0B\SN*<OH,$'$3(+Q9#2UK/K()*/G)ON9NS;(//''Q.E3$\4A'R[G5FB
M0PT[\^U!AAX4YO#"QL_8+^_HCU0G9%3ZWQN"C#8"._#QP10Q],P#E%$] 0%L
M9>_+BA"Z[^*H?E^74M$  W9@U+(^:L,X@H3IQ:AA0WUY1%&A +.\^K$^8[W
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M=V6W9/2S3^G0"_NAPBB'CUBRSKC@!5<E=Z9&&B8RB@*7IL8X]I>5R!RL$*6
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MX2-@4!77L*[0\0$DE)(KV=!J2@,=BYK[<;\7U5@1:'K3SNB&Q\+2\[!FI7?
M@VU#915(U8Y*BP36ELK"D;8]U;-F<R-A+FLL-6UQ8S*5J2+QWCESO?^MZT_
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M8+\U#0,LC$E8&9IN"H(TXK392@)A OX2JAB?JO(SQ>/OB0U63B=O2DB8*-S
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MC;]"E /$6$ 2#RM$N4"4C?Y!.=3&%FJ&V31LZ32TU5Y3C\SG](%L2VZ:*@$
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MBD[B5F3Y%%5% =X2$'C V_P5)OA#X_'X?#SZ-"H;JO[3";Q1WNJHVFS6?03
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MJ4M<4E"P=,E_Q5!%A<X6[A*XW]'?$N#BWJ)_+2)G]25T=CV"Q2K;KR42Y*'
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M;</@(QSI"!) TM5F1Y<:Q3IM3AIIT?0Q@C%Q@J"^HB3V?A.8*Z>?D@^]2!_
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M[AQM/#'\+H'@NV'0A^&/#MFVP=PO'-6?;SU\QOIU^^\(/CJ69P>?@NZ+AXU
M IH>!4*(./DHD=V'QTJ=7^3QN<I//;^48HTGEAG,$S\*)6E(CK,!G[-A?JN,
MKN:,DRSSR4Y!'Z4GA)+UDZS-2$!0E]E^"J2I]35@QP**P-'.F&2N<%B6>7KS
M]G$.&/@#7G]4X<L6$\,/YM=#BZD:_#7H[-K5_5XC\N[? !Y'J/S[]]$W_+L=
MVN- ?A^C>A)4(!X'[4+0^Z4>ORZ"(BB!X.3C<QY_>V2?^L*EVU^VG[<O^7V
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M'*V12+QFZO'PNI[0H>%Z*R8WM@'=1\.[#H8Y@@:QDVPNV4&*Y,?)1!TMT<3
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M[06#N:OTQ=*Y(A\K"Z4$7S\:?I[57?%!\UM:,P!\/ SE]MR4[6 59"XO)BC
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MEL.UT41?<'<Q%2C:6#*<?^[0N]AZ,[5_[K2%^V!Z8]5R-S_?Q4QI#)GA.<A
MDB8/OMIPINK_A]_I#.<F)=M>0BZV),,#=S$'"@0$3]ZLOB"0S@AD2%+V5R=Z
M.&B,6I5Q3:3]E2H8\2N.HK\8&OO[]R$O;C0[CY0Q4L9]9<1PD<!\;41%K%P2
MZP0[EGBJU4Y4:6>PZ/:^7!N5)F*6>S0YXG'&G3FTD!XJ!5\;*7\7G5\$C?UB
M_-UT7M3&F\T@GT0!=>"XMJ:X8!T'?+-H/$R!:Q2V?W\[=ZF@8Z>E'S5XNM#+
MCA-)OLY/RST\WQPEC3H]$!D__*!AY!'_A:+H2=%'9 XB<_#]S$&P^Q!^N]E\
M"O2![1_D9&B*OS<.-$Y.E,I_;VW\?DH7H31":>A0>EL9\=81)'W[OYDK/!(/
M%EA, +V,F]$S0Y !$@JZ\SX' UB8 &._*!1](Q[\+OEO<>,N^P $Q7"PF 2?
M;:"-9<]VUIOWP8\*@,&V;("C/C6*B:.8^/O%Q#>1(H,E,!\V6IP& .;&_%J%
MZP<:7-\I\!%KV-6-;'V\&*;1=@IG=3HOI99FL"D>3(]9"OV%,5%R'!F"R!"$
M.0(ZBR48+>;,9)YM&KJ&#O-F*ZW8[?[ MP3^S, OEJ)^H03[OL HS/%/U083
M27N,>]:G/5O!"5/*IM%,VBQ#B9*TTVW7%1? 7K)M=6V9KDW<M2W7I:K\&UW<
M6"UHOX*3WM9]GB]G<IC72]/NJ))$@9OAN6I56U&]@;]+K]]9\ O#B5\X\YK%
MBO0YTN<?K<\7J\5\3*$;W6IO49^-&53"T#K?+,SX<3O8=AN&(&2<^$72W[(S
M(5Q1^&T:MQO.P+Z@<_KJB56XA!Q!/()XJ"!^,[DSA@<O:%JN9,0.%V1%<?4-
MJM_-:=E-Y[EO!<"YE8O97,G*Z6W-K@$CSY>$87"8#,QH83I+QME?!'E:03Y2
MO4CU;E#U+I:2OJ5[ E%P^]T::0J59&9BCCFN72\,?-V#R2=!_")8#.I>/,H_
MH^ \"LYOSG:%2\@1Q".(APKB8<\_@_E::P*'M%PWJTT];>)/:O^*F<"-PM\;
M5+R;TZ^;SCRWVE,U)-/U&T2V"E0&QX+A1;S2YY%N>:5+)7EH3-6<4FD/_*-*
M@ZE5$B-^X6BT9CM2Q&^KB!><&GV7)DKJO-*M]?@^[YDBX2(S"VMA-5\3_;24
MI7X1KS9HWG).V@"*9T-%A(P.CD"*(O++1N37[H:X3L1^;:JO;>@N%7%LM3>U
M5MXCIHU;KHK#1:] \=I,S\BH.ANFZ."0<S_(P-A?*/%:N2TR I$1B(Q R*.=
MMZW :FA.51GO%83".&N8O%QP"I.Y;P6H4ZS #50N?L2VU%$2=5M)U",UM[PM
M=02Z;P*ZFTU3CS=&O=P0%86JEPI5"1BTJ98G&^ ZL>K131$O&J9>@>)KQZF7
M;<PZ$IWRJZ11Z_2DLEY1ZQT#+0L(WQJ(6+!]&$[^8EGL5YRFHC0UTOU(]V\T
M1WU1^2=)#O>:?($2QDIFQ65H@*_LN:_\ZY8P%J5^T=0[R^^A"E^B[#1*%&XJ
M48A %X$NRD[? \+7SEDM:E* 26VS_47#M11]"'\#MA-L44C_%?/GI]WE-SR+
M-70Q;4CT]EMU1'[C Y<B_/Y8_$9IQ;=1P5O6M.^C4!'H(M"%P8K?3%JQ7?J_
MET%\MP-9H_CJQ\97$7XC_-XR?L.>'SS9BI53%"@.UXE-I*6_/6T4EX56K:*C
M'Z_?J[#1ENI:65[>T8)!BBUAY3DTF@%)!+,<DBUF!R).K!?Q40SYBR:(:!%?
MI'W?4/LNURUPJOJ!V9RDJ5X"".WBM-UHL$!J \Y7O^"D&9*"*DA]R_UDGKOW
M_\?>F_8HSF1IP]]'>OX#RNY^U2WA:N]+]=TE&3#[9L!LHY%EL 'C#6R,@5__
MVB8S*RLA]P4#IS53=R4991P1Y[KB;'&.ZT=M5ATK*@>K1-,$71MT;2"M[U(9
M>HYK:*Z7?0# .\?-]FD"FPR]_JS3V':,=KO:Y-@*YEC#0,;)V_KJH?Z $Y#Z
M"- &:)]0'WDGMKFLC8A5A49U7%O."ADTR%!BA.U8.<$H-$TS^!EG-CZA@SS3
M[<7\[<H&$^@,"0EXY]NZSMVBZ;:]@W?7W^%!,.AIYA'M+4$L^.)6L/)9O,TN
MZ#';"IDG+BU$47B:>*5. 8 $0)XA(+^F^]M'$#F;V,@F:U=:AB;B/#E5!:U5
MCA&Y=U2PH2[ O5$7.$M'Q7TK^5@?0.XU@X7C@L_BP@R;),W^.HCOJYP;=ZAM
MA5#-AO_55T]3W;+7PWDE'YHW> .MXVI/W.KKJ8SO2PY%'2X9\&< [ 'V"=9W
MWH-[MR9C5F\YV4E91@DFU-I9&DZ,^U#%8=(L>D&-;>^U&'/?$3@UT2"CXJ(9
M"8CG._6-;/A-T8OV]-4LZWOA4O^VLY[QN!;S+61'DLQ$6.*C'2/H'7;H\#+.
MQ*H'FD;1^/_!]0'0O7KH?IG.\$[L+DTD*UL[KX?Z/$<'(\.SUT&,W<A#0KX"
MNY?B(JD[*^T^3Q-<)%==G35)JP-E7+^TEO,LA'='<ZV,8AM51[$C!W-,!;=9
M<$<XT_*E]8I0Q:*T;*,+M#\N2-M-R)EQY2PFC;,X>%N 09*S.L @7UL(^AT4
MLLUSMBS/5W.CLEZ;\S6!UO+S:40AH=K%,6F*.&>WS4D,B/.DP.2;@A<4!0>Y
M!+F\-+D\?_/[C_K21V[?@]Y\05%*R+I.N$'\JKRJ%FM*C*SV=U)6)*7:*.M@
MPR$?O5%4.QI-,QB7)ICG5%B ,D 9H/S%ENFKL%QUG&VK-V,GJ+8F>JZ->RMV
M%T18CB( ;!KCV!#+S[FSDFZ./G+T_X':_2C$U":K^.O!) "3( G$ Z8JR.6E
MR>79FJI'$NC#DQ"!"#$HMZ#<)B8WON[8XR>U7**OXOB4R&!&3QF2\JS6SS9V
MHDS@L<5*IU$*K%4 -  Z45GOSR+:T=K+'6MD U3OETTQ2RGB8,E'B(Y:&+%1
M$; SMEF/)*2]4N6X"B*"!)%W&P^G7H4W\%?<J 6'8N8@Y9<LY>=U2E<=>QHE
M.[V0X#0J,5AGDT'#-U61<N!,<DPP#V0B+A%(T%2:Q=YX/)^-JR!!>O9YTAY8
M&:>W,I*ZIR#1(-%)=VHGZD ZGF;U0GK558#R_+7KSXXKG7IRIU::OR&GZHBJ
M/%]O\JX_=4K2LK##&U:GG5?,J4Q0=\E4))4F"1:N3P-P ;BGRZ Z@EQ?+>G4
M/.B2*")L%Z.URJ&YLA@A=Y\Z1:-XFF4NLA!^LO3B\^0QL J2;A5 #S60W\N3
MWZ2;K.$SLXYEZ2M+BUJG1?7,HR,__$;-'H<G<>J?D?-Y/ROF7Z &GR'*+@=,
M('0@=$E@<# ;0.TZ8VQ>@=H%\@OR>\[R>P9F0WOEC(V98ZJ:Z\7)8\Q_4L+2
MCP04-+8S1-7E@ >$#H0N"8Q]'F;"HQO;3??N]IT7$7PZ]??GHT@Y?:VK6AQ#
M\F:*JWFR;3I9NM+T26DYGN@YE66WC,5_- 9<JN??$$NZGT5\2C45M^&V5\I*
M4[N*Z6M-S6U'[_HXS%177%=>ZH,9ZZ]1%]5Q;IOW6EN'J/+APG_9,KPIHO9M
MZU#-^D8'I3J2U-NN)^HFKS9;3'#S*X0@BF)'XFR//D@M%#>UCKXF_=I Y.W*
MX4*O9Q#\G!2L*3O7M1Y;:@LG%:!XE3S>7\T<-X20>G3!6BVL1#G60I0LI8,X
MT[8H#8GI2X+S_LE_F]B\:O;#?BX;!-Q<0K<MME/TB]42UQ%O?M'/E+5^+#'[
M)4@I]]_TGPN1G)+G^4^LFX54*PU\NMRARFA=Q?)S&9W.7Z2;LY&:9V;>J9<-
MI3;3=,-J+<2-6YULJU@X\S=(BAX_?=^%U5]YT:*$)V5*\5+.)-76%BO-&FEN
MBD#3J6BOXX$Y;1Q_NC_ "2S^53@@?-Y""Q^_ULPM.!+ D7!6:FG24_9VFNNH
MBC=[GC)BI>1([L]:K+,505*&DE^C)(ESB[*S"F0R+H%V?W$-;I0#A@'#7YB]
M]S$0<YN=MC'F]%AHVQ8Y7L^[I9S.1R"F7P/BI'M$'YG145*%8Y^U#;V?PML-
MQQHV=$FB;%)2VPDT/R<V-J7QN1K0[UV$-3NM%(P2Z:!:L5N=T$5N*PKBM5C/
M#U;M5<:CJG047"QTYD)OFT7S1AN3UYWS-(+>.O4</LF(-64P0Q6YT=)I6>MX
MK5!0N.=ZN5VDX7RP<HW?)MW1I2,\O^X+_=$&M6I\0QYF%YTQ&BX=3J4YFDAC
M[&$V>&P!7H)4O;0V3(L64(M&%\)V.QEK:EVK"D(0K@V9YA@V31U;FULI^D/3
M1#QMC.@;9*]F_BS&_Y&)HKHC"!LI&#TT:%:$)=>VE_QC+?5#)^O^Q^A!X4N&
MJV3N/PFT2&NZ^^B!-A55%0U?8.\1N%>"X__L-_WE6:E<H'4'!5XSEH&UQ2K(
MG!5T,0FS>N#<>#RUKW!U7(4U=,Y&3^)L&^Y-ILTAGO8/^4$ETWOQ6FI^RO39
M=4MLDU.YHK#=4"7#\+J-V2@T?;#XUF&:XHY5?(9"LX!.\#Q\#@ 7/#]LEG*$
M("P7:G&U92?H:B1& *0C )+<<S=^+R6RSX=?%DU-,4/C4E<1W4Z-E86^4DQP
ME8*K-%&$=<7JQ&^4-D.0ENSL'J+'RNPVEEIGS?FTL"R3BMU?==K9?DAJ<9E=
MCDF3))W&\&,WHB'9'T"?/-!?MI;R>EP+M6YN,&\Q(XENMR>61%8SG740X3KJ
M5XJG&1)/$RA].;$2?CSV+=^,'.OAXD[TL;X"NP?JK22_WDK$0O\\*^VBI:T4
MW=9407'M<*6\!]#+[9$7$E(XU?_>($>8"=VV5K/\9.8(A=7 H;+\1&XBH<9!
MQ!H'D0Y?.$T=*04.]\8!SE<-YR_3*CZ&9S.++;S-TA:D=E;(3NG94,QMIA&>
M0TV#B2P(-,UAA\TZ_G4!SI%DF0SGR6Y@,"7:8$K6)H.(@X@G2L3/QDK^HYKP
MT]>N0<D&)?OT2O85N^X?0G,/R6.Y &HI7V\*TDS2ES@[+?5E'^^$.G=<@9A,
MXY'3_F@!8L@' (PG!..7[:E_%8R#DNJS:W^7%=I&SB-P/$<5JWP$XZ@<,94F
M4"+-'DFR!,L9S HP*R[9K  1!Q&_<!$_3\OY07^!.#L>+.FOT+*)4!%5'3]J
MHWL2-?OO7Z5A?^_$KMB,?H!3WE9?I8WCV1[G,Y7&1%!*/;HH;&K4I!YJXTR<
M8$^F.0Y+4\RQE!FPJ@'O2<#[99O4[X#T"./I-6,U<@8^ZVR'3C8WSI%!!.FH
MJ2V1YE ZS=#'+L?^H:7\>Q4US?UZ_/T>&%'N*]'XZ5(SUL(M=?]\S<Y,2RGC
ML6.%7[N-JB/9<:][Q0T_ME-Z^ ^F;GPEP%U%5PE7,\W3(MD(W]K3U-1$MQ5[
MK(<CO.CJ>]PFXL<GOOUKEI1Y_9+^6]77O_X*_[A[RMC4%#=B@-GM5]WC._K*
M._RC__@2%/^Y'SCY0#7=3QA_\-+QG__O?QZ^_*&Y<<M$#V8UV]\=Q6-2FFK(
MR-44 U$FX1?_5,Q V7JWLV39'SAYQW(_[]DL6H<4]8-E_Y'Z_==H-0Z6TE(V
MR(,%NZ5 )+JC^G/_K^X^BMGK[C/'BQ-??[J:J41W3J-G__'4>%=6SN(GCOV(
M,D*M\,?;66'D#_*+MNF1N4 \T*:4U,R-6/%OG48V ;=_.Q&%1=C,1HP=XN]>
MX)77"/V?FW9L-Y28=&5*PPB5I,8R16.:3+(*(W-C2I-9"D5)C%-14B-O]M_Z
M.5OP</:C\#QXELKV!MWO71(&0KW1+?'IO;5>JF?WM+2?3/N>K)Q)8Z&Y2C1I
M3\9ICB+Q3YW$"_3[U^B/;WDXVZA*S!W-_G[?:*-_O_%?_QY]XUGQ[,O^T[<5
M7PU5*/5?G_Q6'U9K;P5XI$U8CAI1,A6*<J@J4*P\(IA08]"PL<9ARD@CF=N]
M5^[TC!JJ%[P\W=!0I-ND#:(WYLN90 [5H,<C+39;W6*8T#2R33[+-Q>!U\.G
MX4CV\<@FNV)Z:RJH"/J:=-UN#7&M0)3QPV>66[.FU*FK74GK=+,[H^U+ZUHT
M\N"9E4RV-<LQK(,BUM 2J[AFZ30O$X?/K#.UOBGXA4#PV5'.Q/K9ZA0)PI'4
MP=S;E5+'QWW/P%5'V R8G6F-HY$'W[Z17<2;<"R+]OR%37#=GC.I1R,Q[/'0
M_&;@VDB'QHPEI[>ZA%$?M6>B3,KHXY'.?!*@DT M&$N_,EI[Y*2?'XLR=3A2
M+@\U=-$F44/G1NM./6]P>8L/1QY,/L]ON[NE0+NH[PS6FV'1J-65J1Q'5Q^-
MS%A"#LW-*0/?9=>+=3 /<NWHF0?+-,B@]6Q7*N>%RKRM"%F>=-1E]$SZ\<@Y
M@U#CN==SA'9YT]6"[@(1M2 <>;"@5##/S332U5"Z,>^NJZIM5&;1W \7U%?\
M;JU$D3FCEQO)W&05..-.]/78P>R%^<+MCU9U2=)+J.MM\TQ&Q469/EQ1NZ#U
M^VM_$QC(VNVNMGW)T9QHY,$Z=>2&@?=S%4.J,/0ZOZGF<J-L$(X\F#V]62_:
MV0;&"!5TNBY6Y?I&+4W#D8<O.A4VBE=>Y3QAVYGF9TYI(^1M7F8.7W2X)HBV
MRZR7DJ8*X?)Z;JM*BS)S^*)4 VMV&86M"DJ]8AJ;"3G+=**1!R^Z*B"<W=\@
M>6'9T":<H U"K$[#D8<O.@BP:<?N>9R!MS6ME1GT2H(YE;G#%\7R37/ %J9U
MH\"6$$1F9CY&B#*&'@XM[?I3?SJ<Z *]G&S[#7DWV(18QK##H?0:1\NH/LT*
MV4QVLAOJY>[4$B-+[6!H4"FR,UG(U0V=++4UB2ZHFVWXU"/(RUM3=ZRO9PL!
M;RHUJ6153&D<#CTB*(N:FJGO2@72R+K5>GU:]ZW)).3'(ULUZ$V9N9:?="3%
M=VL#;Z+5,S(?#3W8*\<D*4FD*B5)$<7IP),=>JK&0P\Q-9FVMF9C5T9]R3"U
MI;GU\YEI-)1[/+3K#>HM7\B6C:RCZZR$%.UY$#Z5/7S7L=O:L4RQK@K*8K(N
M-OGII+@)HJ$'+[#6J;5H-$8%H9)QG9[$%CC5BI]Z*"YJD5B,0@RT))WH-E4J
M,RSED/!EC\@+,Z%&Y0:;Q:6ELM@HFF%UEE(\]. -VI1A-3G/,@6KERFU#;9)
M,H@8#3U\@[ID5R<TU2?1-KTH3W-E7FZ'I(H?$4/?76_$9HMQ!'_ 5M5906WV
M,N'0(V(83-<U8I'3?:.08>LH0V'MP2@<2AP.+:!T6QJN,F,C*V<&?$7W.!,-
MHJ&'JZ715@G%-YY$ER>[%EWO]?N%^*D''#RK;L5572^14A99RHUU>5%&@WCH
M ;6N.RU]DR%&:+BU'M[3BKI0(.,7..367<^:.&J V<)65VS-T-HNKD]E_,@9
M-&MM2H/I*!BBRP5B-7J#76[1Y$.-\G H.\G@>9:K;H6VN1.9H=)3FG[XLD?D
MD)1D9(Q/:=NPAMNB,V)QPF'"H;\%)G9@W!N$>Q=5: R:X>2TGW=_>:A112;4
MK?D4*?_CO=%P9_W&UIKBKYR[#_:V6OS)'Q;= R_7[9A#@WGEWKW8G;VV5^%>
M%Q>BL!\4]YS3](%%\^#Y3OC,B>D$=QKAW<](Y-'[N3=_@W"=7K0\;QT!\1??
M#55&GF/Z*^V+3<ZG?1W86WT=MW]^T+%+LK 1"=@(] >'PT8D8".X'\2S60>P
M$4!-U[410$T)V0B@IH1L!%!30C8"J"DA&_%B6B/L!'#3=6T$<%-"-@*XZ9-W
MXHU9X"]Z^[YOUNRQW(-ORJ!\GI:_)\K_]*J\<1'&CAE]^-\;ZN:]>;/X5U^$
M8#^8]I!W;NOGKV9:JC-S-2U5"T?-O)1@JYJ:NL^% ,GX7,D@?I#G(QAUW7Y6
M+H L 1*?198GO/G]4<S<-RJY;4F"IN_NV@&)?AV)7KS  +LF$"NOV/K]7A[^
M>1P%^'M1$)I^.'/6,(BNV9T+1\*^?^J^H[#O[]AWCC[W?0>\7^>^HR^J-N\J
M$W02G>>YJ=[><;&GJ9(]=BSM*7'_O#HB2;,-3EM7Y:7 Q(ELI8_KP9^U0"_E
M65S] @&B %& *$ 4(.IT O/M=<3.;H4 4@"I:X94TGWCCYK!M;2U9OO:.3@^
MO@GYB03XI]?@^G;=\*4*6W%)2/Q3"G:#(((@@B!>N""^,.U/K%-XXIE\=NW!
MG+^O=21C,K:O)]IQ'A07K:[YUE9A![ZQ)(=;=*$UMZ/U]/T-\V+U(N\Z5E1-
M*YI"3U_-LKX7KKSF"INQZ4<KRGN>%OZ?VE$V1XH3.DAN*Q2")66T!_5U<6.0
M,X^,ZKQP40\/%$6C_W^F-"$@^ P1_&PTX^^?%:T[>6'PQZ6%GYOU[[/I(D)6
MCTR1K./%)3'=ITT2\%)\I9<B02UNSLV+L==B$[2 ']!R 60 ,@ 9@ Q =HT@
M2UZ[NZ-&\6<WCO]6JSC2=!N36]OXB+V+=KFZ2!*MFM1&$8L:3P*KC? R'=F[
M6)I^PM[]%_ ,\ SP3+(M\V0:X+>-NPJNXWFIINM,]!5XS\[;>_8%T(?(#D@V
M2#9(-DCVQ4HVA#P_;-S%2M1>ASIBVM'\(J,A>&8G^%52-MK:LDCR@1Q7U\?3
M)(0R =@7 NPWGUGG'\>\-:/^V.[]L-\U_B$].WENG"2M1\+<-,F[0P0 2M)Z
M (  0  @ -!571 "!"5I/0!!B4/08]OO4Q<HZ5&UEV*%ORNQ")M%U([8^WDN
MM8<.9WJDL%"2'34G]D:=/'!PDEF#6()8@EB"6)Z?SQKD$N3RTN3R_,,L=Y4K
M/$UQQ[.48JLI55MKIK.P0LOL_$WOZS:T3S5[*WRDJ25%(WH<+?VJC CF>$8$
M7MKNZO,.+FA;$ZV0"YOO<A^X!+Y'*F^KN=\XO35^C^1(6"U+GV$K(B^TT2)?
MQWJ&FLE,90R5B9M?1)IDT#3&LJ]*D@#@ _ !^,\ 'WT(?%3N!JU6U6L7NX9E
MM+W";+<4L\5O _[(6F!.MM;H"5DKP,;V>CWF%C'PZ0CX!$VD&8H#X /P/Q_X
MIU?JOPOYWU/WY6W(%VD>73=;E:[1$]8!MECG2K,Y'R$_NO*&I0F"3.,<#= '
MZ /T/PS]1X?^H.#+NZ8<((:/E<M$%L6V9"WX+N@OAKF:5;!'F%1@^$I.8#/Z
MM!E#'\-O?G%I#B->@'[2 X*/'!<%S=9<Q8S]%HIJZ;;NK=RXA>UY.@]/E=1]
MZJNC[_.@'K$V3CV1!!#3=[@A;G$7\A+_!^J>IB9;S#:7V+Q1DY;M%5D6LS1)
MU$)[!(L<$7B:)*@T1F+G>UL#8 PP/CNGPMMA3-1GQ=5DIW2E);]9;TM"K;'M
MQS"FHWH:#,ZF"?IUM@7 ^()A?'8E*<[:1?!V'&>,79G \UQ#R-IH?CE6"^M\
M2XQPS-W\8M(HBZ?I5[H' <> X^O!\9?:^V_'\:2,35>V/,VB&M8<<C4LMRA'
M%C\66_Q4FJ:Y-($]IU>??P[#[571CK-2S-1A1C#X-2^[<-<K6>YJ*V>>LY_A
M'LUW8#Y"@?616F]+K>9 L+9U!,ORN<+:#RD0CSP+5)I#J32!0Z03: %HX5+\
M%J^AA?&BUE)RALX;-"UDBMLQ7\Q@040+=$0+*(>G,9P"6@!:@-*<E^('>0TO
M8-*88#HLKJ%T=NNSC=YLEM_%ZD*4'L&F28Q.<Q00 Q #$,/%.%9>0PR$L-,W
MBEH5I8)9<@?<8#.LC6*%(7*E8%2:BIRB*',)V1-?5UWK*I@O^?E?GW8+[>1)
MW-=R;Q#$$L02Q/+,Q?+TZ:\@ER"7ER:7%Q.BK$8]0:(&OG=A2L>&\.0E7;OX
MKCC#:8'\=1W#OC6F6++'CJ5%F+Q)>>%4_WN#'$M<YJL(B[H+0^JU-SW?:;%M
MO,_+&/E\>/$".H@!K@'7YQ@4?!VN%T.IV\B0X['A-UMRIUK:%8J*&.'ZV?@@
MX!IP?7::]WFW^'PCL+OH<*&7%7I@]&IKT38=OM[F8F!' 3XZC3X1X -D [(!
MV:<)R[T.V:X1U"71)3.2-NU7V@[MHV1E&B'[A0C=O]X3HGMJWT]2!!E<>N#2
M2Y[!L)_,YWDI0>9 YD#F0.82IV:!T('0)43HSC88%CWSV5X>JYGFIO:60.J?
MMXEZ_WJRGP=8YF"9GU1-2>J6@D!?[^Q!\J]W]A=)Y=^DB"5U3T&B0:)/N:=G
M<Z%E7PZT;2FFF<KXGFYKGI=Z6$3%L5/"V+$=2Q^'-L;<=[>IG.XIWBJT.0JN
M<KS7R56@-?F@O,(N;H\OWT4SQ'#P/8&0@I!>ROY=A9">WI,*4@I2>GY2>HYI
M/=I6LW_&.OB="OZG!GZG@._U[SOU.]:^CV3[#%EV7MXBU!SUB;K@C)LX2>*B
MC#'[;!\TC:+H1=<UW-LTPB9*D/)U;Q;U?D@YDU2SV4PQ_U3^E3(=Q0;OPP5Y
M'Q(T^\0IE^=\Y:B@Z+8793=J7L/^$]"-24X;':,_=%OJH=6U411P+FNYM>UD
MV,KS,L9&]XY(FD@3% %%BH -KI,-GE'B0=Y!WL_$29^ X^];VA.\X_AK4-I&
M"_"Y:R"HH2_:F_)D1(C1\<?!\0=T<.UT<'#^G5FD;I_LI^V3_, 5=\D@/#=5
M\S]G7^ BPE;=L9T_;]?];B+RY 6[.F\.,KJ]&$OM1H-K5/L^VZN$-B<7V9QL
M&L4.'6Y';\T"> &\"3TG04BO7DA/K\U]Z1'S+249WGW$=(VFXF_<OH1F&<X6
MVZ04Y(GXB.'@B 'TG@-ZWV.+G67HL12RBZMYJ^?L-'"O@'OE[*,+9V_RW2'U
MZ4:1L]IHO,24HF4H+<]2UF2[JQ6#\%TBTP[#N'1(85 2Z:(1?RD7+R^YB.'+
M0.:7)K'5FIVZ0'>S4KO:6F?*TC0",GWSBTQS)%0VNVP8)VCVI]?%S]Z2?AGP
MF]4@@W%CSQ J7+G;+,^EU;C(1X /+>;PC=+D\Q7/ /( >8!\ M*C7P_Y:6=,
M=>@<ITC9L1 (@30B<D:LK,>IS^$ISUQ:D<.G7 ]Z[%@$#^!;N.G4305?:75
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MNT^/QXW#5=3<._+!R=]'X^WQ2#YXZ?C/__<_KR+=![.ZY5\\/NJG&C)R-<5
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M92>5YLB;,^@_A60V')*9E1K%F:!L*C0UK#H-FMJ3#'FK">$89*&=7> KR2L
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MMK8(U@MB4B)?24HO)W.MG._S]R8^3G"!SF#(Y#H/H3BS)8&(XJ5&% $G@!/
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MDFQVYLEF+T&IXM!6$KW1=;,U,:?V,%WON+TRMOM(OMGI<R(!*:)6?7*^V4M
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M\^0&D&^*"ZV^$A8#%- XI%>_;/>T7HL9&VH_G64&0!S[.(1Z, &E8C,#9BA
M>G7NXXRQKK4K+3CTR,$R2KYZ;PU,10;S3FO6U(H]OS= 0P\X-E5)E]KZ;8*7
M,\W$N-(JSH>K&ES6$1HP;[NM2FTUF[5FMZ7F>-CIR'H&3N (&_9]_]8OC*^[
M\JRU:DS://#NQ0$:>K"LN3D;+Z6Y/9!+=*M5L-/J?0XMZPAEK93;]JSH\4G9
MT!FA4_2EI523T-"#917,(@,:J_FD!;A2FZ8=5=57<%E'F#O1X9.3=->>R6)G
MJ@.O%1?34%CS1XAPUFX,L^L;VFW->$4!I?5B[BW@T",T8&:[0G9\O;R6)U ?
M%N5N=0 @;_%'3BM?[MM#3[I>C//:D+%S.;I23\.A1_:5U9;>];TQG8PKM4+6
M5B6[.5W@H0=R>,B*=X5;4:-EMMOEY7L]HR;[>&@DB'&X;&-/!D%0:$N:ZM0%
M/Z,?=A4P9(&%]@"R';3 YHB,9VSLH1!4]$%@ZN%/]@S"G3AJ..;0WO:<:&([
MP;%O+[A]@Y^28*YX_JD<@!V#:.?Y-GQF'ZK2D0(9_1Y'(>.?@?6\@/OTK.&Z
M$S'<#%5[KFWZWL/XX'NKQ3L#7Y%ML!/8^[-+3^PS11G(07S004".8,A!G,)!
MT%<B.8@3. @"32=R$ 2:3N4@"#2]Z4$\7\+L=5KKQZTZ><SC_B&WY)]#Y8_=
M@U<N&1I-Z,/_?!.^_>[RQ2OV_6_!_XEO/V>'5]Z](:#*A@6H6SAHZ%*RI0.=
MVK_[3CB <,#O<<#I%/5\-8<\5AJ"L,;)LT;RX18$)W?X[W&B9W^7Z!GVBF;.
MFNA9&B7H]\@I7_HIT\_"V&MOYWP>OCV9<+%)K*!RCCVA*E. LBVM 25IT'B!
MY@EPW[O0SR>H D<(_\WOG#UM[I](HLA[K?X9&_O=;R<^@#M"OH1\+X)\3UV?
MWJ3WBOCY3S4(/7TV>P.*/'VV.WKU^ SYY?UZ3H37UIC=>R>,<C.7ZBLUV?7'
M,_Y^14]!==6;OW_/B=JD5%VWDW<MF?42W6$[QTMY9:$(*.6$$6()D8F)HO"R
M6@2$ PD'GA,'/KCYU<W[RKJJ+.)CGRD6N0S-K/C;Q;MS8*(Z;#@S@4Z,*[D[
M)35.WU[WBC7(@2+F0$'D8C3]) >>K37Y0+KO7):C/)MR #P\S3 !985B'WV*
M?M:0E>FCM'[#HNR-B:EN3,R?%Z:@GY(N^_& ]@'FR0G W07;EX1\ORKYGHU]
MR23Q"[)@"L6.@=4$=%%LZB#QXJTHJ&I08.8;4R2>B/)[ALQV;CP55+%ZMQ)6
M'VJ.[K(5_-D$Z ?)TJ6)#0]EC3\_5BH/Q#NMDB@RK;S&9H;CNTRYZ"^4!#9.
M^62,Y0_U8L*;A#<OC3??U5#]3=Z\:8]K=STOF:)7W<5Z=E<6V>)"4O"MH@03
M$]FGRGR?O\4:Z@N[FX3T!1WT/$HW7 TNY*B:0+3X,]7B3VGU7PS^WD4UP06S
M=MFWTL]"YLV&O'L$\>9B8CWNWB?S<OXFMUP54[W%HH1NR4-MA&=B*?Y8[26"
M  0!O@ "X 9?[!D;_O(2N9!]PQTB Q^)\FJU2B6^JS^H&UNUB%5QR6QY;MQW
M]N'IO&I8+@J, ;=B[;->((:/B-^DK92J)LM>RZ)\F_8J4S\USZ&",DC\BER,
M$S@2IB9\>\I\^SM2\SSM8ES3--Y348P6%<<$EHO1A2C$%Z00?X' UB58NGL=
M1-.()3,[''E$T@HY)VVN 'TO=_)>W%N#P32SP&76.-3!CTXPL03W,L\[X6W"
MVX2WW]^)_V+>7C4$?^9VE34]&5F&&D\NBQ:->1NEF\62K!A+\<\VC3D'PS[(
M*<L,56L '[6?* 8-#\_%,7W34#%?/Y8T]B5PZISAZ-Q0YU-.C) E(<OW(\N+
ML5JK#IBJADZ!)1*A() 0MC<$#J7YCH,<PX'H(*HN477/B;LOR8PM6)H#H*:;
M!<%_"U;(MEG0!Y!)=3G@7LG2*XAU)<RQ3]W \/(MOUGPXW.ZLO(7#4&:B T:
M%P"']BXGQ 3^6%LN@@ $ <X' <[^/M5OL_U#;M?J0.E+"G,[!I64RC#W6I>N
M8VZ'%C#+,3'F2!.MIV];G;12<V-H:%^H/@!!%GNP3Y0#C$G/=]RP*XH#-&#,
M47%K<KOZ=)&*!,W.4G?!R6:'"!:R9@X@U KQJ[['EO4M5SZEP7"2=FT,F5Y.
M+JFS0:=LJ\4D6T/-1@*//2W$DL++E!C"Z(313X/1+S<Z'JDLE!G*9MP0E9@4
M%V12G-+J3XVQSU&"/VZ&1,R<&<(%/RVF.ZHXT/*]UKB5[_<+G?%2O^FQ$FKT
MA2ZTQ43<:)DFO@8"#%\#&"[0*7&(!@<1^$FCO/0*8-9:]>X*R=$LWG6D!0(!
M\2D0.&,/A*3A*S4N-557R)0A9L?)HM/E!#0O6^F(6*H:<-01F%D4="M=Z/3<
M\8R-2Z/<C37G]0'J%(I< BP7H\6G;N@2SB2<2:3^[[/CHS: P#3*;@6L*W2G
M5&K.O+8TSLNX@R^Z."_&A)1XV;7>MDJ!XY/; 9=KZ'R!H.K%ZQB(0V^V&;)'
MX,SM+F_-D=&_H1O]VS8WF7>3U^4!ZC*.<B>XF""26_&$S<^;S2]383GD[4=U
M%B5Q?3^WB_>UL5^]ZYK#M-0;LIC)D<LBP<8XYM"6.&^'!=9-GL@#W;DW0(RF
M,P0G@D&?KE\$:5K[EA.J._8J:&HSD^NBK0Z'K55IS9L55AY/FS6%P34"4VPR
MQ@E/VE.$90G+GC'+?K#:\"8LF^1Z_=K*2XMT9WZWO#;DJ=M9+!#+(FV"%F-\
MXO "XB6Z0 [20/K@:&R$V$9G:AN=TNJ_ AI^L *3@5-!*^D8WC#CNW#_@1-A
MX.HI!"SHK?;U36,Q'D]D[JX\;ZOWRAS:4T$I013^?2X$3,"!@,,%@<,EE6)X
M/4X\A(=XO7W=K-*=W+CDCB3[QA!FT_@"P8/X%#R<K[^E 33?@7L!=WQJNP;I
MKW#1J'7NX'20ETZ(E!#I9Q/I!3H;(JF0#83"DSZ%\6!\[9;;@DO/*KU<_\[Q
MBC?W4*-.!4F5[)%R91?M47 >Z5)$K(6WLQ9ZMJ,#)QX,_LE,EY1KFX9._8/&
M_SL5M^G;&@F?O>A+]# \<CLT8N8ZP.T('L6^LETR&,><"N.*5=(GZ[G:GS8E
M.,' F\"E$L230+"!8,-9JD=_B UWDQYMRG;*;\WL&9.V)GUMZ0\0-F"]B&$.
M+X6?4=[&IZCZYPEOIV^T753@EY E(<M+(LN+L9#_W=M[P0*@38)S-'7XQS+P
MJ SJ+=]"?0L*%E79E R6-KWE__U7CV0P$_69J,_G8%I'WD7(V8BQJXX]-W2@
MIU>(PPO6AK^W[/V4-IV[Z=[71+ZDR49\SM>&V09;+T%+FPT:$L=2J40L21-S
MF^ %P8OS-+??%B_,L<-SS56:I3-C7I@U3:_&\S6$%\CZ9F))@8MQ(C'!B:U#
M;)TW!Z!@,6^V)$)SA.9^D^;.UGA^SE[&MG+.M!<NE7/L";28Y\ EYC+)6_TJ
M>:NGM1V$%;[PZL^9%5YNY#RV_,]N,U?U'6VHHJOB=I^:.JC5G+<*RNW/?&.*
M>\H3)?1L73J?E5#ZV9MPR2[AJKK")?:;MJ1!'G5 -63;JJE:'BK('W'NL8+[
M/)"79K-BRJ5)OA?W5[.$S2X45@@J^3*B$*-%<O&<8 #!@%-V\_X1!A1 8>WU
M%-6A05Q+>Y7\4JJD)80!J)$0S<9H_KU+^9VJ.K3'*\&HN GZ'GX],9*(D42,
MI!/8#L(*7WCUY\P*Y^PO^*T\M-<XUK\$"!!S@I@3I^=2>"1K9,.]+\L:87-N
MOK&>],>M_&VV,N#F2V,^&2AL@O@6"!@0,#@7W\+;@($@IFS'NVNP\BH#IO2]
M712MF83 X,.<#.><6$9,)6(J?6E3B; "807""F>32OV:;+N<8:F61IP")-GU
M<QB1)%@3FCL-FCM;(V?K%6;Q"Z"Q"&>INU0? ;P+;4&43Z;9DXF-Z-36QCBG
M;*$ZCHH:JAH6-76,N>H!:FK" \-Y9O_'_)?H?Q>D_WV!#DNO*+%)R)B0\;F0
M\3F[+R-1A$R-@NOZT-0 E7XUD#;52-@<\5BF;IM2W<]P_=9LD!GTXN-<*I->
MH%F*WWX),4%,Q1CNT&=Y/G;:;PAM)*?]GFEH\"]]^'AHL_T?>U1*?PD4.WVP
M^H(5A$F9:T*D9T>DER9A"W#:AFI6L;"HA++BB)"]SWKS_CP#I#%@JM;@AF:9
M-3=0. 97EF!C"0[UB6!?)V4OP68&2^!HAHM%<"![(V.9&!,79$R<TNJ_&":^
M[Z6L'4SL!(PKAQQ]K/MX@KN^CY=G68,VW'@B*TQ&>BL-81 7Y&)C#,W%4JG#
M9H($"@@4$"@X(_7H!5!@NIHC)W-]NJ5.DLO&R)S7IBJ& I0H%1-Y,48_"07G
M[7:H5JM4XKOZ@[JQ58O8;)>,5N<.2L2Q0(CTY(GT'"4G[A6Q*S:KZDH; FT,
M/_, 7@?\:>"H$R0DCLA06KKF$HXSG]+L(G>S;C?$ZT5WH7 <;CPI<C%.X+Z>
M2Z'13E/F(U*56 W$:B!6PXDZ$,H0]5R(@6K/!$?0;K@<CNU>)\>TC+IPJW=F
MV=SH6E(X'CD/$C'AV3:[! 8(#%PP#!SHZ>=F(=?!-*SO@J(!%D(#:AK  3$^
M3I8E+RI?];SO,V\9J-)_1IAFBXNQ(;<3]7%&$ML5ULS/"LV!PN&": *?B+'"
MDW7N"1L2-CQC-GQ73_@KV+#>2HZ+=RZ]EC/NG&-K0S%GCC ;0@N>$Y,Q-OG:
M=A-G:L('.X8$_R;ES@B3+.!)NB0?X*+T^"^87$QRY D9GR$9GZTT#KSKH2#.
MV0Z4RF'1[TK_V7R]UO5UPQBWE9I<8CDQ;]$MLUR0%$[$<IE-Q6@N><YMH)X0
MO\AU_@+1^R6@Z?01Z N&_B[*3+^QK4$3.),LZ!V[G%.1VLD"F.84N3&U*C*X
M[>4:\9K"X=IBHA@3F2=AB+ K8=?/9M??<5.??UWM%R:[VU/$LA=EVS[<@A.N
M+7Z> ' QIL6EQK$;B+4K 6='*;#Z$>&>,9+SK)2U^G)&&Y?-2;]::X^A<$_B
MPJ$),99\\D;0^4/%B?$#08,OA 8?E@O_4C10Z][P6D_.ES3+2=S=36M8RE<'
M" W0/7PVQG"'C>K/NL3Z0_K?>VP&3KKG&/ QU\"< [00]$C5<N/A<]]$>Y[
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M34+#B6A=Q#% #"MB6!'Z)?1[8?1[MHZ!YWP!&X-?0S^ K0) Q:DT@ ^Q4&J
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MTA9XAHN)?/(].O\2%KV817X-%GUSA> 5/#JL^5[7&+'%5GQ4Z372LTRYV%Q
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MY"<'7DJ\;?5%Q/,BNH\5XVGN35P IZC!]' E=+M/Z88#- \U/$)M?8GI<<D
M17#HHU6/;,A=.<A;88G7(S@T:R1<01\F$K0JIUO]R7WESJ]*J+HP5#X2B1A-
MORP*03B5<.HE<^J[:@PO8U7 W)3]59W-TFKOQM6KMR YF@P0JT*=04S&6.$I
M5KU0=TA0]1DE2 #-=U"#"QW@*F[$0KH@"XEDB9^!PE%'E?,MO1$R8C;@PR-
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M\]P/@G3:/)6#()TV3^0D"#:=R$$0;#J5@R#8]+8G<09U0DB;3-(*]K'-(%V
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MXR%Y[U&#L '1]=&H\"Z5CP:]\MAN5A,*O5,+[8:Z,\JI0H/\(-!3NN[P6CN
MS7,8*)")#MEEJEW:J4^RF<4 &Y NQ "6BB?3V!D*#D0++PBF V3HGB' ?S$3
MH@5@X4HD $DG<=N^LL*'M?F676IS>3GF2TY;N1,LD&_&0M6'2Q= !)S7ED3
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M&"(*OYR1)">L;4Z6:O2:I=7)MK2KK3(P5_@A<UXUX.DB(?,@''@O#0O0^"!
M=(=1Z2OKPWS T?N3P2T<1J6G);/3GM4M.K'0,]:"+CPR20 S6])1285U&JOR
MDFF@'!+])%8HAZ F^1"C[(NA3V,%P7,LO&"2#KIF_$1&0/FBR6]CHK'53[)P
M;Y@6_17:S:NNH\.D^:H/9V@@O'!)Y=J#F9Y/Y<:JY/0WP\JJOK5* *OXL[<4
MN/EGIF%9^\H%J MLC4!/L/;JC Z B?Z$: 38$C#-*@R3\L)<D39A<IX%\["
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MU^8BIJB%IC)<U;+=61][@>*.^G:#W7EOBFD^5N#L@GUKO8-N]4#(ZI)XC",
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MT[Z31^TF/>&6Q(-F_A=D*7+G@7_,L)GJS]"3<KT410-JKQ>BM^VH[5%2^BR
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MG1DL]JD[S&0YM32?R 4Y8ON@DN%IYD\\]9PG>E/?6;9V'@A" *L[3--F!-N
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M]<ZWG8-O3=TGK(R9Z>=A>XMY6(SI/S9(Z'<34T"]<$]ARBH@!>BD7<($3]$
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MD0 K2QGYZ"J\8&NX]+0M#O1Z$7/J3*K8)KJ6.8 IZP_D,U-D 4\<)7+X:5"
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MQA_3;"G+E:;(BB0&@YJ7DCTWT+-$:2-IQBH&""+85#"_^WCGX$/_<2N-5W0
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M>EQ6!3RU=2S<EDCM43:M=9A"(ROVW2'O3<;C2HF?="<SP(5IZ#8EGH@H(?#
M"8&'TY)OYMS[<((\?$OWJ61QC"_%0JDW5.E&9>5")H4G%49IN\?FTGM)V[U@
M/FM9[CFJ)PI<P[3CK:;7MQ+9^VV&0L@SQ:(R99QK% NK?EQ.KIT""WD0)NZ8
MJ*5GE+B+].2U#X>@=WQ233!37IEG$^Y6R'ES!QFSP*5,Q%+4&QN@1)F[R 6]
M$H,JLP/^7+?,@>4DF1WGC)OM8B)>:EFK1^GH.?-P9=>FBAZWKA V*3;K.W/%
M J ''FB4N(O"^P^MB]_(ZE=7Q9>=0:$5B%V<)"J JQ/=='U2IRG&A5P--]#%
M&"H9L77$UE'6+LK:1;+]CI)VR1W)C-QEIL6MF>2\6W"UC5I#8CU*VD4>TU4/
MNP0,\\QJ<SM1Z?*\T."=>KO!U]?RALL]2JFC1>W80:HBXGRG9JQV[?K2MF:M
M,0"Y[S&EHVS XV8#'DY'OI5Q[\/_R6>EHJ6-BUV\T8CCV_F\U-;S+.11"C5C
M3D0YNT?FTGO)V1TS7Q8L;L<41B5N+;B>;:07#69WORD[SZYFF_+&:'.*S:08
MCQ^V-VT9\F"4LHM2=I&:O %_DFE6MLMZIF'P?=,<Z!FW(%<'2$TF+U"34<HN
M2MG=#H/"EDH'+"H6>+5?=EV;;[3<1:6QF.E:_E&2=K)A)COE4;?,]>6^Z7'I
M\K0L !>4]%U0,A%%]Z/H_B-KXS<S^]7U\65INP;=W4UG,L=+BVEA*6Q2)9-"
M? VWVS$QYL(V3A%G?Q/.OAM']P7#VI30L@?K28U?>\.Q-K;2N)J_WU,8>FPM
MT\_,4GD^KE&IC:!NEVY#AGP+7=W$$_Z]CNJ[+::-G.-(';_//6[GVBUZ95@N
MIS1Z@YXXK9;S+F+KY 7J.,JVW@B_/9ZSRR']]'RLBM--]=4B9_+>9N/,V*(R
M']4?I;$I.VU8LZ&PG:G9!&%DT\H$'\KNF*1\7S=Y627;=]2A#V#?/IRJ?#/G
M7EU37N2X=N1)D5=[ZDXM2/H*S^WRE2G1@DP*'-<$'NV1?' V?:5\-$)IY*0\
M@N2]O6I0:X&7<F9Y-> 44BWU!V2^K'219?3>:M H?1=Y--?ASKJB2P?<6>GH
MV^*Z4(RKI.?UG)E22A3GC^+1-.1TB>Z:U$)=%D8[;5Y<5)R\/"9IZ-$P3WBT
MY2Z*\3^R)GXSK]^'#V3DZ+9@:R6)5\J)<:D_S7JK3 NR-6P3DR!CJ?1EI>$1
M9W\7SHYVW479H$B\W[ZCI=?+U55K5^!(ABUUJ37)Z;@+)7NT[2YRFZY\!(AN
M>P&G53/-9F:Y8D2N4W><=&H[+L751REY=/,S/J5O<PKNI#+KS<ZIS[HLL*X2
MOM-$1O'E1XXO/YJ.?"/?WH<#A+/#Y5S,;#.<5^PW2PV\N7)=%[(H<( H'(]1
MJ2A9^\!<>B_%B$?,EREVC/BVB(]Q4JXR*8?1JX5DZVXK$76R8TCX6DCP4KTI
M21.O.V.&2$WZF^Y2T::[*&47:<DK.I/3N#%UG!99X\E.3566J3KN>3+DT.0E
M6C+*VD59NQMCT(8>'D)IYB?Y;IU1'34>9ZWF2C*&U8?I^\).^^)R6>32>"._
MV.:\I*;-RD"U,KX'2GVW@[#^SW\(!O_4V/4M,O&#*MFW\/#5]>Q%WJA::<W<
M:7S541MMOL&UX@3;E%G(KC ==WE)XN,P[&TE8FZ.L^_+?7UFV!0N4I5E8=?#
MI8E5'LQ,J5[D[M>#M>P^I67-P@"OE)1R79R5-KTUXMLW>+"/P[1?HF4C5S;2
MLN_S9G.KKM=T6V2?]S9Q6R1(9UE.R)!;DQ=HV>^6&;U#=?APWFK7-0(>K OQ
M06.:I)/<>IV5:G9#R*=;C^*MEDM5<IDIE1PNJY7CVU)C;-I5X*TFH;>:>DJ2
M42;F0S,Q$\,$F(W[HW\0JRUF&9HB8O_!T7^WQ=L/JE[?PMI75Z\7.;$3?%/L
M">7ZG!,ZQKR?']7Y..RAF/3[F#*Q-'%91YB(D>]9"=^)3_K,?].XN-.X#EG$
MF2W%3^2,9"R2]]O*E*]16GS!TUN5]/+=:LT>++PF4J:^3YJ(LJH?F56-=&FD
M2S_>5=T4$[N\(%%C56IFR$+1ZKF5+=*ER4MTZ4,G7K]?:/A.H/$06N"#2>-8
M/5! /8B& UC_-O7#YZN'BEX0V[-*HXEG<R6E1"J+E;J]PPUT<S/%*<X@V>2R
M"9V:RC(W+96!@$Y!9X>.47@BEDY%2;MKL]\M<M<['*3JAFU[0FKHJ&MZY.$K
MJ>E--O+=NBC37'.,]\EU%X]W9\WZG,:K4P4QS[=,F]T6VYPZ-;>NM;[ J[D#
MM7617]'D.UJ]9"[GJD2)25ED3&<!=R:E4)?(&,70,3Q)_\JS^!\;?N7?$R[]
M<-PO',M69MXAN;U@%__.WOV&(R[DH$_A:P(_S]5H38 :#%_,_W @;C5%E\#
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M7\<[1%(O#E25L>J[I;YLR/;"A0=.4S&&NJKTC4$R6DE3^+CF'5G8.O U[L'
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M#7$F'CZ,B<;402.>,'XO[_R@2J!K_&_X+X8&Z]FYB1**_(66 ]"#P>.*B:Q
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MVY\4W(;=&?TR>WCE3;6ZP*HS'$V$._:!P W[/B\<_:#Q,Y@+L/H$Q\_G0.#
M.MY#@%GAAN3G#4@Z2I[ 3?(2#"2BG?6P"%BS)!=>]--6 "\M1S!M:%$"0EP9
MI@V]I#R0(>&VOW@+O7,_DW >[_DZ^"9\A5_?^;/O54*8^E>@S1/ ,2=-$1C]
M&Q3A=YB&^)DI6EB9"3_//W5@JFKJ!$DV."UN&^3KLL^;^O>=H[CL'ML&W.9F
M3N?!1\).GL# ^DA^?*?X 8""QB-6-0P5,MM^)[IU4_*B"PG+]-$+_0K@,5LA
M9\W\)<2U8 G/U/,4\F$'.-PHSZS!/I/@WT,2\QL_V'.D3)^OSC#P3=LPX5/8
M#'A0UA'9V<\SBF'/?29@2-Q$?T&Z?";I4+_%L$F8W;1L(*PDV?-STG"S*_K+
M0'MV@ 9$<UCN-0(BXIGCYT#W@BZ&MB&^ @(8B[->&X%>X+?4",(9$TE3I-G+
MSPNV+Y90*P[TSH-WH*:)2T&44)[<A9T\8+[<LIQE$ :$-_U^(Q!\OE,$.0:P
ME E> :2%L!$4+=Q0^?SA)ZP_EW381.04[JC//72F]JU)]'"+Z$NAC!:U.;D,
MG:;EF>$PW3VU7UY="B?B?PFYZ40G*)KV\EJPP5UZ<1DF]'4Q=D9CK)[WT/H"
M$RT4$,%J;@)T(?Q8"N!&(,Y@TA^PAH#$L.T+-R@G(6\!5KN 0 Z0"6Q,N$,0
M47" 'FRC $Y_&;X*J%':[$4UG,#!KC-3L51 HK#F VT_V\O.0\I %I\_WXT
MG%?'0NP&MYL"ID3%"T"?30781@9<AX(^U/FA=@ X1"PW"^<"M^0JJ!L?1*[I
MMYU!=6[!G,,W #S#;;:0^!$4 9&@T@G+F<Y?A5K^9U/TF\7XY?N(E-&K_-G
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M+N)&".O%3&&%GK.>E14D[8/JL(,*,-C"%C5\@EU\:FP3, :=(O_Y^^A%0+.
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MA-1U!@?G]BT@UBO5<ZCB%6@E6T&^Y8&!<J1 D+6"Q/\>X4A[98MLDVLWZAP
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MBOZ51X$4YN?>" N88CFK.$]\%&B]'4FSZVA();K]<,1[["'$@NO,WK"!X0>
M,T 3$G"DMO'0OX C,5SC"1USAKPP1;Z!M,H3R_/]_"[GG1* ,/"C#*!/X=W$
M3J\[-;WSUDFX%=9D]DQH<7 'TT(@*>E#",2]!P&$,*T'@@^GA5O -82V=0+?
M,#Q[[=0J#;TW4BL?RHT9!F_@+7'RG2K>"S:A1QERCRK>(W:Z!>8"\(:HV&F]
MHV%D6%288++S[G7=6,J9]!'5['SQK<.*0,T5M%*M\&;8V VMB6#@(Q =P!R#
M1YO+<O8RH'B69AX5@M\1#;]1:7> OD'$TB[QHA1170\'EE$=5##G (_U8+#,
MHFQMH!!"R!Q1J5VL:'H3R_X#8<*ULKT,Y)2']5Q!I3Z&7J+%;@ L#A_@"JH^
M%PV!&_!M\-I,(/E(-C((!VGX0!5&J1@]<,+?<@"@(?8VN I'<8(OL#[&R1U,
M[?1OA.NC-,W#H&)]@1%/?7H H#G.Y$L HJ#UQ3\)[>?=Q3FU,T#^'7@@E-'^
MD'H7_@[%CX.(UP3U.$WISGL$90[R &16ZB6/5GH;YX, >06^SH=28\Q9/Q[Y
MDFL=A-A.(,55&*/0#:&P#"F*2C9": TZ#/0%WB\KM6))W>)]S 9HKBNMSYLL
MNTWB_.:6%@C!!"Z%W% )<W6*SQ>K$9.!0!1"0N19#K0QQ2'.4OP- QJ&8: (
MSST&0$P,15E@>AY?'-+S>CG(1EAB6]R"CY!42W!4 O#U<ZJ1.\/%Z^&^Y/'J
MQRA3)\W@"U3!X^*&Q1I_)@@":P6S$W,24Y47B-&(_ABBSK 7P+>>CZ*(U__>
MBP;$&SA@P T@/01MD;1W6"*8NS(49CQ&NC3WD>VX)K&)#GG-5+%D$H\*8)!A
M233(0O]V",;&C3+3&2J::Y;::A)(,GPM'4F%41&K#F :PG!)N9HX0S9"X4-<
M:90./JW)M)_T&)B)PN$M:PN^;A!RK6H]'7,VB+5"Y&\@Q64?-QT*!+WKEMX3
MQ,C3=@%)?;')33Z#RS,@(0UL)KL!7X%<154@.,'[7GC''4A,Y",VA6%RH3+'
M+?*U"6F LV62HG*M6!]6*]I,[V85AL\0"(OM;K3-T+1 I?V <A=K7%.!T/3M
M059HKI<5F@59R@K-AUZA>05T]P7+VS]:+8G+S5KSM&>H2Q29KI]BCW'K-6OO
M1]TOP#K!^Q LN]5W>!U]=-Z]8<E^_<=[!GMP_PW<<X.B%>Q50%PC5""DCW%9
M\Q$Y7]R&KFK/_D)Z=P^6$F4<C@H0HY?1 X?#'+4G/A)UY4!B,W@/>C#QL2?>
M&T8C^1W^Z53<QD\ &W+9HP@6DQ] K0H0BW!O+'SS/SS0L-<93#2S_@(2<"@T
MWDGO#6Q0(*0Q0("=K! "LN(' UDZ6:RH,"_@M=[P)D)68HAH/.+.(X2 RASI
MPC9$P[A *).4A3?Y57D]3N,A_"7J\Z,EE(&:H98"_!!7>EXCPNP9NE%N59,$
M?+8M.CD9! &;1=M7HI,#MYJ "9J\$A?X"+3J$!70,/39'D4NT*\Q;V043DTD
M@$L>O(1\T_CW"-3-+?I .H[=;M<!(7N)T#H 6>(A6VZ"#<(?B&%2HB:H0T"
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M,A!)A[E-[P9]1E T5$JGJ_0  ,I"D'J^)=E(^72/P%@E+P"><0<  1"@Q;R
M#3I,D'__^]\%(O6/=?6,-+I=!)H'1LY!SUFBHX"VU '09<&0,6>5"6K\:-S<
M_M&L 5C?U(WGFRX02LY!P ZI8,1TA><**B%2ZG.4>#8U&7&[I!/ZW&&^3VA
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MN!X=R1LZ0(<&.6"-8N:4.U'X/32$]>;#K-1E2>-9F0A0>Z(>BF;IOKPF)?3
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ML^,,>/ "?][VH-NZ''JY";W1:)=KCGDD_H9&XG_*9B3^W$ZW^WC5>*#B23&
MU$>^QTAQMSN^Y>?U8OF/IUQ=E^KC8GD%WBMIW*IY C*5%T"F*]@Y@^E8-2G
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M1#C<<MSN-$\O.JWC$OO7;[_]]F^8W7&[":_MP"0:W>63O6H=-YI=>&8CEP0
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M_L#G08<_YGF0?287%/M#=15Z,!*6,;J*0HBRKZ#*=]+)I6H44DHCE5ZR4UL
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M]VA7H&<ZMOV()/I]F2L6KS]CT2B%4*0I#76<E;E0)2R'=TLBT1=\#5.:":E
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M!J+X2N/D3U!+ 0(4 Q0    ( #F";%-E("CNY1(   S6   1
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M,BYH=&U02P$"% ,4    "  Y@FQ3.W!U7OD@  !T;@$ &
M@ %,\P( 97EE;BTR,#(Q,#DS,'AE>#$P9#,N:'1M4$L! A0#%     @ .8)L
M4TP9[+Y2"0  Q#8  !@              ( !>Q0# &5Y96XM,C R,3 Y,S!X
M97@S,60Q+FAT;5!+ 0(4 Q0    ( #F";%-IC(IV<0D  'HW   8
M      "  0,> P!E>65N+3(P,C$P.3,P>&5X,S%D,BYH=&U02P$"% ,4
M"  Y@FQ3W[[7/(D%  #8%   &               @ &J)P, 97EE;BTR,#(Q
M,#DS,'AE>#,R9#$N:'1M4$L! A0#%     @ .8)L4]I-L D3!@  IQD  !@
M             ( !:2T# &5Y96XM,C R,3 Y,S!X97@S,F0R+FAT;5!+!08
1    #0 - '@#  "R,P,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
